U.S. patent application number 15/470419 was filed with the patent office on 2017-09-14 for antibacterial compounds.
The applicant listed for this patent is SPERO GYRASE, INC.. Invention is credited to Lorraine Claire Axford, David Davies, Christopher James Lunniss, James T. Palmer, Gary Robert William Pitt.
Application Number | 20170260178 15/470419 |
Document ID | / |
Family ID | 49212365 |
Filed Date | 2017-09-14 |
United States Patent
Application |
20170260178 |
Kind Code |
A1 |
Lunniss; Christopher James ;
et al. |
September 14, 2017 |
ANTIBACTERIAL COMPOUNDS
Abstract
The present invention provides a compound of the following
formula, salts, racemates, diastereomers, enantiomers, esters,
carbamates, phosphates, sulfates, deuterated forms and prodrugs
thereof. Also provided is the use of these compounds as
antibacterials, compositions comprising them and processes for
their manufacture. ##STR00001##
Inventors: |
Lunniss; Christopher James;
(Notting Hill, AU) ; Palmer; James T.; (Notting
Hill, AU) ; Pitt; Gary Robert William; (Notting Hill,
AU) ; Axford; Lorraine Claire; (Notting Hill, AU)
; Davies; David; (Yarnton, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SPERO GYRASE, INC. |
CAMBRIDGE |
MA |
US |
|
|
Family ID: |
49212365 |
Appl. No.: |
15/470419 |
Filed: |
March 27, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14384237 |
Sep 10, 2014 |
9604976 |
|
|
PCT/AU2013/000286 |
Mar 21, 2013 |
|
|
|
15470419 |
|
|
|
|
61614044 |
Mar 22, 2012 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 15/00 20180101;
C07F 9/65583 20130101; A61P 31/04 20180101; A61P 7/00 20180101;
C07D 417/04 20130101; A61P 11/00 20180101; A61P 17/00 20180101;
C07D 417/14 20130101 |
International
Class: |
C07D 417/04 20060101
C07D417/04; C07F 9/6558 20060101 C07F009/6558; C07D 417/14 20060101
C07D417/14 |
Claims
1. A compound of Formula (I) ##STR00195## salts, racemates,
diastereomers, enantiomers, esters, carbamates, phosphates,
sulfates, deuterated forms and prodrugs thereof wherein X.sub.1 is
N or C--R.sub.1 where R.sub.1 is selected from H, OH, optionally
substituted C.sub.1-3alkyl, optionally substituted
C.sub.2-3alkenyl, optionally substituted C.sub.2-3alkynyl,
optionally substituted C.sub.1-3alkoxyl, halo, haloC.sub.1-3alkyl,
NH.sub.2, optionally substituted NHC.sub.1-3alkyl, optionally
substituted N(C.sub.1-3alkyl).sub.2, optionally substituted
SC.sub.1-3alkyl and CN; ##STR00196## represents Ring A which is
selected from saturated or unsaturated monocyclic
C.sub.3-7cycloalkyl, saturated or unsaturated monocyclic 3-7
membered heterocycle, saturated or unsaturated fused bicyclic
C.sub.8-10cycloalkyl, saturated or unsaturated fused bicyclic 8-10
membered-heterocyclyl, C.sub.6-10aryl and 5-10 membered heteroaryl
and may be optionally substituted; Z.sub.1 is a secondary or
tertiary alcohol of general formula ##STR00197## an ester,
carbamate, phosphate, sulfate or prodrug thereof as defined below
or Z.sub.1 is selected from H, OH, optionally substituted
C.sub.1-6alkyl, optionally substituted C.sub.2-6alkenyl, optionally
substituted C.sub.2-6alkynyl, optionally substituted
(CH.sub.2).sub.mOC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl, CN and optionally substituted
(CH.sub.2).sub.mNR.sup.aR.sup.b where each R.sup.a and R.sup.b is
independently selected from H, optionally substituted
C.sub.1-6alkyl, optionally substituted C.sub.3-6cycloalkyl and
optionally substituted 4-6-membered heterocycle or R.sup.a and
R.sup.b join together to form an optionally substituted
4-6-membered heterocyclyl where each m is an integer independently
selected from 0, 1, 2 and 3; X.sub.2 is N or C--R.sub.2 where
R.sub.2 is selected from H, OH, optionally substituted
C.sub.1-6alkyl, optionally substituted C.sub.2-6alkenyl, optionally
substituted C.sub.2-6alkynyl, optionally substituted
(CH.sub.2).sub.mOC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mO(CH.sub.2).sub.mC.sub.3-7cycloalkyl, optionally
substituted (CH.sub.2).sub.mC.sub.3-7cycloalkyl, optionally
substituted (CH.sub.2).sub.mO(CH.sub.2).sub.mphenyl, optionally
substituted (CH.sub.2).sub.mphenyl, optionally substituted
(CH.sub.2).sub.mO(CH.sub.2).sub.m-5-10-membered heterocycle,
optionally substituted (CH.sub.2).sub.m-5-10-membered heterocycle,
halo, optionally substituted haloC.sub.1-3alkyl, CN, and optionally
substituted (CH.sub.2).sub.mNR.sup.aR.sup.b; X.sub.3 is N or
C--R.sub.3 where R.sub.3 is selected from H, OH, optionally
substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6alkynyl,
optionally substituted (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mO(CH.sub.2).sub.mC.sub.3-7cycloalkyl, optionally
substituted (CH.sub.2).sub.mC.sub.3-7cycloalkyl, optionally
substituted (CH.sub.2).sub.mO(CH.sub.2).sub.mphenyl, optionally
substituted (CH.sub.2).sub.mphenyl, optionally substituted
(CH.sub.2).sub.mO(CH.sub.2).sub.m-5-10-membered heterocycle,
optionally substituted (CH.sub.2).sub.m-5-10-membered heterocycle,
halo, haloC.sub.1-3alkyl, CN and optionally substituted
(CH.sub.2).sub.mNR.sup.aR.sup.b or R.sub.3 is a group of formula
##STR00198## where * represents the point of attachment to the
carbon ring atom; n is an integer selected from 0, 1, 2 and 3;
##STR00199## represents Ring B which is selected from saturated or
unsaturated monocyclic C.sub.3-7cycloalkyl, saturated or
unsaturated monocyclic 3-7 membered heterocycle, saturated or
unsaturated fused bicyclic C.sub.8-10cycloalkyl, saturated or
unsaturated fused bicyclic 8-10 membered-heterocyclyl,
C.sub.6-10aryl and 5-10 membered heteroaryl and may be optionally
substituted; and Z.sub.2 is a secondary or tertiary alcohol of
general formula ##STR00200## an ester, carbamate, phosphate,
sulfate or prodrug thereof as defined below or Z.sub.2 is selected
from H, OH, optionally substituted C.sub.1-6alkyl, optionally
substituted C.sub.2-6alkenyl, optionally substituted
C.sub.2-6alkynyl, (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(C.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl, CN, optionally substituted
(CH.sub.2).sub.mNR.sup.aR.sup.b, optionally substituted
(CH.sub.2).sub.p-4-6-membered heterocycylic ring, optionally
substituted (CH.sub.2).sub.p-spiro-bicyclic-7-11-membered
heterocycylic ring and optionally substituted ##STR00201## where p
is an integer selected from 0, 1, 2 and 3 and ##STR00202##
represents an optionally substituted 4-6 membered heterocyclic ring
or an optionally substituted spiro bicyclic 7-11-membered
heterocyclic ring; and Alk is optionally substituted
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl,
C.sub.3-6cycloalkyl; and with the proviso that Z.sub.1 or Z.sub.2
is a secondary or tertiary alcohol of general formula ##STR00203##
an ester, carbamate, phosphate, sulfate or prodrug thereof wherein
q is an integer selected from 0, 1, 2 and 3; R.sub.4 is H or is
selected from optionally substituted C.sub.1-6alkyl, optionally
substituted C.sub.2-6alkenyl, optionally substituted
C.sub.2-6alkynyl, optionally substituted
(CH.sub.2).sub.tOC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tOC(.dbd.O)C.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl and optionally substituted
(CH.sub.2).sub.tNR.sup.aR.sup.b; R.sub.5 is selected from
optionally substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6alkynyl,
optionally substituted C.sub.3-7cycloalkyl ring, optionally
substituted phenyl, optionally substituted 4-6-membered
heterocyclyl ring, optionally substituted 5-6-membered heteroaryl
ring, optionally substituted (CH.sub.2).sub.tOC.sub.1-6alkyl,
optionally substituted (CH.sub.2).sub.tOC(.dbd.O)C.sub.1-6alkyl,
optionally substituted (CH.sub.2).sub.tSC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.tS(.dbd.O)C.sub.1-6alkyl, halo,
optionally substituted haloC.sub.1-3alkyl and optionally
substituted (CH.sub.2).sub.mNR.sup.aR.sup.b; t is an integer
selected from 1, 2, 3, 4, 5 and 6; or R.sub.4 and R.sub.5 together
with the carbon atom to which they are attached form an optionally
substituted 4-6-membered heterocyclic ring or C.sub.3-7cycloalkyl
ring; and * represents the point of attachment to Ring A or Ring B
respectively; and further wherein each (CH.sub.2) entity when
present may be independently optionally substituted.
2. A compound according to claim 1 wherein Z.sub.1 is a secondary
or tertiary alcohol of general formula ##STR00204## or an ester,
carbamate, phosphate, sulfate or prodrug thereof wherein q,
R.sub.4, R.sub.5 and * are as defined in claim 1.
3. A compound according to claim 1 or claim 2 wherein Z.sub.1 is a
chiral alcohol of general formula ##STR00205## or an ester,
carbamate, phosphate, sulfate or prodrug thereof wherein q,
R.sub.4, R.sub.5 and * are as defined in claim 1 provided that
R.sub.4 and R.sub.5 are different.
4. A compound according to any one of claims 1 to 3 wherein X.sub.1
is C--R.sub.1, X.sub.2 is C--R.sub.2 and X.sub.3 is C--R.sub.3.
5. A compound according to any one of claims 1 to 4 wherein ring A
is an optionally substituted 5-6-membered heteroaryl.
6. A compound according to any one of claims 1 to 5 wherein X.sub.1
is C--R.sub.1 and R.sub.1 is H or halo.
7. A compound according to any one of claims 1 to 6 wherein X.sub.2
is C--R.sub.2 where R.sub.2 is selected from H, OH, optionally
substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted OC.sub.1-6alkyl,
optionally substituted SC.sub.1-6alkyl, optionally substituted
S(.dbd.O)C.sub.1-6alkyl, an optionally substituted 5-6-membered
heterocycle, halo, haloC.sub.1-3alkyl, CN and optionally
substituted (CH.sub.2).sub.mNR.sup.aR.sup.b.
8. A compound according to any one of claims 1 to 7 wherein X.sub.3
is C--R.sub.3 and R.sub.3 is H.
9. A compound according to any one of claims 1 to 7 wherein X.sub.3
is C--R.sub.3 and R.sub.3 is selected from optionally substituted
C.sub.1-3alkyl, optionally substituted OC.sub.1-3alkyl, optionally
substituted (CH.sub.2).sub.mNH.sub.2, optionally substituted
(CH.sub.2).sub.mNHC.sub.1-3alkyl and optionally substituted
(CH.sub.2).sub.mN(C.sub.1-3alkyl).sub.2 where m is as defined in
claim 1.
10. A compound according to any one of claims 1 to 7 wherein
X.sub.3 is C--R.sub.3 and R.sub.3 is a group of formula
##STR00206## as defined in claim 1.
11. A compound according to claim 10 wherein the compound is of
Formula (II): ##STR00207## salts, racemates, diastereomers,
enantiomers, esters, carbamates, phosphates, sulfates, deuterated
forms and prodrugs thereof wherein X.sub.1, X.sub.2, Alk, Ring A,
Ring B, Z.sub.2, R.sub.4, R.sub.5 and q are as defined in claim
1.
12. A compound according to any one of claims 1 to 11 wherein ring
B is an optionally substituted 5-6 membered heteroaryl.
13. A compound according to any one of claims 1 to 12 wherein
Z.sub.2 is H.
14. A compound according to any one of claims 1 to 12 wherein
Z.sub.2 is selected from OH, optionally substituted C.sub.1-6alkyl,
optionally substituted C.sub.2-6alkenyl, optionally substituted
C.sub.2-6alkynyl, optionally substituted
(CH.sub.2).sub.mOC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl, (CH.sub.2).sub.mNH.sub.2,
optionally substituted (CH.sub.2).sub.mNHC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mN(C.sub.1-6alkyl).sub.2, optionally
substituted (CH.sub.2).sub.p-4-6-membered heterocyclic ring,
optionally substituted
(CH.sub.2).sub.p-spiro-bicyclic-7-11-membered heterocyclic ring and
optionally substituted ##STR00208##
15. A compound according to claim 1 wherein the compound is of
general formula (III): ##STR00209## salts, racemates,
diastereomers, enantiomers, esters, carbamates, phosphates,
sulfates, deuterated forms and prodrugs thereof wherein X.sub.1,
X.sub.2, Alk, R.sub.4, R.sub.5 and q are as defined in claim 1;
X.sub.4 is N, CH, C-halo or C--C.sub.1-3alkoxy; X.sub.5, X.sub.6,
X.sub.7 and X.sub.8 are each independently selected from N, C--H or
C--Z.sub.2 where Z.sub.2 is as defined in claim 1 provided that no
more than one of X.sub.5, X.sub.6, X.sub.7 or X.sub.8 is N.
16. A compound according to any one of claims 1 to 15 wherein q is
0.
17. A compound according to claim 1 selected from the group
consisting of: 1)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(2-pyr-
idyl)-1,3-benzothiazol-2-yl]urea; 2)
1-ethyl-3-[7-[4-[(3-hydroxy-3-methyl-azetidin-1-yl)methyl]-2-pyridyl]-5-[-
2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
3)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(tetrahydrofu-
ran-2-ylmethoxy)-1,3-benzothiazol-2-yl]urea; 4)
1-ethyl-3-[6-fluoro-5-[6-[hydroxy(3-pyridyl)methyl]-3-pyridyl]-1,3-benzot-
hiazol-2-yl]urea; 5)
1-(2-hydroxyethyl)-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(2-
-pyridyl)-1,3-benzothiazol-2-yl]urea; 6)
1-ethyl-3-[5-[5-(1-hydroxyethyl)pyrazin-2-yl]-7-(2-pyridyl)-1,3-benzothia-
zol-2-yl]urea; 7)
1-[5-[2-[(1S*,2R*)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3--
benzothiazol-2-yl]-3-ethyl-urea (mixture
1-[5-[2-[(1S,2R)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]-3-ethyl-urea; and
1-[5-[2-[(1R,2S)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]-3-ethyl-urea); 8)
1-[5-[2-[(3R*,4S*)-3,4-dihydroxytetrahydropyran-4-yl]pyrimidin-5-yl]-7-(2-
-pyridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea (mixture
1-[5-[2-[(3R,4S)-3,4-dihydroxytetrahydropyran-4-yl]pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea; and
1-[5-[2-[(3S,4R)-3,4-dihydroxytetrahydropyran-4-yl]pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea); 9)
1-ethyl-3-[5-[4-(1-hydroxyethyl)triazol-1-yl]-7-(2-pyridyl)-1,3-benzothia-
zol-2-yl]urea; 10)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-pyrimidin-2-y-
l-1,3-benzothiazol-2-yl]urea; 11)
1-ethyl-3-[5-[4-(1-hydroxy-1-methyl-ethyl)imidazol-1-yl]-7-(2-pyridyl)-1,-
3-benzothiazol-2-yl]urea; 12)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-methoxy-1,3-b-
enzothiazol-2-yl]urea; 13)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(methoxymethy-
l)-1,3-benzothiazol-2-yl]urea; 14)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[(6-methyl-3-pyridyl)me-
thoxy]-1,3-benzothiazol-2-yl]urea; 15)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(methylsulfanylmethy-
l)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 16)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(methylsulfinylmethy-
l)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 17)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzoth-
iazol-2-yl]urea; 18)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl 4-methylpiperazine-1-carboxylate; 19)
4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]ethoxy]-4-oxo-butanoic acid; 20)
O4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyr-
imidin-2-yl]-1-methyl-ethyl] O1-methyl butanedioate; 21)
4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]-1-methyl-ethoxy]-4-oxo-butanoic acid; 22)
1-ethyl-3-[5-[2-[(1R)-1-hydroxyethyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]urea; 23)
1-ethyl-3-[5-[2-[(1S)-1-hydroxyethyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]urea; 24)
1-ethyl-3-[5-[6-[hydroxy-(1-methylimidazol-2-yl)methyl]-3-pyridyl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]urea; 25)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[5-(morpholin-
omethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 26)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(pyrrolidi-
n-1-ylmethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 27)
1-ethyl-3-[5-[6-(1-hydroxy-1-methyl-ethyl)-3-pyridyl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]urea; 28)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(morpholin-
omethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 29)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(3-hydrox-
ypyrrolidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 30)
1-ethyl-3-[7-[4-[(3-hydroxyazetidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydro-
xy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; 31)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(3-methox-
yazetidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 32)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(2-morphol-
inoethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 33)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(1-morphol-
inoethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 34)
1-[7-[4-[(3,3-difluoropyrrolidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxy--
1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
35)
1-ethyl-3-[7-[4-[[(3S)-3-fluoropyrrolidin-1-yl]methyl]-2-pyridyl]-5-[2-(1-
-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
36)
1-ethyl-3-[7-[4-[[(3R)-3-fluoropyrrolidin-1-yl]methyl]-2-pyridyl]-5-[2-(1-
-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
37)
1-[7-[4-[(3,3-difluoro-1-piperidyl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-1-m-
ethyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
38)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(3-morphol-
inopropoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 39)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-pyrazin-2-yl--
1,3-benzothiazol-2-yl]urea; 40)
1-[5-[2-(1,2-dihydroxyethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzothiazo-
l-2-yl]-3-ethyl-urea; 41)
1-[7-(dimethylaminomethyl)-6-hydroxy-5-[6-(1-hydroxy-1-methyl-ethyl)-3-py-
ridyl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; 42)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[[(3R)-3-m-
ethoxypyrrolidin-1-yl]methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
43)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(6-methylpyri-
midin-4-yl)-1,3-benzothiazol-2-yl]urea; 44)
1-ethyl-3-[6-hydroxy-5-[6-(1-hydroxy-1-methyl-ethyl)-3-pyridyl]-7-(morpho-
linomethyl)-1,3-benzothiazol-2-yl]urea; 45)
1-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]-3-pyridyl]-4-methyl-piperidine-4-carboxylic
acid; 46)
2-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)py-
rimidin-5-yl]-1,3-benzothiazol-7-yl]-3-pyridyl]acetic acid; 47)
1-ethyl-3-[5-[2-(1-hydroxycyclohexyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]urea; 48)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)thiazol-5-yl]-7-(2-pyridyl)-1,3-
-benzothiazol-2-yl]urea; 49)
1-ethyl-3-[5-[5-(1-hydroxy-1-methyl-ethyl)pyrazin-2-yl]-7-(2-pyridyl)-1,3-
-benzothiazol-2-yl]urea; 50)
1-[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]-4-pyridyl]-4-methyl-piperidine-4-carboxylic
acid; 51)
1-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)py-
rimidin-5-yl]-1,3-benzothiazol-7-yl]-2-pyridyl]-4-methyl-piperidine-4-carb-
oxylic acid; 52)
1-[4-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylic
acid; 53)
1-[7-[4-[(cyclopropylamino)methyl]-2-pyridyl]-5-[2-(1-hydroxy-1-
-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
54)
4-[[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-
-yl]-1,3-benzothiazol-7-yl]-4-pyridyl]amino]-1-methyl-cyclohexanecarboxyli-
c acid; 55)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(morpholinomethyl)-2-
-pyridyl]-1,3-benzothiazol-2-yl]urea; 56)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[5-(2-morphol-
inoethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 57)
1-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzo-
thiazol-2-yl]-3-propyl-urea; 58)
1-[5-[2-[cyclopropyl(hydroxy)methyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-ben-
zothiazol-2-yl]-3-ethyl-urea; 59)
1-ethyl-3-[5-[2-(1-hydroxypropyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzot-
hiazol-2-yl]urea; 60)
1-ethyl-3-[5-[2-(1-hydroxy-2,2-dimethyl-propyl)pyrimidin-5-yl]-7-(2-pyrid-
yl)-1,3-benzothiazol-2-yl]urea; 61)
1-ethyl-3-[5-[2-(1-hydroxybutyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzoth-
iazol-2-yl]urea 62)
[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] (2R)-2-amino-3-methyl-butanoate; 63)
[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] (2R)-2-amino-3-methyl-butanoate; 64)
1-ethyl-3-[7-[4-[[(3S)-3-fluoropyrrolidin-1-yl]methyl]-2-pyridyl]-5-[2-(1-
-hydroxyethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; 65)
1-ethyl-3-[7-[4-[(3-hydroxyazetidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydro-
xyethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; 66)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(3-hydroxy-3-methyl-
-azetidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 67)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(3-hydrox-
y-3-methyl-pyrrolidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
68)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(3-methylmorpho-
lin-4-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 69)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-(1-h-
ydroxyethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
70)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(2,2,3,3,5,5,6,6-oc-
tadeuteriomorpholin-4-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
71)
1-[7-[4-[(2,5-dimethylmorpholin-4-yl)methyl]-2-pyridyl]-5-[2-(1-hydro-
xyethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; 72)
(2S)-1-[[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxyethyl)pyrimidin-5-yl]--
1,3-benzothiazol-7-yl]-4-pyridyl]methyl]pyrrolidine-2-carboxylic
acid; 73)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(6-oxa-2-azaspiro[3.-
3]heptan-2-ylmethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 74)
1-[5-[2-(ethylcarbamoylamino)-7-[4-(1-hydroxy-1-methyl-ethyl)-2-pyridyl]--
1,3-benzothiazol-5-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylic
acid; 75)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(2-morphol-
inoethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 76)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(3-methoxyazetidin--
1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 77)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[[(3R)-3-hydroxypyrr-
olidin-1-yl]methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 78)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(2-methoxy-
ethylamino)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; 79)
1-ethyl-3-[7-[4-(4-ethylpiperazin-1-yl)pyrimidin-2-yl]-5-[2-(1-hydroxy-1--
methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; 80)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(2-methoxy-
ethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 81)
1-ethyl-3-[5-[2-(1-hydroxy-2-morpholino-ethyl)pyrimidin-5-yl]-7-(2-pyridy-
l)-1,3-benzothiazol-2-yl]urea; 82)
1-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzo-
thiazol-2-yl]-3-methyl-urea; 83)
1-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzothiazol-2--
yl]-3-methyl-urea; 84)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(3-hydroxy-3-methyl-
-pyrrolidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 85)
1-ethyl-3-[7-[4-(2-hydroxyethylamino)pyrimidin-2-yl]-5-[2-(1-hydroxy-1-me-
thyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; 86)
1-ethyl-3-[7-[4-(3-hydroxy-3-methyl-azetidin-1-yl)pyrimidin-2-yl]-5-[2-(1-
-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
87)
1-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]pyrimidin-4-yl]-4-methyl-piperidine-4-carboxylic
acid; 88)
1-[5-[2-(ethylcarbamoylamino)-7-[4-(1-hydroxyethyl)-2-pyridyl]--
1,3-benzothiazol-5-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylic
acid; 89)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-
-yl]pyrimidin-2-yl]-1-methyl-ethyl]
4-methylpiperazine-1-carboxylate; 90)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(4-hydroxy-2-pyridyl)-1-
,3-benzothiazol-2-yl]urea; 91)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(2-morphol-
inoethylamino)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; 92)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(2-methoxyethoxy)-2--
pyridyl]-1,3-benzothiazol-2-yl]urea; 93)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(3-methoxyazetidin-1-
-yl)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; 94)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(4-morpholinopyrimidin--
2-yl)-1,3-benzothiazol-2-yl]urea; 95)
1-ethyl-3-[5-[6-(1-hydroxyethyl)-3-pyridyl]-7-(2-pyridyl)-1,3-benzothiazo-
l-2-yl]urea; 96)
1-ethyl-3-[7-(2-pyridyl)-5-[6-(2,2,2-trifluoro-1-hydroxy-ethyl)-3-pyridyl-
]-1,3-benzothiazol-2-yl]urea; 97)
1-[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]pyrimidin-4-yl]-4-methyl-piperidine-4-carboxylic
acid; 98)
1-ethyl-3-[5-[2-(1-ethyl-1-hydroxy-propyl)pyrimidin-5-yl]-7-(2--
pyridyl)-1,3-benzothiazol-2-yl]urea; 99)
1-[5-[2-(ethylcarbamoylamino)-7-[5-(1-hydroxy-1-methyl-ethyl)-2-pyridyl]--
1,3-benzothiazol-5-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylic
acid; 100)
1-[7-[4-(diethoxyphosphorylmethyl)-2-pyridyl]-5-[2-(1-hydroxyethyl)pyrimi-
din-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; 101)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(morpholin-
omethyl)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; 102)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[6-(morpholin-
omethyl)pyrazin-2-yl]-1,3-benzothiazol-2-yl]urea; 103)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(2-hydrox-
y-2-methyl-propyl)amino]pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea;
104)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(tetrahydrofuran-2-y-
lmethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 105)
1-ethyl-3-[7-[4-(3-hydroxyazetidin-1-yl)pyrimidin-2-yl]-5-[2-(1-hydroxyet-
hyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; 106)
1-ethyl-3-[7-(5-fluoro-4-morpholino-pyrimidin-2-yl)-5-[2-(1-hydroxyethyl)-
pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; 107)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[4-(2-meth-
oxyethyl)piperazin-1-yl]pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea;
108)
1-ethyl-3-[7-[4-(morpholinomethyl)-2-pyridyl]-5-[6-(2,2,2-trifluoro-1-hyd-
roxy-ethyl)-3-pyridyl]-1,3-benzothiazol-2-yl]urea; 109)
1-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-1,3-be-
nzothiazol-7-yl]pyrimidin-4-yl]-4-methyl-piperidine-4-carboxylic
acid; 110)
1-[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimid-
in-5-yl]-1,3-benzothiazol-7-yl]-4-pyridyl]piperidine-4-carboxylic
acid; 111)
1-ethyl-3-[5-[2-(4-hydroxytetrahydropyran-4-yl)pyrimidin-5-yl]-7-(2--
pyridyl)-1,3-benzothiazol-2-yl]urea; 112)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(2-oxa-7-azaspiro[3.-
5]nonan-7-ylmethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 113)
1-ethyl-3-[5-[2-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]urea; 114)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(3-methox-
y-3-methyl-azetidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
115)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-pyrimidin-2-yl-1,3-
-benzothiazol-2-yl]urea; 116)
1-ethyl-3-[7-[4-(2-morpholinoethoxy)-2-pyridyl]-5-[6-(2,2,2-trifluoro-1-h-
ydroxy-ethyl)-3-pyridyl]-1,3-benzothiazol-2-yl]urea; 117)
1-[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-1,3-be-
nzothiazol-7-yl]pyrimidin-4-yl]-4-methyl-piperidine-4-carboxylic
acid; 118)
1-[5-[2-[(1R*,2R*)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-
-1,3-benzothiazol-2-yl]-3-ethyl-urea (mixture
1-[5-[2-[(1R,2R)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]-3-ethyl-urea; and
1-[5-[2-[(1S,2S)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]-3-ethyl-urea); 119)
1-ethyl-3-[5-[2-(1-hydroxycyclopentyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]urea; 120)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[5-(morpholin-
omethyl)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; 121)
1-ethyl-3-[5-[2-[(1R)-1-hydroxyethyl]pyrimidin-5-yl]-7-[4-(morpholinometh-
yl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 122)
1-ethyl-3-[5-[2-[(1S)-1-hydroxyethyl]pyrimidin-5-yl]-7-[4-(morpholinometh-
yl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 123)
4-[3-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]oxetan-3-yl]oxy-4-oxo-butanoic acid; 124)
4-[2-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]-2-hydroxy-propoxy]-4-oxo-butanoic acid; 125)
1-ethyl-3-[5-[2-(4-hydroxytetrahydropyran-4-yl)pyrimidin-5-yl]-7-[4-(morp-
holinomethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 126)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl 2-aminoacetate; 127)
1-ethyl-3-[5-[2-(4-hydroxytetrahydrothiopyran-4-yl)pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]urea; 128)
1-ethyl-3-[5-[2-(4-hydroxy-1-methyl-4-piperidyl)pyrimidin-5-yl]-7-(2-pyri-
dyl)-1,3-benzothiazol-2-yl]urea; 129)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 2-(2-aminoethylamino)acetate; 130)
1-[5-[2-[(1R*,2S*)-3,3-difluoro-1,2-dihydroxy-propyl]pyrimidin-5-yl]-7-(2-
-pyridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea (mixture
1-[5-[2-[(1R,2S)-3,3-difluoro-1,2-dihydroxy-propyl]pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea; and
1-[5-[2-[(1S,2R)-3,3-difluoro-1,2-dihydroxy-propyl]pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea); 131)
1-ethyl-3-[7-(2-pyridyl)-5-[2-[(1R*,2S*)-3,3,3-trifluoro-1,2-dihydroxy-pr-
opyl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea (mixture
1-ethyl-3-[7-(2-pyridyl)-5-[2-[(1R,2S)-3,3,3-trifluoro-1,2-dihydroxy-prop-
yl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; and
1-ethyl-3-[7-(2-pyridyl)-5-[2-[(1S,2R)-3,3,3-trifluoro-1,2-dihydroxy-prop-
yl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea); 132)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] (2S)-2-aminopropanoate; 133)
4-[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl-
]pyrimidin-2-yl]ethoxy]-4-oxo-butanoic acid; 134)
4-[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl-
]pyrimidin-2-yl]ethoxy]-4-oxo-butanoic acid; 135)
1-[5-[2-(1,2-dihydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(morpholinomet-
hyl)-2-pyridyl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; 136)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl 2-amino-2-methyl-propanoate; 137)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl 3-aminopropanoate; 138) tert-butyl
4-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]-4-hydroxy-piperidine-1-carboxylate; 139)
1-ethyl-3-[5-[2-(4-hydroxy-1-oxo-thian-4-yl)pyrimidin-5-yl]-7-(2-pyridyl)-
-1,3-benzothiazol-2-yl]urea; 140)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 2-(dimethylamino)acetate; 141)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-l-methyl-ethyl] 2-morpholinoacetate; 142)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-[(1R-
)-1-hydroxyethyl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
143)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-[(1S-
)-1-hydroxyethyl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
144)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 5-aminopentanoate; 145)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 5-(dimethylamino)pentanoate; 146)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 2-aminoacetate; 147)
1-[7-[4-[(3,3-difluoroazetidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-1--
methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
148)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-(3-h-
ydroxyoxetan-3-yl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
149)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]py-
rimidin-2-yl]ethyl dihydrogen phosphate; 150)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyeth-
ylamino)-1,3-benzothiazol-2-yl]urea; 151)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-morpholino-1,-
3-benzothiazol-2-yl]urea; 152)
[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] dihydrogen phosphate; 153)
[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] dihydrogen phosphate; 154)
1-ethyl-3-[5-[2-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl]-7-[4-(morpholinomet-
hyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 155)
1-ethyl-3-[7-[4-[(3-methoxyazetidin-1-yl)methyl]-2-pyridyl]-5-[6-[2,2,2-t-
rifluoro-1-hydroxy-ethyl]-3-pyridyl]-1,3-benzothiazol-2-yl]urea;
156)
1-[7-[4-[(4,4-difluoro-1-piperidyl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-1-m-
ethyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
157)
1-[5-[2-[1,2-dihydroxy-1-methyl-ethyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]-3-ethyl-urea; 158)
1-ethyl-3-[5-[2-[1-hydroxyethyl]pyrimidin-5-yl]-7-(5-methyl-2-pyridyl)-1,-
3-benzothiazol-2-yl]urea; 159)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(4-methyl-
piperazin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 160)
[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] (2S)-pyrrolidine-2-carboxylate; 161)
[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] (2S)-pyrrolidine-2-carboxylate; 162)
tert-butyl
3-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]-3-hydroxy-azetidine-1-carboxylate; 163)
1-ethyl-3-[5-[2-(3-hydroxyazetidin-3-yl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-
-benzothiazol-2-yl]urea; 164)
1-[7-[4-1[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-(1--
hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea-
; 165)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]-
pyrimidin-2-yl]-1-methyl-ethyl]
2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetate; 166)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] (2S)-pyrrolidine-2-carboxylate; 167)
4-[3-[5-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-2-(-
ethylcarbamoylamino)-1,3-benzothiazol-5-yl]pyrimidin-2-yl]oxetan-3-yl]oxy--
4-oxo-butanoic acid; 168)
1-ethyl-3-[7-[5-(1-hydroxyethyl)-2-pyridyl]-5-[2-(1-hydroxyethyl)pyrimidi-
n-5-yl]-1,3-benzothiazol-2-yl]urea; 169)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 2-(2-morpholinoethylamino)acetate; 170)
2-[[2-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]-
pyrimidin-2-yl]-1-methyl-ethoxy]-2-oxo-ethyl]amino]acetic acid;
171)
(2S)-2-amino-4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothia-
zol-5-yl]pyrimidin-2-yl]-1-methyl-ethoxy]-4-oxo-butanoic acid; 172)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 4-aminobutanoate; 173)
1-ethyl-3-[5-[2-(4-hydroxy-1,1-dioxo-thian-4-yl)pyrimidin-5-yl]-7-(2-pyri-
dyl)-1,3-benzothiazol-2-yl]urea; 174)
1-ethyl-3-[5-[2-(4-hydroxy-4-piperidyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3--
benzothiazol-2-yl]urea; 175)
1-[7-[4-[(3-ethoxyazetidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-1-meth-
yl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; 176)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-methoxy-1,3-b-
enzothiazol-2-yl]urea; 177)
1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-be-
nzothiazol-2-yl]urea; 178)
1-ethyl-3-[7-(3-fluoro-4-methoxy-2-pyridyl)-5-[2-[1-hydroxyethyl]pyrimidi-
n-5-yl]-1,3-benzothiazol-2-yl]urea; 179)
3-[[2-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]-
pyrimidin-2-yl]-1-methyl-ethoxy]-2-oxo-ethyl]amino]propanoic acid;
180)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] (3R)-pyrrolidine-3-carboxylate; 181)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] (3R)-morpholine-3-carboxylate; 182)
1-[6-(cyclopropylmethoxy)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]--
1,3-benzothiazol-2-yl]-3-ethyl-urea; 183)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyeth-
oxy)-1,3-benzothiazol-2-yl]urea; 184)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 2-(2-phosphonooxyethylamino)acetate; 185)
1-ethyl-3-[5-[2-[1-hydroxyethyl]pyrimidin-5-yl]-7-[4-(thiomorpholinomethy-
l)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 186)
1-ethyl-3-[6-(2-hydroxyethoxy)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-
-yl]-1,3-benzothiazol-2-yl]urea; 187)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(thiomorph-
olinomethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; 188)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(1-oxo-1,-
4-thiazinan-4-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
189)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-[2-methoxyeth-
yl(methyl)amino]-1,3-benzothiazol-2-yl]urea; 190)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] dihydrogen phosphate; 191)
1-[7-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-
-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
192)
1-[6-[(3,4-dimethoxyphenyl)methoxy]-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimi-
din-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; 193)
1-ethyl-3-[5-[2-[1-hydroxyethyl]pyrimidin-5-yl]-6-(tetrahydrofuran-2-ylme-
thoxy)-1,3-benzothiazol-2-yl]urea; 194)
1-ethyl-3-[5-[2-[1-hydroxyethyl]pyrimidin-5-yl]-6-morpholino-1,3-benzothi-
azol-2-yl]urea; 195)
1-[7-[(3S)-3-aminopyrrolidin-1-yl]-5-[2-(l-hydroxy-1-methyl-ethyl)pyrimid-
in-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; 196)
1-ethyl-3-[7-[4-[(2-hydroxyethylamino)methyl]-2-pyridyl]-5-[2-(1-hydroxy--
1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; 197)
1-ethyl-3-[5-[5-(1-hydroxyethyl)-3-pyridyl]-7-(2-pyridyl)-1,3-benzothiazo-
l-2-yl]urea; 198)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(2,2,3,3,-
5,5,6,6-octadeuteriomorpholin-4-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-y-
l]urea; 199)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-morpholino-
ethoxy)-1,3-benzothiazol-2-yl]urea; 200)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyeth-
ylsulfanyl)-1,3-benzothiazol-2-yl]urea; 201)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyeth-
ylsulfinyl)-1,3-benzothiazol-2-yl]urea; and 202)
1-ethyl-3-[5-[2-[(1R)-1-hydroxyethyl]pyrimidin-5-yl]-7-(5-methoxy-2-pyrid-
yl)-1,3-benzothiazol-2-yl]urea; salts, racemates, diastereomers,
enantiomers, esters, carbamates, phosphates, sulfates, deuterated
forms and prodrugs thereof.
18. A method for the treatment of a bacterial infection comprising
administration of a compound as defined in any one of claims 1 to
17 or a pharmaceutically acceptable salt, racemate, diastereomer,
enantiomer, ester, carbamate, phosphate, sulfate, deuterated form
or prodrug thereof to a subject suffering from said infection.
19. A compound as defined in any one of claims 1 to 17 or a
pharmaceutically acceptable salt, racemate, diastereomer,
enantiomer, ester, carbamate, phosphate, sulfate, deuterated form
or prodrug thereof for use in the treatment of a bacterial
infection.
20. Use of a compound as defined in any one of claims 1 to 17 or a
pharmaceutically acceptable salt, racemate, diastereomer,
enantiomer, ester, carbamate, phosphate, sulfate, deuterated form
or prodrug thereof in the preparation of a medicament for the
treatment of a bacterial infection in a subject.
21. A method according to claim 18, a compound according to claim
19 or a use according to claim 20 wherein the bacterial infection
is a Gram-positive infection, Gram-negative infection, community
acquired bacterial pneumonia (CABP), hospital acquired bacterial
pneumonia (HABP), or ventilator acquired bacterial pneumonia
(VABP).
22. A method according to claim 18, a compound according to claim
19 or a use according to claim 20 wherein the bacterial infection
is a respiratory infection, a skin or skin structure infection, a
urinary tract infection, an intra-abdominal infection or a blood
stream infection.
23. An antibacterial agent comprising a compound as defined in any
one of claims 1 to 17 or a pharmaceutically acceptable salt,
racemate, diastereomer, enantiomer, ester, carbamate, phosphate,
sulfate, deuterated form or prodrug thereof.
24. A pharmaceutical composition comprising a compound as defined
in any one of claims 1 to 17 or a pharmaceutically acceptable salt,
racemate, diastereomer, enantiomer, ester, carbamate, phosphate,
sulfate, deuterated form or prodrug thereof and an excipient or
carrier.
25. A compound as defined in any one of claims 1 to 17 or a
pharmaceutically acceptable salt, racemate, diastereomer,
enantiomer, ester, carbamate, phosphate, sulfate, deuterated form
or prodrug thereof for use as a gyrase inhibitor.
26. A process for the manufacture of a compound as defined in any
one of claims 1 to 17 comprising the step(s) of: coupling an
intermediate of formula (i-a) with a precursor of formula (ii-a):
##STR00210## or alternatively coupling an intermediate of formula
(i-b) with a precursor of formula (ii-b): ##STR00211## under
coupling conditions wherein W.sub.1 and W.sub.2 are selected from
halo, boronic acid or a boronate ester thereof, a stannylated
moiety and triflate; Y.sub.1 and Y.sub.2 are selected from H, halo,
boronic acid or a boronate ester thereof, a stannylated moiety and
triflate; and ring A, ring B, Alk, X.sub.1, X.sub.2, X.sub.3,
R.sub.4, R.sub.5 and q are as defined in claim 1.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to a novel class of compounds,
their use as antibacterials, compositions comprising them and
processes for their manufacture.
BACKGROUND
[0002] Type II topoisomerases catalyse the interconversion of DNA
topoisomers by transporting one DNA segment through another.
Bacteria encode two type II topoisomerase enzymes, DNA gyrase and
DNA topoisomerase IV. Gyrase controls DNA supercoiling and relieves
topological stress. Topoisomerase IV decatenates daughter
chromosomes following replication and can also relax supercoiled
DNA. Bacterial type II topoisomerases form a heterotetrameric
complex composed of two subunits. Gyrase forms an A.sub.2B.sub.2
complex comprised of GyrA and GyrB whereas topoisomerase forms a
C.sub.2E.sub.2 complex comprised of ParC and ParE. In contrast
eukaryotic type II topoisomerases are homodimers. Ideally, an
antibiotic based on the inhibition of bacterial type II
topoisomerases would be selective for the bacterial enzymes and be
relatively inactive against the eukaryotic type II isomerases.
[0003] The type II topoisomerases are highly conserved enzymes
allowing the design of broad-spectrum inhibitors. Furthermore, the
GyrB and ParE subunits are functionally similar, having an ATPase
domain in the N-terminal domain and a C-terminal domain that
interacts with the other subunit (GyrA and ParC respectively) and
the DNA. The conservation between the gyrase and topoisomerase IV
active sites suggests that inhibitors of the sites might
simultaneously target both type II topoisomerases. Such
dual-targeting inhibitors are attractive because they have the
potential to reduce the development of target-based resistance.
[0004] Type II topoisomerases are the target of a number of
antibacterial agents. The most prominent of these agents are the
quinolones. The original quinolone antibiotics included nalidixic
acid, cinoxacin and oxolinic acid. The addition of fluorine yielded
a new class of drugs, the fluoroquinolones, which have a broader
antimicrobial spectrum and improved pharmacokinetic properties. The
fluoroquinolones include norfloxacin, ciprofloxacin, and fourth
generation quinolones gatifloxacin and moxifloxacin. The coumarins
and the cyclothialidines are further classes of antibiotics that
inhibit type II topoisomerases, however they are not widely used
because of poor permeability in bacteria, eukaryotic toxicity, and
low water solubility. Examples of such antibiotics include
novobiocin and coumermycin A1, cyclothialidine, cinodine, and
clerocidin.
[0005] Linezolid is currently the standard treatment for acute
bacterial skin and skin structure infections (ABSSSI) caused by
Gram-positive bacteria. It belongs to the class of oxazolidinones
and is a protein synthesis inhibitor.
[0006] However, the continual emergence of antibiotic resistance
demands that novel classes of antibiotics continue to be developed
and alternative compounds that inhibit bacterial topoisomerases are
required.
[0007] WO2007/148093, WO2009/074812, WO2009/074810 and
WO2012/045124 describe the applicant's earlier compounds that
inhibit bacterial gyrase activity. The applicant has now discovered
a class of related compounds that includes a carbocyclic or
heterocyclic ring comprising a branched i.e. secondary or tertiary
alcohol substituent and prodrugs thereof which appears to confer
advantage(s) to the compounds. One or more advantage(s) include
desirable pharmacokinetic properties, prodrugability, solubility
and introduced chirality to provide a further subclass of active
enantiomers.
SUMMARY
[0008] According to a first aspect there is provided a compound of
Formula (I)
##STR00002##
salts, racemates, diastereomers, enantiomers, esters, carbamates,
phosphates, sulfates, deuterated forms and prodrugs thereof wherein
X.sub.1 is N or C--R.sub.1, preferably C--R.sub.1 where R.sub.1 is
selected from H, OH, optionally substituted C.sub.1-3alkyl,
optionally substituted C.sub.2-3alkenyl, optionally substituted
C.sub.2-3 alkynyl, optionally substituted C.sub.1-3alkoxyl, halo,
haloC.sub.1-3alkyl, NH.sub.2, optionally substituted
NHC.sub.1-3alkyl, optionally substituted N(C.sub.1-3alkyl).sub.2,
optionally substituted SC.sub.1-3alkyl and CN;
##STR00003##
represents Ring A which is selected from saturated or unsaturated
monocyclic C.sub.3-7cycloalkyl, saturated or unsaturated monocyclic
3-7 membered heterocycle, saturated or unsaturated fused bicyclic
C.sub.8-10cycloalkyl, saturated or unsaturated fused bicyclic 8-10
membered-heterocyclyl, C.sub.6-10aryl and 5-10 membered heteroaryl
and may be optionally substituted; Z.sub.1 is a secondary or
tertiary alcohol of general formula
##STR00004##
an ester, carbamate, phosphate, sulfate or prodrug thereof as
defined below or Z.sub.1 is selected from H, OH, optionally
substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6alkynyl,
optionally substituted (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl halo, optionally
substituted haloC.sub.1-3alkyl, CN and optionally substituted
(CH.sub.2).sub.mNR.sup.aR.sup.b where each R.sup.a and R.sup.b is
independently selected from H, optionally substituted
C.sub.1-6alkyl, optionally substituted C.sub.3-6cycloalkyl and
optionally substituted 4-6-membered heterocyclyl or R.sup.a and
R.sup.b join together to form an optionally substituted
4-6-membered heterocyclyl and where each m is an integer
independently selected from 0, 1, 2 and 3; X.sub.2 is N or
C--R.sub.2, preferably C--R.sub.2 where R.sub.2 is selected from H,
OH, optionally substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-4alkenyl, optionally substituted C.sub.2-6 alkynyl,
optionally substituted (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mO(CH.sub.2).sub.mC.sub.3-7cycloalkyl, optionally
substituted (CH.sub.2).sub.mC.sub.3-7cycloalkyl, optionally
substituted (CH.sub.2).sub.mO(CH.sub.2).sub.mphenyl, optionally
substituted (CH.sub.2).sub.mphenyl, optionally substituted
(CH.sub.2).sub.mO(CH.sub.2).sub.m-5-10-membered heterocycle,
optionally substituted (CH.sub.2).sub.m-5-10-membered heterocyclyl,
halo, optionally substituted haloC.sub.1-3alkyl, CN and optionally
substituted (CH.sub.2).sub.mNR.sup.aR.sup.b; X.sub.3 is N or
C--R.sub.3, preferably C--R.sub.3 where R.sub.3 is selected from H,
OH, optionally substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6 alkynyl,
optionally substituted (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.m(CH.sub.2).sub.mC.sub.3-7cycloalkyl, optionally
substituted (CH.sub.2).sub.mC.sub.3-7cycloalkyl, optionally
substituted (CH.sub.2).sub.mO(CH.sub.2).sub.mphenyl, optionally
substituted (CH.sub.2).sub.mphenyl, optionally substituted
(CH.sub.2).sub.mO(CH.sub.2).sub.m-5-10-membered heterocycle,
optionally substituted (CH.sub.2).sub.m-5-10-membered heterocyclyl,
halo, optionally substituted haloC.sub.1-3 alkyl, CN and optionally
substituted (CH.sub.2).sub.mNR.sup.aR.sup.b or R.sub.3 is a group
of formula
##STR00005##
where * represents the point of attachment to the C ring atom; n is
an integer selected from 0, 1, 2 and 3;
##STR00006##
represents Ring B which is selected from saturated or unsaturated
monocyclic C.sub.3-7cycloalkyl, saturated or unsaturated monocyclic
3-7 membered heterocycle, saturated or unsaturated fused bicyclic
C.sub.8-10cycloalkyl, saturated or unsaturated fused bicyclic 8-10
membered-heterocyclyl, C.sub.6-10aryl and 5-10 membered heteroaryl
and may be optionally substituted; and Z.sub.2 is a secondary or
tertiary alcohol of general formula
##STR00007##
an ester, carbamate, phosphate, sulfate or prodrug thereof as
defined below or Z.sub.2 is selected from H, OH, optionally
substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6alkynyl,
optionally substituted (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl, CN, optionally substituted
(CH.sub.2).sub.mNR.sup.aR.sup.b, optionally substituted
(CH.sub.2).sub.p-4-6-membered heterocyclylic ring, optionally
substituted (CH.sub.2).sub.p-spiro-bicyclic-7-11-membered
heterocyclic ring and optionally substituted
##STR00008##
where p is an integer selected from 0, 1, 2 and 3 and
##STR00009##
represents an optionally substituted 4-6 membered heterocyclic ring
or an optionally substituted spiro bicyclic 7-11-membered
heterocyclic ring; and Alk is optionally substituted
C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl,
C.sub.3-6cycloalkyl; and with the proviso that Z.sub.1 or Z.sub.2
is a secondary or tertiary alcohol of general formula
##STR00010##
an ester, carbamate, phosphate, sulfate or prodrug thereof wherein
q is an integer selected from 0, 1, 2 and 3, preferably q is 0;
R.sub.4 is H or is selected from optionally substituted
C.sub.1-6alkyl, optionally substituted (C.sub.2-6alkenyl,
optionally substituted C.sub.2-6alkynyl, optionally substituted
(CH.sub.2).sub.tOC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tOC(.dbd.O)C.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl and optionally substituted
(CH.sub.2).sub.tNR.sup.aR.sup.b; R.sub.5 is selected from
optionally substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6alkynyl,
optionally substituted C.sub.3-7cycloalkyl ring, optionally
substituted phenyl, optionally substituted 4-6-membered
heterocyclyl ring, optionally substituted 5-6-membered heteroaryl
ring, optionally substituted (CH.sub.2).sub.tOC.sub.1-6alkyl,
optionally substituted (CH.sub.2).sub.tOC(.dbd.O)C.sub.1-6alkyl,
optionally substituted (CH.sub.2).sub.tSC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.tS(.dbd.O)C.sub.1-6alkyl, halo,
optionally substituted haloC.sub.1-3alkyl and optionally
substituted (CH.sub.2).sub.tNR.sup.aR.sup.b; t is an integer
selected from 1, 2, 3, 4, 5 and 6; or R.sub.4 and R.sub.5 together
with the carbon atom to which they are attached form an optionally
substituted 4-6-membered heterocyclic ring or C.sub.3-7cycloalkyl
ring; and * represents the point of attachment to Ring A or Ring B
respectively; and further wherein each (CH.sub.2) entity when
present may be independently optionally substituted.
[0009] In one embodiment there is provided a compound of Formula
(I), salts and prodrugs thereof.
[0010] In one embodiment Z.sub.1 is a secondary or tertiary alcohol
of general formula
##STR00011##
or prodrug thereof wherein the prodrug is selected from an ester,
carbamate, phosphate or sulfate formed from the hydroxyl
moiety.
[0011] According to a second aspect there is provided a method for
the treatment of a bacterial infection comprising administration of
a compound of Formula (I) or a pharmaceutically acceptable salt,
racemate, diastereomer, enantiomer, ester, carbamate, phosphate,
sulphate, deuterated form or prodrug thereof to a subject suffering
from said infection. In one embodiment, the infection is a Gram
positive bacterial infection. In a further embodiment the Gram
positive infection is caused by a bacterial strain selected from S.
aureus, E. faecalis and S. pyogenes, even more preferably S.
aureus. In another embodiment, the infection is a Gram negative
bacterial infection. In a further embodiment the Gram negative
infection is caused by a bacterial strain of H. influenzae, A.
baumannii, E. coli, K. pneumoniae, Legionella pneumophila,
Moraxella catarrhalis and Neisseria gonorrhoeae.
[0012] According to a third aspect there is provided a compound of
Formula (I) or a pharmaceutically acceptable salt, racemate,
diastereomer, enantiomer, ester, carbamate, phosphate, sulphate,
deuterated form or prodrug thereof for use in the treatment of a
bacterial infection.
[0013] According to a fourth aspect there is provided an
antibacterial agent comprising a compound of Formula (I) or a
pharmaceutically acceptable salt, racemate, diastereomer,
enantiomer, ester, carbamate, phosphate, sulphate, deuterated form
or prodrug thereof.
[0014] According to a fifth aspect there is provided a composition
comprising a compound of Formula (I) or a salt, racemate,
diastereomer, enantiomer, ester, carbamate, phosphate, sulphate,
deuterated form or prodrug thereof and an excipient or carrier. In
one embodiment the composition is a pharmaceutical composition, the
salt is a pharmaceutically acceptable salt and the excipient or
carrier is pharmaceutically acceptable.
[0015] According to a sixth aspect there is provided a compound of
Formula (I) or a pharmaceutically acceptable salt, racemate,
diastereomer, enantiomer, ester, carbamate, phosphate, sulphate,
deuterated form or prodrug thereof for use as a gyrase inhibitor.
In one embodiment the compound of Formula (I) is active against the
ATPase enzyme.
[0016] According to a seventh aspect there is provided a process
for the manufacture of a compound of Formula (I), salt, racemate,
diastereomer, enantiomer, ester, carbamate, phosphate, sulphate,
deuterated form or prodrug thereof comprising the step(s) of:
coupling an intermediate of formula (i-a) with a precursor of
formula (ii-a):
##STR00012##
or alternatively coupling an intermediate of formula (i-b) with a
precursor of formula (ii-b):
##STR00013##
under coupling conditions wherein W.sub.1 and W.sub.2 are selected
from halo (preferably Cl, Br and I), boronic acid or a boronate
ester thereof, a stannylated moiety and triflate; Y.sub.1 and
Y.sub.2 are selected from H, halo (preferably Cl, Br and I),
boronic acid or a boronate ester thereof, a stannylated moiety and
triflate; and ring A, ring B, Alk, X.sub.1, X.sub.2, X.sub.3,
R.sub.4, R.sub.5 and q are as previously defined.
[0017] In one embodiment, the process comprises the additional step
of forming an ester, carbamate, phosphate or sulphate of the
hydroxyl (alcohol) moiety.
[0018] According to an eighth aspect, there is provided a method of
treating bacterial contamination of a substrate comprising applying
to the site of such contamination an amount of a compound of
Formula (I) or a pharmaceutically acceptable salt, racemate,
diastereomer, enantiomer, ester, carbamate, phosphate, sulphate, or
deuterated form thereof sufficient to inhibit bacterial growth.
[0019] According to a ninth aspect, there is provided the use of a
compound of Formula (I) or a pharmaceutically acceptable salt,
racemate, diastereomer, enantiomer, ester, carbamate, phosphate,
sulphate, deuterated form or prodrug thereof in the preparation of
a medicament for the treatment of a bacterial infection in a
subject.
BRIEF DESCRIPTION OF THE FIGURES
[0020] FIG. 1: Shows the intravenous (IV) pharmacokinetic profile
in the rat assay, where the X axis denotes the time (hours) and the
Y axis denotes the plasma concentration (.mu.g/mL), of (A)
comparative Compound A against Compounds 1 and 17 of the invention;
and (B) comparative Compound B against Compound 27 of the
invention.
[0021] FIG. 2: Shows the comparative survival of mice dosed IV at
10 mg/kg with Compound 1 or Linezolid in the S. pneumoniae 9 day
lung infection model where the X axis denotes the number of days
and the Y axis denotes the percentage survival.
DETAILED DESCRIPTION
[0022] The present invention is predicated on the discovery of a
new class of compounds that have shown on-target gyrase enzyme
activity. Accordingly, in one embodiment the compounds of Formula
(I) are useful in modulating the activity of gyrase, more
particularly as gyrase inhibitors.
[0023] Compounds of this class also exhibit antibacterial activity,
more particularly antibacterial activity against strains of
Gram-positive and/or Gram-negative classes, such as staphylococci,
enterococci, streptococci and haemophili for example Staphylococcus
aureus, Staphylococcus epidermidis, Enterococcus faecalis,
Enterococcus faecium, Streptococcus pyogenes, Streptococcus
pneumoniae, Haemophilus influenzae, Acinetobacter baumannii,
Escherichia coli, Klebsiella pneumoniae, Legionella pneumophila,
Moraxella catarrhalis and Neisseria gonorrhoeae. The compounds with
which the invention is concerned are therefore useful for the
treatment of bacterial infection or contamination, for example in
the treatment of, inter alia, Gram-positive infections,
Gram-negative infections and community acquired bacterial
pneumonias (CABPs), hospital acquired bacterial pneumonias (HABPs)
and ventilator acquired bacterial pneuomias (VABPs). Accordingly,
in one embodiment the compounds of Formula (I) are useful in the
treatment of bacterial infections caused by Gram positive bacterial
strains. In another embodiment, the compounds of Formula (I) are
useful in the treatment of bacterial infections caused by Gram
negative bacterial strains. The sites of bacterial infections are
many and include respiratory infections, particularly lung
infections, skin and skin structure infections, urinary tract
infections, intra-abdominal infections and blood stream
(septicaemia) infections.
[0024] The development of antibacterial resistance is particularly
common in a hospital setting. Hospital patients are therefore
especially at risk of infection by resistant strains of
bacteria.
Definitions
[0025] Unless otherwise herein defined, the following terms will be
understood to have the general meanings which follow.
[0026] The term "C.sub.1-6alkyl" encompasses optionally substituted
straight chain or branched chain hydrocarbon groups having from 1,
2, 3, 4, 5 or 6 carbon atoms or a range comprising any of two of
those integers. Examples include methyl (Me), ethyl (Et), propyl
(Pr), isopropyl (i-Pr), butyl (Bu), isobutyl (i-Bu), sec-butyl
(s-Bu), tert-butyl (t-Bu), pentyl, neopentyl, hexyl and the like.
Unless the context requires otherwise, the term "C.sub.1-6alkyl"
also encompasses alkyl groups containing one less hydrogen atom
such that the group is attached via two positions i.e. divalent.
Such groups are also referred to as "C.sub.1-6alkylene" groups.
C.sub.1-3alkyl and C.sub.1-3alkylene groups are preferred.
[0027] The term "C.sub.2-6alkenyl" refers to optionally substituted
straight chain or branched chain hydrocarbon groups having at least
one double bond of either E or Z stereochemistry where applicable
and 2, 3, 4, 5 or 6 carbon atoms or a range comprising any of two
of those integers. Examples include vinyl, 1-propenyl, 1- and
2-butenyl, 2-methyl-2-propenyl, hexenyl, butadienyl, hexadienyl,
hexatrienyl and the like. Unless the context requires otherwise,
the term "C.sub.1-4alkenyl" also encompasses alkenyl groups
containing one less hydrogen atom such that the group is attached
via two positions i.e. divalent. Such groups are also referred to
as "C.sub.2-6alkenylene" groups. C.sub.2-3alkenyl and
C.sub.2-3alkenylene groups are preferred.
[0028] The term "C.sub.2-6alkynyl" refers to optionally substituted
straight chain or branched chain hydrocarbon groups having at least
one triple bond and 2, 3, 4, 5 or 6 carbon atoms or a range
comprising any of two of those integers. Examples include ethynyl,
1-propynyl, 1- and 2-butynyl, 2-methyl-2-propynyl, 2-pentynyl,
3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl
and the like. Unless the context indicates otherwise, the term
"C.sub.2-6alkynyl" also encompasses alkynyl groups containing one
less hydrogen atom such that the group is attached via two
positions i.e. divalent. Such groups are also referred to as
"C.sub.2-6alkynylene" groups. C.sub.2-3alkynyl and
C.sub.2-3alkynylene groups are preferred.
[0029] The term "C.sub.3-8cycloalkyl" refers to non-aromatic cyclic
hydrocarbon groups having from 3, 4, 5, 6, 7 or 8 carbon atoms or a
range comprising any of two of those integers, including
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl,
cycloheptyl and the like. It will be understood that cycloalkyl
groups may be saturated such as cyclohexyl or unsaturated such as
cyclohexenyl. C.sub.3-6cycloalkyl groups are preferred.
[0030] The terms "hydroxy" and "hydroxyl" refer to the group
--OH.
[0031] The term "oxo" refers to the group .dbd.O.
[0032] The term "C.sub.1-6alkoxyl" refers to the group
OC.sub.1-6alkyl. Examples include methoxy, ethoxy, propoxy,
isoproxy, butoxy, tert-butoxy, pentoxy and the like. The oxygen
atom may be located along the hydrocarbon chain, and need not be
the atom linking the group to the remainder of the compound.
C.sub.1-3alkoxyl groups are preferred.
[0033] The term "aryloxy" refers to the group --Oaryl and may
include variations thereof such as "alkoxyaryl", wherein aryl is
defined herein. Examples include, but are not limited to, phenoxy
and naphthoxy and benzyloxy.
[0034] The terms "halo", "halogen", "halogenated" and similar terms
refers to fluoro, chloro, bromo and iodo (F, Cl, Br, I).
[0035] The term "C.sub.1-6alkylhalo" refers to a C.sub.1-6alkyl
which is substituted with one or more halogens. C.sub.1-3alkylhalo
groups are preferred, such as for example, --CHF.sub.2 and
--CF.sub.3.
[0036] The term "C.sub.1-6alkoxylhalo" refers to a C.sub.1-4alkoxyl
which is substituted with one or more halogens.
C.sub.1-3alkoxylhalo groups are preferred, such as for example,
--OCHF.sub.2 and --OCF.sub.3.
[0037] The term "carboxylate" or "carboxyl" refers to the group
--COO.sup.- or --COOH.
[0038] The term "ester" refers to a carboxyl group having the
hydrogen replaced with, for example a C.sub.1-6alkyl group
("carboxylC.sub.1-6-alkyl" or "alkylester"), an aryl or aralkyl
group ("arylester" or "aralkylester") and so on. Examples include
but are not limited to CO.sub.2C.sub.1-3alkyl, such as for example,
methylester (CO.sub.2Me), ethylester (CO.sub.2Et) and propylester
(CO.sub.2Pr) and includes reverse esters thereof (e.g. --OCOMe,
--OCOEt and --OCOPr).
[0039] The term "cyano" refers to the group --CN.
[0040] The term "nitro" refers to the group --NO.sub.2.
[0041] The term "amino" refers to the group --NH.sub.2.
[0042] The term "substituted amino" or "secondary amino" refers to
an amino group having a hydrogen replaced with, for example a
C.sub.1-6alkyl group ("C.sub.1-6alkylamino"), an aryl or aralkyl
group ("arylamino", "aralkylamino") and so on. C.sub.1-3alkylamino
groups are preferred, such as for example, methylamino (NHMe),
ethylamino (NHEt) and propylamino (NHPr).
[0043] The term "disubstituted amino" or "tertiary amino" refers to
an amino group having the two hydrogens replaced with, for example
a C.sub.1-6alkyl group, which may be the same or different
("dialkylamino"), an aryl and alkyl group ("aryl(alkyl)amino") and
so on. Di(C.sub.1-3alkyl)amino groups are preferred, such as for
example, dimethylamino (NMe.sub.2), diethylamino (NEt.sub.2),
dipropylamino (NPr.sub.2) and variations thereof (e.g. N(Me)(Et)
and so on).
[0044] The term "acyl" or "aldehyde" refers to the group
--C(.dbd.O)H.
[0045] The term "substituted acyl" or "ketone" refers to an acyl
group having a hydrogen replaced with, for example a C.sub.1-6alkyl
group ("C.sub.1-6alkylacyl" or "alkylketone" or "ketoalkyl"), an
aryl group ("arylketone"), an aralkyl group ("aralkylketone") and
so on. C.sub.1-3alkylacyl groups are preferred.
[0046] The term "amido" or "amide" refers to the group
--C(O)NH.sub.2.
[0047] The term "aminoacyl" refers to the group --NHC(O)H.
[0048] The term "substituted amido" or "substituted amide" refers
to an amido group having a hydrogen replaced with, for example a
C.sub.1-6alkyl group ("C.sub.1-6alkylamido" or
"C.sub.1-6alkylamide"), an aryl ("arylamido"), aralkyl group
("aralkylamido") and so on. C.sub.1-3alkylamide groups are
preferred, such as for example, methylamide (--C(O)NHMe),
ethylamide (--C(O)NHEt) and propylamide (--C(O)NHPr) and includes
reverse amides thereof (e.g. --NHMeC(O)--, --NHEtC(O)-- and
--NHPrC(O)--).
[0049] The term "disubstituted amido" or "disubstituted amide"
refers to an amido group having the two hydrogens replaced with,
for example a C.sub.1-6alkyl group ("di(C.sub.1-6 alkyl)amido") or
"di(C.sub.1-6alkyl)amide"), an aralkyl and alkyl group
("alkyl(aralkyl)amido") and so on. Di(C.sub.1-3alkyl)amide groups
are preferred, such as for example, dimethylamide
(--C(O)NMe.sub.2), diethylamide (--C(O)NEt.sub.2) and dipropylamide
(--C(O)NPr.sub.2) and variations thereof (e.g. --C(O)N(Me)Et and so
on) and includes reverse amides thereof.
[0050] The term "carbamic acid" refers to the group
NH.sub.2CO.sub.2H.
[0051] The term "carbamate" refers to a carbamic acid group having
one or both amino hydrogens independently replaced with, for
example a C.sub.1-6alkyl group ("C.sub.1-6alkyl carbamate"), an
aryl ("arylcarbamate"), aralkyl group ("aralkylcarbamate") and so
on.
[0052] The term "thiol" refers to the group --SH.
[0053] The term "C.sub.1-6alkylthio" refers to a thiol group having
the hydrogen replaced with a C.sub.1-6alkyl group.
C.sub.1-3alkylthio groups are preferred, such as for example,
thiolmethyl, thiolethyl and thiolpropyl.
[0054] The term "thioxo" refers to the group .dbd.S.
[0055] The term "sulfinyl" refers to the group --S(.dbd.O)H.
[0056] The term "substituted sulfinyl" or "sulfoxide" refers to a
sulfinyl group having the hydrogen replaced with, for example a
C.sub.1-6alkyl group ("C.sub.1-6alklkylsulfinyl" or
"C.sub.1-6alkylsulfoxide"), an aryl ("arylsulfinyl"), an aralkyl
("aralkyl sulfinyl") and so on. C.sub.1-3alkylsulfinyl groups are
preferred, such as for example, --SOmethyl, --SOethyl and
--SOpropyl.
[0057] The term "sulfonyl" refers to the group --SO.sub.2H.
[0058] The term "substituted sulfonyl" refers to a sulfonyl group
having the hydrogen replaced with, for example a C.sub.1-6alkyl
group ("sulfonylC.sub.1-6alkyl"), an aryl ("arylsulfonyl"), an
aralkyl ("aralkylsulfonyl") and so on. SulfonylC.sub.1-3alkyl
groups are preferred, such as for example, --SO.sub.2Me,
--SO.sub.2Et and --SO.sub.2Pr.
[0059] The term "sulfonylamido" or "sulfonamide" refers to the
group --SO.sub.2NH.sub.2.
[0060] The term "substituted sulfonamido" or "substituted
sulphonamide" refers to an sulfonylamido group having a hydrogen
replaced with, for example a C.sub.1-6alkyl group
("sulfonylamidoC.sub.1-6alkyl"), an aryl ("arylsulfonamide"),
aralkyl ("aralkylsulfonamide") and so on.
SulfonylamidoC.sub.1-3alkyl groups are preferred, such as for
example, --SO.sub.2NHMe, --SO.sub.2NHEt and --SO.sub.2NHPr and
includes reverse sulfonamides thereof (e.g. --NHSO.sub.2Me,
--NHSO.sub.2Et and --NHSO.sub.2Pr).
[0061] The term "disubstituted sulfonamido" or "disubstituted
sulphonamide" refers to a sulfonylamido group having the two
hydrogens replaced with, for example a C.sub.1-6alkyl group, which
may be the same or different ("sulfonylamidodi(C.sub.1-6alkyl)"),
an aralkyl and alkyl group ("sulfonamido(aralkyl)alkyl") and so on.
Sulfonylamidodi(C.sub.1-3alkyl) groups are preferred, such as for
example, --SO.sub.2NMe.sub.2, --SO.sub.2NEt.sub.2 and
--SO.sub.2NPr.sub.2 and variations thereof (e.g. --SO.sub.2N(Me)Et
and so on) and includes reverse sulfonamides thereof.
[0062] The term "sulfate" refers to the group OS(O).sub.2OH and
includes groups having the hydrogen replaced with, for example a
C.sub.1-6-alkyl group ("alkylsulfates"), an aryl ("arylsulfate"),
an aralkyl ("aralkylsulfate") and so on. C.sub.1-3sulfates are
preferred, such as for example, OS(O).sub.2OMe, OS(O).sub.2OEt and
OS(O).sub.2OPr.
[0063] The term "sulfonate" refers to the group SO.sub.3H and
includes groups having the hydrogen replaced with, for example a
C.sub.1-6alkyl group ("alkylsulfonate"), an aryl ("arylsulfonate"),
an aralkyl ("aralkylsulfonate") and so on. C.sub.1-3sulfonates are
preferred, such as for example, SO.sub.3Me, SO.sub.3Et and
SO.sub.3Pr.
[0064] The term "phosphate" refers to a group --OP(O)(OH).sub.2 and
includes groups having each hydrogen independently replaced with,
for example a C.sub.1-6alkyl group ("alkylphosphate"), an aryl
("arylphosphate"), an aralkyl ("aralkylphosphate") and so on.
[0065] The term "phosphonate" refers to a group --P(O)(OH).sub.2
and includes groups having each hydrogen independently replaced
with, for example a C.sub.1-6alkyl group ("alkylphosphonate"), an
aryl ("arylphosphonate"), an aralkyl ("aralkylphosphpmate") and so
on.
[0066] The term "aryl" refers to any group containing a carbocyclic
(non-heterocyclic) aromatic ring and may be a mono-, bi- or
tri-cyclic ring system. The aromatic ring or ring system is
generally composed of 6 or 10 carbon atoms. Such groups may contain
fused ring systems (such as naphthyl, tetrahydronaphthyl,
fluorenyl, indenyl, azulenyl, anthracenyl and the like), linked
ring systems (such as biphenyl groups), and may be substituted or
unsubstituted. Examples of aryl groups include, but are not limited
to, phenyl, biphenyl, naphthyl and tetrahydronaphthyl. Phenyl is
preferred.
[0067] The term "aralkyl" refers to an aryl group substituted with
a C.sub.1-6alkyl group.
[0068] Examples include benzyl and phenethyl.
[0069] The term "heterocyclyl" refers to a moiety obtained by
removing a hydrogen atom from a ring atom of a heterocyclic
compound which moiety has from 3 to 10 ring atoms (unless otherwise
specified), of which 1, 2, 3 or 4 are ring heteroatoms each
heteroatom being independently selected from O, S and N.
[0070] In this context, the prefixes 3-, 4-, 5-, 6-, 7-, 8-, 9- and
10-membered denote the number of ring atoms, or range of ring
atoms, whether carbon atoms or heteroatoms.
[0071] For example, the term "3-10 membered heterocyclyl", as used
herein, pertains to a heterocyclyl group having 3, 4, 5, 6, 7, 8, 9
or 10 ring atoms or a range comprising any of two of those
integers. Examples of heterocyclyl groups include 5-6-membered
monocyclic heterocyclyls and 9-10 membered fused bicyclic
heterocyclyls.
[0072] Examples of monocyclic heterocyclyl groups include, but are
not limited to, those containing one nitrogen atom such as
aziridine (3-membered ring), azetidine (4-membered ring),
pyrrolidine (tetrahydropyrrole), pyrroline (e.g., 3-pyrroline,
2,5-dihydropyrrole), 2H-pyrrole or 3H-pyrrole (isopyrrole,
isoazole) or pyrrolidinone (5-membered rings), piperidine,
dihydropyridine, tetrahydropyridine (6-membered rings), and azepine
(7-membered ring); those containing two nitrogen atoms such as
imidazoline, pyrazolidine (diazolidine), imidazoline, pyrazoline
(dihydropyrazole) (5-membered rings), piperazine (6-membered ring);
those containing one oxygen atom such as oxirane (3-membered ring),
oxetane (4-membered ring), oxolane (tetrahydrofuran), oxole
(dihydrofuran) (5-membered rings), oxane (tetrahydropyran),
dihydropyran, pyran (6-membered rings), oxepin (7-membered ring);
those containing two oxygen atoms such as dioxolane (5-membered
ring), dioxane (6-membered ring), and dioxepane (7-membered ring);
those containing three oxygen atoms such as trioxane (6-membered
ring); those containing one sulfur atom such as thiirane
(3-membered ring), thietane (4-membered ring), thiolane
(tetrahydrothiophene) (5-membered ring), thiane
(tetrahydrothiopyran) (6-membered ring), thiepane (7-membered
ring); those containing one nitrogen and one oxygen atom such as
tetrahydrooxazole, dihydrooxazole, tetrahydroisoxazole,
dihydroisoxazole (5-membered rings), morpholine, tetrahydrooxazine,
dihydrooxazine, oxazine (6-membered rings); those containing one
nitrogen and one sulfur atom such as thiazoline, thiazolidine
(5-membered rings), thiomorpholine (6-membered ring); those
containing two nitrogen and one oxygen atom such as oxadiazine
(6-membered ring); those containing one oxygen and one sulfur such
as: oxathiole (5-membered ring) and oxathiane (thioxane)
(6-membered ring); and those containing one nitrogen, one oxygen
and one sulfur atom such as oxathiazine (6-membered ring).
[0073] Heterocyclyls also encompass aromatic heterocyclyls and
non-aromatic heterocyclyls.
[0074] Such groups may be substituted or unsubstituted.
[0075] The term "aromatic heterocyclyl" may be used interchangeably
with the term "heteroaromatic" or the term "heteroaryl" or
"hetaryl". The heteroatoms in the aromatic heterocyclyl group may
be independently selected from N, S and O. "Heteroaryl" is used
herein to denote a heterocyclic group having aromatic character and
embraces aromatic monocyclic ring systems and polycyclic (e.g.
bicyclic) ring systems containing one or more aromatic rings. The
term aromatic heterocyclyl also encompasses pseudoaromatic
heterocyclyls. The term "pseudoaromatic" refers to a ring system
which is not strictly aromatic, but which is stabilized by means of
delocalization of electrons and behaves in a similar manner to
aromatic rings. The term aromatic heterocyclyl therefore covers
polycyclic ring systems in which all of the fused rings are
aromatic as well as ring systems where one or more rings are
non-aromatic, provided that at least one ring is aromatic. In
polycyclic systems containing both aromatic and non-aromatic rings
fused together, the group may be attached to another moiety by the
aromatic ring or by a non-aromatic ring.
[0076] Examples of heteroaryl groups are monocyclic and bicyclic
groups containing from five to ten ring members. The heteroaryl
group can be, for example, a five membered or six membered
monocyclic ring or a bicyclic structure formed from fused five and
six membered rings or two fused six membered rings or two fused
five membered rings. Each ring may contain up to about four
heteroatoms typically selected from nitrogen, sulfur and oxygen.
The heteroaryl ring will contain up to 4 heteroatoms, more
typically up to 3 heteroatoms, more usually up to 2, for example a
single heteroatom. In one embodiment, the heteroaryl ring contains
at least one ring nitrogen atom. The nitrogen atoms in the
heteroaryl rings can be basic, as in the case of an imidazole or
pyridine, or essentially non-basic as in the case of an indole or
pyrrole nitrogen. In general the number of basic nitrogen atoms
present in the heteroaryl group, including any amino group
substituents of the ring, will be less than five. Aromatic
heterocyclyl groups may be 5-membered or 6-membered mono-cyclic
aromatic ring systems.
[0077] Examples of 5-membered monocyclic heteroaryl groups include
but are not limited to furanyl, thienyl, pyrrolyl, oxazolyl,
oxadiazolyl (including 1,2,3 and 1,2,4 oxadiazolyls and furazanyl
i.e. 1,2,5-oxadiazolyl), thiazolyl, isoxazolyl, isothiazolyl,
pyrazolyl, imidazolyl, triazolyl (including 1,2,3, 1,2,4 and 1,3,4
triazolyls), oxatriazolyl, tetrazolyl, thiadiazolyl (including
1,2,3 and 1,3,4 thiadiazolyls) and the like.
[0078] Examples of 6-membered monocyclic heteroaryl groups include
but are not limited to pyridinyl, pyrimidinyl, pyridazinyl,
pyrazinyl, triazinyl, pyranyl, oxazinyl, dioxinyl, thiazinyl,
thiadiazinyl and the like. Examples of 6-membered heteroaryl groups
containing nitrogen include pyridyl (1 nitrogen), pyrazinyl,
pyrimidinyl and pyridazinyl (2 nitrogens). It will be understood
that, such as in the case of pyridyl when substituted with an oxo
(.dbd.O) substituted the group may be interchangeably referred to
as a pyridinone group.
[0079] Aromatic heterocyclyl groups may also be bicyclic or
polycyclic heteroaromatic ring systems such as fused ring systems
(including purine, pteridinyl, napthyridinyl, 1H
thieno[2,3-c]pyrazolyl, thieno[2,3-b]furyl and the like) or linked
ring systems (such as oligothiophene, polypyrrole and the like).
Fused ring systems may also include aromatic 5-membered or
6-membered heterocyclyls fused to carbocyclic aromatic rings such
as phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl and
the like, such as 5- or 6-membered aromatic heterocyclyls fused to
a phenyl ring including 5-membered aromatic heterocyclyls
containing nitrogen fused to a phenyl ring, 5-membered aromatic
heterocyclyls containing 1 or 2 nitrogens fused to a phenyl ring
and such as 5- or 6-membered aromatic heteroaryls fused to a
6-membered aromatic or non-aromatic heterocyclyls.
[0080] A bicyclic heteroaryl group may be, for example, a group
selected from: a) a benzene ring fused to a 5- or 6-membered ring
containing 1, 2 or 3 ring heteroatoms; b) a pyridine ring fused to
a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; c) a
pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2
ring heteroatoms; d) a pyrrole ring fused to a 5- or 6-membered
ring containing 1, 2 or 3 ring heteroatoms; e) a pyrazole ring
fused to a 5- or 6-membered ring containing 1 or 2 ring
heteroatoms; f) an imidazole ring fused to a 5- or 6-membered ring
containing 1 or 2 ring heteroatoms; g) an oxazole ring fused to a
5- or 6-membered ring containing 1 or 2 ring heteroatoms; h) an
isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2
ring heteroatoms; i) a thiazole ring fused to a 5- or 6-membered
ring containing 1 or 2 ring heteroatoms; j) an isothiazole ring
fused to a 5- or 6-membered ring containing 1 or 2 ring
heteroatoms; k) a thiophene ring fused to a 5- or 6-membered ring
containing 1, 2 or 3 ring heteroatoms; l) a furan ring fused to a
5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; m) a
cyclohexyl ring fused to a 5- or 6-membered ring containing 1, 2 or
3 ring heteroatoms; and n) a cyclopentyl ring fused to a 5- or
6-membered ring containing 1, 2 or 3 ring heteroatoms.
[0081] Particular examples of bicyclic heteroaryl groups containing
a five membered ring fused to another five membered ring i.e.
8-membered fused bicyclic rings include but are not limited to
imidazothiazole (e.g. imidazo[2,1-b]thiazole) and imidazoimidazole
(e.g. imidazol[1,2-a]imidazole).
[0082] Particular examples of bicyclic heteroaryl groups containing
a six membered ring fused to a five membered ring i.e. 9-membered
fused bicyclic rings include but are not limited to benzofuran,
benzothiophene, benzimidazole, benzoxazole, isobenzoxazole,
benzisoxazole, benzothiazole, benzisothiazole, isobenzofuran,
indole, isoindole, indolizine, indoline, isoindoline, purine (e.g.,
adenine, guanine), indazole, imidazopyridine (e.g.
imidazo[1,2-a]pyridine and imidazo[4,5-b]pyridine],
pyrazolopyrimidine (e.g. pyrazolo[1,5-a]pyrimidine), benzodioxole
and pyrazolopyridine (e.g. pyrazolo[1,5-a]pyridine) groups. A
further example of a six membered ring fused to a five membered
ring is a pyrrolopyridine group such as a pyrrolo[2,3-b]pyridine
group.
[0083] Particular examples of bicyclic heteroaryl groups containing
two fused six membered rings i.e. 10-membered fused bicyclic rings
include but are not limited to quinoline, isoquinoline, chroman,
thiochroman, chromene (including optionally substituted with oxo
(.dbd.O) i.e. oxochromene), isochromene, isochroman, benzodioxan,
quinolizine, benzoxazine, benzodiazine, pyridopyridine,
quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and
pteridine groups.
[0084] Examples of heteroaryl groups containing an aromatic ring
and a non-aromatic ring include tetrahydronaphthalene,
tetrahydroisoquinoline, tetrahydroquinoline, dihydrobenzothiophene,
dihydrobenzofuran, 2,3-dihydro-benzo[1,4]dioxine,
benzo[1,3]dioxole, 4,5,6,7-tetrahydrobenzofuran, indoline,
isoindoline and indane groups.
[0085] Examples of aromatic heterocyclyls fused to carbocyclic
aromatic rings may therefore include but are not limited to
benzothiophenyl, indolyl, isoindolyl, benzofuranyl,
isobenzofuranyl, benzimidazolyl, indazolyl, benzoxazolyl,
benzisoxazolyl, isobenzoxazoyl, benzothiazolyl, benzisothiazolyl,
quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl,
benzotriazinyl, phthalazinyl, carbolinyl and the like.
[0086] The term "non-aromatic heterocyclyl" encompasses optionally
substituted saturated and unsaturated rings which contain at least
one heteroatom selected from the group consisting of N, S and
O.
[0087] Non-aromatic heterocyclyls may be 3-7 membered mono-cyclic
rings. The term "3-7 membered monocyclic", as used herein, pertains
to a mono-cyclic group having 3, 4, 5, 6 or 7 ring atoms or a range
comprising any of two of those integers. Examples of 5-membered
non-aromatic heterocyclyl rings include 2H-pyrrolyl, 1-pyrrolinyl,
2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1-pyrrolidinyl,
2-pyrrolidinyl, 3-pyrrolidinyl, tetrahydrofuranyl,
tetrahydrothiophenyl, pyrazolinyl, 2-pyrazolinyl, 3-pyrazolinyl,
pyrazolidinyl, 2-pyrazolidinyl, 3-pyrazolidinyl, imidazolidinyl,
3-dioxalanyl, thiazolidinyl, isoxazolidinyl, 2-imidazolinyl and the
like.
[0088] Examples of 6-membered non-aromatic heterocyclyls include
piperidinyl, piperidinonyl, pyranyl, dihyrdopyranyl,
tetrahydropyranyl, 2H pyranyl, 4H pyranyl, thianyl, thianyl oxide,
thianyl dioxide, piperazinyl, diozanyl, 1,4-dioxinyl,
1,4-dithianyl, 1,3,5-triozalanyl, 1,3,5-trithianyl,
1,4-morpholinyl, thiomorpholinyl, 1,4-oxathianyl, triazinyl,
1,4-thiazinyl and the like.
[0089] Examples of 7-membered non-aromatic heterocyclyls include
azepanyl, oxepanyl, thiepanyl and the like.
[0090] Non-aromatic heterocyclyl rings may also be bicyclic
heterocyclyl rings such as linked ring systems (for example
uridinyl and the like) or fused ring systems. Fused ring systems
include non-aromatic 5-membered, 6-membered or 7-membered
heterocyclyls fused to carbocyclic aromatic rings such as phenyl,
naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like.
Examples of non-aromatic 5-membered, 6-membered or 7-membered
heterocyclyls fused to carbocyclic aromatic rings include
indolinyl, benzodiazepinyl, benzazepinyl, dihydrobenzofuranyl and
the like.
[0091] The term "spiro ring system" means a bicyclic ring system in
which the rings are connected via a single shared atom or
"spiroatom" more particularly a quaternary carbon ("spiro carbon")
and encompasses spiro bicyclic 7-11-membered carbocyclic rings and
spiro bicyclic 7-11-membered heterocyclic rings containing one,
two, three or four heteroatoms independently selected from O, N and
S.
[0092] The term "derived from an amino acid" refers to any side
chain that may be present in natural (L-) or unnatural (D-) amino
acids. Examples of amino acid side chain moieties derived from
natural amino acids, with the amino acids from which they are
derived shown in brackets, are --H (Glycine), --CH.sub.3 (Alanine),
--CH(CH.sub.3).sub.2 (Valine), --CH.sub.2CH(CH.sub.3).sub.2
(Leucine), --CH(CH.sub.3)CH.sub.2CH.sub.3 (Isoleucine),
--(CH.sub.2).sub.4NH.sub.2 (Lysine),
--(CH.sub.2).sub.3NHC(.dbd.NH)NH.sub.2 (Arginine),
--CH.sub.2-(5-1H-imidazolyl) (Histidine), --CH.sub.2CONH.sub.2
(Asparagine), --CH.sub.2CH.sub.2CONH.sub.2 (Glutamine),
--CH.sub.2COOH (Aspartic acid), --CH.sub.2CH.sub.2COOH (Glutamic
acid), --CH.sub.2-phenyl (Phenylalanine), --CH.sub.2-(4-OH-phenyl)
(Tyrosine), --CH.sub.2-(3-1H-indolyl) (Tryptophan), --CH.sub.2SH
(Cysteine), --CH.sub.2CH.sub.2SCH.sub.3 (Methioine), --CH.sub.2OH
(Serine), --CH(OH)CH.sub.3 (Threonine) and the cyclic side chain
pyrrolidinyl (Proline) whereby the covalent bond between the
nitrogen and carbon in the pyrrolidinyl ring forms the backbone.
Examples of amino acid side chain moieties derived from unnatural
amino acids, with the amino acids from which they are derived shown
in brackets, are --(CH.sub.2).sub.2--C(O)--O--C(CH.sub.3).sub.3
(glutamic acid t-butyl ester),
--(CH.sub.2).sub.4--NH--C(O)--O--C(CH.sub.3).sub.3
(N.sub..epsilon.-(tert-butoxycarbonyl)-lysine),
--(CH.sub.2).sub.3--NH--C(O)NH.sub.2 (citrulline),
--CH.sub.2--CH.sub.2OH (homoserine) and
--(CH.sub.2).sub.2--CH.sub.2NH.sub.2 (ornithine). Examples can also
include alkyl, alkenyl, alkynyl, aryl, saturated and unsaturated
heterocycles (functionalized and unfunctionalized). The term
"amino-acid side chain moiety" can also include a number of
unnatural amide and sulfonamide, aryl and heteroaryl side
chains.
[0093] Unless otherwise defined, the term "optionally substituted"
or "optional substituent" as used herein refers to a group which
may or may not be further substituted with 1, 2, 3, 4 or more
groups, preferably 1, 2 or 3, more preferably 1 or 2 groups
selected from the group consisting of C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkynyl, C.sub.3-8cycloalkyl, hydroxyl,
oxo, C.sub.1-6alkoxy, aryloxy, C.sub.1-6alkoxyaryl, halo,
C.sub.1-6alkylhalo (such as CF.sub.3 and CHF.sub.2),
C.sub.1-6alkoxyhalo (such as OCF.sub.3 and OCHF.sub.2), carboxylic
acid, carboxyl, esters, cyano, nitro, amino, mono substituted
amino, disubstituted amino, acyl, ketones, amides, aminoacyl,
substituted amides, disubstituted amides, carbamic acid,
carbamates, thiol, alkylthio, thioxo, sulfates, sulfonates,
sulfinyl, substituted sulfinyl, sulfonyl, substituted sulfonyl,
sulfonylamides, substituted sulfonamides, disubstituted
sulfonamides, phosphates, phosphonates, aryl, arC.sub.1-6alkyl,
heterocyclyl, heteroaryl and spiro ring systems wherein each alkyl,
alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl and
spiro ring system and groups containing them may be further
optionally substituted. Unless otherwise defined, particularly
preferred optional substituents in one embodiment of the invention
include 1, 2, 3 or 4, preferably 1 or 2 substituents each
independently selected from the group consisting of C.sub.1-4alkyl
(particularly methyl), halo (particularly F), haloC.sub.1-3alkyl
(particularly CHF.sub.2 and CF.sub.3), OH, C.sub.1-4alkoxyl
(particularly OCH.sub.3), CO.sub.2H, CO.sub.2C.sub.1-4alkyl
(particularly CO.sub.2CH.sub.3), NH.sub.2, NHC.sub.1-4alkyl
(particularly NHCH.sub.3), N(C.sub.1-4alkyl).sub.2 (particularly
N(CH.sub.3).sub.2), NHC(.dbd.O)C.sub.1-4alkyl,
NHC(.dbd.O)-4-6-membered heterocyclyl, OP(.dbd.O)(OR).sub.2 (where
each R is independently H or C.sub.1-4alkyl), P(.dbd.O)(OR).sub.2
(where each R is independently H or C.sub.1-4alkyl),
C.sub.3-6cycloalkyl (particularly cyclopropyl, cyclobutyl,
cyclopenyl and cyclohexyl), phenyl, 4-6-membered heterocylyl
(particularly oxetanyl, azetidinyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl,
oxothiazinyl, dioxothiazinyl, thianyl (also known as
tetrahydrothiopyranyl), oxothianyl, dioxothianyl, piperidinyl, and
piperazinyl) and further where C.sub.1-4alkyl either alone or as
part of a substituent group includes methyl, ethyl, n-propyl,
iso-propyl, n-butyl, iso-butyl, sec-butyl and tert-butyl and may be
further optionally substituted.
[0094] Optional substituents in the case of heterocycles,
heteroaryls and spiro bicyclic heterocyclic ring systems containing
N may also include but are not limited to alkyl i.e.
N--C.sub.1-3alkyl, more preferably methyl, particularly
N-methyl.
[0095] It will be understood that suitable derivatives of aromatic
heterocyclyls containing nitrogen include N-oxides thereof.
[0096] Embodiments will now be described with reference to the
following non-limiting examples.
Compounds
[0097] In one embodiment Alk is optionally substituted
C.sub.1-6alkyl, preferably C.sub.1-3alkyl and even more preferably
is unsubstituted ethyl.
[0098] In one embodiment X.sub.1 is C--R.sub.1, X.sub.2 is
C--R.sub.2 and X.sub.3 is C--R.sub.3.
[0099] In one embodiment X.sub.1 is C--R.sub.1 and R.sub.1 is H or
halo, preferably H.
[0100] In one embodiment ring A is an optionally substituted
5-6-membered heteroaryl, preferably containing at least one N
heteroatom. In one embodiment ring A is a 5-membered heteroaryl.
Preferred 5-membered heteroaryl include triazolyl, imidazolyl and
thiazolyl rings. In one embodiment, ring A is a 6-membered
heteroaryl with pyrimidine, pyridine and pyrazine rings being most
preferred.
[0101] In one embodiment Z.sub.1 is a secondary or tertiary alcohol
of general formula
##STR00014##
an ester, carbamate, phosphate, sulfate or prodrug thereof wherein
q, R.sub.4 and R.sub.5 are as previously defined.
[0102] In one embodiment X.sub.2 is C--R.sub.2 where R.sub.2 is H.
In another embodiment X.sub.2 is C--R.sub.2 where R.sub.2 is
selected from H, OH, optionally substituted C.sub.1-6alkyl,
optionally substituted C.sub.2-6alkenyl, optionally substituted
OC.sub.1-6alkyl, optionally substituted SC.sub.1-6alkyl, optionally
substituted S(.dbd.O)C.sub.1-6alkyl, an optionally substituted
5-6-membered heterocycle, halo, haloC.sub.1-3alkyl, CN and
optionally substituted (CH.sub.2).sub.mNR.sup.aR.sup.b.
[0103] In one embodiment R.sub.2 is selected from H, halo
preferably F, OH, optionally substituted NHC.sub.1-3alkyl
(preferably NHCH.sub.3 or NHCH.sub.2CH.sub.3), optionally
substituted N(C.sub.1-3alkyl).sub.2 (preferably N(CH.sub.3).sub.2
or N(CH.sub.3)CH.sub.2CH.sub.3), optionally substituted
SC.sub.1-3alkyl (preferably SCH.sub.2CH.sub.3), optionally
substituted S(.dbd.O)C.sub.1-3alkyl (preferably
S(.dbd.O)CH.sub.2CH.sub.3), an optionally substituted 6-membered
heterocycle (preferably 6-membered such as morpholine) and
optionally substituted OC.sub.1-3alkyl (preferably methoxy or
ethoxy) wherein the optional substituents may be, for example OH,
methoxy, C.sub.3-6cycloalkyl (e.g. such as cyclopropyl), phenyl or
a 5-6-membered heterocycle (e.g. such as tetrahydrofuran,
tetrahydropyran, pyrrolidine, pyrazolidine, imidazolidine,
piperidine, piperazine and morpholine).
[0104] In one embodiment X.sub.3 is C--R.sub.3 where R.sub.3 is
H.
[0105] In another embodiment X.sub.3 is C--R.sub.3 where R.sub.3 is
selected from optionally substituted C.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mNR.sup.aR.sup.b or is a group of formula
##STR00015##
where * represents the point of attachment to the carbon ring
atom;
##STR00016##
represents Ring B which is selected from saturated or unsaturated
monocyclic 3-7 membered heterocycle, saturated or unsaturated fused
bicyclic 8-10 membered-heterocyclyl. C.sub.6-10aryl and 5-10
membered heteroaryl and may be optionally substituted; and Z.sub.2
is a secondary or tertiary alcohol or Z.sub.2 is selected from H,
OH, optionally substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6alkynyl,
optionally substituted (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mNR.sup.aR.sup.b, optionally substituted
(CH.sub.2).sub.p-4-6-membered heterocyclylic ring, optionally
substituted (CH.sub.2).sub.p-spiro-bicyclic-7-11-membered
heterocyclic ring and optionally substituted
##STR00017##
[0106] In a further embodiment R.sub.3 is selected from optionally
substituted C.sub.1-3alkyl, optionally substituted OC.sub.1-3alkyl,
optionally substituted (CH.sub.2).sub.mNH.sub.2, optionally
substituted (CH.sub.2).sub.mNHC.sub.1-3alkyl and optionally
substituted (CH.sub.2).sub.mN(C.sub.1-3alkyl).sub.2. In still a
further particular embodiment R.sub.3 is selected from optionally
substituted methyl (such as optionally substituted with methoxy,
dimethylamino or a 6-membered heterocycylic group such as
morpholinyl) or optionally substituted methoxy (such as optionally
substituted with pyridyl wherein pyridyl is further optionally
substituted with methyl).
[0107] In another embodiment R.sub.3 is a group of formula
##STR00018##
where * represents the point of attachment to the carbon ring
atom;
##STR00019##
represents Ring B which is selected from saturated or unsaturated
monocyclic 5-6 membered heterocycle (such as pyrrolidinyl and
morpholinyl), C.sub.6aryl and 5-6 membered heteroaryl and may be
optionally substituted.
[0108] In a preferred embodiment Ring B is an optionally
substituted 5-6 membered heteroaryl, with 6-membered heteroaryl
being particularly preferred and 6-membered heteroaryl selected
from pyridine, pyridazine, pyrimidine and pyrazine being most
preferred.
[0109] In one embodiment Z.sub.2 is H.
[0110] In one embodiment Z.sub.2 is selected from OH, optionally
substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6alkynyl,
optionally substituted (CH.sub.2).sub.mOC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl, (CH.sub.2).sub.mNH.sub.2,
optionally substituted (CH.sub.2).sub.mNHC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.mN(C.sub.1-6alkyl).sub.2, optionally
substituted (CH.sub.2).sub.p-4-6-membered heterocyclic ring,
optionally substituted
(CH.sub.2).sub.p-spiro-bicyclic-7-11-membered heterocyclic ring and
optionally substituted
##STR00020##
[0111] In a further embodiment Z.sub.2 is selected from OH, halo
(particulary F), an optionally substituted C.sub.1-6alkyl
(particularly methyl, ethyl and propyl, most preferably methyl),
optionally substituted OC.sub.1-6alkyl (particulary methoxy, ethoxy
and propoxy), halo (particulary F), (CH.sub.2).sub.mNH.sub.2
(particulary NH.sub.2), optionally substituted
(CH.sub.2).sub.mNHC.sub.1-3alkyl (particularly NHCH.sub.3 and
NHCH.sub.2CH.sub.3), optionally substituted
(CH.sub.2).sub.mNHC.sub.3-6cycloalkyl (particularly
CH.sub.2NHC.sub.3-6cycloalkyl such as CH.sub.2NHcyclopropyl and
NHC.sub.3-6cycloalkyl such as NH-cyclohexyl) optionally substituted
(CH.sub.2).sub.mN(C.sub.1-3alkyl).sub.2 (particulary
N(CH.sub.3).sub.2 and N(CH.sub.3)CH.sub.2CH.sub.3), optionally
substituted (CH.sub.2).sub.p-4-6-membered heterocyclic ring,
optionally substituted
(CH.sub.2).sub.p-spiro-bicyclic-7-11-membered heterocyclic ring and
optionally substituted
##STR00021##
In still another embodiment Z.sub.2 is optionally substituted
##STR00022##
where p is 0, 1 or 2, preferably 0 or 1, even more preferably is
1.
[0112] In a particulary preferred embodiment Z.sub.2 is an
optionally substituted (CH.sub.2).sub.p-4-6-membered heterocyclic
ring or optionally substituted
(CH.sub.2).sub.p-spiro-bicyclic-7-11-membered heterocyclic ring
where p is an integer selected from 0, 1 and 2, preferably 0 or 1.
Particularly preferred 4-6-membered heterocyclic rings contain at
least one nitrogen heteroatom and include azetidinyl, pyrrolidinyl,
piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl,
oxothiazinyl and dioxothiazinyl and further may be optionally
substituted. Particulary preferred spiro-bicyclic-7-11-membered
heterocyclic rings include oxa-azaspiroheptane and
oxa-azaspirononane and may be optionally substituted.
[0113] Suitable optional substituents for Z.sub.2 include but are
not limited to one or more substituents, preferably 1 or 2
substituents independently selected from OH, C.sub.1-3alkyl
(particularly methyl), C.sub.1-3alkoxyl (particulary methoxy), halo
(particularly F), CO.sub.2H, CO.sub.2C.sub.1-3alkyl (particularly
CO.sub.2CH.sub.3), P(.dbd.O)(OH).sub.2 and
P(.dbd.O)(OC.sub.1-3alkyl).sub.2.
[0114] In one embodiment the compound is of Formula (Ia)
##STR00023##
salts, isomers, racemates, diastereomers, enantiomers, esters,
carbamates, phosphates, sulfates, deuterated forms and prodrugs
thereof wherein X.sub.1, X.sub.2, Alk, Ring A, Ring B, Z.sub.1 and
Z.sub.2 are as previously defined.
[0115] In one embodiment Z.sub.1 is a secondary or tertiary alcohol
of general formula
##STR00024##
or an ester, carbamate, phosphate, sulfate or prodrug thereof
wherein q is an integer selected from 0, 1, 2 or 3 and each
(CH.sub.2) entity when present may be independently optionally
substituted; R.sub.4 is H or is selected from optionally
substituted C.sub.1-6alkyl, optionally substituted C.sub.2-6
alkenyl, optionally substituted C.sub.2-6alkynyl, optionally
substituted (CH.sub.2).sub.tOC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tOC(.dbd.O)C.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.tS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl and optionally substituted
(CH.sub.2).sub.tNR.sup.aR.sup.b; R.sub.5 is selected from
optionally substituted C.sub.1-6alkyl, optionally substituted
C.sub.2-6alkenyl, optionally substituted C.sub.2-6alkynyl,
optionally substituted C.sub.3-7cycloalkyl ring, optionally
substituted phenyl, optionally substituted 4-6-membered
heterocyclyl ring, optionally substituted 5-6-membered heteroaryl
ring, optionally substituted (CH.sub.2).sub.tOC.sub.1-6alkyl,
optionally substituted (CH.sub.2).sub.tO((.dbd.O)C.sub.1-6alkyl,
optionally substituted (CH.sub.2).sub.tSC.sub.1-6alkyl, optionally
substituted (CH.sub.2).sub.tOC(.dbd.O)C.sub.1-6alkyl, halo,
optionally substituted haloC.sub.1-3alkyl and optionally
substituted (CH.sub.2).sub.tNR.sup.aR.sup.b; t is selected from 1,
2, 3, 4, 5 and 6 preferably 1, 2 or 3; R.sup.a and R.sup.b are each
independently selected from H or optionally substituted
C.sub.1-6alkyl; or R.sub.4 and R.sub.5 together with the carbon
atom to which they are attached form an optionally substituted
4-6-membered heterocyclic ring or C.sub.3-6cycloalkyl ring; and *
represents the point of attachment to Ring A.
[0116] In one embodiment q is 0 or 1, preferably 0.
[0117] In one embodiment R.sub.4 is H or optionally substituted
C.sub.1-3alkyl (particularly methyl and ethyl); and R.sub.5 is
selected from optionally substituted C.sub.1-3alkyl (particularly
methyl and ethyl), optionally substituted haloC.sub.1-3alkyl
(particularly CHF.sub.2, CH.sub.2CHF.sub.2, CF.sub.3 and
CH.sub.2CF.sub.3), optionally substituted C.sub.3-7cycloalkyl ring
(particularly cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl),
optionally substituted 4-6-membered heterocyclyl ring (particularly
morpholinyl), optionally substituted 5-6-membered heteroaryl ring
(particularly containing at least one nitrogen heteroatom such as
imidazolyl and pyridinyl); or R.sub.4 and R.sub.5 together with the
carbon atom to which they are attached form an optionally
substituted 4-6-membered heterocyclic ring or C.sub.3-6cycloalkyl
ring.
[0118] 4-6-membered heterocyclic rings R.sub.4 and R.sub.5 together
with the carbon atom to which they are attached include 4-membered
rings such as oxetane and azetidine, 5-membered rings such as
pyrrolidine, pyrazolidine, imidazole, tetrahydrofuran and thiophene
and 6-membered rings such as piperidine, piperazine, morpholine,
tetrahydropyran, and tetrahydrothiopyran. Heteroatom ring
substituents in the case of heterocyclic rings include .dbd.O, e.g.
S.dbd.O (e.g. to form oxo-thianes and dioxo-thianes from
tetrahydrothiopyran), oxides e.g. N-oxides and C.sub.1-3alkyl e.g.
N-methyl. C.sub.3-6cycloalkyl rings R.sub.4 and R.sub.5 together
with the carbon atom to which they are attached include saturated
cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl rings,
particularly cyclopentyl and cyclohexyl.
[0119] Suitable optional substituents for R.sub.4 and R.sub.5 may
include but are not limited to, for example, one or more preferably
1 or 2 substituents independently selected from OH, C.sub.1-3alkyl
such as methyl, haloC.sub.1-3alkyl such as CHF.sub.2 and CF.sub.3,
CO.sub.2H, CO.sub.2C.sub.1-4alkyl, C.sub.1-3alkoxyl such as
methoxy, oxo (.dbd.O), NH.sub.2, NHC.sub.1-3alkyl and
N(C.sub.1-3alkyl).sub.2.
[0120] In a further embodiment Z.sub.1 or Z.sub.2, preferably
Z.sub.1, is a chiral alcohol of general formula
##STR00025##
or an ester, carbamate, phosphate, sulfate or prodrug thereof
wherein q, R.sub.4, R.sub.5 and * are as previously defined
provided that R.sub.4 and R.sub.5 are different. In a preferred
embodiment q is 0 or 1, preferably 0.
[0121] In one embodiment when Z.sub.1 is a chiral alcohol, the
compound of Formula (I) or (Ia) as previously defined may exist in
the form of a racemic mixture, a single enantiomer and/or mixtures
thereof.
[0122] In one embodiment the compound is of Formula (II):
##STR00026##
salts, racemates, diastereomers, enantiomers, esters, carbamates,
phosphates, sulfates, deuterated forms and prodrugs thereof wherein
X.sub.1, X.sub.2, Alk, Ring A, Ring B, Z.sub.2, R.sub.4, R.sub.5
and q are as previously defined. In a preferred embodiment q is 0
or 1, preferably 0.
[0123] In a preferred embodiment X.sub.1 is C--H, q is 0 or 1,
preferably 0 and Alk is ethyl.
[0124] In still another embodiment, R.sub.4 is H or optionally
substituted C.sub.1-6alkyl and R.sub.5 is optionally substituted
C.sub.1-6alkyl. In a further more particular embodiment R.sub.4 is
H or an optionally substituted methyl, ethyl or propyl and R.sub.5
is an optionally substituted methyl, ethyl or propyl.
[0125] In one embodiment the compound of Formula (II) is in the
form of a single enantiomer of Formula (IIa):
##STR00027##
salts, esters, carbamates, phosphates, sulfates, deuterated forms
and prodrugs thereof wherein X.sub.1, X.sub.2, Alk, Ring A, Ring B,
Z.sub.2, R.sub.4, R.sub.5 and q are as previously defined provided
that R.sub.4 and R.sub.5 are different. In a preferred embodiment q
is 0 or 1, preferably 0.
[0126] In another embodiment the compound of formula I is in the
form of a single enantiomer of Formula (IIb):
##STR00028##
salts, esters, carbamates, phosphates, sulfates, deuterated forms
and prodrugs thereof wherein X.sub.1, X.sub.2, Alk, Ring A, Ring B,
Z.sub.2, R.sub.4, R.sub.5 and q are as previously defined provided
that R.sub.4 and R.sub.5 are different. In a preferred embodiment q
is 0 or 1, preferably 0.
[0127] In one embodiment the compound is of Formula (III)
##STR00029##
salts, racemates, diastereomers, enantiomers, esters, carbamates,
phosphates, sulfates, deuterated forms and prodrugs thereof wherein
X.sub.1, X.sub.2, Alk, R.sub.4, R.sub.5 and q are as previously
defined; X.sub.4 is N, CH, C-halo or C--C.sub.1-3alkoxy, preferably
N or CH; X.sub.5, X.sub.6, X.sub.7 and X.sub.8 are each
independently selected from N, C--H or C--Z.sub.2 where Z.sub.2 is
as previously defined provided that no more than one of X.sub.5,
X.sub.6, X.sub.7 or X.sub.8 is N.
[0128] In a preferred embodiment X.sub.1 is C--H, q is 0 or 1,
preferably 0 and Alk is ethyl.
[0129] In one embodiment any one of X.sub.5, X.sub.6, X.sub.7 or
X.sub.8 is C--Z.sub.2 where Z.sub.2 is selected from OH, optionally
substituted C.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mOC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mSC.sub.1-6alkyl, optionally substituted
(CH.sub.2).sub.mS(.dbd.O)C.sub.1-6alkyl, halo, optionally
substituted haloC.sub.1-3alkyl, optionally substituted
(CH.sub.2).sub.mNR.sup.aR.sup.b, optionally substituted
(CH.sub.2).sub.p-4-6-membered heterocyclic ring, optionally
substituted (CH.sub.2).sub.p-spiro-bicyclic-7-11-membered
heterocyclic ring and optionally substituted
##STR00030##
[0130] In one embodiment X.sub.5, X.sub.6, X.sub.7 and X.sub.8 are
each independently C--H or C--Z.sub.2.
[0131] In another embodiment one of X.sub.5, X.sub.6, X.sub.7 and
X.sub.8 is N and each of the remainder independently selected from
C--H or C--Z.sub.2.
[0132] In still another embodiment, R.sub.4 is H or optionally
substituted C.sub.1-6alkyl and R.sub.5 is optionally substituted
C.sub.1-6alkyl. In a further more particular embodiment R.sub.4 is
H or an optionally substituted methyl, ethyl or propyl and R.sub.5
is an optionally substituted methyl, ethyl or propyl.
[0133] In one embodiment of the compounds of any one of Formula
(I), (Ia), (II), (IIa), (IIb) or (III), the Z.sub.1 and/or Z.sub.2
secondary or tertiary alcohol is in the form of an ester including
those derived from amino acids and dipeptides, a carbamate, a
phosphate or sulphate.
[0134] In one embodiment of the compounds of any one of Formula
(I), (Ia), (II), (IIa), (IIb) or (III), the ester of the Z.sub.1
and/or Z.sub.2 secondary or tertiary alcohol is of general formula
OC(.dbd.O)R.sub.6 where R.sub.6 is a 5-6-membered heterocycle or an
optionally substituted C.sub.1-6alkyl wherein the optional
substituents are independently selected from 1, 2, 3 or 4 moieties
selected from C.sub.1-3alkyl, C.sub.1-3alkoxyl, OH,
OC.sub.1-3alkyl, CO.sub.2H, CO.sub.2C.sub.1-3alkyl, optionally
substituted 5-6-membered heterocycles, NHC(O)C.sub.1-6alkyl,
NHC(O)-5-6-membered heterocycles, C(O)NHC.sub.1-6alkyl, NH.sub.2,
NHC.sub.1-3alkyl and N(C.sub.1-3alkyl).sub.2 wherein
NHC(O)C.sub.1-6alkyl, C(O)NHC.sub.1-6alkyl, NHC.sub.1-3alkyl and
N(C.sub.1-3alkyl).sub.2 may be further optionally substituted with,
for example, CO.sub.2H, CO.sub.2CH.sub.3, a 5-6-membered
heterocycle, NH.sub.2, NHC.sub.1-3alkyl and N(C.sub.1-3alkyl).sub.2
and OP(.dbd.O)(OR.sub.9).sub.2 where each R.sub.9 is independently
selected from H or C.sub.1-3alkyl. Preferred 5-6 membered
heterocycles include optionally substituted morpholino and
optionally substituted pyrrolidine, pyrazolidine, imidazoline,
piperidine and piperazine (such as N-methyl piperazine). In a
particular embodiment there is provided a succinate ester of the
Z.sub.1 and/or Z.sub.2 secondary or tertiary alcohol.
[0135] In another embodiment there is provided an ester of the
Z.sub.1 and/or Z.sub.2 secondary or tertiary alcohol wherein the
ester is derived from an amino acid or a dipeptide moiety.
[0136] In one embodiment of the compounds of any one of Formula
(I), (Ia), (II), (IIa), (IIb) or (III), the carbamate of the
Z.sub.1 and/or Z.sub.2 secondary or tertiary alcohol is of general
formula OC(.dbd.O)NR.sub.7R.sub.8 where R.sub.7 and R.sub.8 are
each independently selected from H and optionally substituted
C.sub.1-6alkyl or join together with the N to which they are
attached to form an optionally substituted 5-6-membered
heterocycle. Preferred 5-6 membered heterocycle include optionally
substituted morpholino and optionally substituted pyrrolidine,
pyrazolidine, imidazoline, piperidine and piperazine (such as
N-methyl piperazine).
[0137] In another embodiment of the compounds of any one of Formula
(I), (Ia), (II), (IIa), (IIb) or (III), the phosphate of the
Z.sub.1 and/or Z.sub.2 secondary or tertiary alcohol is of general
formula OP(O)(OR.sub.9).sub.2 where each R.sub.9 is independently
selected from H or an optionally substituted C.sub.1-6alkyl.
[0138] In still another embodiment of the compounds of any one of
Formula (I), (Ia), (II), (IIa), (IIb) or (III), the sulphate of the
Z.sub.1 and/or Z.sub.2 secondary or tertiary alcohol is of general
formula OSO.sub.2OR.sub.10 where R.sub.10 is H or an optionally
substituted C.sub.1-6alkyl.
[0139] In one embodiment of the compounds of any one of Formula
(I), (Ia), (II), (IIa), (IIb) or (III), the prodrug is selected
from an ester, carbamate, phosphate or sulphate formed from the
hydroxyl moiety of the secondary or tertiary alcohol as previously
defined.
[0140] In a particularly preferred embodiment of the compounds of
any one of Formula (I), (Ia), (II), (IIa), (IIb) or (III), Z.sub.1
is a secondary or tertiary alcohol of general formula
##STR00031##
or an ester or phosphate thereof as previously defined.
[0141] Accordingly, in one embodiment of the compounds of any one
of Formula (I), (Ia), (II), (IIa), (IIb) or (III) there is provided
an ester of the Z.sub.1 secondary or tertiary alcohol of general
formula:
##STR00032##
wherein the ester is derived from an amino acid, a dipeptide, a
carbamate, a phosphate or a sulphate.
[0142] In one embodiment of the compounds of any one of Formula
(I), (Ia), (II), (IIa), (IIb) or (III) there is provided an ester
of the Z.sub.1 secondary or tertiary alcohol of general
formula:
##STR00033##
wherein R.sub.11 is R.sub.6 or NR.sub.7R.sub.8 and wherein R.sub.6,
R.sub.7, R.sub.8, q, R.sub.4 and R.sub.5 are as previously defined.
In one embodiment, R.sub.11 is selected from the group consisting
of an optionally substituted 5-6-membered heterocyclyl or an
optionally substituted C.sub.1-6alkyl. Particularly preferred
5-6-membered heterocyclyl include pyrrolidinyl, morpholinyl and
piperazinyl and may be optionally substituted with C.sub.1-3alkyl,
preferably methyl. In one embodiment R.sub.11 is an optionally
substituted C.sub.1-6alkyl wherein particularly preferred optional
substituents are independently selected from methyl, methoxy, OH,
CO.sub.2H, CO.sub.2C.sub.1-3alkyl (particularly CO.sub.2CH.sub.3),
optionally substituted 5-6-membered heterocycles, NHC(.dbd.O)--
5-6-membered heterocycles, NH.sub.2, NHC.sub.1-3alkyl and
N(C.sub.1-3alkyl).sub.2 (particularly N(CH.sub.3).sub.2) and
wherein NHC.sub.1-3alkyl may be further optionally substituted with
NH.sub.2, CO.sub.2H, CO.sub.2CH.sub.3, 5-6-membered heterocyclyls
and OP(.dbd.O)(OR.sub.9).sub.2 where each R.sub.9 is independently
selected from H or C.sub.1-3alkyl and wherein particularly
preferred 5-6-membered heterocycles include pyrrolidinyl,
piperazinyl and morpholinyl.
[0143] In yet another embodiment of the compounds of any one of
Formula (I), (Ia), (II), (IIa), (IIb) or (I) there is provided a
phosphate of the Z.sub.1 secondary or tertiary alcohol of general
formula:
##STR00034##
wherein each R.sub.9 is independently selected from H or an
optionally substituted C.sub.1-3alkyl and q, R.sub.4 and R.sub.5
are as previously defined. In one embodiment each R.sub.9 is H.
[0144] In one embodiment the compound is selected from the group
consisting of any one of compounds 1 to 202:
##STR00035## ##STR00036## ##STR00037## ##STR00038## ##STR00039##
##STR00040## ##STR00041## ##STR00042## ##STR00043## ##STR00044##
##STR00045## ##STR00046## ##STR00047## ##STR00048## ##STR00049##
##STR00050## ##STR00051## ##STR00052## ##STR00053## ##STR00054##
##STR00055## ##STR00056## ##STR00057## ##STR00058## ##STR00059##
##STR00060## ##STR00061## ##STR00062## ##STR00063## ##STR00064##
##STR00065## ##STR00066## ##STR00067## ##STR00068## ##STR00069##
##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074##
##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079##
##STR00080## ##STR00081## ##STR00082## ##STR00083##
##STR00084##
salts, racemates, diastereomers, enantiomers, esters, carbamates,
phosphates, sulfates, deuterated forms and prodrugs thereof wherein
compounds 1 to 202 are named as follows: [0145] 1)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1-
,3-benzothiazol-2-yl]urea; [0146] 2)
1-ethyl-3-[7-[4-[(3-hydroxy-3-methyl-azetidin-1-yl)methyl]-2-pyridyl]-5-[-
2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
[0147] 3)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(te-
trahydrofuran-2-ylmethoxy)-1,3-benzothiazol-2-yl]urea; [0148] 4)
1-ethyl-3-[6-fluoro-5-[6-[hydroxy(3-pyridyl)methyl]-3-pyridyl]-1,3-benzot-
hiazol-2-yl]urea; [0149] 5)
1-(2-hydroxyethyl)-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(2-
-pyridyl)-1,3-benzothiazol-2-yl]urea; [0150] 6)
1-ethyl-3-[5-[5-(1-hydroxyethyl)pyrazin-2-yl]-7-(2-pyridyl)-1,3-benzothia-
zol-2-yl]urea; [0151] 7)
1-[5-[2-[(1S*,2R*)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3--
benzothiazol-2-yl]-3-ethyl-urea (mixture
1-[5-[2-[(1S,2R)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]-3-ethyl-urea; and
1-[5-[2-[(1R,2S)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]-3-ethyl-urea); [0152] 8)
1-[5-[2-[(3R*,4S*)-3,4-dihydroxytetrahydropyran-4-yl]pyrimidin-5-yl]-7-(2-
-pyridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea (mixture
1-[5-[2-[(3R,4S)-3,4-dihydroxytetrahydropyran-4-yl]pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea; and
1-[5-[2-[(3S,4R)-3,4-dihydroxytetrahydropyran-4-yl]pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea); [0153] 9)
1-ethyl-3-[5-[4-(1-hydroxyethyl)triazol-1-yl]-7-(2-pyridyl)-1,3-benzothia-
zol-2-yl]urea; [0154] 10)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-pyrimidin-2-y-
l-1,3-benzothiazol-2-yl]urea; [0155] 11)
1-ethyl-3-[5-[4-(1-hydroxy-1-methyl-ethyl)imidazol-1-yl]-7-(2-pyridyl)-1,-
3-benzothiazol-2-yl]urea; [0156] 12)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-methoxy-1,3-b-
enzothiazol-2-yl]urea; [0157] 13)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(methoxymethy-
l)-1,3-benzothiazol-2-yl]urea; [0158] 14)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[(6-methyl-3-pyridyl)me-
thoxy]-1,3-benzothiazol-2-yl]urea: [0159] 15)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(methylsulfanylmethy-
l)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0160] 16)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(methylsulfinylmethy-
l)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0161] 17)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzoth-
iazol-2-yl]urea; [0162] 18)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl 4-methylpiperazine-1-carboxylate; [0163] 19)
4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]ethoxy]-4-oxo-butanoic acid; [0164] 20)
O4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyr-
imidin-2-yl]-1-methyl-ethyl] O1-methyl butanedioate; [0165] 21)
4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]-1-methyl-ethoxy]-4-oxo-butanoic acid; [0166] 22)
1-ethyl-3-[5-[2-[(1R)-1-hydroxyethyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]urea; [0167] 23)
1-ethyl-3-[5-[2-[(1S)-1-hydroxyethyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]urea; [0168] 24)
1-ethyl-3-[5-[6-[hydroxy-(1-methylimidazol-2-yl)methyl]-3-pyridyl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]urea; [0169] 25)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[5-(morpholin-
omethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0170] 26)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(pyrrolidi-
n-1-ylmethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0171] 27)
1-ethyl-3-[5-[6-(1-hydroxy-1-methyl-ethyl)-3-pyridyl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]urea; [0172] 28)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(morpholin-
omethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0173] 29)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(3-hydrox-
ypyrrolidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea:
[0174] 30)
1-ethyl-3-[7-[4-[(3-hydroxyazetidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydro-
xy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
[0175] 31)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(3-methox-
yazetidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0176] 32)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(2-morphol-
inoethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0177] 33)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(1-morphol-
inoethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0178] 34)
1-[7-[4-[(3,3-difluoropyrrolidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxy--
1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0179] 35)
1-ethyl-3-[7-[4-[[(3S)-3-fluoropyrrolidin-1-yl]methyl]-2-pyridyl]-5-[-
2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
[0180] 36)
1-ethyl-3-[7-[4-[[(3R)-3-fluoropyrrolidin-1-yl]methyl]-2-pyridyl]-5-[2-(1-
-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
[0181] 37)
1-[7-[4-[(3,3-difluoro-1-piperidyl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-
-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0182] 38)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(3-morphol-
inopropoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0183] 39)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-pyrazin-2-yl--
1,3-benzothiazol-2-yl]urea; [0184] 40)
1-[5-[2-(1,2-dihydroxyethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzothiazo-
l-2-yl]-3-ethyl-urea; [0185] 41)
1-[7-(dimethylaminoethyl)-6-hydroxy-5-[6-(1-hydroxy-1-methyl-ethyl)-3-pyr-
idyl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; [0186] 42)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[[(3R)-3-m-
ethoxypyrrolidin-1-yl]methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0187] 43)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(6-methylpyri-
midin-4-yl)-1,3-benzothiazol-2-yl]urea; [0188] 44)
1-ethyl-3-[6-hydroxy-5-[6-(1-hydroxy-1-methyl-ethyl)-3-pyridyl]-7-(morpho-
linomethyl)-1,3-benzothiazol-2-yl]urea; [0189] 45)
1-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]-3-pyridyl]-4-methyl-piperidine-4-carboxylic
acid; [0190] 46)
2-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]-3-pyridyl]acetic acid; [0191] 47)
1-ethyl-3-[5-[2-(1-hydroxycyclohexyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]urea; [0192] 48)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)thiazol-5-yl]-7-(2-pyridyl)-1,3-
-benzothiazol-2-yl]urea; [0193] 49)
1-ethyl-3-[5-[5-(1-hydroxy-1-methyl-ethyl)pyrazin-2-yl]-7-(2-pyridyl)-1,3-
-benzothiazol-2-yl]urea; [0194] 50)
1-[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]-4-pyridyl]-4-methyl-piperidine-4-carboxylic
acid; [0195] 51)
1-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]-2-pyridyl]-4-methyl-piperidine-4-carboxylic
acid; [0196] 52)
1-[4-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylic
acid; [0197] 53)
1-[7-[4-[(cyclopropylamino)methyl]-2-pyridyl]-5-[2-(1-hydroxy-1-methyl-et-
hyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; [0198] 54)
4-[[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-
-yl]-1,3-benzothiazol-7-yl]-4-pyridyl]amino]-1-methyl-cyclohexanecarboxyli-
c acid; [0199] 55)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(morpholinomethyl)-2-
-pyridyl]-1,3-benzothiazol-2-yl]urea; [0200] 56)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[5-(2-morphol-
inoethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0201] 57)
1-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzo-
thiazol-2-yl]-3-propyl-urea; [0202] 58)
1-[5-[2-[cyclopropyl(hydroxy)methyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-ben-
zothiazol-2-yl]-3-ethyl-urea; [0203] 59)
1-ethyl-3-[5-[2-(1-hydroxypropyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzot-
hiazol-2-yl]urea; [0204] 60)
1-ethyl-3-[5-[2-(1-hydroxy-2,2-dimethyl-propyl)pyrimidin-5-yl]-7-(2-pyrid-
yl)-1,3-benzothiazol-2-yl]urea; [0205] 61)
1-ethyl-3-[5-[2-(1-hydroxybutyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzoth-
iazol-2-yl]urea [0206] 62)
[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] (2R)-2-amino-3-methyl-butanoate; [0207] 63)
[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] (2R)-2-amino-3-methyl-butanoate; [0208] 64)
1-ethyl-3-[7-[4-[[(3S)-3-fluoropyrrolidin-1-yl]methyl]-2-pyridyl]-5-[2-(1-
-hydroxyethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; [0209]
65)
1-ethyl-3-[7-[4-[(3-hydroxyazetidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydro-
xyethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; [0210] 66)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(3-hydroxy-3-methyl-
-azetidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0211] 67)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(3-hydrox-
y-3-methyl-pyrrolidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0212] 68)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(3-methylmorpholin--
4-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea: [0213] 69)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-(1-h-
ydroxyethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0214] 70)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(2,2,3,3,5,5,6,-
6-octadeuteriomorpholin-4-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea-
; [0215] 71)
1-[7-[4-[(2,5-dimethylmorpholin-4-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxyet-
hyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; [0216] 72)
(2S)-1-[[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxyethyl)pyrimidin-5-yl]--
1,3-benzothiazol-7-yl]-4-pyridyl]methyl]pyrrolidine-2-carboxylic
acid; [0217] 73)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(6-oxa-2-azaspiro[3.-
3]heptan-2-ylmethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0218]
74)
1-[5-[2-(ethylcarbamoylamino)-7-[4-(1-hydroxy-1-methyl-ethyl)-2-pyridyl]--
1,3-benzothiazol-5-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylic
acid; [0219] 75)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(2-morpholinoethoxy)-
-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0220] 76)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(3-methoxyazetidin--
1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0221] 77)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[[(3R)-3-hydroxypyrr-
olidin-1-yl]methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0222]
78)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(2-methoxy-
ethylamino)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; [0223] 79)
1-ethyl-3-[7-[4-(4-ethylpiperazin-1-yl)pyridin-2-yl]-5-[2-(1-hydroxy-1-me-
thyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea: [0224] 80)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(2-methoxy-
ethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0225] 81)
1-ethyl-3-[5-[2-(1-hydroxy-2-morpholino-ethyl)pyrimidin-5-yl]-7-(2-pyridy-
l)-1,3-benzothiazol-2-yl]urea; [0226] 82)
1-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzo-
thiazol-2-yl]-3-methyl-urea; [0227] 83)
1-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzothiazol-2--
yl]-3-methyl-urea; [0228] 84)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-[(3-hydroxy-3-methyl-
-pyrrolidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0229] 85)
1-ethyl-3-[7-[4-(2-hydroxyethylamino)pyrimidin-2-yl]-5-[2-(1-hydroxy-1-me-
thyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; [0230] 86)
1-ethyl-3-[7-[4-(3-hydroxy-3-methyl-azetidin-1-yl)pyrimidin-2-yl]-5-[2-(1-
-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea;
[0231] 87)
1-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidi-
n-5-yl]-1,3-benzothiazol-7-yl]pyrimidin-4-yl]-4-methyl-piperidine-4-carbox-
ylic acid; [0232] 88)
1-[5-[2-(ethylcarbamoylamino)-7-[4-(1-hydroxyethyl)-2-pyridyl]-1,3-benzot-
hiazol-5-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylic acid;
[0233] 89)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]py-
rimidin-2-yl]-1-methyl-ethyl] 4-methylpiperazine-1-carboxylate;
[0234] 90)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(4-hydroxy-2-pyridyl)-1-
,3-benzothiazol-2-yl]urea; [0235] 91)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(2-morphol-
inoethylamino)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; [0236]
92)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(2-methoxyethoxy)-2--
pyridyl]-1,3-benzothiazol-2-yl]urea; [0237] 93)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(3-methoxyazetidin-1-
-yl)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; [0238] 94)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(4-morpholinopyrimidin--
2-yl)-1,3-benzothiazol-2-yl]urea; [0239] 95)
1-ethyl-3-[5-[6-(1-hydroxyethyl)-3-pyridyl]-7-(2-pyridyl)-1,3-benzothiazo-
l-2-yl]urea; [0240] 96)
1-ethyl-3-[7-(2-pyridyl)-5-[6-(2,2,2-trifluoro-1-hydroxy-ethyl)-3-pyridyl-
]-1,3-benzothiazol-2-yl]urea; [0241] 97)
1-[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]pyrimidin-4-yl]-4-methyl-piperidine-4-carboxylic
acid; [0242] 98)
1-ethyl-3-[5-[2-(1-ethyl-1-hydroxy-propyl)pyrimidin-5-yl]-7-(2-pyridyl)-1-
,3-benzothiazol-2-yl]urea; [0243] 99)
1-[5-[2-(ethylcarbamoylamino)-7-[5-(1-hydroxy-1-methy-ethyl)-2-pyridyl]-1-
,3-benzothiazol-5-yl]pyrimidin-2-yl]-4-methyl-piperidine-4-carboxylic
acid; [0244] 100)
1-[7-[4-(diethoxyphosphorylmethyl)-2-pyridyl]-5-[2-(1-hydroxyethyl)pyrimi-
din-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; [0245] 101)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(morpholin-
omethyl)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; [0246] 102)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[6-(morpholin-
omethyl)pyrazin-2-yl]-1,3-benzothiazol-2-yl]urea; [0247] 103)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(2-hydrox-
y-2-methyl-propyl)amino]pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea;
[0248] 104)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(tetrahydrofura-
n-2-ylmethoxy)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0249] 105)
1-ethyl-3-[7-[4-(3-hydroxyazetidin-1-yl)pyrimidin-2-yl]-5-[2-(1-hydroxyet-
hyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; [0250] 106)
1-ethyl-3-[7-(5-fluoro-4-morpholino-pyrimidin-2-yl)-5-[2-(1-hydroxyethyl)-
pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; [0251] 107)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[4-(2-meth-
oxyethyl)piperazin-1-yl]pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea;
[0252] 108)
1-ethyl-3-[7-[4-(morpholinomethyl)-2-pyridyl]-5-[6-(2,2,2-trifluoro--
1-hydroxy-ethyl)-3-pyridyl]-1,3-benzothiazol-2-yl]urea; [0253] 109)
1-[6-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-1,3-be-
nzothiazol-7-yl]pyrimidin-4-yl]-4-methyl-piperidine-4-carboxylic
acid;
[0254] 110)
1-[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5--
yl]-1,3-benzothiazol-7-yl]-4-pyridyl]piperidine-4-carboxylic acid;
[0255] 111)
1-ethyl-3-[5-[2-(4-hydroxytetrahydropyran-4-yl)pyrimidin-5-yl]-7-(2--
pyridyl)-1,3-benzothiazol-2-yl]urea; [0256] 112)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(2-oxa-7-azaspiro[3.-
5]nonan-7-ylmethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0257]
113)
1-ethyl-3-[5-[2-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]urea; [0258] 114)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(3-methox-
y-3-methyl-azetidin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0259] 115)
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-pyrimidin-2-yl-1,3-benz-
othiazol-2-yl]urea; [0260] 116)
1-ethyl-3-[7-[4-(2-morpholinoethoxy)-2-pyridyl]-5-[6-(2,2,2-trifluoro-1-h-
ydroxy-ethyl)-3-pyridyl]-1,3-benzothiazol-2-yl]urea; [0261] 117)
1-[2-[2-(ethylcarbamoylamino)-5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-1,3-be-
nzothiazol-7-yl]pyrimidin-4-yl]-4-methyl-piperidine-4-carboxylic
acid; [0262] 118)
1-[5-[2-[(1R*,2R*)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3--
benzothiazol-2-yl]-3-ethyl-urea (mixture
1-[5-[2-[(1R,2R)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]-3-ethyl-urea; and
1-[5-[2-[(1S,2S)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-be-
nzothiazol-2-yl]-3-ethyl-urea); [0263] 119)
1-ethyl-3-[5-[2-(1-hydroxycyclopentyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]urea; [0264] 120)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[5-(morpholin-
omethyl)pyrimidin-2-yl]-1,3-benzothiazol-2-yl]urea; [0265] 121)
1-ethyl-3-[5-[2-[(1R)-1-hydroxyethyl]pyrimidin-5-yl]-7-[4-(morpholinometh-
yl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0266] 122)
1-ethyl-3-[5-[2-[(1S)-1-hydroxyethyl]pyrimidin-5-yl]-7-[4-(morpholinometh-
yl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0267] 123)
4-[3-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]oxetan-3-yl]oxy-4-oxo-butanoic acid; [0268] 124)
4-[2-[5-[2-(ethylcarbanoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]-2-hydroxy-propoxy]-4-oxo-butanoic acid; [0269] 125)
1-ethyl-3-[5-[2-(4-hydroxytetrahydropyran-4-yl)pyrimidin-5-yl]-7-[4-(morp-
holinomethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0270] 126)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl 2-aminoacetate; [0271] 127)
1-ethyl-3-[5-[2-(4-hydroxytetrahydrothiopyran-4-yl)pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]urea; [0272] 128)
1-ethyl-3-[5-[2-(4-hydroxy-1-methyl-4-piperidyl)pyrimidin-5-yl]-7-(2-pyri-
dyl)-1,3-benzothiazol-2-yl]urea; [0273] 129)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 2-(2-aminoethylamino)acetate; [0274] 130)
1-[5-[2-[(1R*,2S*)-3,3-difluoro-1,2-dihydroxy-propyl]pyrimidin-5-yl]-7-(2-
-pyridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea (mixture
1-[5-[2-[(1R,2S)-3,3-difluoro-1,2-dihydroxy-propyl]pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea; and
1-[5-[2-[(1S,2R)-3,3-difluoro-1,2-dihydroxy-propyl]pyrimidin-5-yl]-7-(2-p-
yridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea); [0275] 131)
1-ethyl-3-[7-(2-pyridyl)-5-[2-[(1R*,2S*)-3,3,3-trifluoro-1,2-dihydroxy-pr-
opyl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea (mixture
1-ethyl-3-[7-(2-pyridyl)-5-[2-[(1R,2S)-3,3,3-trifluoro-1,2-dihydroxy-prop-
yl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; and
1-ethyl-3-[7-(2-pyridyl)-5-[2-[(1S,2R)-3,3,3-trifluoro-1,2-dihydroxy-prop-
yl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea); [0276] 132)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] (2S)-2-aminopropanoate; [0277] 133)
4-[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl-
]pyrimidin-2-yl]ethoxy]-4-oxo-butanoic acid; [0278] 134)
4-[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl-
]pyrimidin-2-yl]ethoxy]-4-oxo-butanoic acid; [0279] 135)
1-[5-[2-(1,2-dihydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(morpholinomet-
hyl)-2-pyridyl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; [0280] 136)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl 2-amino-2-methyl-propanoate; [0281] 137)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl 3-aminopropanoate; [0282] 138) tert-butyl
4-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]-4-hydroxy-piperidine-1-carboxylate; [0283] 139)
1-ethyl-3-[5-[2-(4-hydroxy-1-oxo-thian-4-yl)pyrimidin-5-yl]-7-(2-pyridyl)-
-1,3-benzothiazol-2-yl]urea; [0284] 140)
[1-[5-[2-(ethylcarbamoylamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]-1-methyl-ethyl] 2-(dimethylamino)acetate; [0285]
141)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 2-morpholinoacetate; [0286] 142)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-[(1R-
)-1-hydroxyethyl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0287] 143)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-[(1S-
)-1-hydroxyethyl]pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0288] 144)
[1-[5-[2-(ethylcarbamoylamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]-1-methyl-ethyl] 5-aminopentanoate; [0289] 145)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 5-(dimethylamino)pentanoate; [0290] 146)
[1-[5-[2-(ethylcarbamoylamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]-1-methyl-ethyl] 2-aminoacetate; [0291] 147)
1-[7-[4-[(3,3-difluoroazetidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-1--
methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0292] 148)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-
-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea-
; [0293] 149)
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl dihydrogen phosphate; [0294] 150)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyeth-
ylamino)-1,3-benzothiazol-2-yl]urea; [0295] 151)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-morpholino-1,-
3-benzothiazol-2-yl]urea; [0296] 152)
[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] dihydrogen phosphate; [0297] 153)
[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] dihydrogen phosphate; [0298] 154)
1-ethyl-3-[5-[2-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl]-7-[4-(morpholinomet-
hyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0299] 155)
1-ethyl-3-[7-[4-[(3-methoxyazetidin-1-yl)methyl]-2-pyridyl]-5-[6-[2,2,2-t-
rifluoro-1-hydroxy-ethyl]-3-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0300] 156)
1-[7-[4-[(4,4-difluoro-1-piperidyl)methyl]-2-pyridyl]-5-[2-(1-hydrox-
y-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0301] 157)
1-[5-[2-[1,2-dihydroxy-1-methyl-ethyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]-3-ethyl-urea; [0302] 158)
1-ethyl-3-[5-[2-[1-hydroxyethyl]pyrimidin-5-yl]-7-(5-methyl-2-pyridyl)-1,-
3-benzothiazol-2-yl]urea; [0303] 159)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(4-methyl-
piperazin-1-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0304] 160)
[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] (2S)-pyrrolidine-2-carboxylate; [0305] 161)
[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl] (2S)-pyrrolidine-2-carboxylate; [0306] 162)
tert-butyl
3-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]-3-hydroxy-azetidine-1-carboxylate; [0307] 163)
1-ethyl-3-[5-[2-(3-hydroxyazetidin-3-yl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-
-benzothiazol-2-yl]urea; [0308] 164)
1-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-5-[2-(1-h-
ydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0309] 165)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl]
2-[[(2S)-pyrrolidine-2-carbonyl]amino]acetate; [0310] 166)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] (2S)-pyrrolidine-2-carboxylate; [0311]
167)
4-[3-[5-[7-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-2-pyridyl]-2-(-
ethylcarbamoylamino)-1,3-benzothiazol-5-yl]pyrimidin-2-yl]oxetan-3-yl]oxy--
4-oxo-butanoic acid; [0312] 168)
1-ethyl-3-[7-[5-(1-hydroxyethyl)-2-pyridyl]-5-[2-(1-hydroxyethyl)pyrimidi-
n-5-yl]-1,3-benzothiazol-2-yl]urea; [0313] 169)
[1-[5-[2-(ethylcarbamoylamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]-1-methyl-ethyl] 2-(2-morpholinoethylamino)acetate;
[0314] 170)
2-[[2-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol--
5-yl]pyrimidin-2-yl]-1-methyl-ethoxy]-2-oxo-ethyl]amino]acetic
acid; [0315] 171)
(2S)-2-amino-4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothia-
zol-5-yl]pyrimidin-2-yl]-1-methyl-ethoxy]-4-oxo-butanoic acid;
[0316] 172)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 4-aminobutanoate; [0317] 173)
1-ethyl-3-[5-[2-(4-hydroxy-1,1-dioxo-thian-4-yl)pyrimidin-5-yl]-7-(2-pyri-
dyl)-1,3-benzothiazol-2-yl]urea; [0318] 174)
1-ethyl-3-[5-[2-(4-hydroxy-4-piperidyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3--
benzothiazol-2-yl]urea; [0319] 175)
1-[7-[4-[(3-ethoxyazetidin-1-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-1-meth-
yl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0320] 176)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-methoxy-1,3-b-
enzothiazol-2-yl]urea; [0321] 177)
1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-be-
nzothiazol-2-yl]urea; [0322] 178)
1-ethyl-3-[7-(3-fluoro-4-methoxy-2-pyridyl)-5-[2-[1-hydroxyethyl]pyrimidi-
n-5-yl]-1,3-benzothiazol-2-yl]urea; [0323] 179)
3-[[2-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]-
pyrimidin-2-yl]-1-methyl-ethoxy]-2-oxo-ethyl]amino]propanoic acid;
[0324] 180)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]-1-methyl-ethyl] (3R)-pyrrolidine-3-carboxylate;
[0325] 181)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-l-methyl-ethyl] (3R)-morpholine-3-carboxylate; [0326]
182)
1-[6-(cyclopropylmethoxy)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]--
1,3-benzothiazol-2-yl]-3-ethyl-urea; [0327] 183)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyeth-
oxy)-1,3-benzothiazol-2-yl]urea; [0328] 184)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] 2-(2-phosphonooxyethylamino)acetate;
[0329] 185)
1-ethyl-3-[5-[2-[1-hydroxyethyl]pyrimidin-5-yl]-7-[4-(thiomorpholinomethy-
l)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0330] 186)
1-ethyl-3-[6-(2-hydroxyethoxy)-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-
-yl]-1,3-benzothiazol-2-yl]urea; [0331] 187)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-(thiomorph-
olinomethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]urea; [0332] 188)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(1-oxo-1,-
4-thiazinan-4-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-yl]urea;
[0333] 189)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-[2-metho-
xyethyl(methyl)amino]-1,3-benzothiazol-2-yl]urea; [0334] 190)
[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimi-
din-2-yl]-1-methyl-ethyl] dihydrogen phosphate; [0335] 191)
1-[7-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]-2-pyridyl]-5-[2-(1-hydroxy-
-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea;
[0336] 192)
1-[6-[(3,4-dimethoxyphenyl)methoxy]-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimi-
din-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; [0337] 193)
1-ethyl-3-[5-[2-[1-hydroxyethyl]pyrimidin-5-yl]-6-(tetrahydrofuran-2-ylme-
thoxy)-1,3-benzothiazol-2-yl]urea; [0338] 194)
1-ethyl-3-[5-[2-[1-hydroxyethyl]pyrimidin-5-yl]-6-morpholino-1,3-benzothi-
azol-2-yl]urea; [0339] 195)
1-[7-[(3S)-3-aminopyrrolidin-1-yl]-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimid-
in-5-yl]-1,3-benzothiazol-2-yl]-3-ethyl-urea; [0340] 196)
1-ethyl-3-[7-[4-[(2-hydroxyethylamino)methyl]-2-pyridyl]-5-[2-(1-hydroxy--
1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-2-yl]urea; [0341]
197)
1-ethyl-3-[5-[5-(1-hydroxyethyl)-3-pyridyl]-7-(2-pyridyl)-1,3-benzothiazo-
l-2-yl]urea; [0342] 198)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[4-[(2,2,3,3,-
5,5,6,6-octadeuteriomorpholin-4-yl)methyl]-2-pyridyl]-1,3-benzothiazol-2-y-
l]urea; [0343] 199)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-morpholino-
ethoxy)-1, 3-benzothiazol-2-yl]urea; [0344] 200)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyeth-
ylsulfanyl)-1,3-benzothiazol-2-yl]urea; [0345] 201)
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyeth-
ylsulfinyl)-1,3-benzothiazol-2-yl]urea; and [0346] 202)
1-ethyl-3-[5-[2-[(1R)-1-hydroxyethyl]pyrimidin-5-yl]-7-(5-methoxy-2-pyrid-
yl)-1,3-benzothiazol-2-yl]urea.
[0347] In a further particular embodiment, esters preferably ester
prodrugs of these compounds and their salts, racemates,
diastereomers, enantiomers and deuterated forms thereof are
preferred. In yet another further particular embodiment,
phosphates, preferably phosphate prodrugs of these compounds and
their salts, racemates, diasteromers, enantiomers and deuterated
forms thereof are preferred.
[0348] Accordingly, in one embodiment the compound is an ester or
phosphate selected from the group consisting of any one of
compounds 18, 19, 20, 21, 62, 63, 123, 126, 129, 132, 133, 134,
136, 137, 140, 141, 144, 145, 146, 149, 152, 153, 160, 161, 165,
166, 167, 169, 170, 171, 172, 179, 180, 181, 184 and 190, their
salts, racemates, diastereomers, enantiomers and deuterated forms
thereof.
[0349] The salts of the compound of Formula (I) are preferably
pharmaceutically acceptable, but it will be appreciated that
non-pharmaceutically acceptable salts also fall within the scope of
the present invention, since these are useful as intermediates in
the preparation of pharmaceutically acceptable salts.
[0350] Suitable pharmaceutically acceptable salts include, but are
not limited to, salts of pharmaceutically acceptable inorganic
acids such as hydrochloric, sulfuric, phosphoric, nitric, carbonic,
boric, sulfamic, and hydrobromic acids, or salts of
pharmaceutically acceptable organic acids such as acetic,
propionic, butyric, tartaric, maleic, malonic, hydroxymaleic,
fumaric, malic, citric, lactic, mucic, gluconic, benzoic, succinic,
oxalic, phenylacetic, methanesulphonic, toluenesulphonic,
benzenesulphonic, ethane-1,2-disulfonic, salicylic, sulphanilic,
aspartic, glutamic, gentisic, edetic, stearic, palmitic, pamoic,
oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.
[0351] Base salts include, but are not limited to, those formed
with pharmaceutically acceptable cations, such as sodium,
potassium, lithium, calcium, magnesium, zinc, ammonium,
alkylammonium such as salts formed from triethylamine,
alkoxyammonium such as those formed with ethanolamine and salts
formed from ethylenediamine, choline or amino acids such as
arginine, lysine or histidine. General information on types of
pharmaceutically acceptable salts and their formation is known to
those skilled in the art and is as described in general texts such
as "Handbook of Pharmaceutical salts" P. H. Stahl, C. G. Wermuth,
1.sup.st edition, 2002, Wiley-VCH.
[0352] Basic nitrogen-containing groups may be quarternized with
such agents as lower alkyl halide, such as methyl, ethyl, propyl,
and butyl chlorides, bromides and iodides; dialkyl sulfates like
dimethyl and diethyl sulfate; and others such as alkylphosphonates
or phosphoramidates.
[0353] Hydroxyl groups may be esterified with groups including
lower alkyl carboxylic acids, such as acetic acid and
2,2-dimethylpropionic acid, or sulfonated with groups including
alkyl sulfonic acids, such as methyl sulfonic acid or
phosphorylated with groups including alkylphosphonic acids, such as
methylenephosphonic acid, or directly attached to phosphonate
esters, phosphinate esters, or phosphate esters.
[0354] It will be recognised that the compounds of formula I may
possess asymmetric centres and are therefore capable of existing in
more than one stereoisomeric form. The invention thus also relates
to compounds in substantially pure isomeric form at one or more
asymmetric centres eg., greater than about 90% ee, such as about
95% or 97% ee or greater than 99% ee, as well as mixtures,
including racemic mixtures, thereof.
[0355] Such isomers may be prepared by asymmetric synthesis, for
example using chiral intermediates, or by chiral resolution.
[0356] This invention also encompasses prodrugs of compounds of
Formula (I). Compounds of Formula (I) having free amino, amido,
hydroxy or carboxylic groups can be converted into prodrugs.
[0357] Particularly preferred are prodrugs of hydroxyl groups such
as carbamates, phosphates, sulfates and ester groups including
those derived from amino acids and dipeptides and moieties designed
to release the parent via hydrolysis or internal cyclisation of the
prodrug moiety.
Compositions
[0358] There is also provided a composition comprising a compound
of Formula (I) its salts, isomers, racemates, diastereomers,
enantiomers and prodrugs thereof.
[0359] Preferably, the composition further comprises a
pharmaceutically acceptable carrier, diluent or excipient.
[0360] The compositions of the present invention may be formulated,
for example, by employing conventional solid or liquid vehicles or
diluents, as well as pharmaceutical additives of a type appropriate
to the mode of desired administration (for example, excipients,
binders, preservatives, stabilizers, flavors, etc.) according to
techniques such as those well known in the art of pharmaceutical
formulation.
[0361] Pharmaceutical formulations include those for oral, rectal,
nasal, topical (including buccal and sub-lingual), vaginal or
parenteral (including intramuscular, sub-cutaneous and intravenous)
administration or in a form suitable for administration by
inhalation or insufflation. The compounds of the invention,
together with a conventional adjuvant, carrier or diluent, may thus
be placed into the form of pharmaceutical compositions and unit
dosages thereof, and in such form may be employed as solids, such
as tablets or filled capsules, or liquids as solutions,
suspensions, emulsions, elixirs or capsules filled with the same,
all for oral use, in the form of suppositories for rectal
administration; or in the form of sterile injectable solutions for
parenteral (including subcutaneous) use.
[0362] In one embodiment the compositions of the present invention
are formulated for oral administration and/or intravenous (IV)
administration.
[0363] In another embodiment the compositions of the present
invention may be administered in combination with or additionally
comprise another antibacterial agent. Suitable antibacterial agents
will be familiar to those in the art and may include penicillins,
cephalosporins, carbapenems, monobactams, beta-lactams,
glycopetides, aminoglycosides, tetracyclines, macrolides,
ketolides, quinolones, fluoroquinolones, oxazolidinones, coumarins,
cyclothialidines, vancomycin and derivatives thereof.
Methods of Treatment
[0364] The present invention provides a method for the treatment of
a bacterial infection comprising administration of a compound of
Formula (I) or a pharmaceutically acceptable salt thereof to a
subject suffering from said infection.
[0365] The compounds of the present invention may be administered
by any suitable means, for example, orally, parenterally, such as
by subcutaneous, intravenous, intramuscular, or intracisternal
injection or infusion techniques (e.g., as sterile injectable
aqueous or non-aqueous solutions or suspensions).
[0366] The present invention also provides compound of Formula (I)
or a pharmaceutically acceptable salt thereof for use in the
treatment of a bacterial infection.
[0367] The term "effective amount" means the amount of the subject
composition that will elicit the biological or medical response of
a tissue, system, animal or human that is being sought by the
researcher, veterinarian, medical doctor or other clinician.
[0368] The term "composition" as used herein is intended to
encompass a product comprising the specified ingredients in the
specified amounts, as well as any product which results, directly
or indirectly, from combination of the specified ingredients in the
specified amounts. By "pharmaceutically acceptable" it is meant the
carrier, diluent or excipient must be compatible with the other
ingredients of the formulation and not deleterious to the recipient
thereof.
[0369] The terms "administration of" and or "administering a"
compound should be understood to mean providing a compound of the
invention to the individual in need of treatment.
[0370] The pharmaceutical compositions for the administration of
the compounds of this invention may conveniently be presented in
dosage unit form and may be prepared by any of the methods well
known in the art of pharmacy. All methods include the step of
bringing the active ingredient into association with the carrier
which constitutes one or more accessory ingredients. In general,
the pharmaceutical compositions are prepared by uniformly and
intimately bringing the active ingredient into association with a
liquid carrier or a finely divided solid carrier or both, and then,
if necessary, shaping the product into the desired formulation. In
the pharmaceutical composition the active object compound is
included in an amount sufficient to produce the desired effect upon
the process or condition of diseases. As used herein, the term
"composition" is intended to encompass a product comprising the
specified ingredients in the specified amounts, as well as any
product which results, directly or indirectly, from combination of
the specified ingredients in the specified amounts.
[0371] The pharmaceutical compositions may be in the form of a
sterile injectable aqueous or oleagenous suspension. This
suspension may be formulated according to the known art using those
suitable dispersing or wetting agents and suspending agents which
have been mentioned above. The sterile injectable preparation may
also be a sterile injectable solution or suspension in a non-toxic
parenterally-acceptable diluent or solvent, for example as a
solution in 1,3-butane diol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, fixed oils
are conventionally employed as a solvent or suspending medium. For
this purpose any bland fixed oil may be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid find use in the preparation of injectables.
[0372] In the treatment or prevention of bacterial infections, an
appropriate dosage level will generally be about 0.01 to 500 mg per
kg patient body weight per day which can be administered in single
or multiple doses. For oral administration, the compositions are
preferably provided in the form of tablets containing 1.0 to 1000
milligrams of the active ingredient.
[0373] It will be understood, however, that the specific dose level
and frequency of dosage for any particular patient may be varied
and will depend upon a variety of factors including the activity of
the specific compound employed, the metabolic stability and length
of action of that compound, the age, body weight, general health,
sex, diet, mode and time of administration, rate of excretion, drug
combination, the severity of the particular condition, and the host
undergoing therapy.
[0374] In addition to primates, such as humans, a variety of other
mammals can be treated according to the method of the present
invention. For instance, mammals including, but not limited to,
cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other
bovine, ovine, caprine, equine, canine, feline, rodent or murine
species can be treated. However, the method can also be practiced
in other species, such as avian species (e.g., chickens).
[0375] The subjects treated in the above method are mammals,
including, but not limited to, cows, sheep, goats, horses, dogs,
cats, guinea pigs, rats or other bovine, ovine, caprine, equine,
canine, feline, rodent or murine species, and preferably a human
being, male or female.
Methods of Preparation
[0376] Generally, the compounds of the invention may be prepared by
coupling an intermediate of formula (i-a) with a precursor of
formula (ii-a):
##STR00085##
or alternatively coupling an intermediate of formula (i-b) with a
precursor of formula (ii-b):
##STR00086##
under the conditions described including suitable variations or
alternatives thereof in the methods and examples which follow.
Formation of compounds of the invention as their salts, racemates,
enantiomers, esters, carbamates, phosphates, sulfates, deuterated
forms and prodrugs thereof is also described.
General Method A
[0377] Compounds of the invention may be prepared under Suzuki
coupling conditions familiar to those skilled in the art. Suitable
conditions include (i) coupling a precursor comprising a boronic
acid or a boronate ester thereof with an intermediate comprising a
halo (particularly Cl, Br and I) or triflate (or vice versa); (ii)
in the presence of a base, such as cesium carbonate or potassium
carbonate; (iii) a palladium catalyst, such as Pd(dppf)Cl.sub.2 or
Pd(PPh.sub.3).sub.2Cl.sub.2; and (iv) an organic solvent, such as
dioxane or DMF.
General Method B
[0378] Compounds of the invention may be prepared by reduction of a
keto moiety to a secondary alcohol under reduction conditions.
Suitable conditions include (i) a reducing agent such as
NaBH.sub.4; and (ii) an organic solvent, such as THF.
General Method C
[0379] Compounds of the invention comprising a diol moiety may be
prepared by oxidation of an alkene moiety under oxidation
conditions. Suitable conditions include (i) an oxidizing reagent
such as OsO.sub.4; and (ii) an organic solvent, such as
pyridine.
General Method D
[0380] Compounds of the invention comprising a diol moiety may be
prepared under epoxide ring opening conditions familiar to those in
the art.
General Method E
[0381] Compounds of the invention may be prepared by alkylation of
an aldehyde moiety to a secondary alcohol via organo-metallic
addition. Suitable conditions include (i) a Grignard reagent such
as halo(alkyl)magnesium; and (ii) an organic solvent, such as
Et.sub.2O.
General Method F
[0382] Compounds of the invention may be prepared under Stille
coupling conditions familiar to those in the art. Suitable
conditions include (i) coupling a precursor comprising a halo
(particularly Cl, Br and I) with an intermediate comprising a
stannylated moiety such as tributyltin (or vice versa); (ii) in the
presence of palladium catalyst, such as Pd(PPh.sub.3).sub.4; and
(iii) an organic solvent, such as DMF.
General Method G
[0383] Compounds of the invention may be prepared under Chan-Lam
coupling conditions familiar to those in the art. Suitable
conditions include (i) coupling a precursor containing an N--H
moiety with an intermediate comprising a boronic acid (or vice
versa); (ii) in the presence of a copper reagent such as
Cu(OAc).sub.2.H.sub.2O in an oxygen atmosphere.
General Method H
[0384] Compounds of the invention containing prodrug forms of the
secondary or tertiary alcohol moieties may be formed under suitable
conditions familiar to those in the art. Prodrug forms include
carbamates, phosphates and esters including those derived from
amino acids and dipeptides and suitable conditions to form them are
described in the examples which follow.
General Method I
[0385] Compounds of the invention may be prepared under
Buchwald-Hartwig coupling conditions familiar to those in the art.
Suitable conditions include (i) coupling a precursor comprising of
a halo with an intermediate comprising of a N--H moiety (or vice
versa); (ii) in the presence of a palladium catalyst, such as
Pd.sub.2(dba).sub.3; (iii) a suitable ligand, such as Xantphos;
(iv) a suitable base such as Cs.sub.2CO.sub.3; and (v) an organic
solvent, such as 1,4-dioxane.
Salt Formation Method(s)
[0386] Salts of the compounds of the invention may be formed using
conditions familiar to those in the art, for example, as
follows.
General Salt Formation Conditions
[0387] The free base material is dissolved or suspended in an
organic solvent, organic solvent mixture or organic solvent water
mixture (for example; DCM, THF, THF/MeOH, EtOH) and a
solution/suspension of the acid in the same organic solvent or
organic solvent mixture in molar equivalents of 1 or greater than 1
is added. The acid may also be added neat. The salt product may
precipitate at room temperature or alternatively the addition may
be done at a higher temperature with subsequent cooling to enable
precipitation of the salt product. An antisolvent (for example;
hexanes, n-heptane, Isopropyl acetate) may be added after the
addition of acid to enable precipitation of the salt product which
is collected by vacuum filtration and washed with an appropriate
organic solvent.
Example Hydrochloride Salts
[0388] Hydrochloride salts can be made, for example, by suspending
the compound in a suitable solvent, such as acetonitrile, and
adding aqueous 2M hydrochloric acid solution. Dilution of the
mixture with water and then removal of the solvent gives the
hydrochloride salt of the compound.
Example Methanesulphonic Acid Salts
[0389] Methanesulphonic acid salts can be made, for example, by
suspending the compound in a suitable solvent, such as
acetonitrile, and adding 1 equivalent of methanesulphonic acid in
water. Removal of the solvent gives the methanesulphonic acid salt
of the compound.
Chiral Separation Method(s) and Synthesis
[0390] Compounds of the invention may be separated into their
diastereoisomers or enantiomers under chiral HPLC conditions
familiar to those in the art. Alternatively, chiral precursor
moieties may be resolved from their racemates via derivatization
with a chiral auxiliary, such as a blocked amino acid, e.g,
Boc-valine, separated by fractional crystallization of
diastereomers from a suitable solvent, such as heptane, and
reconstitution of the enantiomeric precursors through cleavage of
the auxiliary, such as base-mediated cleavage on resin or in
solution. Mitsonobu-type inversion of enantiomerically enriched
mixtures of chiral alcohols can also be accomplished by coupling
the alcohol with the chiral auxiliary, such as an amino acid, e.g.
Boc-valine, in the presence of trialkylated phosphines, such as
triphenylphosphine, and dialkylazodicarboxylates, and fractionally
crystallizing the enriched diastereomeric mixture as above.
Protecting Groups
[0391] During the reactions a number of the moieties may need to be
protected. Suitable protecting groups are well known in industry
and have been described in many references such as Protecting
Groups in Organic Synthesis, Greene T W, Wiley-Interscience, New
York, 1981. It will be understood that in addition to protecting
groups such as hydroxyl and amino groups during the course of
reaction, the urea moiety may require protection under any of the
reactions conditions described herein, for example, as a
5-methyl-1,3,5-triazinan-2-one.
Functional Group Interconversions
[0392] Further, it will be understood that compounds of the
invention produced under any of the reaction conditions described
herein may undergo further functionalisation under suitable
conditions familiar to those in the art. That is, the skilled
person will appreciate that a wide diversity of compounds may be
provided by functional group interconversions of hydroxyls and
carboxylates including but not limited to halogens, ethers,
ketones, carboxylic acids, esters, carbonates, amines, amides,
ureas, carbamates, sulfates, sulfonamides, phosphates,
heterocycles, heteroaryls, optionally substituted alkyl chain
extensions and so on.
EXAMPLES
[0393] Those skilled in the art will appreciate that the invention
described herein is susceptible to variations and modifications
other than those specifically described.
[0394] The invention will now be described without limitation by
reference to the examples which follow.
[0395] The abbreviations used in the Examples are as follows unless
indicated otherwise.
Abbreviations
[0396] Ac: acetyl [0397] ACN: acetonitrile [0398] cfus: colony
forming units [0399] DCM: dichloromethane [0400] DIPEA:
N,N-diisopropylethylamine [0401] DMAP: N,N-dimethylpyridin-4-amine
[0402] DMF: N,N-dimethylformamide [0403] DMSO: dimethylsulfoxide
[0404] EtOAc: ethyl acetate [0405] Et.sub.2O: diethyl ether [0406]
EtOH: ethanol [0407] g: gram(s) [0408] h: hour(s) [0409] H.sub.2O:
Water [0410] HPLC: high performance liquid chromatography [0411]
IPA: propan-2-ol [0412] kg: kilogram(s) [0413] L: litre(s) [0414]
LCMS: liquid chromatography coupled mass spectrometry [0415] LDA:
lithium diisopropylamide [0416] M: molar [0417] mg: milligram(s)
[0418] min: minute(s) [0419] mL: millilitre(s) [0420] MeOH:
methanol [0421] mol: mole(s) [0422] mmol: millimole(s) [0423] MS:
mass spectrometry [0424] NBS: N-bromosuccinimide [0425] NMP:
1-methylpyrrolidin-2-one [0426] NMR: nuclear magnetic resonance
[0427] Pd(dppf)Cl.sub.2:
[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), DCM
adduct [0428] Pd.sub.2(dba).sub.3
Tris(dibenzylideneacetone)dipalladium(0) [0429] Pd(PPh.sub.3).sub.4
Tetrakis(triphenylphosphine)palladium(0) [0430] RT: room
temperature [0431] THF: tetrahydrofuran [0432] TLC: thin-layer
chromatography
Compound Synthesis
[0433] .sup.1H NMR spectra were recorded on either a Bruker Avance
DRX 400, AC 200 or AM 300 spectrometer. Spectra were recorded in
deuterated solvents (CDCl.sub.3, MeOD, DMSO-d.sub.6, CD.sub.3CN, or
Acetone-d.sub.6) using the residual solvent peak as a reference.
Chemical shifts are reported on the 6 scale in parts per million
(ppm) using the following conventions to assign the multiplicity: s
(singlet), d (doublet), t (triplet), q (quartet), p (pentet), m
(multiplet) and prefixed br (broad). Mass spectra (ESI) were
recorded on either a Micromass Platform QMS or Thermo Finnigan LCQ
Advantage spectrometer. Flash chromatography was performed on 40-63
.mu.m silica gel 60 (Merck No. 9385). Automated flash
chromatography was performed either on a Combi-Flash.TM.
purification system using Combi-Flash.TM. silica gel columns or on
a Biotage SP4 purification system using either GraceResolv.TM.
silica gel cartridges, Grace Reveleris.TM. C-18 reverse phase
silica gel cartridges or Biotage SNAP.TM. C-18 reverse phase silica
gel cartridges. Preparative HPLC was carried out using either a
Gilson 322 pump with a Gilson 215 liquid handler and a HP1100 PDA
detector or an Agilent 1200 Series mass detected preparative LCMS
using a Varian XRs C-18 100.times.21.2 mm column. Unless otherwise
specified, the HPLC systems employed Phenomenex C8(2) columns using
either acetonitrile or acetonitrile containing 0.06% TFA in water,
water containing 0.1% TFA or water containing 0.1% formic acid.
Example(s) of Intermediates
[2-(ethylcarbamoyl
amino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]boronic acid
(Intermediate 1)
##STR00087##
[0435] .sup.1H-NMR (DMSO-d.sub.6, 400 MHz): .delta. 1.10 (t, J=7.20
Hz, 3H), 3.20 (m, 2H), 6.84 (br s, 1H), 7.41 (m, 1H), 8.01 (m, 1H),
8.12 (s, 1H), 8.25 (m, 3H), 8.40 (s, 1H), 8.79 (d, J=4.0 Hz, 1H)
and 10.57 (br s, 1H). MS: 343.25 [M+H].sup.+.
2-amino-3-bromo-5-nitro-phenol (i)
[0436] To a stirred solution of 2-amino-5-nitro-phenol (500 g, 3.24
mol) in ACN (12 L) was added bromine (290 mL, 5.63 mol) drop wise
over a period of 30 min. The mixture was stirred at 30-35.degree.
C. for 1 h, then the solvent was evaporated to dryness. Hexane (2
L) was added and the mixture evaporated to dryness. Hexane (5 L)
was added and the mixture stirred for 1 h and filtered. The solid
(1102 g) was washed with hexane (2 L). The residue was added to
ice-cold H.sub.2O (2.5 L) followed by the addition of a saturated
solution of sodium thiosulfate (2.5 L) and extraction with EtOAc
(2.times.10 L). The combined organic layers were washed with brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated at
40-45.degree. C. in vacuo to obtain i (643 g, 85%).
3-bromo-5-nitro-phenol (ii)
[0437] To a cooled solution (-10.degree. C.) of i (643 g, 2.76 mol)
in EtOH (13 L) was added conc. H.sub.2SO.sub.4 (515 mL, 9.97 mol)
over a period of 35 min at -10 to -2.degree. C. The mixture was
allowed to warm to RT and then heated to 50-55.degree. C. followed
by the portion-wise addition of NaNO.sub.2 (671 g, 9.72 mol) over
30 min and the mixture heated at reflux for 3 h. The mixture was
concentrated to 3 L and cooled to 0.degree. C. followed by the
addition of H.sub.2O (5 L) and extraction with EtOAc (3.times.6
L).
[0438] The combined organic layers were washed with brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The residue
was treated with 25% ether-hexane mixture (6 L) and stirred for 1
h, filtered and the solid and washed with hexane (3 L) to obtain ii
(505 g, 84%).
1-benzyloxy-3-bromo-5-nitro-benzene (iii)
[0439] To a solution of ii (770 g, 3.53 mol) in acetone (10 L) was
added K.sub.2CO.sub.3 (2.45 kg, 17.75 mol) at RT followed by benzyl
bromide (632 mL, 5.32 mol) over a period of 30 min. The mixture was
stirred for 15 min and then heated at reflux for 3 h. The mixture
was filtered through celite and the acetone was distilled off. The
residue was purified over silica eluting with EtOAc:hexane (5:95)
to obtain iii (551 g, 51%).
3-benzyloxy-5-bromo-aniline (iv)
[0440] To a solution of iii (551 g, 1.78 mol) in THF (11 L) was
added SnCl.sub.2.2H.sub.2O (2.17 kg, 9.62 mol) at RT. The mixture
was refluxed for 3 h.
[0441] The mixture was cooled to 0-5.degree. C. and basified with
saturated NaHCO.sub.3 solution and extracted with EtOAc (4.times.5
L). The combined organic layer were washed with brine, dried
(Na.sub.2SO.sub.4), filtered and concentration in vacuo gave iv
(480 g, 97%).
N-[(3-benzyloxy-5-bromophenyl)carbamothioyl]benzamide (v)
[0442] To a solution of iv (480 g, 1.73 mol) in acetone (10 L) was
added benzoylisothiocyanate (280 mL, 2.08 mol) at RT and the
mixture stirred for 45 min. The acetone was distilled off and
hexane (2 L) added and the mixture concentrated to dryness. To the
residue was added hexane (4 L) and the mixture heated to 40.degree.
C. for 30 min The solid was collected by filtration and washed with
hexane (2.times.2 L) to obtain v (648 g, 85%).
(3-benzyloxy-5-bromo-phenyl)thiourea (vi)
[0443] To a solution of v (648 g, 1.47 mol) in THF (12 L) was added
NaOH solution (300 g, 7.5 mol in 3 L H.sub.2O) at RT. The mixture
was heated at 70.degree. C. overnight. The THF layer was decanted
off and the aqueous layer was extracted with EtOAc (3.times.2 L).
The combined organic layers were washed with brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The residue
was treated with mixture of Et.sub.2O and hexane (5:95, 3.0 L),
filtered, washed with hexane and dried under high vacuum to obtain
vi (387 g, 78%).
5-benzyloxy-7-bromo-1,3-benzothiazol-2-amine (vii)
[0444] To an ice-cold suspension of vi (372 g, 1.10 mol) in ACN (6
L) was added dropwise a solution of bromine (65 mL 1.26 mol in 50
mL ACN) over a period of 30 min. The mixture was stirred for 30 min
at 0-5.degree. C. and then slowly allowed to warm to RT and stirred
for 1 h. The solid was filtered off and washed with hexane
(2.times.3 L). The solid residue was taken in ice H.sub.2O,
basified with aq. NH.sub.3 (pH 10-12) and stirred for 30 min at
5-10.degree. C. The resulting solid was filtered off and washed
with H.sub.2O and dried under high vacuum to obtain vii (216 g,
59%). .sup.1H-NMR (DMSO-d.sub.6, 400 MHz): .delta. 5.12 (s, 2H),
6.92 (d, J=2.40 Hz, 1H), 6.98 (d, J=2.0 Hz, 1H), 7.30-7.45 (m, 5H)
and 7.69 (br s, 2H). MS: 334.79 [M+H].sup.+.
1-(5-benzyloxy-7-bromo-1,3-benzothiazol-2-yl)-3-ethyl-urea
(viii)
[0445] To a suspension of vii (216 g, 0.64 mol) in 1,4-dioxane (4
L) was added ethylisocyanate (380 mL, 4.81 mol). The mixture was
heated up to 80-85.degree. C. overnight. The solvent was distilled
off and the residue was co-evaporated with hexane. The residue was
treated with H.sub.2O at 78-80.degree. C. for 3-5 h. The resulting
solid was filtered off and washed with hot H.sub.2O, dried under
high vacuum to obtain viii (196 g, 75%). .sup.1H-NMR (DMSO-d.sub.6,
400 MHz): .delta. 1.08 (t, J=7.20 Hz, 3H), 3.18 (q, J=6.80 Hz, 2H),
5.17 (s, 2H), 6.71 (br s, 1H), 7.15 (d, J=2.0 Hz, 1H), 7.26 (br s,
1H), 7.31-7.47 (m, 5H) and 10.82 (br s, 1H). MS: 405.90
[M+H].sup.+.
1-[5-benzyloxy-7-(2-pyridyl)-1,3-benzothiazol-2-yl]-3-ethyl-urea
(ix)
[0446] To a stirred solution of viii (110 g, 0.27 mol) in DMF (1.1
L1) was added 2-tributylstannyl pyridine (298 g, 0.81 mol). The
resulting solution was purged with N.sub.2 for 15-20 min followed
by addition of Pd(PPh.sub.3).sub.4 (25.41 g, 0.022 mol). The
resulting reaction mixture was heated to 100.degree. C. under
N.sub.2 atmosphere for 15-16 h. The reaction was cooled to
40-45.degree. C. and filtered through celite. The celite was washed
with DMF (500 mL) and hot EtOAc (1.50 L) and the combined filtrate
concentrated at 60-70.degree. C. in vacuo. The residue was purified
through silica (20% EtOAc-Hexanes to 100% EtOAc) to obtain ix (76
g, 70%). .sup.1H-NMR (DMSO-d.sub.6, 400 MHz): .delta. 1.08 (t,
J=7.20 Hz, 3H), 3.19 (q, J=6.80 Hz, 2H), 5.26 (s, 2H), 6.84 (br s,
1H), 7.32-7.43 (m, 5H), 7.51 (d, J=7.20 Hz, 2H), 7.69 (d, J=2.0 Hz,
1H), 7.95 (m, 1H), 8.25 (m, 1H), 8.78 (m, 1H) and 10.46 (br s, 1H).
MS: 405.30 [M+H].sup.+.
1-ethyl-3-[5-hydroxy-7-(2-pyridyl)-1,3-benzothiazol-2-yl]urea
(x)
[0447] To a stirred solution of ix (76 g, 0.187 mol) in DCM (1.7 L)
was added methane sulfonic acid (270 mL, 4.17 mol) dropwise over 30
min. The mixture was stirred at RT for 3 h. The reaction was
concentrated in vacuo. EtOAc (1 L) was added to the residue and
this solution was poured carefully onto the crushed ice. The pH of
the solution was modified to 8-9 by addition of saturated
NaHCO.sub.3 solution followed by extraction with EtOAc (3.times.5
L). The combined organics were washed with H.sub.2O, brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The residue
was stirred in Et.sub.2O (1.0 L) for 1 h at RT and then filtered to
obtain x (57.0 g, 97%). .sup.1H-NMR (DMSO-d.sub.6, 400 MHz):
.delta. 1.08 (t, J=7.20 Hz, 3H), 3.20 (m, 2H), 6.86 (br s, 1H), 7.0
(s, 1H), 7.46 (s, 2H), 7.96 (m, 1H), 8.10 (m, 1H), 8.76 (m, 1H),
9.59 (br s, 1H) and 10.41 (br s, 1H). MS: 315.06 [M+H].sup.+.
[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]trifluorometh-
anesulfonate (xi)
[0448] To a stirred solution of x (57 g, 0.181 mol) in DMF (1.7 L)
was added N-phenylbis(trifluromethane sulphonimide) (80.74 g, 0.226
mol) and DIPEA (28 g, 0.217 mol). The mixture was stirred at RT for
3 h. The reaction was concentrated at 60-70.degree. C. in vacuo.
Et.sub.2O was added to the residue and evaporated to dryness. The
residue thus obtained was stirred with Et.sub.2O (1.5 L) for 1 h
and then filtered to obtain xi (55.0 g, 68%). .sup.1H-NMR
(DMSO-d.sub.6, 400 MHz): .delta. 1.11 (t, J=7.20 Hz, 3H), 3.20 (m,
2H), 6.81 (br s, 1H), 7.50 (m, 1H), 7.78 (d, J=2.0 Hz, 1H), 8.01
(m, 1H), 8.12 (d, J=2.40 Hz, 1H), 8.35 (m, 1H), 8.84 (m, 1H) and
10.77 (br s, 1H). MS: 446.98 [M+H].sup.+.
[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]boronic
acid (Intermediate 1)
[0449] To a stirred solution of xi (25 g, 56.1 mmol) in DMSO (250
mL) at RT was added bis(neopentylglycolato) diboron (25.2 g, 112
mmol) and KOAc (16.5 g, 168 mmol). The resulting reaction mixture
was de-gassed by purging N.sub.2 for 15-20 min followed by addition
of Pd(dppf)Cl.sub.2 (6.8 g, 8.4 mmol). The mixture was purged with
N.sub.2 for 15-20 min and then heated to 80.degree. C. for 90 min.
The reaction was poured onto saturated NH.sub.4Cl solution (1 L).
The resulting precipitate was filtered and dried under vacuum. The
solid cake was taken in 2M NaOH (200 mL) and stirred for 45 min at
RT. The solution was filtered and the filtrate was acidified up to
pH 5-6 and the resulting solid collected by filtration to give
Intermediate 1 (17 g, 88%).
[0450] The following intermediate(s) were similarly prepared:
[2-(Ethylcarbamoyl
amino)-7-[4-(morpholinomethyl)-2-pyridyl]-1,3-benzothiazol-5-yl]boronic
acid (Intermediate 2)
##STR00088##
[0452] MS: 413.13 [M+H].sup.+.
[0453] Prepared in analogous manner to Intermediate 1 with the
exception that the addition of the C7-substituent to
1-(5-benzyloxy-7-bromo-1,3-benzothiazol-2-yl)-3-ethyl-urea was
performed under Suzuki coupling conditions instead of Stille
coupling conditions as follows:
1-[5-benzyloxy-7-[4-(morpholinomethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]-3-
-ethyl-urea (i)
[0454] A mixture of
1-(5-benzyloxy-7-bromo-1,3-benzothiazol-2-yl)-3-ethyl-urea (27.7 g,
68.3 mmol),
2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxab-
orinane (18.2 g, 80.7 mmol) and potassium acetate (12.2 g, 124
mmol) was suspended in DMSO (120 mL). The mixture was degassed for
15 min with a stream of N.sub.2. Pd(dppf)Cl.sub.2 (5.07 g, 6.21
mmol) was added and the mixture heated for 6 h at 85.degree. C.,
then cooled to RT. A solution of Precursor 10 (13.2 g, 62.1 mmol)
in DMSO (20 mL) was added, followed by Cs.sub.2CO.sub.3 (30.3 g,
93.1 mmol) and H.sub.2O (30 mL). The mixture was degassed for 10
min under a stream of N.sub.2. Pd(PPh.sub.3).sub.2Cl.sub.2 (4.36 g,
6.21 mmol) was added and the mixture heated at 85.degree. C.
overnight. The solution was cooled and diluted with water (400 mL),
stirred vigorously until a solid formed and the supernatant
discarded. The solids were suspended in EtOAc/DCM (300 mL) and
filtered through a short plug of silica gel, eluting with 5-10%
MeOH/DCM. The solution was then concentrated, dissolved in DCM (500
mL) and stirred with 3M HCl (150 mL) for 2 days at RT. The
precipitate was collected by filtration, washing with DCM and
H.sub.2O. The resulting solid material was suspended in EtOAc/DCM
(200 mL), sonicated and the solid collected by filtration to obtain
i (25.5 g). MS: 504.17 [M+H].sup.+.
1-(7-bromo-5-iodo-1,3-benzothiazol-2-yl)-3-ethyl-urea (Intermediate
3)
##STR00089##
[0456] .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta. 1.08 (t, J=7.20
Hz, 3H), 3.20 (q, J=6.80, 2H), 6.73 (br s, 1H), 7.72 (s, 1H), 7.96
(s, 1H) and 11.07 (br s, 1H). MS: 426.0 [M+H].sup.+.
2-bromo-4,6-dinitroaniline (i)
[0457] To a stirred mixture of H.sub.2O (3.75 L) and acetic acid
(375 mL) at RT was added 2,4-dinitroaniline (500 g, 2.73 mol)
followed by drop wise addition of bromine (210 mL, 4.09 mol) over
30 min. The reaction mixture was stirred at RT for 15 min and then
heated to 100.degree. C. for 2 h. The reaction was cooled to RT and
poured onto ice-cold H.sub.2O (5-6 L) and basified (pH 8-10) with
aqueous ammonia. The solid was filtered, washed with cold H.sub.2O
and dried under vacuum. This solid was washed with n-pentane to
obtain i (600 g, 84%).
1,2-dibromo-3,5-dinitrobenzene (ii)
[0458] To a stirred solution of i (600 g, 2.28 mol) in ACN (5 L) at
RT was added tert-butylnitrite (680 mL, 5.7 mol) and cupric bromide
(767 g, 3.43 mol). The mixture was heated to 70.degree. C. for 1 h
under N.sub.2. The reaction was cooled to RT, acidified with 1M HCl
solution, H.sub.2O (4 L) added and extracted with EtOAc (3.times.4
L). The combined organics were dried (Na.sub.2SO.sub.4), filtered
and concentrated in vacuo to obtain ii (723 g, 97%). .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 8.48 (d, J=2.40 Hz, 1H) and 8.68 (d,
J=2.40 Hz, 1H).
(2-bromo-4,6-dinitro-phenyl) thiocyanate (iii)
[0459] To a stirred solution of ii (723 g, 2.22 mol) in MeOH (7.5
L) at RT was added potassium thiocyanate (431 g, 4.44 mol) and the
mixture stirred under N.sub.2 for 16 h. The reaction was filtered
and washed with MeOH. The filtrate was concentrated in vacuo. The
residue was purified over silica (2-6% EtOAc-hexane) to obtain iii
(549 g, 81%).
7-bromobenzothiazole-2,5-diamine (iv)
[0460] To a stirred mixture of EtOH (8.37 L) and H.sub.2O (8.37 L)
at RT was added iii (549 g, 1.81 mol) followed by addition of Fe
powder (2.02 kg, 36.11 mol) and drop wise addition of HCl (12M, 527
mL) over 30 min. The mixture was stirred at RT for 20 min and then
heated to 80.degree. C. for 45 min.
[0461] The reaction was cooled to RT, basified to pH 8-10 by
addition of aqueous ammonia solution. The solution was passed
through celite, washed with EtOAc and the combined filtrate
evaporated in vacuo. H.sub.2O (8 L) was added and extracted with
EtOAc (2.times.4 L). The combined organics were washed with brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo to
obtain iv (412 g, 93%). .sup.1H NMR (DMSO-d.sub.6, 400 MHz):
.delta. 5.16 (br s, 2H), 6.50 (d, J=2.0 Hz, 1H), 6.53 (d, J=1.60
Hz, 1H) and 7.44 (br s, 2H). MS: 243.86 [M+H].sup.+.
7-bromo-5-iodobenzothiazol-2-amine (v)
[0462] To THF (6 L) at -78.degree. C. under N.sub.2 was added
BF.sub.3-etherate (50% assay, 708 mL, 2.81 mol) followed by a slow
addition of a solution of iv (275 g, 1.02 mol) in THF (500 mL) over
20 min. Tert-butyl nitrite (548 L, 4.61 mol) was then added to the
solution at -78.degree. C. and the mixture was stirred at the same
temperature for 40 min and then warmed to -5-0.degree. C. Et.sub.2O
was added (at -5-0.degree. C.) and the mixture stirred for 20 min.
The solid was filtered and taken in acetone at 0.degree. C.
followed by sequential addition of KI (510 g, 3.07 mol) and iodine
(519 g, 2.04 mol) and the mixture stirred at 0.degree. C. for 30
min. The reaction was quenched with saturated solution of sodium
metabisulfite and extracted with EtOAc (3.times.5 L). The combined
organics were dried (Na.sub.2SO.sub.4), filtered and concentrated
in vacuo at 45.degree. C. The residue was purified over basic
alumina (30-35% EtOAc-hexane) to obtain v (235 g, 65%). .sup.1H NMR
(DMSO-d.sub.6, 400 MHz): .delta. 7.50 (d, J=1.20 Hz, 1H), 7.63 (d,
J=1.20 Hz, 1H) and 7.91 (br s, 2H). MS: 354.90 [M+H].sup.+.
1-(7-bromo-5-iodobenzothiazol-2-yl)-3-ethylurea (Intermediate
3)
[0463] To a stirred solution of vi (250 g, 0.70 mol) in 1,4-dioxane
at RT was added ethylisocyanate (278 mL, 3.52 mol). The mixture was
heated to 80.degree. C. for 10-12 h under N.sub.2. The solvent was
evaporated, n-hexane added and the mixture concentrated to dryness.
The residue was stirred in hot H.sub.2O (2 L) at 60-65.degree. C.
for 30-40 min and then filtered. The residue was then treated with
a mixture of Et.sub.2O and n-pentane and filtered to obtain
Intermediate 3 (264 g, 88%).
1-[7-Bromo-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-
-2-yl]-3-ethyl-5-methyl-1,3,5-triazinan-2-one (Intermediate 4)
##STR00090##
[0465] .sup.1H NMR (DMSO-d.sub.6 400 MHz): .delta. 9.20 (s, 2H),
8.13 (s, 1H), 7.91 (s, 1H), 5.14 (m, 3H), 4.39 (s, 2H), 3.36 (q,
J=7.20 Hz, 2H), 2.54 (s, 3H), 1.53 (s, 6H) and 1.12 (t, J=7.20 Hz,
3H).
2-(5-bromopyrimidin-2-yl)propan-2-ol) (i)
[0466] To an ice-cold solution of methyl
5-bromopyrimidine-2-carboxylate (10 g, 46.1 mmol) in Et.sub.2O (200
mL) was added drop wise methyl magnesium bromide (3.0 M in
Et.sub.2O, 61.4 mL, 184 mmol) over 30 min. The reaction mixture was
slowly warmed up to RT and continued to stir for 2 h. The mixture
was quenched with saturated NH.sub.4Cl solution at 0.degree. C. and
the organic layer separated from the biphasic solution. The aqueous
layer was re-extracted with EtOAc (2.times.250 mL). The combined
organic layers were washed with brine solution, dried over
Na.sub.2SO.sub.4, filtered and evaporated in vacuo. The crude
residue was purified over silica eluting with 20% EtOAc:hexane to
obtain i (6.0 g, 62%). 1HNMR (DMSO-d6, 400 MHz): .delta. 8.97 (s,
2H), 5.15 (s, 1H) and 1.47 (s, 6H).
2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)propan-2--
ol (ii)
[0467] To the solution of i (6.0 g, 27.6 mmol) in 1,4-dioxane (60
mL) was added bis(pinacolato)diboron (8.42 g, 33.2 mmol) and KOAc
(4.06 g, 41.5 mmol). The reaction mass was degassed by purging
N.sub.2 for 15 min. Pd.sub.2(dba), (1.43 g, 1.4 mmol) and
tricyclohexylphosphine (0.93 g, 3.31 mmol) was added to the
reaction mixture that was degassed for 10 min. The resulting
reaction mixture was heated at 80.degree. C. for 2 h. The mixture
was cooled to RT and filtered through a celite bed. The filtrate
was concentrated in vacuo to obtain ii (5.11 g, 70%). MS: 265.13
[M+H].sup.+.
1-(7-bromo-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)benzo[d]thiazol-2-yl)-
-3-ethyl-5-methyl-1,3,5-triazinan-2-one (Intermediate 4)
[0468] To a solution of Intermediate 3 (7.50 g, 15.48 mmol) and ii
(5.11 g, 19.36 mmol) in 1,4-dioxane:MeOH (75:50 mL) was added
potassium phosphate (6.15 g, 29.03 mmol) at RT. The resulting
mixture was degassed for 15-20 min by purging N.sub.2 followed by
the addition of Pd(PPh.sub.3).sub.4 (2.23 g, 1.93 mmol). The
reaction mixture was again degassed for another 15-20 min and then
heated up to 80.degree. C. for 2 h. The mixture was cooled to RT
and passed through celite bed and washed with EtOAc. The filtrate
was evaporated in vacuo and the residue purified over silica
eluting with 3% MeOH:DCM to obtain Intermediate 4 (7.50 g,
97%).
[0469] The following intermediate(s) were similarly prepared.
1-[7-bromo-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-benzothiazol-
-2-yl]-3-ethyl-urea (Intermediate 5)
##STR00091##
[0471] MS: 437.91 [M+H].sup.+.
1-(5-Bromo-6-methoxy-1,3-benzothiazol-2-yl)-3-ethyl-urea
(Intermediate 6)
##STR00092##
[0473] MS: 329.94 & 331.91 [M+H].sup.+.
1-Ethyl-3-(6-methoxy-1,3-benzothiazol-2-yl)urea (i)
[0474] 6-methoxy-1,3-benzothiazol-2-amine (5.0 g, 27.7 mmol) was
dissolved in anhydrous DMSO (20 mL) and triethylamine (15.5 mL, 111
mmol) followed by ethyl isocyanate (4.39 mL, 55.5 mmol) were added.
The mixture was stirred at RT under N.sub.2 for 4 h then quenched
with H.sub.2O (.about.200 mL) and stirred for 1 h. The resulting
white solid was collected by filtration and rinsed with H.sub.2O
and then with acetone (100 mL) and the filtrate collected
separately to the aqueous filtrate. The filtrate was concentrated
to dryness in vacuo and combined with the solid collected by
filtration to obtain i (6.27 g, 90%). MS: 251.96 [M+H].sup.+.
1-(5-Bromo-6-methoxy-1,3-benzothiazol-2-yl)-3-ethyl-urea
(Intermediate 6)
[0475] Compound i (1.10 g, 4.38 mmol) was suspended in DCM (50 mL)
and MeOH (5 mL) and bromine (0.34 mL, 6.60 mmol) added. The mixture
was stirred at RT for 1.5 h then concentrated to dryness in vacuo
to give Intermediate 6 (2.17 g).
Ethyl
1-[5-[7-bromo-2-(ethylcarbamoylamino)-1,3-benzothiazol-5-yl]pyrimidi-
n-2-yl]-4-methyl-piperidine-4-carboxylate (Intermediate 7)
##STR00093##
[0477] .sup.1H NMR (DMSO-d.sub.6 400 MHz): .delta. 1.09 (t, J=7.20
Hz, 3H), 1.20 (m, 6H), 1.45 (m, 2H), 2.03 (m, 2H), 3.16 (m, 2H),
3.30 (q, J=7.20, 2H), 4.12 (q, J=6.80 Hz, 2H), 4.25 (m, 2H), 6.75
(br s, 1H), 7.69 (s, 1H), 7.86 (s, 1H); 8.75 (s, 2H) and 10.91 (br
s, 1H). MS: 547.11 [M+H].sup.+.
O1-tert-butyl O4-ethyl 4-methylpiperidine-1,4-dicarboxylate (i)
[0478] A solution of O1-tert-butyl O4-ethyl
piperidine-1,4-dicarboxylate (1.5 g, 5.84 mmol) in THF (25 mL) was
cooled to -78.degree. C. followed by dropwise addition of LDA (1.80
M in THF, 6.5 mL, 11.68 mmol) at -78.degree. C. The resulting
mixture was stirred at -78.degree. C. for 45 min followed by
addition of methyl iodide (1.2 mL, 17.52 mmol). The temperature was
slowly raised up to RT and left at RT for 6 h. The reaction was
cooled to 0.degree. C. and quenched by the dropwise addition of
saturated NH.sub.4Cl solution (50 mL). The reaction was extracted
with EtOAc (3.times.100 mL). The combined organics were washed with
brine, dried (Na.sub.2SO.sub.4), filtered and concentrated in
vacuo. Purification by chromatography on silica eluting with 2%
EtOAc in hexane gave i (1.0 g, 65%).
Ethyl 4-methylpiperidine-4-carboxylate hydrochloride (ii)
[0479] To an ice-cold solution of i (1 g, 3.68 mmol) in 1,4-dioxane
(10 mL) was added HCl-1,4-dioxane (4.0 M, 15 mL) solution and
stirred at RT for 30 min. The solvent was evaporated to obtain ii
(0.90 g). MS: 172.16 [M+H].sup.+.
Ethyl 1-(5-bromopyrimidin-2-yl)-4-methylpiperidine-4-carboxylate
(iii)
[0480] To a solution of ii (0.9 g, 4.35 mmol) in EtOH (10 mL) was
added DIPEA (2.30 mL, 13 mmol) at RT and the mixture stirred at RT
for 10 min followed by addition of 5-bromo-2-chloropyrimidine (0.7
g, 3.6 mmol). The mixture was heated at 70.degree. C. for 1 h. The
solvent was evaporated and the crude residue purified by
chromatography on silica eluting with 1.5% EtOAc:hexane to obtain
iii (0.90 g, 75%). .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta.
1.17 (s, 3H), 1.21 (t, J=7.20 Hz, 3H) 1.40 (m, 2H), 2.00 (m, 2H),
3.24 (m, 2H), 4.11 (m, 2H), 4.15 (q, J=7.20 Hz, 2H), 8.43 (s, 2H).
MS: 328.08 [M+H].sup.+.
Ethyl
4-methyl-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-
-2-yl)piperidine-4-carboxylate (iv)
[0481] To the solution of iii (25 g, 76.2 mmol) in 1,4-dioxane (250
mL) was added potassium acetate (22.4 g, 228.6 mmol) and
bis(pinacolato)diboron (38.7 g, 152.4 mmol). The mixture was
degassed for 15-20 min by purging with N.sub.2 followed by the
addition of Pd.sub.2(dba).sub.3 (4.0 g, 3.80 mmol) and
tricyclohexyl phosphine (2.55 gm, 9.12 mmol). The mixture was again
degassed for another 15-20 min and then heated up to 80.degree. C.
for 3 h. The mixture was cooled to RT and diluted with 500 mL of
EtOAc and passed through a celite bed. The filtrate was evaporated
to obtain iv (20 g, 70%). MS: 376.30 [M+H].sup.+.
Ethyl
1-(5-(7-bromo-2-(3-ethylureido)benzothiazol-5-yl)pyrimidin-2-yl)-4-m-
ethylpiperidine-4-carboxylate (Intermediate 7)
[0482] To a solution of Intermediate 3 (22.7 g, 53.2 mmol) and iv
(20 g, 53.2 mmol) in 1,4-dioxane:MeOH (300:180 mL) was added
potassium phosphate (17 g, 79 mmol) at RT. The resulting mixture
was degassed for 15-20 min by purging N.sub.2 followed by the
addition of Pd(PPh.sub.3).sub.4 (6.1 g, 5.32 mmol). The reaction
mixture was again degassed for another 15-20 min and then heated up
to 80.degree. C. for 5 h. The reaction mixture was cooled to RT,
diluted with EtOAc (500 mL) and passed through celite bed. The
filtrate was evaporated and the crude residue was purified by
chromatography on silica eluting with 1.5% MeOH:DCM to obtain
Intermediate 7 (12 g, 41%).
1-(7-bromo-5-iodobenzo[d]thiazol-2-yl)-3-ethyl-5-methyl-1,3,5-triazinan-2--
one (Intermediate 8)
##STR00094##
[0484] .sup.1H-NMR (DMSO-d.sub.6, 400 MHz): .delta. 1.11 (t, J=7.20
Hz, 3H), 2.50 (s, 3H), 3.35 (m, 2H), 4.37 (s, 2H), 5.07 (s, 2H),
7.48 (s, 1H), 8.01 (s, 1H).
[0485] To a solution of Intermediate 3 (50 g, 117.37 mmol) in MeOH
(1 L) was added formaldehyde (37% aq solution, 95 mL), methylamine
(2M solution in THF, 587 mL, 1.17 mol) and N-methylmorpholine (130
mL, 1.17 mmol). The resulting solution was stirred at 75.degree. C.
for 5-6 h. The MeOH was evaporated in vacuo. Then ice-cold
H.sub.2O, was added and the mixture stirred for 30 min and then
filtered. The residue was washed with cold H.sub.2O followed by
n-hexane and EtOAc. The residue was dried under high vacuum to give
Intermediate 8 (56 g, quantitative).
1-Ethyl-3-[7-hydroxy-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-be-
nzothiazol-2-yl]-5-methyl-1,3,5-triazinan-2-one (Intermediate
9)
##STR00095##
[0487] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.68 (s, 1H), 8.83
(s, 2H), 7.34 (s, 1H), 6.82 (s, 1H), 5.07 (s, 2H), 4.63 (s, 1H),
4.21 (s, 2H), 3.37 (q, J=7.0 Hz, 2H), 2.55 (s, 3H), 1.52 (s, 6H),
1.13-1.08 (m, 4H). MS: 429 [M+H].sup.+.
[2-(3-ethyl-5-methyl-2-oxo-1,3,5-triazinan-1-yl)-5-[2-(1-hydroxy-1-methyl--
ethyl)pyrimidin-5-yl]-1,3-benzothiazol-7-yl]boronic acid (i)
[0488] A mixture of Intermediate 4 (500 mg), potassium acetate (300
mg), bis(neopentyl glycolato) diboron (460 mg) and
Pd(dppf).sub.2Cl.sub.2 (70 mg) in toluene (10 mL) was degassed
(.times.3) under vacuum then heated at 130.degree. C. for 90 min.
The mixture was cooled and filtered through Celite. The filtrate
was concentrated to give i (465 mg). MS: 457.02 [M+H].sup.+.
1-ethyl-3-[7-hydroxy-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-1,3-be-
nzothiazol-2-yl]-5-methyl-1,3,5-triazinan-2-one (Intermediate
9)
[0489] A solution of Compound ii (465 mg) in acetone (5 mL) was
chilled to 0.degree. C. then treated dropwise with a solution of
oxone (940 mg) in sat NaHCO.sub.3 (35 mL). The reaction was stirred
at RT overnight, then oxone (100 mg) in sat NaHCO.sub.3 (5 mL) was
added. The mixture was neutralised with 1M HCl and extracted with
4:1 DCM:IPA (3.times.30 mL). The organic extract was washed with
brine (20 mL) then concentrated. The residue was suspended in 5%
MeOH:DCM and purified by chromatography on silica eluting with
0-10% MeOH:DCM to give Intermediate 9 (240 mg).
[0490] The following intermediate(s) were similarly prepared.
1-ethyl-3-[7-hydroxy-5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-1,3-benzothiazol-
-2-yl]-5-methyl-1,3,5-triazinan-2-one (Intermediate 10)
##STR00096##
[0492] MS: 415.1 [M+H].sup.+.
1-[5-bromo-7-(dimethylaminomethyl)-6-hydroxy-1,3-benzothiazol-2-yl]-3-ethy-
l-urea (Intermediate 11)
##STR00097##
[0494] MS 372.89 & 374.87 [M+H].sup.+.
Preparation of
1-(5-bromo-6-hydroxy-1,3-benzothiazol-2-yl)-3-ethyl-urea (i)
[0495] Intermediate 6 (1.30 g, 3.94 mmol) was suspended in hydrogen
bromide solution (6.82 mL, 47% aq., 59.1 mmol) and the resulting
suspension warmed to 110.degree. C. Hydrogen bromide solution (14
mL, 47% aq., 121.3 mmol) was added portion-wise over the course of
the reaction. After 47 h, the reaction mixture was cooled to RT
then in ice and the pH adjusted with sodium hydroxide solution (1
M, aq.) to pH 8. The mixture was filtered and the resulting solid
washed with H.sub.2O and ACN. The solid was sucked dry to give i
(1.01 g, 81%). MS 315.87 & 317.84 [M+H].sup.+.
1-[5-bromo-7-(dimethylaminomethyl)-6-hydroxy-1,3-benzothiazol-2-yl]-3-ethy-
l-urea (Intermediate 11)
[0496] To a mixture of i (209 mg, 0.66 mmol) in DMF (2 mL) was
added triethylamine (0.14 mL, 0.99 mmol) followed by
N,N-dimethylmethyleneiminium chloride (147 mg, 0.79 mmol) were
added. The mixture was stirred at RT. After 4.25 h, more
N,N-dimethylmethyleneiminium chloride (.about.10 mg) was added and
stirring continued. After 6 h, the solvent was evaporated with a
stream of N.sub.2. The residue was suspended in DCM (.about.10 mL)
and filtered through a PTFE filter. The solid was washed with DCM
(.about.15 ml) and the filtrate concentrated in vacuo to give an
oil. The oil was purified by chromatography, on silica eluting with
0-5% MeOH in DCM to give Intermediate 11 (176 mg, 71%).
1-[5-bromo-6-hydroxy-7-(morpholinomethyl)-1,3-benzothiazol-2-yl]-3-ethyl-u-
rea (Intermediate 12)
##STR00098##
[0498] MS 414.93 & 416.91 [M+H].sup.+.
[0499] Paraformaldehyde (29 mg, 0.05 mmol) was suspended in
anhydrous DMF (2 mL) under argon and morpholine (0.08 mL, 0.95
mmol) added. The mixture was stirred at RT for 10 min then
Intermediate 6 (200 mg, 0.63 mmol) added. The mixture was stirred
at RT overnight, heated to 90.degree. C. for 2 h then cooled to RT.
The mixture was diluted with H.sub.2O and a precipitate formed.
EtOAc was added but the precipitate remained insoluble. The
suspension was filtered through a PTFE filter and the solid rinsed
with H.sub.2O and EtOAc. The biphasic filtrate was extracted into
EtOAc (4.times.20 mL). The combined organic layers were washed with
H.sub.2O (3.times.50 mL), dried (Na.sub.2SO.sub.4) and concentrated
in vacuo. The material was purified by chromatography, on silica
eluting with 0-10% MeOH in DCM to give Intermediate 12 (28 mg,
11%).
1-(5-Bromo-6-fluoro-benzothiazol-2-yl)-3-ethyl-urea (Intermediate
13)
##STR00099##
[0501] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 1.08 (t, J=6.80
Hz, 31H), 3.17 (m, 2H), 6.69 (br s, 1H), 7.92 (d, J=6.40 Hz, 1H),
8.0 (d, J=8.40 Hz, 1H) and 10.86 (br s, 1H).
1-Benzoyl-3-(5-bromo-2,4-difluoro-phenyl)-thiourea (i)
[0502] To a solution of 5-bromo-2,4-difluoro-aniline (1.0 g, 4.81
mmol) in acetone (25.0 mL) was added drop wise benzoyl
isothiocyanate (0.71 mL, 5.29 mmol) and the mixture stirred at RT
for 30 min. The solvent was evaporated and the residue washed with
hexane and Et.sub.2O to get i (1.70 g). .sup.1H-NMR (400 MHz,
CDCl.sub.1): .delta. 7.02-7.06 (m, 1H), 7.56 (t, J=8.0 Hz, 2H),
7.68 (t, J=7.60 Hz, 1H), 7.91 (d, J=7.60 Hz, 2H), 8.67 (t, J=7.60
Hz, 1H), 9.15 (br s, 1H) and 12.65 (br s, 1H).
(5-Bromo-2,4-difluoro-phenyl)-thiourea (ii)
[0503] To a solution of i (1.70 g, 4.60 mmol) in THF (35.0 mL) was
added a solution of NaOH (0.97 g, 24.25 mmol) in H.sub.2O (13.0
mL). The mixture was stirred at 70.degree. C. for 15 h. The THF was
evaporated, H.sub.2O added and the mixture extracted with EtOAc
(3.times.50 mL). The combined organics were washed with brine and
concentrated to obtain ii (1.0 g, 83%). MS 267.03 (M+H).sup.+.
5-Bromo-6-fluoro-benzothiazol-2-ylamine (iii)
[0504] To a solution of ii (0.75 g, 2.80 mmol) in NMP (5.0 mL) was
added NaH (0.17 g, 4.21 mmol, 60% dispersion in oil) portion wise.
The mixture was heated at 130.degree. C. for 2 h. and then poured
onto crushed ice and extracted with EtOAc (3.times.50 mL). The
combined organics were evaporated. Purification by chromatography
on silica eluting with 12% EtOAc-Hexane gave iii (0.36 g, 52%).
.sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.57 (d, J=6.40 Hz,
1H), 7.66 (br s, 2H) and 7.79 (d, 8.80 Hz, 1H).
1-(5-Bromo-6-fluoro-benzothiazol-2-yl)-3-ethyl-urea (Intermediate
13)
[0505] To a solution of iii (0.36 g, 1.45 mmol) in 1,4-dioxane
(25.0 mL) was added ethyl isocyanate (0.69 mL, 8.74 mmol) and the
mixture heated at 80.degree. C. for 15 h. The solvent was
evaporated and the residue stirred with H.sub.2O at 60.degree. C.
for 5 h. The solution was filtered and washed with Et.sub.2O to
obtain Intermediate 13 (0.30 g, 69%).
Example(s) of Precursor(s)
##STR00100##
[0507] Ethyl 5-bromopyrimidine-2-carboxylate (500 mg) was placed in
Et.sub.2O (10 mL) and the mixture cooled to 0.degree. C. Methyl
magnesium bromide (3M in Et.sub.2O) (1.32 mL) was added dropwise,
the reaction allowed to warm to RT and stirred for 30 min. The
reaction was quenched by the addition of Na.sub.2CO.sub.3 solution
(sat. aq. 2 mL), diluted with H.sub.2O (50 mL) and extracted with
EtOAc (2.times.50 mL). The combined organics were dried
(MgSO.sub.4) and concentrated in vacuo. Purification by
chromatography on silica, eluting with a gradient of 0-100% EtOAc
in hexane gave Precursor 1 (256 mg).
[0508] The following precursor(s) were similarly prepared.
##STR00101##
[0509] A flask containing 5-bromo-2-iodo-pyridine (500 mg) in THF
(2.5 mL) was cooled to -5.degree. C. Isopropyl magnesium chloride
(2M in THF) (0.92 mL) was added slowly and the reaction stirred for
50 min. 1-Methylimidazole-2-carbaldehyde (288 mg) was added and the
mixture stirred for 3 h. The mixture was cooled to 0.degree. C. and
2M HCl added until the pH .about.7, then H.sub.2O (2 mL) and
toluene (10 mL) were added and the organic layer collected and
concentrated. This was partitioned between EtOAc and H.sub.2O and
the organic layer dried (MgSO.sub.4) and concentrated. The residue
was crystallised from EtOAc to give Precursor 3 (150 mg).
##STR00102##
[0510] 5-Bromo-2-iodo-pyrimidine (1 g) was dissolved in THF (15 mL)
and chloro(methyl)magnesium (3M in Et.sub.2O, 2.34 mL) was added at
-78.degree. C., then the mixture was stirred at -78.degree. C. for
30 min. Acetaldehyde (0.60 mL) was added dropwise to the resulting
solution and the reaction was allowed to stir whilst warming to
0.degree. C. over 30 min. MeOH was added and the mixture
concentrated in vacuo. The resultant solid was dissolved in DCM/IPA
(5:1; 80 mL) and washed with brine (50 mL.). Purification by
chromatography on silica, eluting with 0-20% EtOAc in heptane gave
Precursor 4 (244 mg).
[0511] The following precursor(s) were similarly prepared.
##STR00103##
[0512] To a solution of 2-chloro-4-(chloromethyl)pyridine (10 g) in
THF (200 mL) was added morpholine (5.94 mL) and K.sub.2CO.sub.3
(18.8 g). The mixture was stirred at RT for 3 days. The reaction
was filtered, the solids washed with EtOAc, and the filtrate
concentrated. This material was purified on a plug of silica (0-50%
EtOAc/DCM) to give Precursor 10 (6.87 g).
TABLE-US-00001 Ethyl 1-(2-chloro-4-pyridyl)- 4-methyl-piperidine-4-
carboxylate (Precursor 11) ##STR00104## .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.91 (d, J = 5.60 Hz, 1H), 6.81-6.83 (m,
2H), 4.10 (q, J = 6.80 Hz, 2H), 3.64-3.70 (m, 2H), 3.01-3.08 (m,
2H), 1.97- 2.01 (m, 2H), 1.39-1.46 (m, 2H) and 1.16-1.23 (m,
6H).
[0513] To a solution of 4-bromo-2-chloro-pyridine (2.0 g, 10.39
mmol) in EtOH (25 mL) was added DIPEA (5.50 mL, 31.17 mmol)
followed by ethyl 4-methylpiperidine-4-carboxylate hydrochloride
(2.60 g, 12.50 mmol). The resulting reaction mixture was heated up
to 85.degree. C. for 16 h. The solvent was evaporated and the
residue purified over silica eluting with 20% EtOAc-hexanes to give
Precursor 11 (1.80 g, 75%).
[0514] The following precursor(s) were similarly prepared.
TABLE-US-00002 ethyl 1-(6-bromo-2- pyridyl)-4-methyl-
piperidine-4-carboxylate (Precursor 12) ##STR00105## MS: 327.0 [M +
H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.22 (s, 1H),
6.70 (d, J = 7.60 Hz, 1H), 6.51 (d, J = 8.40 Hz, 1H), 4.16 (q, J =
6.80 Hz, 2H), 3.88-3.94 (m, 2H), 3.07-3.14 (m, 2H), 2.15-2.18 (m,
2H), 1.43-1.50 (m, 2H) and 1.22-1.28 (m, 6H). ethyl 1-(6-chloro-3-
pyridyl)-4-methyl- piperidine-4-carboxylate (Precursor 13)
##STR00106## MS 283.11 [M + H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.14 (d, J = 2.40 Hz, 1H), 7.63 (dd, J =
2.40 and 9.20 Hz, 1H), 6.81 (d, J = 9.20 Hz, 1H), 4.10 (q, J = 7.20
Hz, 2H), 3.84-3.89 (m, 2H), 3.05-3.12 (m, 2H), 1.96-2.0 (m, 2H),
1.36-1.43 (m, 2H) and 1.16-1.20 (m, 6H). ethyl 1-(4-
chloropyrimidin-2-yl)-4- meihyl-piperidine-4- carboxylate
(Precursor 14) ##STR00107## MS 284.19 [M + H].sup.+. .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 8.0 (d, J = 6.40 Hz, 1H), 6.37 (d, J
= 6.40 Hz, 1H), 4.20 (q, J = 6.80 Hz, 2H), 4.11 (m, 2H), 3.13-3.20
(m, 2H), 2.19-2.22 (m, 2H), 1.40-1.48 (m, 2H) and 1.24-1.29 (m,
6H). ethyl 1-(2- chloropyrimidin-4-yl)-4- methyl-piperidine-4-
carboxylate (Precursor 15) ##STR00108## MS 284.05 [M + H].sup.+.
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.05 (d, J = 6.0 Hz,
1H), 6.85 (d, J = 5.60 Hz, 1H), 4.13 (q, J = 7.20 Hz, 2H), 3.99 (m,
2H), 3.15-3.21 (m, 2H), 1.98-2.02 (m, 2H), 1.38-1.45 (m, 2H) and
1.17-1.22 (m, 6H). ethyl 1-(6- chloropyrimidin-4-yl)-4-
methyl-piperidine-4- carboxylate (Precursor 16) ##STR00109## MS
284.09 [M + H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
8.30 (s, 1H), 6.96 (s, 1H), 4.13 (m, 2H), 4.05 (m, 2H), 3.15-3.22
(m, 2H), 1.97-2.01 (m, 2H), 1.37-1.47 (m, 2H) and 1.15-1.21 (m,
6H). ethyl 1-(2-chloro-4- pyridyl)piperidine-4- carboxylate
(Precursor 17) ##STR00110## MS [M + H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.92 (d, J = 5.60 Hz, 1H), 6.82-6.84 (m,
2H), 4.07 (q, J = 7.20 Hz, 2H), 3.85-3.89 (m, 2H), 2.96-3.02 (m,
2H), 2.60-2.66 (m, 1H), 1.84-1.87 (m, 2H), 1.48-1.57 (m, 2H) and
1.17 (t, J = 7.20 Hz, 3H). 2-chloro-N-(2- morpholinoethyl)
pyrimidin-4-amine (Precursor 18) ##STR00111## MS 243.11 [M +
H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.87 (m,
2H), 6.48 (d, J = 5.60 Hz, 1H), 3.57 (m, 4H), 3.39 (m, 2H), 2.45
(m, 6H), 2-chloro-N-(2- methoxyethyl)pyrimidin- 4-amine (Precursor
19) ##STR00112## MS 188.01 [M + H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 7.99 (d, J = 5.60 Hz, 1H), 6.26 (d, J = 5.60
Hz, 1H), 5.47 (br s, 1H), 3.55 (br s, 4H) and 3.37 (s, 3H).
1-(2-chloropyrimidin-4- yl)azetidin-3-ol (Precursor 20)
##STR00113## MS 185.98 [M + H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.04 (d, J = 6.0 Hz, 1H), 6.37 (d, J = 6.0
Hz, 1H), 5.86 (m, 1H), 4.60 (m, 1H), 4.27 (m, 2H) and 3.79 (m, 2H).
2-chloro-4-(3- methoxyazetidin-1- yl)pyrimidine (Precursor 21)
##STR00114## MS 200.04 [M + H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 8.00 (d, J = 4.80 Hz, 1H), 6.08 (d, J = 6.0
Hz, 1H), 4.28-4.36 (m, 3H), 4.0 (m, 2H) and 3.33 (s, 3H).
1-(2-chloropyrimidin-4- yl)-3-methyl-azetidin-3-ol (Precursor 22)
##STR00115## MS 200.06 [M + H].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 7.96 (d, J = 5.20 Hz, 1H), 6.05 (d, J = 5.60
Hz, 1H), 4.04 (br s, 4H) and 1.61 (s, 3H). 4-(2-chloropyrimidin-4-
yl)morpholine (Precursor 23) ##STR00116## MS 200.06 [M + H].sup.+.
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 8.08 (d, J = 6.0 Hz,
1H), 6.39 (d, J = 6.0 Hz, 1H), 3.78 (m, 4H) and 3.64 (m, 4H).
2-chloro-4-(4- ethylpiperazin-1- yl)pyrimidine (Precursor 24)
##STR00117## .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 8.02 (d, J
= 6.0 Hz, 1H), 6.38 (d, J = 5.60 Hz, 1H), 3.67 (m, 4H), 2.52 (m,
4H), 2.48 (q, J = 7.20 Hz, 2H) and 1.12 (t, J = 7.20 Hz, 3H).
2-chloro-4-[4-(2- methoxyethyl)piperazin-1- yl]pyrimidine
(Precursor 25) ##STR00118## .sup.1H NMR (CDCl.sub.3, 400 MHz):
.delta. 8.03 (d, J = 6.40 Hz, 1H), 6.38 (d, J = 6.0 Hz, 1H), 3.7
(m, 4H), 3.60 (t, J = 5.20 Hz, 2H), 3.29 (s, 3H), 2.64 (t, J = 5.20
Hz, 2H) and 2.60 (m, 4H). 4-(2-chloro-5-fluoro- pyrimidin-4-
yl)morpholine (Precursor 26) ##STR00119## MS 218.0 [M + H].sup.+.
.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 7.95 (d, J = 6.0 Hz, 1H)
and 3.74-3.81 (m, 8H). ethyl 4-[(2-chloro-4-
pyridyl)amino]-1-methyl- cyclohexanecarboxylate (Precursor 27)
##STR00120## MS 297.07 [M + H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.76 (d, J = 5.60 Hz, 1H), 6.75 (d, J = 8.0
Hz, 1H), 6.45 (m, 2H), 4.11 (q, J = 7.20 Hz, 2H), 2.50 (m, 1H),
2.06-2.08 (m, 2H), 1.78-1.81 (m, 2H), 1.29-1.36 (m, 4H), 1.21 (t, J
= 7.20 Hz, 3H) and 1.19 (s, 3H). 1-[(2-bromo-4-
pyridyl)methyl]-3-methyl- pyrrolidin-3-ol (Precursor 28)
##STR00121## MS 271.97 [M + H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.29- 8.31 (d, J = 4.80Mz, 1H), 7.57 (s,
1H), 7.37-7.38 (d, J = 4.40 Hz, 1H), 4.58 (s, 1H), 3.64 (s, 2H),
2.64- 2.68 (m, 2H), 2.42-2.44 (m, 2H), 1.72-1.75 (m, 2H) and 1.23
(s, 3H). 1-[(2-bromo-4- pyridyl)methyl]-3-methyl- azetidin-3-ol
(Precursor 29) ##STR00122## .sup.1H NMR (400 MHz, DMSO-d.sub.6):
.delta. 8.29 (d, J = 5.20 Hz, 1H), 7.50 (s, 1H), 7.32 (d, J = 4.8
Hz, 1H), 5.21 (s, 1H), 3.61 (s, 2H), 3.33 (s, 2H), 2.90 (d, J =
6.40 Hz, 2H) and 1.36 (s, 3H). 1-[(2-bromo-4-
pyridyl)methyl]azetidin-3- ol (Precursor 30) ##STR00123## MS 243.07
[M + H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 8.28
(d, J = 4.80 Hz, 1H), 7.50 (s, 1H), 7.31 (d, J = 5.20 Hz, 1H), 5.35
(d, 1H), 4.17-4.25 (m, 1H), 3.59 (s, 2H), 3.48- 3.54 (m, 2H) and
2.77-2.81 (t, J = 6.80 Hz, 2H). 2-bromo-4-[(3,3-
difluoropyrrolidin-1- yl)methyl]pyridine (Precursor 31)
##STR00124## MS 277.07 [M + H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 8.34 (d, J = 5.20 Hz, 1H),7.57 (s, 1H), 7.39
(d, J = 5.20 Hz, 1H), 3.67 (s, 2H), 2.90 (m, 2H), 2.72 (m, 2H) and
2.27 (m, 2H). (3R)-1-[(2-bromo-4- pyridyl)methyl]pyrrolidin- 3-ol
(Precursor 32) ##STR00125## MS 257.05 [M + H].sup.+. .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 8.30 (d, J = 5.20 Hz, 1H), 7.56
(s, 1H), 7.37 (d, J = 4.80 Hz, 1H), 5.75 (s, 1H), 4.72 (d, J = 440
Hz, 1H), 3.55-3.65 (m, 2H), 2.61-2.68 (m, 2H), and 2.38-2.50 (m,
1H), 2.31-2.38 (m, 1H), 1.95- 2.04 (m, 1H) and 1.52-1.59 (m, 1H).
4-[(6-chloro-3- pyridyl)methyl] morpholine (Precursor 33)
##STR00126## MS 213.04 [M + H].sup.+. N-[(2-bromo-4-
pyridyl)methyl] cyclopropanamine (Precursor 34) ##STR00127## MS
227.05 [M + H].sup.+. 4-[(2-bromo-4- pyridyl)methyl]-3-methy]-
morpholine (Precursor 35) ##STR00128## MS 271.10 [M + H].sup.+.
(2R,6S)-4-[(2-bromo-4- pyridyl)methyl]-2,6- dimethyl-morpholine
(Precursor 36) ##STR00129## MS 285.07 [M + H].sup.+. 4-[(2-bromo-4-
pyridyl)methyl]- 2,2,3,3,5,5,6,6- octadeuterio-morpholine
(Precursor 37) ##STR00130## MS 265.17 [M + H].sup.+. 4-[(2-bromo-4-
pyridyl)methyl]-2,5- dimethyl-morpholine (Precursor 38)
##STR00131## MS 285.12 [M + H].sup.+. methyl (2S)-1-[(2-chloro-
4-pyridyl)methyl] pyrrolidine-2-carboxylate (Precursor 39)
##STR00132## MS 255.06 [M + H].sup.+. 2-[(2-bromo-4-
pyridyl)methyl]-6-oxa-2- azaspiro[3.3]heptane (Precursor 40)
##STR00133## MS 269.07 [M + H].sup.+. 2-bromo-4-
(methylsulfanylmethyl) pyridine (Precursor 41) ##STR00134## MS
220.0 [M + H].sup.+. 7-((2-bromo-4- pyridyl)methyl]-2-oxa-7-
azaspiro[3.5]nonane (Precursor 42) ##STR00135## MS 297.16 [M +
H].sup.+. Elhyl 4-amino-1- methylcyclohexane- carboxylate
(Precursor 43) ##STR00136## MS 186.20 [M + H].sup.+.
Ethyl 4-aminocyclohexanecarboxylate (i)
[0515] To an ice-cold solution of 4-aminocyclohexanecarboxylic acid
(5.0 g, 34.92 mmol) in EtOH (20 mL) was added thionyl chloride
(7.60 mL, 104.76 mmol). The mixture was heated at 80.degree. C. for
3 h. The solvent was evaporated in vacuo to obtain i (7.23 g).
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 4.19 (q, J=7.20 Hz,
2H), 3.71 (m, 1H), 2.71 (m, 1H), 2.06 (m, 2H), 1.90 (m, 2H), 1.69
(m, 2H), 1.55 (m, 2H), and 1.25 (t, J=7.20 Hz, 3H).
Ethyl 4-(1,3-dioxoisoindolin-2-yl) cyclohexanecarboxylate) (ii)
[0516] A solution of i (0.50 g, 2.92 mmol) in toluene (10 mL) was
added Et.sub.3N (1.02 mL, 7.30 mmol) and phthalic anhydride (0.56
g, 3.80 mmol). The mixture was refluxed for 8 h using a dean-stark
apparatus for removal of H.sub.2O. The solvent was evaporated in
vacuo, H.sub.2O (50 mL) added and the mixture stirred for 30 min at
RT. The solid material thus obtained was collected by filtration
and dried to obtain ii (0.30 g, 34%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.84 (s, 4H), 4.19 (q, J=7.20 Hz, 2H), 3.71
(m, 1H), 2.71 (m, 1H), 2.06 (m, 2H), 1.90 (m, 2H), 1.69 (m, 2H),
1.60 (m, 2H), and 1.23 (t, J=7.20 Hz, 3H).
Ethyl 4-(1,3-dioxoisoindolin-2-yl)-1-methylcyclohexanecarboxylate
(iii)
[0517] A solution of ii (0.30 g, 1.0 mmol) in THF (10 mL) was
cooled to -78.degree. C. followed by dropwise addition of LDA (1.60
M in THF, 1.88 mL, 3.0 mmol) at -78.degree. C. The mixture was
stirred at -78.degree. C. for 30 min followed by addition of methyl
iodide (0.311 mL, 5.0 mmol) at -78.degree. C. The temperature of
the reaction mass was slowly raised up to RT and left to stir
overnight. The reaction was cooled to 0.degree. C. and quenched by
dropwise addition of saturated NH.sub.4Cl solution (30 mL). The
reaction was extracted with EtOAc (3.times.50 mL). The combined
organics were washed with brine, dried (Na.sub.2SO.sub.4), filtered
and concentrated in vacuo to obtain iii (0.30 g, 97%). MS 316.12
[M+H].sup.+.
Ethyl 4-amino-1-methylcyclohexanecarboxylate (Precursor 43)
[0518] To an ice-cold solution of iii (0.30 g, 0.95 mmol) in EtOH
(20 mL) was added hydrazine hydrate (0.115 mL, 2.38 mmol) and the
resulting reaction mixture was heated at 80.degree. C. for 3 h. The
solvent was evaporated in vacuo, H.sub.2O (20 mL) added and
extracted with EtOAc (3.times.50 mL). The organics were washed with
brine, dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo
to give Precursor 43 (0.18 g).
TABLE-US-00003 (S)-2-bromo-4-((3- fluoropyrrolidin-1-
yl)methyl)pyridine (Precursor 44) ##STR00137## .sup.1H NMR
(DMSO-d.sub.6, 400 MHz): .delta. 8.29 (d, J = 4.8 Hz, 1H), 7.50 (s,
1H), 7.24-7.26 (d, J = 4.8, 1H), 5.12-5.25 (m, 1H), 3.65 (s, 2H)
and 2.70-2.91 (m, 3H), 2.45-2.51 (m, 1H), and 2.03-2.25 (m, 2H). MS
259.05 [M + H].sup.+
(2-Bromopyridin-4-yl)methanol (i)
[0519] To a solution of 2-bromopyridine-4-carbaldehyde (20 g,
107.52 mmol) in MeOH (150 mL) was added portion wise sodium
borohydride (12.0 g, 322.56 mmol) at 0.degree. C. under inert
atmosphere. The mixture was stirred at RT for 1 h. Saturated
NH.sub.4Cl solution was added followed by extraction with EtOAc
(3.times.200 mL). The combined organic layers were dried
(Na.sub.2SO.sub.4) and evaporated in vacuo to obtain i (18.0 g,
90%). .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta. 8.30 (d, J=4.8
Hz, 1H), 7.54 (s, 1H), 7.35 (d, J=4.8 Hz, 1H), 5.55 (t, J=6.0 Hz,
1H) and 4.53-4.54 (d, J=5.6 Hz, 2H).
2-Bromo-4-(bromomethyl)pyridine) (ii)
[0520] To the solution of i (18 g, 95.74 mmol) in toluene (180 mL)
was added dropwise phosphorous tribromide (13.4 mL, 143.62 mmol) at
0.degree. C. under inert atmosphere. The mixture was heated at
100.degree. C. for 30 min. The reaction was cooled at 0.degree. C.
and NaHCO.sub.3 solution added followed by extraction with EtOAc
(2.times.500 mL). The combined organic layer were dried
(Na.sub.2SO.sub.4) and evaporated in vacuo. The residue was
purified over silica eluting with 15% EtOAc:Hexane to obtain ii
(12.0 g, 50%). .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta. 8.35 (d,
J=4.8 Hz, 1H), 7.51 (s, 1H), 7.26 (d, J=6.0 Hz, 1H) and 4.34 (s,
2H). MS 251.80 [M+H].sup.+.
(S)-2-Bromo-4-((3-fluoropyrrolidin-1-yl)methyl)pyridine (Precursor
44)
[0521] To an ice-cold solution of ii (3.0 g, 11.95 mmol) in DMSO
(10 mL) was added KOH (1.0 g, 17.92 mmol) followed by the addition
of (S)-3-fluoropyrrolidine hydrochloride (2.2 g, 17.92 mmol) under
inert atmosphere. The mixture was stirred at 0.degree. C. to RT for
20 min. The mixture was diluted with ice cold H.sub.2O followed by
extraction with EtOAc (3.times.150 mL). The combined organic layers
were washed with brine, dried (Na.sub.2SO.sub.4) and evaporated in
vacuo to give Precursor 44 (3.0 g, 96%).
[0522] The following precursor(s) were similarly prepared.
TABLE-US-00004 2-bromo-4-[(3- methoxyazetidin-1- yl)methyl]pyridine
(Precursor 45) ##STR00138## MS 257.19 [M + H].sup.+. .sup.1H NMR
(DMSO-d.sub.6, 400 MHz): .delta. 8.29 (d, J = 4.8 Hz, 1H), 7.50 (s,
1H), 7.32 (d, J = 4.8 Hz, 1H), 3.95-4.01 (m, 1H), 3.61 (s, 2H),
3.49-3.52 (m, 2H), 3.14 (s, 3H), and 2.86-2.90 (m, 2H).
2-bromo-4-[(3,3- difluoro-1- piperidyl)methyl] pyridine (Precursor
46) ##STR00139## MS 291.02 [M + H].sup.+. .sup.1H NMR
(DMSO-d.sub.6, 400 MHz): .delta. 8.34 (d, J = 4.80 Hz, 1H), 7.56
(s, 1H), 7.38 (d, J = 4.80 Hz, 1H), 3.62 (s, 2H), 2.65 (m, 2H),
2.40 (m, 2H), 1.84-1.90 (m, 2H) and 1.63-1.67 (m, 2H).
4-[(2-bromo-4- pyridyl)methyl] morpholine (Precursor 47)
##STR00140## MS 257.49 [M + H].sup.+. .sup.1H NMR (DMSO-d.sub.6,
400 MHz): .delta. 8.26 (d, J = 5.2 Hz, 1H), 7.48 (s, 1H), 7.22 (d,
J = 4.80 Hz, 1H), 3.69-3.71 (t, J = 4.80 Hz, 4H), 3.45 (s, 2H) and
2.41- 2.43 (t, J = 4.40 Hz, 4H). 2-bromo-4- (pyrrolidin-1-
ylmethyl)pyridine (Precursor 48) ##STR00141## .sup.1H NMR
(DMSO-d.sub.6, 400 MHz): .delta. 8.30 (d, J = 4.80 Hz, 1H), 7.55
(s, 1H), 7.37 (d, J = 4.80 Hz, 1H), 3.61 (s, 2H), 2.44 (m, 4H) and
1.70 (m, 4H). 2-bromo-4-[(3,3- difluoroazetidin-1-
yl)methyl]pyridine (Precursor 49) ##STR00142## .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 8.32 (d, J = 4.80 Hz, 1H), 7.47 (s,
1H), 7.25 (d, J = 4.80 Hz, 1H), 3.52 (s, 2H) and 3.66 (m, 4H).
[0523] To an ice-cold solution of 2-bromoisonicotinaldehyde (0.40
g, 2.15 mmol) in THF (5 mL) was added 3,3-difluoroazetidine
hydrochloride (0.41 g, 3.12 mmol) and N-methyl morpholine
(catalytic). The reaction was stirred at 0.degree. C. for 15 min
followed by the portion wise addition of sodium cyano borohydride
(0.41 g, 6.45 mmol). The mixture was stirred at RT for 16 h.
H.sub.2O (50 mL) was added followed by extraction with EtOAc
(3.times.100 mL). The combined organics were washed with brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo.
Purification by chromatography on silica (30% EtOAc-Hexane) gave
Precursor 49 (0.18 g, 32%).
TABLE-US-00005 4-((6-bromopyrazin-2- yl)methyl)morpholine
(Precursor 50) ##STR00143## NMR (400 MHz, DMSO- d.sub.6): .delta.
8.76 (s, 1H), 8.70 (s, 1H), 3.64 (s, 2H), 3.58 (br s, 4H) and 2.43
(br s, 4H). MS 258.0 [M + H].sup.+.
2-bromo-6-(bromomethyl)pyrazine (i)
[0524] To a solution of 2-bromo-6-methyl-pyrazine (3.0 g, 17.31
mmol) in CCl.sub.4 (25 mL) was added NBS (4.60 g, 26.01 mmol) and
AIBN (0.248 g, 1.734 mmol) at RT. The mixture was stirred at
55.degree. C. for 48 h. H.sub.2O was added followed by extraction
with EtOAc (3.times.100 mL). The combined organics were washed with
brine, dried (Na.sub.2SO.sub.4) and concentrated in vacuo. The
residue was purified over silica eluting with 5% EtOAc:Hexane to
obtain i (1.40 g, 32%). .sup.1H NMR (CDCl.sub.3, 400 MHz): .delta.
8.64 (s, 1H), 8.62 (s, 1H) and 4.50 (s, 2H).
4-((6-bromopyrazin-2-yl)methyl)morpholine (Precursor 50)
[0525] To an ice-cold solution of i (1.29 g, 4.81 mmol) in ACN (30
mL) was added morpholine (0.46 g, 5.28 mmol) and the mixture
stirred at 0.degree. C. for 45 min. H.sub.2O was added and the
mixture extracted with EtOAc (3.times.50 mL). The combined organics
were washed with brine, dried (Na.sub.2SO.sub.4), and concentrated
in vacuo. The residue was purified over silica eluting with 90%
EtOAc:Hexane to obtain Precursor 50 (0.6 g, 50%).
[0526] The following precursor(s) were similarly prepared.
TABLE-US-00006 4-[(2-chloropyrimidin- 5-yl)methyl] morpholine
(Precursor 51) ##STR00144## MS 214.10 [M + H].sup.+. .sup.1H NMR
(CDCl.sub.3, 400 MHz): .delta. 8.61 (s, 2H), 3.72 (br s, 4H), 3.52
(s, 2H) and 2.48 (br s, 4H). MS [M + H].sup.+.
3-Methylpyrrolidin-3- ol hydrochloride (Precursor 52) ##STR00145##
.sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 4.71 (s, 1H),
3.33-3.46 (m, 2H), 1.72-1.74 (m, 2H) and 1.41 (s, 2H), 1.38 (s, 9H)
and 1.28 (s, 3H). MS 202.28 [M + H].sup.+.
tert-Butyl 3-hydroxy-3-methylpyrrolidine-1-carboxylate (i)
[0527] To an ice-cold solution of tert-butyl
3-oxopyrrolidine-1-carboxylate (1.0 g, 5.40 mmol) in Et.sub.2O (20
mL) was added methylmagnesium bromide (3.50 mL, 10.80 mmoL) drop
wise under an inert atmosphere. The mixture was stirred at RT for 1
h, then quenched with NH.sub.4Cl solution followed by extraction
with EtOAc (3.times.100 mL). The combined organic layers were
washed with brine, dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo. Trituration with n-pentane gave i (1.0 g,
92%).
3-Methylpyrrolidin-3-ol hydrochloride (Precursor 52)
[0528] To a solution of 4M HCl in 1,4-dioxane (10 mL) at 0.degree.
C. was added i (0.850 g, 4.22 mmol) and the mixture stirred for 2 h
at RT. The solvent was removed in vacuo and trituration with
Et.sub.2O gave Precursor 52 (0.490 g). MS 102.15 [M+H].sup.+.
[0529] The following precursor(s) were similarly prepared.
##STR00146##
[0530] To an ice-cold solution of Precursor 29 (0.75 g, 2.92 mmol)
in DMF (15 mL) was added NaH (60% dispersion in mineral oil, 0.175
g, 4.38 mmol) portion wise. The mixture was stirred at 0.degree. C.
for 10 min followed by drop wise addition of methyl iodide (0.27
mL, 4.38 mmol). The reaction mixture was left to stir at 0.degree.
C. for 30 min. H.sub.2O (10 mL) was added, followed by extraction
with EtOAc (3.times.50 mL). The combined organics were washed with
H.sub.2O, brine, dried (Na.sub.2SO.sub.4) and concentrated in
vacuo.
[0531] The residue was purified over silica eluting with 40%
EtOAc:Hexane to obtain Precursor 54 (0.24 g, 30%).
[0532] The following precursor(s) were similarly prepared.
##STR00147##
[0533] 2-bromo-4-(bromomethyl)pyridine (2.3912 mmol; 600 mg and
triethylphosphite (2.6 mmol; 440 mg) were suspended in ACN (5 mL)
in a sealed microwave tube and heated at 100.degree. C. in a
microwave for 1 h. The mixture was concentrated in vacuo to give
Precursor 56 (700 mg, 95%).
TABLE-US-00007 4-(2-((2-chloropyridin-4- yl)oxy)ethyl)morpholine
(Precursor 57) ##STR00148## .sup.1H NMR (400 MHz, DMSO- d.sub.6):
.delta. 8.18 (d, J =6.0 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 6.99-
7.01 (m, 1H), 4.19-4.22 (t, J = 5.60 Hz, 2H), 3.55-3.57 (t, J =
4.80 Hz, 4H), 2.61(t, J = 6.40 Hz, 2H) and 2.45-2.50 (m, 4H). MS
243.09 [M + H].sup.+.
[0534] To an ice-cold solution of 2-chloropyridin-4-ol (1.0 g, 7.72
mmol) and 4-(2-chloroethyl)morpholine hydrochloride (1.16 g, 7.72
mmol) in DMF (10 mL) was added K.sub.2CO.sub.3 (3.20 g, 23.16
mmol). The mixture was stirred at RT for 16 h. H.sub.2O (20 mL) was
added followed by extraction with EtOAc (3.times.100 mL). The
combined organic layer were washed with brine, dried
(Na.sub.2SO.sub.4) and evaporated in vacuo. The residue was
purified on silica eluting with 5% MeOH:DCM to obtain Precursor 57
(0.60 g, 33%).
[0535] The following precursor(s) were similarly prepared.
TABLE-US-00008 4-[3-[(2-chloro-4- pyridyl)oxy]propyl] morpholine
(Precursor 58) ##STR00149## 1H-NMR (400 MHz, DMSO-d.sub.6): .delta.
8.18 (d, J = 6.0 Hz, 1H), 7.10 (d, J = 2.0 Hz, 1H), 6.98-7.10 (dd,
J = 2.0 Hz and 5.60 Hz respectively, 1H), 4.13 (t, J = 6.40 Hz,
2H), 3.55-3.57 (t, J = 4.80 Hz, 4H), 2.34-2.40 (m, 6H) and
1.83-1.90 (m, 2H). 2-chloro-4- (tetrahydrofuran-2-
ylmethoxy)pyridine (Precursor 59) ##STR00150## MS 214.08 [M +
H].sup.+. 2-chloro-4-(2- methoxyethoxy)pyridine (Precursor 60)
##STR00151## 1H NMR (CDCl.sub.3, 400 MHz): .delta. 8.18 (d, J =
5.60 Hz, 1H), 6.88 (s, 1H), 6.79 (d, J = 5.60 Hz, 1H), 4.17 (m,
2H), 3.76 (m, 2H) and 3.43 (s, 3H). 4-[2-[(6-chloro-3-
pyridyl)oxy]ethyl] morpholine (Precursor 61) ##STR00152## MS 243.11
[M + H].sup.+. 2-((2-chloropyrimidin-4- yl)amino)ethanol:
(Precursor 62) ##STR00153## .sup.1H-NMR (400 MHz, DMSO-d.sub.6):
.delta. 7.96 (br s, 1H), 7.87 (d, J = 5.60 Hz, 1H), 6.48 (d, J =
5.60 Hz, 1H), 4.81 (m, 1H) and 3.52 (m, 4H). MS 174.01 [M +
H].sup.+.
[0536] A solution of 2-chloro-N-(2-methoxyethyl)pyrimidin-4-amine
(1.0 g, 5.34 mmol) in DCM (10 mL) was cooled to -10.degree. C.
followed by drop wise addition of BBr.sub.3 (0.70 mL, 8.02 mmol).
The mixture was stirred at RT for 3 h. NaHCO.sub.3 solution (5 mL)
was added followed by extraction with DCM (2.times.50 mL). The
combined organics were washed with H.sub.2O, brine, dried
(Na.sub.2SO.sub.4) and evaporated in vacuo. The residue was
purified on silica eluting with 80% EtOAc:Hexane to obtain
Precursor 62 as a white solid (0.35 g, 38%).
TABLE-US-00009 4-(1-(2-chloropyridin-4- yl)ethyl)morpholine
(Precursor 63) ##STR00154## .sup.1H-NMR (400 MHz, DMSO-d.sub.6):
.delta. 8.36 (d, J = 5.20 Hz, 1H), 7.44 (s, 1H), 7.37 (d, J = 4.80
Hz, 1H), 3.55 (m, 4H), 3.47 (q, J = 6.80 Hz, 1H), 2.24-2.39 (m, 4H)
and 1.27 (d, J = 6.80 Hz, 3H).
1-(2-chloropyridin-4-yl)ethanol (i)
[0537] To an ice-cold solution of 1-(2-chloro-4-pyridyl)ethanone
(1.0 g, 6.42 mmol) in MeOH was added NaBH.sub.4 (0.73 g, 19.21
mmol) and the solution stirred at RT for 30 min. The reaction was
then quenched with saturated NH.sub.4Cl solution followed by
extraction with EtOAc (3.times.100 mL). The combined organic layers
were washed with brine, dried (Na.sub.2SO.sub.4) and evaporated in
vacuo to obtain i (0.61 g, 60%). MS 158.10 [M+H].sup.+.
1-(2-chloropyridin-4-yl)ethyl methanesulfonate (ii)
[0538] To an ice-cold solution of i (0.25 g, 1.58 mmol) in DCM (10
mL) was added Et.sub.3N (0.43 mL, 3.16 mmol) and the resulting
solution was stirred for 15 min at the same temperature followed by
addition of methanesulfonyl chloride (0.18 mL, 2.37 mmol). The
mixture was stirred at RT for 4 h. The reaction was quenched with
H.sub.2O and extracted with EtOAc (3.times.100 mL). The combined
organic layers were washed with brine, dried (Na.sub.2SO.sub.4) and
evaporated in vacuo to obtain ii (0.30 g, 80%). MS 236.38
[M+H].sup.+.
4-(1-(2-chloropyridin-4-yl)ethyl)morpholine (Precursor 63)
[0539] To an ice-cold solution of ii (0.30 g, 1.33 mmol) in DMSO (5
mL) was added powdered KOH (0.11 g, 1.99 mmol). The mixture was
stirred at 0.degree. C. for 15 min followed by addition of
morpholine (0.23 g, 2.66 mmol) and the mixture then stirred at RT
for 16 h. Ice-cold H.sub.2O was added to the reaction mass followed
by extraction with EtOAc (3.times.100 mL). The combined organic
layer were washed with brine, dried (Na.sub.2SO.sub.4) and
evaporated in vacuo to obtain Precursor 63 (0.28 g, 93%).
TABLE-US-00010 1-(5-bromopyridin-2- yl)ethanol (Precursor 64)
##STR00155## .sup.1H NMR (DMSO-d.sub.6, 400 MHz): .delta. 8.59 (m,
1H), 8.03 (d, J = 8.40 Hz, 1H), 7.49 (d, J = 8.40 Hz, 1H), 5.50 (d,
J = 4.40 Hz, 1H), 4.69 (m, 1H), 1.34 (d, J = 6.40 Hz, 3H).
[0540] To an ice-cold solution of 5-bromopyridine-2-carbaldehyde
(1.0 g, 5.37 mmol) in THF (10.0 mL) was added methyl magnesium
bromide (3.44 mL, 6.88 mmol, 2M in Et.sub.2O). The resulting
reaction mixture was stirred at RT for 16 h. H.sub.2O (100 mL) was
added followed by extraction with EtOAc (3.times.100 mL). The
combined organics were washed with brine, dried (Na.sub.2SO.sub.4),
filtered and concentrated in vacuo. The residue was purified over
silica (50% EtOAc-hexanes) to obtain Precursor 64 (0.80 g,
74%).
[0541] The following precursor(s) were similarly prepared.
TABLE-US-00011 1-(2-bromo-4- pyridyl)ethanol (Precursor 65)
##STR00156## MS 202 [M + H].sup.+. 1-(5-bromopyridin-2-yl)-
2,2,2-trifluoroethanol (Precusor 66) ##STR00157## .sup.1H NMR
(DMSO-d.sub.6, 400 MHz): .delta. 8.73 (m, 1H), 8.17 (dd, J = 2.0
and 8.40 Hz, 1H), 7.60 (d, J = 8.40 Hz, 1H), 7.16 (d, J = 6.0 Hz,
1H) and 5.15 (m, 1H). MS 255.88 [M + H].sup.+.
[0542] To an ice-cold solution of 5-bromopyridine-2-carbaldehyde
(0.5 g, 2.69 mmol) in THF (10 mL) was added
trimethyl(trifluoromethyl)silane (0.57 g, 4.03 mmol) followed by
TBAF (6.73 mL, 6.73 mmol, 1.0 M THF). The mixture was stirred at RT
for 16 h. H.sub.2O (100 mL) was added followed by extraction with
EtOAc (3.times.50 mL).
[0543] The combined organics were washed with brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo The residue
was purified over silica (20% EtOAc-hexanes) to obtain Precursor 66
(0.61 g, 89%).
##STR00158##
[0544] To a solution of 1-(6-bromo-3-pyridyl)ethanone (500 mg, 2.68
mmol) in THF (20 mL) to 0.degree. C. was added methyl magnesium
bromide (3 M in diethylether, 1.2 mL, 3.7 mmol) dropwise and the
mixture allowed to warm to RT and stirred for 60 min. The mixture
was re-cooled to 0.degree. C. and NaHCO.sub.3 solution (100 mL)
added. The mixture was extracted with EtOAc (100 mL). The organic
layer was separated and the aqueous layer extracted with a further
portion of EtOAc (100 mL). The organic layers were combined, dried
(MgSO.sub.4) and concentrated in vacuo. Purification by
chromatography, on silica eluting with 0-5% methanol in DCM,
followed by further chromatography, on silica eluting with 0-50%
EtOAc in n-heptane, gave Precursor 67.
##STR00159##
2-(5-bromopyrimidin-2-yl)propan-2-yl 4-nitrophenyl carbonate
(i)
[0545] Sodium hydride (110 mg, 2.8 mmol) was added to a solution of
Precursor 1 in THF (10 ml) at 0.degree. C. and stirred for 1 h. To
this mixture was added 4-nitrophenyl carbonochloridate (560 mg, 2.8
mmol) portionwise and the solution was stirred at 0.degree. C. for
1 h. EtOAc (3 ml) and H.sub.2O were added, the organic layer
separated, dried and concentrated to give i (900 mg).
2-(5-bromopyrimidin-2-yl)propan-2-yl
4-methylpiperazine-1-carboxylate (Precursor 68)
[0546] 1-methylpiperazine (1.05 g, 10.47 mmol) was added to a
solution of i (1 g, 2.1 mmol) in DMF (10 mL) and stirred at RT for
18 h. The mixture was concentrated in vacuo and the residue
partitioned between EtOAc (20 mL) and H.sub.2O (10 mL), the organic
layer was separated and washed with further H.sub.2O (2.times.5
mL), dried (MgSO.sub.4), filtered and concentrated in vacuo.
Purification by chromatography on silica, eluting with 0-10%
MeOH/DCM) gave Precursor 68 (144 mg, 20%).
##STR00160##
[0547] 5-Bromo-2-iodo-pyrimidine (1.14 g, 4 mmol) in toluene (4 mL)
was added dropwise to a solution of n-BuLi (2.76 mL 1.52 M) in
toluene (8 mL) at -78.degree. C. After stirring at -78.degree. C.
for 1 h, and tetrahydro-4H-pyran-4-one (1.6 g, 1.5 mL, 16 mmol)
which had been dried over 3 .ANG. molecular sieves for >30 mins,
was added in one portion with vigorous stirring. The reaction
allowed to warm to RT and stirred for 3 h. The reaction was
quenched with NH.sub.4Cl (10 mL), and extracted with EtOAc
(4.times.20 mL). The organic layers were combined, dried
(Na.sub.2SO.sub.4), concentrated in vacuo. The residue was purified
by flash chromatography (10%-45% EtOAc in heptane) to give
Precursor 69 (535 mg, 53%).
[0548] The following precursor(s) were similarly prepared.
##STR00161##
5-bromo-2-vinyl-pyrimidine (i)
[0549] 5-Bromo-2-iodo-pyrimidine (2.15 g, 7.55 mmol),
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (1.60 mL, 9.43
mmol) and PdCl.sub.2(dppf) (300 mg, 0.40 mmol) were dissolved in
1,4-dioxane (15 mL). A solution of Cs.sub.2CO.sub.3 (4.91 g, 15.1
mmol) in H.sub.2O (5 mL) was added and the mixture heated at
80.degree. C. for 30 min. The reaction mixture was diluted with
EtOAc (100 mL), washed with H.sub.2O, brine and separated. The
organic fraction was dried and concentrated in vacuo. Purification
by chromatography on silica, eluting with 5-25% EtOAc/heptane gave
i (1.10 g, 79%). MS 185.11 & 187.09 [M+H].sup.+.
5-bromo-2-(oxiran-2-yl)pyrimidine (ii)
[0550] Acetic acid (680 .mu.L, 11.9 mmol) and i (1.1 g, 5.95 mmol)
were dissolved in 1,4-dioxane (30 mL) and H.sub.2O (80 mL). The
solution was cooled to 0.degree. C. and NBS (1.27 g, 7.13 mmol)
added portion-wise. The reaction was allowed to warm to RT, then 2M
NaOH (50 mL) was added and stirring was continued for 16 h. The
reaction was diluted with H.sub.2O and extracted with EtOAc. The
organic fraction was washed with brine and dried
(Na.sub.2SO.sub.4). Purification by chromatography on silica,
eluting with 10-50% EtOAc/heptane gave ii (140 mg, 12%). MS 200.92
& 202.91 [M+H].sup.+.
1-(5-bromopyrimidin-2-yl)-2-morpholino-ethanol (Precursor 75)
[0551] A solution of ii (140 mg, 0.70 mmol) in morpholine (2.0 mL)
was heated at 120.degree. C. under microwave irradiation for 1 h.
Concentration to dryness under a stream of N.sub.2 afforded
Precursor 75.
##STR00162##
[0552] Methyl 5-bromopyrimidine-2-carboxylate (250 mg; 1.15 mmol)
was dissolved in anhydrous THF (10 mL) and cooled to 0.degree. C.
Pentamethylenebis(magnesium bromide) (0.5 M in THF 3.0 mL, 1.3
mmol) was introduced drop-wise and the mixture stirred for 15 min.
The reaction was quenched with MeOH (0.5 mL), partitioned with
EtOAc (100 mL), washed with H.sub.2O (100 mL), dried (MgSO.sub.4)
and concentrated in vacuo. Purification by chromatography on
silica, eluting with 0-100%, EtOAc in n-heptane gave Precursor 76
(7%).
[0553] It will be understood that esters of any of the preceding
Precursor(s) may be formed as illustrated by the following
example(s).
##STR00163##
[0554] Precursor 1 (8.0 g, 36.9 mmol) was dissolved in anhydrous
DMF (80 mL) under argon and cooled in an ice bath. Sodium hydride
(1.62 g, 60% in mineral oil, 40.5 mmol) was added portion-wise and
the reaction stirred for 10 min. Methyl 4-chloro-4-oxobutyrate
(13.6 mL, 111 mmol) was added and the mixture warmed to RT. More
methyl 4-chloro-4-oxobutyrate (4.50 mL, 36.9 mmol) was added after
18 h and stirring continued. Further methyl 4-chloro-4-oxobutyrate
(4.50 mL, 36.9 mmol) was added after 25.5 h and stirring continued.
The mixture was quenched with H.sub.2O after 45 h, then cooled in
an ice bath and basified to pH 9 with NaHCO.sub.3 (sat, aq.)
solution. The mixture was extracted into EtOAc (4.times.200 mL).
The combined organic phases were washed with H.sub.2O and brine,
dried (Na.sub.2SO.sub.4) and concentrated to dryness in vacuo to
give an oil. The mixture was purified by chromatography, Biotage
SP4, 120 g Si cartridge, 0-20% EtOAc in cyclohexane to give
Precursor 77, 8.02 g (66%).
##STR00164##
[1-(5-bromopyrimidin-2-yl)-1-methyl-ethyl] 2-chloroacetate (i)
[0555] Precursor 1 (1.03 g, 4.75 mmol) was dissolved in anhydrous
DMF (15 mL) under argon. Sodium hydride (209 mg, 60% in mineral
oil, 5.22 mmol) was added and the mixture stirred for 15 min.
Chloroacetyl chloride (1.13 mL, 14.2 mmol) was added and the
mixture stirred at RT. After 18 h, chloroacetyl chloride (1.13 mL,
14.2 mmol) was added and stirring continued. The mixture was
quenched with H.sub.2O after 42 h and extracted into EtOAc
(4.times.50 mL). The combined organic phases were washed with
H.sub.2O and brine, dried (Na.sub.2SO.sub.4) and concentrated to
dryness in vacuo. Purification by chromatography on silica, eluting
with 0-20% EtOAc in n-heptane gave i (930 mg, 67%).
[1-(5-bromopyrimidin-2-yl)-1-methyl-ethyl]
2-[2-(tert-butoxycarbonylamino) ethylamino]acetate (Precursor
78)
[0556] DMAP (4 mg, 0.03 mmol) and i (97 mg, 0.33 mmol) were
dissolved in anhydrous THF (5 mL) under argon and DIPEA (0.09 mL,
0.50 mmol) and N-Boc-ethylenediamine (0.06 mL, 0.40 mmol) added.
The mixture was stirred at RT for 1 h then warmed to 50.degree. C.
for 17 h. More DIPEA (0.09 mL, 0.50 mmol), DMAP (4 mg, 0.03 mmol)
and N-Boc-ethylenediamine (0.06 mL, 0.40 mmol) were added and the
temperature raised to 60.degree. C. After 30 h, the mixture was
cooled to RT, quenched with H.sub.2O and extracted into EtOAc
(4.times.10 mL). The combined organic phase was washed with brine,
dried (Na.sub.2SO.sub.4) and concentrated to dryness in vacuo to
give Precursor 78 (191 mg). MS 416.97 and 418.95 [M+H].sup.+.
##STR00165##
[0557] (2S)-2-(tert-Butoxycarbonylamino)propanoic acid (95 mg, 0.50
mmol), Precursor 1 (109 mg, 0.50 mmol) and DMAP (61 mg, 0.50 mmol)
were dissolved in THF (2 mL). DCC (104 ing, 0.50 mmol) was added
last and the reaction was stirred at RT under argon for 16 h.
Additional (2S)-2-(tert-butoxycarbonylamino)propanoic acid (95 mg,
0.50 mmol), DMAP (61 mg, 0.50 mmol) and DCC (104 mg, 0.50 mmol)
were added and the reaction stirred at RT for 16 h. The reaction
was filtered and washed with THF and the filtrate concentrated in
vacuo. Purification by chromatography on silica, eluting with
10-50% EtOAc/heptane, followed by purification by chromatography on
silica, eluting with 0-10% MeOH/DCM gave Precursor 79 (148 mg,
76%).
[0558] It will be understood that boronic acid and esters thereof
e.g. boronates such as 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl
and 5,5-dimethyl-1,3,2-dioxaborinan-2-yl, of any of the preceding
Precursor(s) may be formed as illustrated by the following
example(s).
##STR00166##
(5-Bromopyridin-2-yl)(pyridin-3-yl)methanone (i)
[0559] A solution of 3-bromopyridine (2.50 g, 15.82 mmol) in THF
(25.0 mL) was cooled to -78.degree. C. followed by drop wise
addition of n-BuLi (1.60 M in hexane, 11.90 mL, 18.98 mmol). The
mixture was stirred at -78.degree. C. for 30 min followed by
addition of methyl 5-bromopicolinate (4.10 g, 18.98 mmol) dissolved
in minimum amount of THF at -78.degree. C. The temperature of the
reaction was slowly raised up to RT and then stirred overnight. The
reaction was then cooled to 0.degree. C. and saturated NH.sub.4Cl
solution (50 mL) added followed by extraction with EtOAc
(3.times.100 mL). The combined organics were washed with brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The
residue was purified over silica eluting with 25% EtOAc-hexanes to
obtain i (2.50 g, 60%). MS 263.09 [M+H].sup.+.
(5-Bromopyridin-2-yl)(pyridin-3-yl)methanol (ii)
[0560] To an ice-cold solution of i (2.50 g, 9.50 mmol) in MeOH
(25.0 mL) was added sodium borohydride (1.05 g, 28.50 mmol) portion
wise. The resulting mixture was stirred at RT for 30 min, then
H.sub.2O (50 mL) was added followed by extraction with EtOAc
(3.times.100 mL). The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered and evaporated in vacuo to obtain ii
(1.75 g, 70%). MS 265.11 (M+H).sup.+.
3-pyridyl-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]metha-
nol (Precursor 80)
[0561] To the solution of ii (0.50 g, 1.89 mmol) in 1,4-dioxane (10
mL) was added bis(pinacolato)diboron (0.53 g, 2.08 mmol) and KOAc
(0.28 g, 2.84 mmol). The reaction was degassed by purging N.sub.2
for 15 min followed by addition of Pd.sub.2(dba).sub.3 (0) (0.10 g,
0.10 mmol) and tricyclohexylphosphine (0.06 g, 0.23 mmol). The
reaction was degassed for 10 min and heated up to 80.degree. C. for
2 h. The resulting mixture was cooled to RT and filtered through a
celite bed. The filtrate was concentrated in vacuo to obtain
Precursor 80 (0.41 g, 70%).
##STR00167##
[0562] N,N-dimethylpyridin-4-amine (120 mg) was added to a solution
of bis(2,2,2-trichloroethyl)phosphorochloridate (450 mg) and
Precursor 4 (200 mg) in THF (10 mL) and the mixture heated at
70.degree. C. for 1 h. The mixture was cooled to RT and filtered.
The filtrate was concentrated in vacuo and purified by
chromatography on silica, eluting with 40% EtOAc/n-heptane -80%%
EtOAc/n-heptane to give Precursor 81 (300 mg, 56%).
[0563] It will be understood that any of the preceding Precursor(s)
having a chiral alcohol may be synthesised from an enantiomeric
resolving agent and/or separated into their respective enantiomers
by suitable chiral separation methods known to those in the art
such as chiral HPLC as illustrated by the following example(s).
(1S)-1-(5-bromopyrimidin-2-yl)ethanol (Precursor 82) and
(1R)-1-(5-bromopyrimidin-2-yl)ethanol (Precursor 83)
##STR00168##
[0565] .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.78 (s, 2H);
4.92 (dq, J=5.6, 6.8 Hz, 1H); 3.80 (1H, d, J=5.6 Hz); 1.55 (t,
J=6.8 Hz, 3H).
1-(5-bromopyrimidin-2-yl)ethyl
(2R)-2-(tert-butoxycarbonylamino)-3-methyl-butanoate (i)
[0566] A mixture of Precursor 4 (27.8 g, 137 mmol), Boc-D-valine
(32.7 g, 151 mmol) and DMAP (10.0 g, 82.2 mmol) was dissolved in
THF (200 mL). The mixture was cooled in an ice bath. A solution of
DCC (31.1 g, 151 mmol) in THF (50 mL) was added. After 10 min, the
cooling bath was removed. The mixture was stirred overnight,
filtered, the DCU precipitate was washed with several portions of
EtOAc, and the combined filtrates were concentrated. The residue
was then eluted through a plug of silica (20% EtOAc/heptane) to
give i (64.7 g).
[(1S)-1-(5-bromopyrimidin-2-yl)ethyl]
(2R)-2-(tert-butoxycarbonylamino)-3-methyl-butanoate (ii)
[0567] i (64.7 g) was crystallised from hot heptane. The solids
obtained were collected by filtration and recrystallised from hot
heptane, yielding ii (15.4 g).
(1S)-1-(5-bromopyrimidin-2-yl)ethanol (Precursor 82)
[0568] Amberlite.RTM. basic ion exchange resin and ii (15.4 g, 38.3
mmol) were stirred in MeOH (50 mL) overnight at RT. The suspension
was filtered through a pad of silica using 1:1 MeOH/DCM and the
filtrate concentrated in vacuo. Crystallisation from hot heptane
gave Precursor 82 (5.85 g). (1S)-1-(5-bromopyrimidin-2-yl)ethanol
(Precursor 83) was similarly prepared using Boc-L-valine. Mitsunobu
inversion of one enantiomer to the desired enantiomer may also be
employed.
[0569] Chiral HPLC was used to demonstrate the chiral purity of the
enantiomers (Column: Chirapak IC, 0.46 cm.times.25 cm; 20 min
isocratic gradent; 5:95 EtOH:n-hexane+0.1% diethylamine) retention
time=14.65 min/17.53 min.
[0570] Alternatively, Precursor 82 (S-enantiomer) may be
synthesized as follows.
##STR00169##
(Z)-2-bromo-3-(dimethylamino)prop-2-enal
[0571] (3-(Dimethylamino)acrolein (25 g) was dissolved in
chloroform (250 mL), and the mixture cooled in an ice/water bath,
bromine (40 g; 13 mL) was added dropwise and once the addition was
complete, the reaction was allowed to warm to room temperature and
stirred for 1 hour. The reaction was diluted with DCM (150 mL) and
quenched by the addition of aq. sat Na.sub.2SO.sub.5 solution (50
mL) and aq. sat. NaHCO.sub.3 solution (250 mL). The organic layer
was collected and dried (MgSO.sub.4) and the solvent removed in
vacuo. Once the material had solidified, it was suspended in ethyl
acetate:heptane (1:1-100 mL) and the resulting solid material
collected by filtration. Washing with ethyl acetate:heptane and air
drying gave (Z)-2-bromo-3-(dimethylamino)prop-2-enal as a fawn
coloured solid (25 g, 75%). .sup.1H NMR (CDCl.sub.3) 8.85 (s, 1H),
7.2 (s, 1H), 3.36 (s, 6H).
(2S)-2-hydroxypropanamidine hydrochloride hydrochloride Salt
[0572] (2S)-2-hydroxypropanamide (20 g) was placed in a flask with
THF (100 mL) and triethyloxonium tetrafluoroborate (47 g) was added
and the mixture stirred for 1 hour. The solvent was removed and the
residue dissolved in methanol (100 mL) and ammonia (7M in methanol)
(150 mL) added over .about.10 mins cooling the reaction mixture in
a cold water bath. Once the addition was complete the reaction was
allowed to warm to room temperature. The resulting suspension was
concentrated to a thick mixture, diluted with ethyl acetate and
filtered through celite. The filtrate was cooled to
.about.10.degree. C. and HCl (4M in dioxane) (100 mL) added
dropwise. After stirring for 90 mins, the mixture was filtered to
collect the white precipitate (washing with ethyl acetate and then
dried in a vacuum oven at 40.degree. C. to give
(2S)-2-hydroxypropanamidine hydrochloride hydrochloride salt as a
white solid (12 g, 43%). .sup.1H NMR (CDCl.sub.3) .delta. 8.8 (m,
4H), 6.26 (s, 1H), 4.43 (q, J=6.7 Hz, 1H), 1.35 (d, J=6.7 Hz,
3H).
(1S)-1-(5-bromopyrimidin-2-yl)ethanol
[0573] (Z)-2-bromo-3-(dimethylamino)prop-2-enal (11.5 g), potassium
carbonate (13.4 g), ethanol (200 mL) and
2-hydroxy-2-methyl-propanamidine hydrochloride (12.1 g) were placed
in a flask and the mixture heated at 85.degree. C. overnight. The
reaction mixture was cooled and the mixture filtered, washed with
ethanol and the combined filtrates concentrated in vacuo with
silica gel. This residue was purified by chromatography on silica,
eluting with 0-50% ethyl acetate in heptane to give
(1S)-1-(5-bromopyrimidin-2-yl)ethanol as a white solid (2.1 g,
16%). .sup.1H NMR (CDCl.sub.3) .delta. 8.83 (s, 2H), 4.98 (m, 1H),
3.8 (m, 1H), 1.6 (d, J=6.6 Hz, 3H).
[0574] Chiral HPLC: Column: Chirapak IC, 0.46 cm.times.25 cm; 20
min isocratic gradent; 5:95 EtOH:n-hexane+0.1% diethylamine)
retention time=14.08 min. (racemic mixture: .about.14.5 min: S
isomer; .about.17.5 min: R isomer).
[0575] Precursor 83 (R-enantiomer) may be formed using
R-lactamide.
[0576] Once formed, Precursor 82 or Precursor 83 may be coupled to
an Intermediate core then optionally subjected to Mitsunobu
inversion conditions to obtain the other enantiomeric form, if
desired.
Example(s) of General Method A
1-Ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(pyridin-2-yl)benz-
o[d]thiazol-2-yl)urea (1)
##STR00170##
[0578] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.05 (s, 2H), 8.77
(d, J=4.1 Hz, 1H), 8.03 (d, J=8.1 Hz, 1H), 7.93 (t, J=8.7 Hz, 1H),
7.91-7.77 (m, 2H), 7.35-7.29 (m, 1H), 3.44-3.31 (m, 3H), 1.66 (s,
6H), 1.32-1.15 (m, 4H). MS: 435.1 [M+H].sup.+.
[0579] Precursor 1 (50 mg) was placed in a flask with Intermediate
1 (100 mg), Cs.sub.2CO.sub.3 (67 mg), Pd(dppf)Cl.sub.2 (16 mg), DMF
(3 mL) and H.sub.2O (0.5 mL) and the mixture heated at 85.degree.
C. for 16 h. The mixture was cooled to RT and partitioned between
H.sub.2O (50 mL) and EtOAc (50 mL). The organic layer was collected
and the aqueous layer extracted with EtOAc (2.times.50 mL). The
combined organic layers were dried (MgSO.sub.4) and the solvent
removed in vacuo. Purification by chromatography on silica, eluting
with a gradient of 0-10% MeOH in DCM gave Compound 1 (12 mg).
[0580] The following compound(s) were similarly prepared noting
that alternative catalysts, bases, solvents and reaction times may
be employed and the urea may require protection as a
5-methyl-1,3,5-triazinan-2-one.
1-Ethyl-3-(7-(4-((3-hydroxy-3-methylazetidin-1-yl)methyl)pyridin-2-yl)-5-(-
2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)benzo[d]thiazol-2-yl)urea
(2)
##STR00171##
[0582] .sup.1H NMR (DMSO-d.sub.6): .delta. 10.61 (br s, 1H), 9.33
(s, 2H), 8.72 (d, J=5.20 Hz, 1H), 8.34 (m, 2H), 8.12 (s, 1H), 7.36
(m, 1H), 6.84 (m, 1H), 5.21 (s, 1H), 5.15 (s, 1H), 3.74 (s, 2H),
3.17-3.26 (m, 4H), 2.97-2.99 (m, 2H), 1.57 (s, 6H), 1.38 (s, 3H)
and 1.09 (t, J=7.20 Hz, 3H). MS: 534.32 [M+H].sup.+.
1-(7-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5-(2-(2-hydroxypropan-2-yl)pyr-
imidin-5-yl)benzo[d]thiazol-2-yl)-3-ethyl-5-methyl-1,3,5-triazinan-2-one
(i)
[0583] To a solution of Intermediate 4 (0.25 g, 0.51 mmol) in
toluene (10 mL) was added bis(neopentylglycolato) diboron (0.23 g,
1.01 mmol) and potassium acetate (0.15 g, 1.53 mmol). The reaction
mass was degassed by purging N.sub.2 for 15 min followed by
addition of Pd(dppf)Cl.sub.2 (0.041 g, 0.091 mmol). The mixture was
degassed for 10-15 min and then heated at 130.degree. C. for 30
min. The mixture was cooled to RT and filtered through celite. The
filtrate was concentrated in vacuo to obtain i (0.21 g, 80% crude).
MS: 455.20 [M-H].sup.+, (MS of corresponding boronic acid
observed).
1-Ethyl-3-(7-(4-((3-hydroxy-3-methylazetidin-1-yl)methyl)pyridin-2-yl)-5-(-
2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)benzo[d]thiazol-2-yl)-5-methyl-1,3,-
5-triazinan-2-one (ii)
[0584] To a solution of i (0.427 g, 0.81 mmol) in
1,4-dioxane-H.sub.2O (9:1, 10 mL) was added Precursor 29 (0.231 g,
0.90 mmol) and Cs.sub.2CO.sub.3 (0.791 g, 2.43 mmol). The reaction
mixture was degassed by purging N.sub.2 for 15 min followed by
addition of Pd(dppf)Cl.sub.2 (0.066 g, 0.08 mmol). The mixture was
heated in a microwave at 110.degree. C. for 30 min. The mixture was
diluted with H.sub.2O and extracted with EtOAc (2.times.50 mL). The
combined organics were washed with brine, dried (Na.sub.2SO.sub.4)
and concentrated in vacuo. The residue was purified over silica
eluting with 7% MeOH:DCM to obtain ii (0.303 g, 63%). .sup.1H-NMR
(400 MHz, DMSO-d6): .delta. 9.34 (s, 2H), 8.75 (d, J=4.40 Hz, 1H),
8.38 (m, 2H), 8.20 (s, 1H), 7.37 (m, 1H), 5.23 (br s, 1H), 5.15 (s,
3H), 4.38 (s, 2H), 3.75 (br s, 2H), 3.38 (m, 2H), 3.26 (m, 2H),
2.94 (m, 2H), 2.55 (s, 3H), 1.57 (s, 6H), 1.38 (s, 3H), and 1.12
(t, J=7.20 Hz, 3H). MS: 589.31 [M+H].sup.+.
1-ethyl-3-(7-(4-((3-hydroxy-3-methylazetidin-1-yl)methyl)pyridin-2-yl)-5-(-
2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)benzo[d]thiazol-2-yl)urea
(2)
[0585] An ice-cold solution of ii (0.25 g, 0.42 mmol) in MeOH-DCM
(0.50 and 10 mL respectively) was purged with HCl (g) for 10 min
and the mixture stirred at RT for 16 h. The solvent was evaporated
and the residue triturated with a mixture of MeOH and Et.sub.2O to
obtain Compound 2 (0.225 g, 90%).
1-Ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(tetrahydrofur-
an-2-ylmethoxy)-1,3-benzothiazol-2-yl]urea (3)
##STR00172##
[0587] .sup.1HNMR (DMSO-d.sub.6, 400 MHz): .delta. 10.63 (br s,
1H), 9.00 (s, 2H), 7.72 (m, 2H), 6.68 (m, 1H), 5.12 (s, 1H), 4.21
(m, 1H), 4.06 (m, 2H), 3.68 (m, 2H), 3.18 (m, 2H), 1.94 (m, 1H),
1.71 (m, 2H), 1.65 (m, 1H), 1.61 (s, 6H) and 1.22 (t, J=6.8 Hz,
3H). LCMS: 458.20 [M+H].sup.+.
2-((2-Bromo-4-nitrophenoxy)methyl)tetrahydrofuran (i)
[0588] To an ice cold solution of 2-bromo-1-fluoro-4-nitro-benzene
(5.0 g, 22.72 mmol) in DMSO (40 mL) was added NaOH (1.36 g, 34.09
mmol) and (tetrahydrofuran-2-yl)methanol (3.47 g, 34.09 mmol) at
0.degree. C. The mixture was stirred at RT for 1 h, then poured
into H.sub.2O (50 mL), the pH adjusted .about.7 with 1M HCl and
extracted with EtOAc (2.times.250 mL). The combined organics were
washed with H.sub.2O, brine, dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo to obtain i (6.50 g, 95%). .sup.1HNMR
(CDCl.sub.3, 400 MHz): .delta. 8.46 (d, J=2.40 Hz, 1H), 8.20 (dd,
J=2.40 and 9.20 Hz respectively, 1H), 6.98 (d, J=9.20 Hz, 1H), 4.36
(m, 1H), 4.16 (m, 2H) 3.97 (m, 1H) 3.86 (m 1H) 2.07 (m 2H) and 1.95
(m 2H).
3-Bromo-4-((tetrahydrofuran-2-yl)methoxy)aniline (ii)
[0589] To the solution of i (5.5 g, 18.2 mmol) in THF (30 mL) was
added stannous chloride dihydrate (12.3 g, 54.6 mmol) at RT. The
mixture was stirred at 60.degree. C. for 5 h. The mixture was
poured into saturated sodium bicarbonate solution (100 mL) and
extracted with EtOAc (2.times.500 mL). The combined organics were
washed with H.sub.2O, brine, dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The crude residue was purified over silica
(50% EtOAc:Hexanes) to obtain ii (4.0 g, 82%). MS: 272.0
[M+H].sup.+.
5-bromo-6-((tetrahydrofuran-2-yl)methoxy)benzo[d]thiazol-2-amine
(iii)
[0590] To a solution of ii (3.0 g, 11.62 mmol) in acetic acid (50
mL) was added ammonium thiocynate (4.18 g, 55.11 mmol) at RT. The
resulting mixture was stirred at RT for 15 min followed by the
addition of bromine (0.68 mL, 13.22 mmol) in acetic acid (5 mL).
The mixture was stirred at RT for 5 h. The pH was adjusted to >7
with ammonia solution followed by extraction with EtOAc
(2.times.200 mL). The combined organics were washed with H.sub.2O,
brine solution, dried (Na.sub.2SO.sub.4) and concentrated in vacuo.
The residue was purified over silica (60% EtOAc-Hexanes) to obtain
iii (1.0 g, 26%). .sup.1HNMR (DMSO-d.sub.6, 400 MHz): .delta. 7.50
(s, 1H), 7.49 (s, 1H), 7.43 (br s, 2H), 4.18 (m, 1H), 3.96 (m, 2H),
3.80 (m, 1H), 3.69 (m, 1H), 1.96 (m, 2H) and 1.78 (m, 2H). MS:
329.0 [M+H].sup.+.
1-(5-Bromo-6-((tetrahydrofuran-2-yl)methoxy)benzo[d]thiazol-2-yl)-3-ethylu-
rea (iv)
[0591] To a solution of iii (1.0 g, 3.03 mmol) in 1,4-dioxane (10
mL) was added ethyl isocynate (1.23 mL, 15.19 mmol) at RT. The
mixture was stirred at 80.degree. C. for 5 h. The reaction mixture
was evaporated in vacuo, H.sub.2O (50 mL) added to and the mixture
stirred at 70.degree. C. for 4 h. The residue was filtered and
dried under vacuum to obtain iv (1.0 g, 83%). .sup.1HNMR
(DMSO-d.sub.6, 400 MHz): .delta. 10.69 (br s, 1H), 7.80 (s, 1H),
7.68 (s, 1H), 6.65 (m, 1H), 4.21 (m, 1H), 4.04 (m, 2H), 3.83 (m,
1H), 3.70 (m, 1H), 3.16 (m, 2H), 2.0 (m, 2H), 1.82 (m, 2H) and 1.09
(t, J=7.20 Hz, 3H). MS:400 [M+H].sup.+.
1-Ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-6-((tetrahydrofuran--
2-yl)methoxy)benzo[d]thiazol-2-yl)urea (3)
[0592] To a solution of iv (0.303 g, 0.75 mmol) and the
4,4,5,5-tetramethyl-1,3,2-dioxaborolon-2-yl) ester of Precursor 1
(0.20 g, 0.75 mmol) in 1,4-dioxane:MeOH (5:3, 8.0 mL) was added
potassium phosphate (0.24 g, 1.13 mmol) at RT. The mixture was
degassed for 15-20 min by purging N.sub.2 followed by the addition
of Pd(dppf)Cl.sub.2 (0.062 g, 0.075 mmol). The mixture was degassed
for 15-20 min and heated at 80.degree. C. for 5 h. The reaction
mixture was cooled to RT, diluted with EtOAc (500 ml) and filtered
through celite. The filtrate was evaporated in vacuo and the crude
residue was purified over silica (5% MeOH-DCM) to obtain Compound 3
(0.15 g, 43%).
1-Ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-6-(2-methoxyethy-
lamino)-1,3-benzothiazol-2-yl]urea (150)
[0593] Compound 150 was similarly prepared to Compound 3, starting
from
1-[5-bromo-6-(2-methoxyethylamino)-1,3-benzothiazol-2-yl]-3-ethyl-urea
and 2-methoxyethanamine.
##STR00173##
[0594] .sup.1H NMR (400 MHz; DMSO-d.sub.6): .delta. 10.46 (br s,
1H), 8.85 (s, 2H), 7.34 (s, 1H), 7.23 (s, 1H), 6.65 (m, 1H), 5.13
(br s, 1H), 4.87 (m, 1H), 3.48 (m, 2H), 3.17-3.24 (m, 7H), 1.55 (s,
6H), and 1.08 (m, 3H). MS 431.16 [M+H].sup.+
1-Ethyl-3-(6-fluoro-5-(6-(hydroxy(pyridin-3-yl)methyl)pyridin-3-yl)benzo[d-
]thiazol-2-yl)urea (4)
##STR00174##
[0596] .sup.1H NMR (400 MHz; DMSO-d.sub.6): .delta. 8.67 (m, 2H),
8.45 (d, J=3.60 Hz, 1H), 8.05 (m, 1H), 7.95 (m, 1H), 7.73-7.81 (m,
3H), 7.35 (m, 1H), 6.74 (m, 1H), 6.36 (d, =4.0 Hz, 1H), 5.85 (d,
J=4.0 Hz, 1H), 3.38 (m, 1H), 3.21 (m, 2H) and 1.08 (t, J=7.20 Hz,
3H). MS: 424.31 [M+H].sup.+
[0597] To a solution of Precursor 80 (0.2 g, 0.6 mmol) in
1,4-dioxane (5 mL) and MeOH (3 mL) was added Intermediate 13 (0.2
g, 0.6 mmol) and potassium phosphate (0.2 g, 0.96 mmol). The
reaction mass was degassed by purging N.sub.2 for 15 min followed
by addition of Pd(dppf)Cl.sub.2 (0.05 g, 0.06 mmol). The mixture
was degassed for 10 min and heated at 80.degree. C. for 4 h. The
solvent was evaporated, H.sub.2O (50 mL) added and the mixture
extracted with EtOAc (4.times.50 mL). The combined organics were
washed with brine, dried (Na.sub.2SO.sub.4) and concentrated in
vacuo. The residue was purified over silica eluting with 2.50% MeOH
in DCM to obtain Compound 4 (0.02 g, 10%).
1-(2-Hydroxyethyl)-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(pyridi-
n-2-yl)benzo[d]thiazol-2-yl)urea (5)
##STR00175##
[0599] .sup.1H NMR (400 MHz; CD.sub.3OD) .delta.=9.14 (s, 2H), 8.70
(d, J=43 Hz, 1H), 8.20 (d, J=8.0 Hz, 1H), 8.10 (s, 1H), 7.97-7.82
(m, 2H), 7.42-7.25 (m, 1H), 3.75 (t, J=5.5 Hz, 2H), 3.46 (t, J=5.5
Hz, 2H), 1.69 (s, 6H). MS: 451.08 [M+H].sup.+
[2-amino-7-(2-pyridyl)-1,3-benzothiazol-5-yl]
trifluoromethanesulfonate (i)
[0600]
[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]
trifluoromethanesulfonate (1.34 g, 3.0 mmol) was dissolved in DMSO
(10 mL) and stirred at 160.degree. C. for 16 h. The mixture was
diluted with EtOAc, washed with H.sub.2O, brine. The organic
fraction was concentrated in vacuo to afford i (1.01 g, 90%). MS:
375.96 [M+H].sup.+.
[2-(2-hydroxyethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]trif-
luoromethanesulfonate (ii)
[0601] Compound i (445 mg, 1.18 mmol) was dissolved in DMF (7 mL)
and solution of CDI (577 mg, 3.56 mmol) in DMF (3 mL) was added
drop-wise at 0.degree. C. with stirring under argon. The mixture
was warmed to RT and stirred for 16 h. A solution of ethanolamine
(710 .mu.L, 11.85 mmol) in DMF (2 mL) was then added and the
mixture stirred at RT for 4 h. The mixture was diluted with EtOAc,
washed with H.sub.2O, brine. The organic fraction was dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The residue was
washed with MeOH and Et.sub.2O to afford ii (253 mg, 46%). MS:
463.00 [M+H].sup.+.
2-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]propan-2--
ol (iii)
[0602] Precursor 1 (140 mg, 0.645 mmol), bispinacolatodiboron (197
mg, 0.774 mmol) and potassium acetate (95 mg, 0.967 mmol) were
suspended in anhydrous 1,4-dioxane (5 mL). Tricyclohexylphosphine
(23 mg, 0.081 mmol) and Pd.sub.2(dba).sub.3 (30 mg, 0.032 mmol)
were added and the mixture degassed/purged with argon (.times.3).
The reaction mixture was stirred at 100.degree. C. under microwave
irradiation for 1 h. The reaction was cooled to RT, filtered and
washed with 1,4-dioxane (5 mL) to give iii. MS: 182.96 [M+H].sup.+
(boronic acid).
1-(2-hydroxyethyl)-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(pyridi-
n-2-yl)benzo[d]thiazol-2-yl)urea (5)
[0603] To a solution of iii (165 mg, 0.626 mmol) in 1,4-dioxane (12
mL) was added ii (193 mg, 0.417 mmol) and PdCl.sub.2(dppf) (34 mg,
0.042 mmol). A solution of Cs.sub.2CO.sub.3 (410 mg, 1.30 mmol) in
H.sub.2O (3 mL) was added, the reaction vessel sealed, then
evacuated/purged with argon (.times.3). The mixture was then heated
under microwave irradiation at 100.degree. C. for 30 min. LCMS
analysis indicated complete conversion. The mixture was diluted
with EtOAc (100 mL), washed with H.sub.2O, brine, then separated
and dried (Na.sub.2SO.sub.4). The organic fraction was concentrated
in vacuo. Purification by chromatography on silica, eluting with
0-10% MeOH/EtOAc followed by additional chromatography on silica,
eluting with 0-10% MeOH/DCM afforded Compound 5 (9 mg, 5%).
Example(s) of General Method B
1-Ethyl-3-[5-[5-(1-hydroxyethyl)pyrazin-2-yl]-7-(2-pyridyl)-1,3-benzothiaz-
ol-2-yl]urea (6)
##STR00176##
[0605] .sup.1H NMR (400 MHz; d.sub.6-DMSO): .delta.=10.70 (bs, 1H),
9.43 (d, J=1.5 Hz, 1H), 8.96-8.78 (m, 2H), 8.71 (d, J=1.5 Hz, 1H),
8.47 (t, J=5.3 Hz, 2H), 8.14-7.94 (m, 1H), 7.49 (ddd, J=7.5, 4.9,
0.9 Hz, 1H), 6.88 (bt, J=5.4 Hz, 1H), 5.65 (d, J=4.7 Hz, 1H),
5.00-4.84 (m, 1H), 3.29-3.15 (m, 2H), 1.50 (d, J=6.6 Hz, 3H), 1.14
(t, J=7.2 Hz, 3H). MS: 421.08 [M+H].sup.+.
1-[5-(5-acetylpyrazin-2-yl)-7-(2-pyridyl)-1,3-benzothiazol-2-yl]-3-ethyl-u-
rea (i)
[0606] Intermediate 1 (171 mg, 0.5 mmol),
1-(5-chloropyrazin-2-yl)ethanone (94 mg, 0.60 mmol) and
PdCl.sub.2(dppf) (41 mg, 0.05 mmol) were suspended in 1,4-dioxane
(8 mL). A solution of Cs.sub.2CO.sub.3 (488 mg, 1.50 mmol) in
H.sub.2O (2 mL) was added. The mixture was then heated under
microwave irradiation at 100.degree. C. for 30 min. The mixture was
filtered, washed with H.sub.2O, EtOH, MeOH and Et.sub.2O to afford
i (172 mg, 82%). MS: 419.06 [M+H].sup.+.
1-ethyl-3-(5-(5-(1-hydroxyethyl)pyrazin-2-yl)-7-(pyridin-2-yl)benzo[d]thia-
zol-2-yl)urea (6)
[0607] To a suspension of i (63 mg, 0.15 mmol) in THF (5 mL) was
added a solution of NaBH.sub.4 (29 mg, 0.75 mmol) in H.sub.2O (1
mL) and the mixture stirred at RT for 30 min. The reaction was
diluted with EtOAc (50 mL) and washed with H.sub.2O and brine. The
organic fraction was dried (Na.sub.2SO.sub.4) and concentrated in
vacuo to afford Compound 6 (62 mg, 98%).
Example(s) of General Method C
1-[5-[2-[(1S*,2R*)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]-3-ethyl-urea (7)
##STR00177##
[0609] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.14 (s, 2H), 8.70
(s, 1H), 8.14-7.90 (m, 2H), 7.82 (t, J=7.3 Hz, 1H), 7.75 (s, 1H),
7.30 (d, J=10.5 Hz, 1H), 4.55 (s, 1H), 4.14 (d, J=7.2 Hz, 1H), 3.23
(s, 2H), 1.42 (d, J=3.9 Hz, 3H), 1.26 (t, J=7.1 Hz, 3H). MS: 451.1
[M+H].sup.+.
(5-bromopyrimidin-2-yl)methanol (i)
[0610] An solution of NaBH.sub.4 (510 mg, 2.70 mmol) in H.sub.2O
(10 mL) was introduced drop-wise to a solution of methyl
5-bromopyrimidine-2-carboxylate (3.05 g, 14.1 mmol) in THF (100 mL)
at 0.degree. C. The mixture was allowed to warm slowly to RT
overnight. The majority of the THF was evaporated, and the
resulting residue was diluted with EtOAc (200 mL). The organic
fraction was washed with brine (200 mL), dried (MgSO.sub.4) and
purified over silica, eluting with 0-60% EtOAc:n-heptane) to afford
i (510 mg, 19%). MS: 189.0 & 191.0; 1:1 [M+H].sup.+.
5-bromo-2-(bromomethyl)pyrimidine (ii)
[0611] Methanesulfonyl chloride (0.31 mL, 4.0 mmol) was added to a
stirred suspension of i (510 mg, 2.7 mmol) and triethylamine (820
.mu.L, 5.9 mmol) in THF (30 mL) at 0.degree. C. for 10 min. The
solution was treated with LiBr (1.2 g, 13 mmol) in THF (25 mL) and
allowed to stir, whilst warming to RT over 1 h. The majority of the
reaction solvent was removed in vacuo, and the mixture diluted with
EtOAc (200 mL). The organic fraction was sequentially washed with
sat. aq. NH.sub.4Cl (2.times.100 mL), brine (1.times.100 mL) and
dried (MgSO.sub.4) to afford ii (663 mg, 98%). MS: 251.0, 253.0
& 254.8; 1:2:1 [M+H].sup.+.
5-bromo-2-(diethoxyphosphorylmethyl)pyrimidine (iii)
[0612] Compound ii (663 mg, 2.63 mmol) was dissolved in 10 mL of
ACN and triethylphosphite (0.92 mL, 5.26 mmol) added. The reaction
was heated in a microwave for 1 h at 100.degree. C. The reaction
was concentrated in vacuo affording iii (813 mg, 100%) MS: 308.9
& 310.9; 1:1 [M+H].sup.+.
1-[5-[2-(diethoxyphosphorylmethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzot-
hiazol-2-yl]-3-ethyl-urea (iv)
[0613] Intermediate 1 (860 mg, 2.5 mmol), iii (813 mg, 2.63 mmol),
Cs.sub.2CO.sub.3 (2.57 g, 7.90 mmol) and
Pd(PPh.sub.3).sub.2Cl.sub.2 (90 mg, 0.10 mmol) were dissolved in
1-4-dioxane:H.sub.2O (10:1; 10 mL) and degassed with a stream of
N.sub.2 for 10 min. The reaction was sealed under an atmosphere of
N.sub.2 and heated at 100.degree. C. for 1 h in a microwave
reactor. The mixture was concentrated in vacuo, purified over
silica (gradient elution: 0-10% DCM-MeOH) and triturated from
acetone affording iv (410 mg, 29%). MS: 527.1 [M+H].sup.+.
1-ethyl-3-[5-[2-[(E)-prop-1-enyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzoth-
iazol-2-yl]urea (v)
[0614] Sodium methoxide (0.5 M MeOH solution; 0.9 mL, 0.43 mmol)
was added drop-wise to a suspension of iv (104 mg, 0.198 mmol) in
THF (10 mL). Acetaldehyde (40 .mu.L, 0.69 mmol) was introduced and
the mixture stirred for 90 min. The reaction was diluted with EtOAc
(60 mL), washed with sat. NaHCO.sub.3(aq) (60 mL). The organic
fraction was dried (MgSO.sub.4), concentrated in vacuo, and
purified over silica (gradient elution: 0-10%, DCM-MeOH) affording
v (79 mg, 96%). MS: 417.1 [M+H].sup.+.
1-[5-[2-[(1S*,2R*)-1,2-dihydroxypropyl]pyrimidin-5-yl]-7-(2-pyridyl)-1,3-b-
enzothiazol-2-yl]-3-ethyl-urea (7)
[0615] Osmium tetroxide (10 mg; 60 .mu.mol) was added to a solution
of v (230 mg, 600 .mu.mol), N-methylmorpholine N-oxide (160 mg;
1.40 mmol) and pyridine (20 .mu.L) in THF-Me.sub.2CO (5:1; 90 mL).
The reaction was quenched with sat. Na.sub.2S.sub.2O.sub.5 (aq) (20
mL), extracted with EtOAc (150 mL), washed with brine (75 mL),
dried (MgSO.sub.4) and concentrated in vacuo. Purification over
silica (gradient elution: 0-10%, DCM-MeOH) afforded Compound 7 (93
mg, 38%).
Example(s) of General Method D
1-(5-(2-(3,4-dihydroxytetrahydro-2H-pyran-4-yl)pyrimidin-5-yl)-7-(pyridin--
2-yl)benzo[d]thiazol-2-yl)-3-ethylurea (8)
##STR00178##
[0617] .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.62 (s, 1H),
9.34 (s, 2H), 8.83 (dd, J=4.8, 0.8 Hz, 1H), 8.53 (d, J=8.3 Hz, 1H),
8.40 (d, J=1.4 Hz, 1H), 8.15 (d, J=0.9 Hz, 1H), 8.02 (td, J=7.9,
1.8 Hz, 1H), 7.53-7.41 (m, 1H), 6.94-6.77 (m, 1H), 5.41 (s, 1H),
4.76 (t, J=7.5 Hz, 1H), 3.93 (d, J=11.0 Hz, 2H), 3.82-3.70 (m, 2H),
3.69-3.62 (m, 1H), 3.28-3.15 (m, 2H), 2.69-2.55 (m, 1H), 1.81 (d,
J=13.8 Hz, 1H), 1.12 (t, J=7.2 Hz, 3H). MS: 493.1, [M+H].sup.+.
5-bromo-2-(3,6-dihydro-2H-pyran-4-yl)pyrimidine (i)
[0618] 5-bromo-2-iodo-pyrimidine (250 mg; 0.88 mmol) and
2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(196 mg, 0.92 mmol) were dissolved in 1,4-dioxane-H.sub.2O (10:1;
10 mL) and degassed with a stream of N.sub.2 for 10 min.
Pd(Ph.sub.3).sub.2Cl.sub.2 (30 mg, 0.04 mmol) was introduced and
the reaction sealed and heated in a microwave reactor for 30 min at
80.degree. C. The reaction was concentrated in vacuo, re-dissolved
in DCM, filtered and purified over silica (gradient elution, 0-50%
EtOAc-n-heptane) yielding i (105 mg, 50%). MS: 241.1 & 243.0;
1:1 [M+H].sup.+.
5-bromo-2-(3, 7-dioxabicyclo[4.1.0]heptan-6-yl)pyrimidine (ii)
[0619] Compound i (105 mg; 0.436 mmol) was dissolved in DCM (15 mL)
and cooled to 0.degree. C., then solid 3-chlorobenzenecarboperoxoic
acid (280 mg, 1.14 mmol) was added and the mixture stirred
overnight. The mixture was quenched with 1M
Na.sub.2S.sub.2O.sub.3(aq) (5 mL), washed with sat. NaHCO.sub.3(aq)
(3.times.30 mL) followed by brine (1.times.30 mL). The organic
fraction was dried (MgSO.sub.4). Purification by chromatography on
silica eluting with 0-50% EtOAc-n-heptane gave ii (20 mg, 18%). MS:
256.9 & 258.8; 1:1 [M+H].sup.+.
1-[5-[2-(3,7-dioxabicyclo[4.1.0]heptan-6-yl)pyrimidin-5-yl]-7-(2-pyridyl)--
1,3-benzothiazol-2-yl]-3-ethyl-urea (iii)
[0620] Intermediate 1 (29 mg, 0.085 mmol), ii (20 mg, 78 .mu.mol),
Cs.sub.2CO.sub.3 (55 mg 0.17 mmol) and Pd(Ph.sub.3).sub.2Cl.sub.2
(3 mg, 4 .mu.mol) were dissolved in 1,4-dioxane:H.sub.2O (10:1, 10
mL). The mixture was degassed with a stream of N.sub.2 for 10 min,
then heated in a microwave reactor at 80.degree. C. for 1 h. The
reaction was concentrated in vacuo, re-dissolved in a minimum
quantity of DCM and purified by chromatography on silica (0-10%
DCM-MeOH) yielding iii (23 mg 57%). MS: 475.0, [M+H].sup.+.
1-(5-(2-(3,4-dihydroxytetrahydro-2H-pyran-4-yl)pyrimidin-5-yl)-7-(pyridin--
2-yl)benzo[d]thiazol-2-yl)-3-ethylurea (8)
[0621] Compound iii (20 mg; 0.042 mmol) was dissolved in
THF-H.sub.2O (10:1, 11 mL). Conc. sulfuric acid (20 .mu.L) and
p-toluenesulphonic acid (0.7 mg, 4 .mu.mol) were added and the
mixture stirred at RT. The mixture was concentrated in vacuo and
purified over silica (0-100% 0.1% FA (aq)-MeCN) yielding Compound 8
(8.8 mg, 42%).
Example(s) of General Method E
1-Ethyl-3-[5-[4-(1-hydroxyethyl)triazol-1-yl]-7-(2-pyridyl)-1,3-benzothiaz-
ol-2-yl]urea (9)
##STR00179##
[0623] .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.97 (br s,
1H), 8.91 (s, 1H), 8.84 (d, J=3.9 Hz, 1H), 8.46 (d, J=8.2 Hz, 1H),
8.41 (s, 1H), 8.16 (s, 1H), 8.03 (td, J=7.9, 1.8 Hz, 1H), 7.49 (dd,
J=7.2, 5.2 Hz, 1H), 7.02 (br s, 1H), 5.41 (d, J=4.8 Hz, 1H),
5.00-4.92 (m, 1H), 3.26-3.15 (m, 2H), 1.52 (d, J=6.5 Hz, 3H), 1.11
(t, J=7.2 Hz, 3H). MS: 410.0 [M+H].sup.+.
1-(5-azido-7-bromo-1,3-benzothiazol-2-yl)-3-ethylurea (i)
[0624] Intermediate 3 (3.0 g, 7.04 mmol), sodium azide (930 mg,
14.08 mmol), sodium L-ascorbic acid (350 mg, 1.8 mmol) and CuI (120
mg; 0.63 mmol) were suspended in a mixture of DMSO (100 mL) and
H.sub.2O (24 mL). N,N'-dimethylethane-1,2-diamine (100 mg, 1.1
mmol) was added and the suspension heated at 100.degree. C.
overnight. H.sub.2O was added and the resultant solid collected by
filtration. This was rinsed with H.sub.2O and dried in vacuo to
give i (1.68 g). MS: 342.9 [M+H].sup.+.
1-[7-bromo-5-[4-(diethoxymethyl)-1H-1,2,3-triazol-1-yl]-1,3-benzothiazol-2-
-yl]-3-ethyl-5-methyl-1,3,5-triazinan-2-one (ii)
[0625] Compound i (1.68 g, 4.89 mmol) was suspended in MeOH (65 mL)
and formaldehyde (37 wt % in H.sub.2O, 7.94 g, 97.9 mmol) then
methylamine (2 M in MeOH; 24.5 mL, 49 mmol) added. The suspension
was heated to 80.degree. C. for 5 h. H.sub.2 (was added and the
mixture extracted with EtOAc and then DCM. The organic layers were
dried (Na.sub.2SO.sub.4), filtrated and concentrated in vacuo to
give a residue that contained
1-(5-azido-7-bromo-1,3-benzothiazol-2-yl)-3-ethyl-5-methyl-1,3,5-triazina-
n-2-one (1.31 g). A part of this mixture (827 mg; 2.09 mmol) was
suspended in DMF (36 mL), cooled down at 0.degree. C. and then
treated with 3,3-diethoxyprop-1-yne (535 mg, 4.17 mmol), DIPEA (320
mg, 2.5 mmol) and CuI (70 mg; 0.37 mmol). The ice bath was removed
and the reaction let to stir overnight at RT. The mixture was
freeze-dried and the residue purified by chromatography on silica
(0-5% MeOH gradient in DCM) to give a residue that was triturated
with EtOAc affording ii (354 mg, 13%) .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.90 (s, 1H), 8.26 (d, J=1.8 Hz, 1H), 8.10
(d, J=1.8 Hz, 1H), 5.75 (s, 1H), 5.13 (s, 2H), 4.40 (s, 2H), 3.63
(qq, J=9.6, 7.1 Hz, 4H), 3.38 (q, J=7.1 Hz, 2H), 2.55 (s, 3H), 1.18
(t, J=7.1 Hz, 6H), 1.13 (t, J=7.1 Hz, 3H).
1-[5-[4-(diethoxymethyl)-1H-1,2,3-triazol-1-yl]-7-(pyridin-2-yl)-1,3-benzo-
thiazol-2-yl]-3-ethyl-5-methyl-1,3,5-triazinan-2-one (iii)
[0626] Compound ii (415 mg, 0.79 mmol) was suspended in DMF (5 mL)
and tributyl(2-pyridyl)stannane (250 mg, 1.68 mmol) added. The
mixture was degassed by freeze-drying the reaction vessel under
vacuo and back filling with argon. CuI (30 mg, 0.2 mmol) and
Pd(PPh.sub.3).sub.2Cl.sub.2 (1:2) (60 mg, 0.08 mmol) were added.
The mixture was degassed with argon and heated at 110.degree. C.
overnight. The mixture was filtered through celite, washing with
DMF. The filtrate was freeze-dried to give a residue that was
purified by chromatography on silica (0-100% EtOAc gradient in
heptane) to give iii (250 mg, 60%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.06 (br s, 1H), 8.85 (ddd, J=4.8, 1.7, 0.9
Hz, 1H), 8.53 (d, J=2.0 Hz, 1H), 8.52-8.49 (m, 1H), 8.30 (d, J=2.0
Hz, 1H), 8.06-8.01 (m, 1H), 7.49 (ddd, J=7.5, 4.9, 0.9 Hz, 1H),
5.79 (s, 1H), 5.16 (s, 2H), 4.39 (s, 2H), 3.72-3.59 (m, 4H), 3.40
(q, J=7.1 Hz, 2H), 2.56 (s, 3H), 1.20 (t, J=7.1 Hz, 6H), 1.14 (t,
J=7.1 Hz, 3H). MS: 523.0 [M+H].sup.+.
1-Ethyl-3-[5-(4-formyl-1H-1,2,3-triazol-1-yl)-7-(pyridin-2-yl)-1,3-benzoth-
iazol-2-yl]urea (iv)
[0627] Compound iii (250 mg, 0.48 mmol) was suspended in 1M HCl
solution (9 mL) and the mixture heated at 70.degree. C. overnight.
The mixture was concentrated in vacuo to give iv (213 mg,
quantitative). MS: 394.0 [M+H].sup.+.
1-ethyl-3-[5-[4-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]-7-(pyridin-2-yl)-1-
,3-benzothiazol-2-yl]urea (9)
[0628] To a suspension of iv (40 mg, 0.1 mmol) in THF (0.7 mL) was
added bromo(methyl)magnesium 3M in Et.sub.2O (0.250 mL, 0.1 mmol)
and the mixture heated at 40.degree. C. for 1 h. NH.sub.4Cl (sat.
aq.) was added and the mixture extracted with DCM:IPA (5:1). The
organic layers were washed with brine and then concentrated in
vacuo to give a crude product that was purified by reverse phase
SP4 (ACN gradient in 1120) affording Compound 9 (1.9 mg, 4%).
Example(s) of General Method F
1-Ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(pyrimidin-2-yl)be-
nzo[d]thiazol-2-yl)urea (10)
##STR00180##
[0630] .sup.1H NMR (DMSO-d.sub.6): .delta..quadrature.10.72 (br s,
1H), 9.24 (s, 2H), 9.08 (d, J=4.80 Hz, 2H), 8.70 (s, 1H), 8.23 (s,
1H), 7.57 (t, J=4.80 Hz, 1H), 6.82 (m, 1H), 5.17 (s, 1H), 3.22 (m,
2H), 1.56 (s, 6H) and 1.12 (t, J=7.20 Hz, 3H). MS: 436.15
[M+H].sup.+.
[0631] A solution of Intermediate 5 (0.30 g, 0.68 mmol) and
2-(tributylstannyl)pyrimidine (0.253 g, 0.68 mmol) in DMF (10 mL)
was degassed by purging with N.sub.2 for 15 min followed by
addition of Pd(PPh.sub.3).sub.4 (0.078 g, 0.06 mmol). The mixture
was degassed by purging with N.sub.2 for 10 min and then heated to
80.degree. C. for 16 h. Ice-cold H.sub.2O was added to the reaction
followed by extraction with EtOAc (3.times.100 mL). The combined
organics were washed with brine, dried (Na.sub.2SO.sub.4), filtered
and concentrated in vacuo. The residue was purified over silica
(2.50% MeOH-DCM) to give Compound 10 (0.015 g, 5%).
Example(s) of General Method G
1-ethyl-3-(5-(4-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)-7-(pyridin-2-yl)b-
enzo[d]thiazol-2-yl)urea (11)
##STR00181##
[0633] .sup.1H NMR (400 MHz, MeOD) .delta. 8.73 (d, J=4.8 Hz, 1H),
8.22 (d, J=8.2 Hz, 1H), 8.20 (d, J=1.4 Hz, 1H), 8.01 (d, J=2.0 Hz,
1H), 7.92 (td, J=7.9, 1.8 Hz, 1H), 7.77 (d, J=2.0 Hz, 1H), 7.55 (d,
J=1.4 Hz, 1H), 7.37 (dd, J=7.5, 4.9 Hz, 1H), 3.37-3.32 (m, 2H),
1.62 (s, 6H), 1.23 (t, J=7.2 Hz, 3H). MS: 422.99 [M+H].sup.+.
2-(1H-imidazol-4-yl)propan-2-ol (i)
[0634] Methyl 1H-imidazole-4-carboxylate (430 mg) was heated at
reflux in HMDS (1 mL) for 30 min and the excess HMDS then distilled
off. The residue was placed under vacuum then flushed twice with
N.sub.2 before dissolving in THF. The solution was cooled to
0.degree. C., and MeMgBr (4.5 mL; 3M) added dropwise at 0.degree.
C. and the mixture warmed to RT overnight. The mixture was quenched
with 1 mL sat NH.sub.4Cl then diluted with 2-3 mL H.sub.2O. The
mixture was concentrated in vacuo to an aqueous emulsion which was
applied to a 12 g C18 reverse phase column. Elution with 100% ACN
gave a residue that was further purified by chromatography on
silica eluting with MeOH/DCM to afford i (280 mg).
1-ethyl-3-(5-(4-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)-7-(pyridin-2-yl)b-
enzo[d]thiazol-2-yl)urea (11)
[0635] Compound i (74 mg) and Intermediate 1 (100 mg) were
suspended in pyridine with 4 .ANG. mol. sieves. The mixture was
degassed and flushed with oxygen and Cu(OAc).sub.2.H.sub.2O added.
The mixture was again degassed and flushed with oxygen then left
stirring at 80.degree. C. for 280 min. The reaction was quenched by
adding NH.sub.4Cl sat. and diluted with EtOAc and H.sub.2O. The
mixture was extracted with EtOAc and the organics combined, dried
(Na.sub.2SO.sub.4) and evaporated to dryness. Purification by
chromatography on silica, eluting with DCM/MeOH (0-10%) followed by
reverse phase chromatography on a C18 column eluting with
ACN/H.sub.2O afforded Compound 11 (7.5 mg).
Example(s) of Further Functionalisation
Alkylation of a Hydroxyl Group
1-Ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-methoxybenzo[d]thi-
azol-2-yl)urea (12)
##STR00182##
[0637] .sup.1H NMR (400 MHz, Acetone-d.sub.6) .delta. 9.22 (d,
J=2.7 Hz, 2H), 7.65 (s, 1H), 7.22 (s, 1H), 4.11 (s, 3H), 3.44-3.26
(m, 2H), 1.60 (s, 6H), 1.19 (t, J=7.2 Hz, 3H). MS: 388.03
[M+H].sup.+.
[0638] A solution of Intermediate 9 (240 mg) and Cs.sub.2CO.sub.3
(220 mg) in anhydrous DMF (10 mL) was chilled to 0.degree. C. then
treated with iodomethane (83.5 mg). The reaction was allowed to
warm to RT over 90 min then quenched with H.sub.2O. The mixture was
concentrated under vacuum and the resulting residue suspended in
DCM & minimal MeOH for purification by chromatography on silica
(0-5% MeOH:DCM). The residue was suspended in THF (10 mL) and
treated with 1M HCl (10 mL). The reaction was stirred at RT for 90
min then neutralised with NaHCO.sub.3 solution. The mixture was
diluted with EtOAc (15 mL) and a white solid formed between the
aqueous and organic layers. The solid was collected by filtration
and dried under vacuum with heating at 50.degree. C. to give
Compound 12 (83 mg).
Ether Formation from a Halo Moiety Via an Aldehyde
1-Ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(methoxymethyl)ben-
zo[d]thiazol-2-yl)urea (13)
##STR00183##
[0640] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.13 (s, 2H), 7.95
(s, 1H), 7.23 (s, 1H), 4.67 (s, 2H), 3.48 (dd, J=12.1, 6.3 Hz, 2H),
3.44 (s, 3H), 1.63 (s, 6H), 1.33-1.21 (m, 3H). MS 402.04
[M+H].sup.+.
2-(3-ethyl-5-methyl-2-oxo-1,3,5-triazinan-1-yl)-5-[2-(1-hydroxy-1-methyl-e-
thyl)pyrimidin-5-yl]-1,3-benzothiazole-7-carbaldehyde (i)
[0641] A solution of Intermediate 4 (200 mg, 0.41 mmol) in THF (10
mL) was chilled to -80.degree. C. under N.sub.2 then treated with
nBuLi (0.89 mL, 1.22 mmol). After 1 min DMF (0.06 mL, 0.81 mmol)
was added and the reaction allowed to warm to RT over 30 min. The
reaction was diluted with NaHCO.sub.3 (20 mL) then extracted with
EtOAc (2.times.15 mL). The organic extract was dried (MgSO.sub.4),
filtered and concentrated. The residue was suspended in DCM then
purified by chromatography on silica eluting with (0-5% MeOH:DCM)
to give i (38.5 mg, 22%). MS 441.01 [M+H].sup.+.
1-Ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(methoxymethyl)ben-
zo[d]thiazol-2-yl)urea
[0642] A solution of i (23 mg, 0.05 mmol) in MeOH (2 mL) was
treated with H.sub.2SO.sub.4 (20 mL, 0.38 mmol) then stirred at RT
for 90 min. The reaction was neutralised with NaHCO.sub.3, then
extracted with EtOAc (2.times.10 mL). The organic extract was dried
(MgSO.sub.4), filtered and concentrated. The crude material was
suspended in DCM (2 mL) and treated with triethylsilane (50 .mu.L,
0.31 mmol) and BF.sub.3OEt.sub.2 (25 .mu.L, 0.20 mmol). The
reaction was stirred at RT for 30 min, quenched with MeOH (2 mL)
and stirred for 1 h. The mixture was diluted with EtOAc (5 mL) and
washed with NaHCO.sub.3 (5 mL) and H.sub.2O (5 mL). The organic
extract was dried (MgSO.sub.4), filtered and concentrated. The
material was suspended in MeCN:MeOH and purified by reverse phase
chromatography (5-40-50-100% MeCN:H.sub.2O+0.1% FA) to give
Compound 13 (7.3 mg, 21%).
1-ethyl-3-(5-(2-(1-hydroxyethyl)pyrimidin-5-yl)-7-((6-methylpyridin-3-yl)m-
ethoxy)benzo[d]thiazol-2-yl)urea (14)
##STR00184##
[0644] .sup.1H NMR (400 MHz, D.sub.2O) .delta. 8.60 (s, 2H), 8.29
(s, 1H), 8.15 (d, J=7.0 Hz, 1H), 7.77 (d, J=8.3 Hz, 1H), 6.91 (s,
1H), 6.38 (s, 1H), 3.03-2.90 (m, 2H), 2.75 (s, 3H), 1.45 (t, J=10.7
Hz, 3H), 1.00 (dt, J=14.1, 7.1 Hz, 3H). MS: 465.1 [M+H].sup.+.
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[(6-methyl-3-pyridyl)met-
hoxy]-1,3-benzothiazol-2-yl]-5-methyl-1,3,5-triazinan-2-one (i)
[0645] Methanesulfonyl chloride; (120 .mu.L; 1.50 mmol) was
introduced drop-wise to a solution of (6-methyl-3-pyridyl)methanol
(100 mg; 0.812 mmol) and triethylamine (0.32 mL; 2.25 mmol) in
anhydrous DCM (6 mL) at 0.degree. C. and stirring was continued for
30 min at 0.degree. C. The mixture was quenched with MeOH (2 mL),
concentrated in vacuo and purified on silica (gradient elution,
50-100%, n-heptane-EtOAc) affording 6-methyl-3-pyridyl)methyl
methanesulfonate (95 mg, 58%).
[0646] In a separate flask, Intermediate 10 (45 mg, 0.11 mmol) and
K.sub.2CO.sub.3 (68 mg, 0.49 mmol) were dissolved in DMF (10 mL),
and solution of (6-methyl-3-pyridyl)methyl methanesulfonate (95 mg,
0.47 mmol) in DMF (3 mL) was added at RT. The reaction was heated
to 45.degree. C. for 3 h. Concentrating the reaction mixture to
1/3.sup.rd of its original volume and diluting with EtOAc (100 mL),
washing with H.sub.2O (100 mL), followed by brine (100 mL), and
back extracting the aqueous phase with DCM:IPA (5:1, 100 mL)
followed by purification by chromatography on silica eluting with
0-10%, DCM in MeOH gave i (30 mg, 53%).
1-ethyl-3-(5-(2-(1-hydroxyethyl)pyrimidin-5-yl)-7-((6-methylpyridin-3-yl)m-
ethoxy)benzo[d]thiazol-2-yl)urea (14)
[0647] Compound i (30 mg; 58 .mu.mol) was suspended in THF (3 mL)
and concentrated HCl (1 mL) was introduced and heated to 45.degree.
C. for 1.5 h. The reaction was concentrated in vacuo, and purified
by reverse phase chromatography, gradient elution, 25-80%, 0.1%
FA(aq) in ACN) and lyophilized in the presence of 1M HCl (ca. 3 mL)
to give Compound 14 (23 mg, 79%).
Sulfone Formation from a Thioether
1-Ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(methylsulfanylmethyl-
)-2-pyridyl]-1,3-benzothiazol-2-yl]urea (15); and
1-ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-[4-(methylsulfinylmethy-
l)-2-pyridyl]-1,3-benzothiazol-2-yl]urea (16)
##STR00185##
[0649] A solution of oxone (45 mg, 0.073 mmol) in H.sub.2O (0.5 mL)
was added to a solution of Compound 15 (70 mg, 0.146 mmol) in DMF
(4.5 mL) at RT and stirred for 1 h. The mixture was diluted with
EtOAc (50 mL) and washed with H.sub.2O. The aqueous fraction was
saturated with NaCl and re-extracted with EtOAc (3.times.50 mL).
The combined organic layers were dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The residue was purified by chromatography
on silica, eluting with 0-30% MeOH/EtOAc to afford Compound 16 (15
mg, 21%). MS: 496.97 [M+H]+; .sup.1H NMR (400 MHz; d.sub.6-DMSO):
.delta.=10.79 (bs, 1H), 9.36 (s, 2H), 8.87 (d, J=4.9 Hz, 1H), 8.52
(s, 1H), 8.39 (d, J=1.5 Hz, 1H), 8.20 (d, J=1.5 Hz, 1H), 7.47 (dd,
J=5.1, 1.2 Hz, 1H), 7.03 (bd, J=5.2 Hz, 1H), 5.35 (d, J=5.5 Hz,
1H), 4.94 (p, J=6.5 Hz, 1H), 4.36 (d, J=12.5 Hz, 1H), 4.25-4.07 (m,
1H), 3.28 (dd, J=7.1, 5.7 Hz, 2H), 2.64 (s, 3H), 1.54 (d, J=6.6 Hz,
3H), 1.18 (t, J=7.2 Hz, 3H).
Example(s) of General Method H
1-Ethyl-3-[5-[2-(1-hydroxyethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzothi-
azol-2-yl]urea (17); and
1-(5-(2-(3-ethylureido)-7-(pyridin-2-yl)benzo[d]thiazol-5-yl)pyrimidin-2--
yl)ethyl 4-methylpiperazine-1-carboxylate (18)
##STR00186##
[0651] Compound 17, similarly prepared to Compound 1, (0.2378 mmol;
100 mg) was dissolved in DMF (1 mL) and di(imidazol-1-yl)methanone
(0.26 mmol; 42 mg) added and stirred at RT for 18 h.
1-Methylpiperazine (0.29 mmol; 29 mg) was added and the mixture
stirred at RT for 18 h. The mixture was concentrated in vacuo and
the residue was purified by chromatography on silica eluting with
0-12% MeOH/DCM) followed by reverse phase chromatography to give
Compound 18 (12 mg) as the formate salt. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.69 (s, 1H), 9.39 (s, 2H), 8.84 (d, J=4.0
Hz, 1H), 8.55 (d, J=8.2 Hz, 1H), 8.42 (d, J=1.4 Hz, 1H), 8.18 (d,
J=1.1 Hz, 1H), 8.03 (td, J=7.9, 1.7 Hz, 1H), 7.48 (dd, J=7.1, 5.1
Hz, 1H), 6.92 (t, J=5.2 Hz, 1H), 4.54 (d, J=12.9 Hz, 1H), 4.36 (d,
J=12.9 Hz, 1H), 3.27-3.18 (m, 2H), 2.77 (s, 3H), 1.14 (t, J=7.2 Hz,
3H). MS 453.01 [M+H].sup.+.
4-[1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrim-
idin-2-yl]ethoxy]-4-oxo-butanoic acid (19)
##STR00187##
[0653] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.90 (s, 2H),
8.70-8.63 (m, 1H), 7.91 (d, J=8.1 Hz, 1H), 7.83-7.67 (m, 3H),
7.20-7.13 (m, 1H), 5.83 (q, J=6.8 Hz, 1H), 3.30-3.13 (m, 2H), 2.63
(dd, J=6.8, 2.1 Hz, 2H), 2.52 (dd, J=6.5, 2.9 Hz, 2H), 1.57 (d,
J=6.8 Hz, 3H), 1.09 (t, J=7.3 Hz, 2H). MS 521.09 [M+H].sup.+.
[0654] A solution of Compound 17 (250 mg) was treated with DIPEA
(230 mg), DMAP (40 mg) and succinic anhydride (150 mg) then stirred
at 50.degree. C. for 6 h. Then DIPEA (300 .mu.L) and succinic
anhydride (100 mg) were added and the reaction stirred overnight.
The mixture was diluted with H.sub.2O (30 mL) and washed with EtOAc
(3.times.15 mL). The aqueous extract was concentrated to give a
crude brown gum. Purification by chromatography on silica eluting
with 0-5% MeOH in DCM gave a solid that was suspended in hot MeOH,
left to cool to RT and the resulting solid collected by filtration
and dried under vacuum to give Compound 19.
O4-[1-[5-[2-(Ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyri-
midin-2-yl]-1-methyl-ethyl] O1-methyl butanedioate (20); and
4-((2-(5-(2-(3-ethylureido)-7-(pyridin-2-yl)benzo[d]thiazol-5-yl)pyrimidi-
n-2-yl)propan-2-yl)oxy)-4-oxobutanoic acid (21)
##STR00188##
[0656] Compound 20, similarly prepared to Compound 1, (179 mg, 0.33
mmol) was dissolved in MeOH (18 mL) and NaOH (0.65 mL, 1 M, aq)
added. The solution was stirred at RT, then further NaOH (0.65 mL,
1 M, aq) was added after 1.5 h and 3.5 h. H.sub.2O (0.5 mL) was
added after 7 h. The solution was stirred at RT overnight. After 23
h, the mixture was acidified to pH 4.5 with HCl (1 M, aq) and the
solution concentrated to dryness in vacuo, azeotroping with ACN
(3.times.20 mL). The solid was purified by chromatography on
silica, eluting with 0-5% MeOH in DCM, followed by further
chromatography on silica eluting with 0-50% MeOH in EtOAc and
further chromatography on silica eluting with 0-5% MeOH in DCM to
give Compound 21 (47 mg, 27%). .sup.1H NMR (400 MHz, MeOD): .delta.
9.14 (s, 2H), 8.77 (ddd, J=4.3, 1.7, 0.8 Hz, 1H), 8.29 (d, J=7.8
Hz, 1H), 8.19 (d, J=1.5 Hz, 1H), 7.99 (d, J=1.5 Hz, 1H), 7.96 (dt,
J=7.8 and 1.7 Hz, 1H), 7.40 (ddd, J=7.4, 4.3, 0.8 Hz, 1H), 3.37 (q,
J=7.2 Hz, 2H), 2.71 (m, 2H), 2.60 (m, 2H), 1.87 (s, 6H), 1.27 (t,
J=7.2 Hz, 3H). MS: 535.05 [M+H].sup.+.
Example(s) of General Method I
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-morpholino-1,3-
-benzothiazol-2-yl]urea (151)
##STR00189##
[0658] .sup.1H NMR (400 MHz; DMSO-d.sub.6): .delta. 10.75 (br s,
1H), 9.16 (s, 2H), 7.72 (s, 1H), 7.16 (s, 1H), 6.73 (m, 1H), 5.11
(s, 1H), 3.86 (m, 4H), 3.17-3.26 (m, 6H), 1.54 (s, 6H) and 1.09 (t,
J=7.20 Hz, 3H). MS: 443.28 [M+H].sup.+
1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-morpholino-1,3-
-benzothiazol-2-yl]-5-methyl-1,3,5-triazinan-2-one (i)
[0659] To a solution of Intermediate 4 (0.25 g, 0.51 mmol) in
1,4-dioxane (10 mL) was added morpholine (0.066 g, 0.77 mmol)
followed by Cs.sub.2CO.sub.3 (0.25 g, 0.77 mmol). The resulting
solution was purged with nitrogen for 30 min followed by addition
of Pd.sub.2(dba).sub.3 (0.026 g, 0.025 mmol) and Xantphos (0.035 g,
0.061 mmol). The reaction mixture was again purged with nitrogen
for 15 min and then heated up to 80.degree. C. overnight. After the
completion of reaction (TLC monitoring), the reaction was cooled to
RT, filtered through celite bed, washed the celite bed with EtOAc
and concentrated the combined filtrate under reduced pressure. The
crude residue was then purified over silica gel (100-200 M, 3%
MeOH-DCM) to obtain i as off-white solid (0.07 g, 28%). .sup.1H-NMR
(DMSO-d.sub.6, 400 MHz): .delta. 9.18 (s, 2H), 7.79 (s, 1H), 7.19
(s, 1H), 5.12 (s, 3H), 4.37 (s, 2H), 3.80-3.83 (m, 4H), 3.35-3.38
(m, 2H), 3.21-3.23 (m, 4H), 2.54 (s, 3H), 1.54 (s, 6H) and 1.08 (t,
J=6.80 Hz, 3H).
1-Ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-morpholino-1,3-
-benzothiazol-2-yl]urea (151)
[0660] To an ice-cold solution of i (0.065 g, 0.13 mmol) in THF (3
mL) was added 6N-HCl (2 mL). The mixture was stirred at RT for 4 h.
After completion of reaction (TLC monitoring), the mixture was
poured into saturated NaHCO.sub.3 solution followed by extraction
with EtOAc (2.times.50 mL). The combined organics were washed with
brine, dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure. The residue obtained was triturated with
MeOH-Et.sub.2O to afford Compound 151 as a white solid (0.035 g,
61%).
Example(s) of Chiral Separation and Synthesis
(R)-1-ethyl-3-(5-(2-(1-hydroxyethyl)pyrimidin-5-yl)-7-(pyridin-2-yl)benzo[-
d]thiazol-2-yl)urea (22) &
(S)-1-ethyl-3-(5-(2-(1-hydroxyethyl)pyrimidin-5-yl)-7-(pyridin-2-yl)benzo-
[d]thiazol-2-yl)urea (23)
##STR00190##
[0662] The (R) and (S) enantiomers of Compound 17 were separated by
chiral prep-HPLC:
Column: Chiralpak IC (250.times.20 mm) 5.mu.
[0663] Mobile phase: 100% MeOH Sampling details: 25 mg in a mix of
0.5 mL TFA and 0.5 mL of MeOH Flow rate: 18 mL/min. Run time: 20
min. Retention Time 9.3 min; 14.7 min.
[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]py-
rimidin-2-yl]ethyl]dihydrogen phosphate (152); &
[(1S)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]p-
yrimidin-2-yl]ethyl]dihydrogen phosphate (153)
##STR00191##
[0664]
1-ethyl-3-[5-[2-[(1S)-1-hydroxyethyl]pyrimidin-5-yl]-7-(2-pyridyl)--
1,3-benzothiazol-2-yl]-5-methyl-1,3,5-triazinan-2-one (i)
[0665] Compound 23 (12.67 g, 30.13 mmol) was suspended in MeOH (150
mL). Formaldehyde (48.9 mL, 0.603 mol, as a 37% aqueous solution)
was added, along with N-methylmorpholine (33.1 mL, 0.301 mol) and
methylamine (151 mL of a 2M THF solution). The white suspension was
heated at 70.degree. C. overnight. TLC showed almost complete
conversion to product after 19 hrs and the solution was cooled to
room temperature then concentrated to .about.33% volume under
reduced pressure and partitioned between H.sub.2O (150 mL) and
EtOAc (300 mL). Heat was applied to the biphasic mixture to help
solubilize the product. The organic layer was washed with brine,
filtered through MgSO.sub.4, and concentrated to dryness under
reduced pressure. The solid was swished in EtOAc (100 mL),
filtered, washed with EtOAc and heptane, and dried to give i as a
white solid (11.97 g, 76%). MS: 475.93 [M+H].sup.+.
Di-tert-butyl
[(1R)-1-[5-[2-(3-ethyl-5-methyl-2-oxo-1,3,5-triazinan-1-yl)-7-(2-pyridyl)-
-1,3-benzothiazol-5-yl]pyrimidin-2-yl]ethyl] phosphate (ii)
[0666] Preparation of Di-Tert-Butyl Hydrogen Phosphate:
[0667] Potassium di-tert-butyl phosphate (45 g) was dissolved in
water (160 mL). Hydrochloric acid (1 M, aq) was added until the pH
was .about.3. The resultant precipitate was collected by
filtration, washed with water, and dried under vacuum overnight to
give di-tert-butyl phosphonic acid as a white solid. Then, to a
suspension of i (18.68 g, 39.28 mmol), triphenylphosphine (17.51 g,
66.78 mmol), and di-tert-butyl hydrogen phosphate (10.73 g, 51.06
mmol) in THF and triphenylphosphine were suspended in anhydrous THF
(200 mL). A solution of DIAD (13.5 g, 66.78 mmol) in THF (20 mL)
was added dropwise. The mixture was stirred at room temperature and
monitored by LCMS to completion then was concentrated under reduced
pressure. Et.sub.2O (300 mL) was added and the mixture sonicated,
resulting in a bright white solid, which was filtered, washed with
Et.sub.2O (100 mL) and air dried. The filtrate also contained some
product. After concentration to 150 mL the filtrate was chilled in
ice, yielding more solid material. The solids were collected,
redissolved in DCM, and plugged (50-100% EtOAc/DCM to remove
Mitsonobu by-products then 10% MeOH/DCM to elute the desired
product After concentrating the relevant fraction to a white solid,
this material was recrystallized from DCM/ether/heptane, filtered,
washed with heptane, and dried overnight to give ii as a white
solid (17.09 g, 64%). .sup.1H NMR (400 MHz) .delta. 9.41 (s, 2H);
8.83 (d, J=4.4 Hz, 1H); 8.53 (d, J=8 Hz, 1H); 8.43 (d, J=1.2 Hz,
1H); 8.21 (d, J=1.2 Hz, 1H); 8.01 (dt, J=8, 1.6 Hz, 1H); 7.46 (dd,
J=7.2, 4.8 Hz); 5.43 (m, 1H); 5.16 (s, 2H); 4.38 (s, 2H); 3.39 (q,
J=7.2 Hz, 2H); 3.32 (br s, 2H); 2.55 (s, 3H); 1.64 (d, J=6.8 Hz,
3H); 1.38 (s, 9H); 1.36 (s, 9H); 1.14 (t, J=7.2 Hz). MS: 667.78
(M+H).sup.+. Chiral HPLC: Column: Chirapak IC, 0.46 cm.times.25 cm;
25 min isocratic gradent 100% MeOH retention time=17.12 min.
[(1R)-1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]py-
rimidin-2-yl]ethyl] dihydrogen phosphate (152)
[0668] A solution of ii (17.0 g, 25.46 mmol) in anhydrous THF (300
mL) was treated with 4 M HCl in dioxane (63.6 mL, 10 eq.). A
precipitate formed immediately upon addition of acid and the
reaction monitored to completion by LCMS. H.sub.2O (50 mL) was
added and the solution concentrated to remove approx. 150 mL of
THF, at which point a flocculent precipitate began to form. The
mixture was stirred at room temperature overnight, yielding a white
precipitate which was filtered, washed several times with water,
followed by MeOH and Et.sub.2O, then dried at 50.degree. C. for 6
hours to give Compound 152 as a white solid (12.0 g, 95%). MS:
501.7 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
10.7 (br s 1H), 9.35 (s, 2H), 8.85-8.81 (m, 1H), 8.53 (d, J=8.3 Hz,
1H), 8.39 (d, J=1.6 Hz, 1H), 8.15 (d, J=1.6 Hz, 1H), 8.05-7.99 (m,
1H), 7.49-7.44 (m, 1H), 6.93 (t, J=5.5 Hz, 1H), 5.48-5.39 (m, 1H),
3.27-3.17 (m, 2H), 1.63 (d, J=6.6 Hz, 3H), 1.12 (t, J=7.2 Hz,
3H).
[0669] Compound 153 may be similarly prepared, starting from
Compound 22.
##STR00192##
[0670] .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 10.6 (br s,
1H), 9.35 (s, 2H), 8.85-8.81 (m, 1H), 8.53 (d, J=8.3 Hz, 1H), 8.39
(d, J=1.6 Hz, 1H), 8.15 (d, J=1.6 Hz, 1H), 8.05-7.99 (m, 1H),
7.56-7.31 (m, 1H), 6.89 (t, J=5.5 Hz, 1H), 5.47-5.38 (m, 1H),
3.26-3.18 (m, 2H), 1.63 (d, J=6.6 Hz, 3H), 1.12 (t, J=7.2 Hz, 3H).
MS: 501.05 [M+H].sup.+.
[0671] The following compounds were similarly prepared with
reference to the general method(s) and/or examples previously
described.
TABLE-US-00012 TABLE 1 Compounds and characterisation data Observed
LCMS No. [M + H].sup.+ .sup.1H NMR 24 486 (DMSO-d.sub.6): .delta.
10.62 (s, 1H), 9.0 (s, 1H), 8.8 (d, 1H), 8.5 (d, 1H), 8.4 (d, 1H),
8.35 (s, 1H), 8.05 (m, 2H), 7.8 (s, 1H), 7.5 (m, 1H), 7.1 (s, 1H),
6.9 (s, 1H), 6.8 (s, 1H), 6.3 (d, 1H), 6.0 (d, 1H), 3.7 (s, 3H),
3.25 (m, 2H), 1.15 (t, 3H) 25 534.15 (CDCl.sub.3): .delta. 9.22 (s,
2H), 8.66 (s, 1H), 8.13 (s, 1H), 7.89 (s, 1H), 7.82 (d, J = 8.2 Hz,
1H), 7.77 (s, 1H), 3.84-3.67 (m, 4H), 3.58 (s, 2H), 3.41 (s, 2H),
2.51 (s, 4H), 1.61 (s, 6H), 1.31-1.26 (m, 3H). 26 518.17
(CDCl.sub.3) .delta. 9.18 (s, 2H), 8.66 (d, J = 4.7 Hz, 1H), 8.46
(s, 1H), 8.16 (s, 1H), 8.02 (s, 1H), 7.93 (s, 1H), 3.92 (s, 2H),
3.51-3.36 (m, 2H), 2.80 (s, 4H), 1.92 (s, 4H), 1.63 (s, 6H),
1.35-1.22 (m, 3H). 27 434.05 (CDCl.sub.3) .delta. 8.91 (d, J = 1.6
Hz, 1H), 8.59 (d, J = 4.5 Hz, 1H), 8.12-7.98 (m, 4H), 7.82 (t, J =
7.6 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.21 (dd, J = 7.2, 5.0 Hz,
1H), 3.56-3.43 (m, 2H), 1.59 (s, 6H), 1.32 (t, J = 7.2 Hz, 3H). 28
534.18 (DMSO-d.sub.6) .delta. 10.63 (br s, 1H); 9.35 (s, 2H); 8.77
(d, J = 5 Hz, 1H); 8.44 (1H, s); 8.39 (1H, s); 8.15 (1H, s); 7.47
(d, J = 5 Hz, 1H); 6.90 (br s, 1H); 5.15 (s, 1H); 3.66 (s, 2H);
3.63 (s, 4H); 3.23 (m, 2H); 2.46 (s, 4H); 1.59 (s, 6H); 1.14 (t, J
= 7 Hz, 3H). Methano sulphonate salt form: .sup.1H NMR (400 MHz;
D.sub.2O): .delta. = 8.70 (s, 2H), 8.25 (s, 1H), 7.83 (s, 1H), 7.34
(s, 1H), 7.17 (s, 2H), 4.28 (s, 2H), 4.00 (s, 4H), 3.33 (s, 4H),
3.21-3.02 (m, 2H), 2.83 (s, 3H), 1.66 (s, 6H), 1.12 (t, J = 7.2 Hz,
3H). MS: 534.19 [M + H].sup.+ HCl salt form: .sup.1H NMR (400 MHz;
DMSO-d.sub.6): .delta. = 12.24 (bs, 1H), 9.45 (s, 2H), 9.11 (s,
1H), 8.92 (d, J = 5.0 Hz, 1H), 8.55 (d, J = 1.5 Hz, 1H), 8.22 (d, J
= 1.5 Hz, 1H), 7.66 (dd, J = 5.0, 0.9 Hz, 1H), 7.20 (bs, 1H), 4.54
(s, 2H), 3.96 (s, 4H), 3.46-3.29 (m, 2H), 3.29-3.09 (m, 4H), 1.59
(s, 6H), 1.14 (t, J = 7.2 Hz, 3H). MS: 534.18 [M + H].sup.+ 29
534.3 (DMSO-d.sub.6) .delta. 10.80 (br s, 1H), 9.32 (s, 2H), 8.75
(d, J = 4.80 Hz, 1H), 8.42 (s, 1H), 8.37 (s, 1H), 8.12 (s, 1H),
7.42 (d, J = 4.80 Hz, 1H), 7.05 (m, 1H), 5.16 (br s, 1H), 4.74 (br
s, 1H), 4.22 (br s, 1H), 3.67-3.78 (m, 2H), 3.38 (m, 2H), 3.17-3.24
(m, 2H), 2.73-2.75 (m, 1H), 2.63-2.67 (m, 1H), 2.37-2.40 (m, 1H),
2.01-2.06 (m, 1H), 1.56 (s, 6H) and 1.11 (t, J = 7.20 Hz, 3H). 30
520.25 (DMSO-d.sub.6) .delta. 10.67 (br s, 1H), 9.33 (s, 2H), 8.73
(d, J = 4.80 Hz, 1H), 8.36 (br s, 2H), 8.12 (s, 1H), 7.35 (d, J =
4.80 Hz, 1H), 6.92 (m, 1H), 5.35 (d, J = 6.40 Hz, 1H), 5.15 (s,
1H), 4.21-4.26 (m, 1H), 3.71 (s, 2H), 3.58 (t, J = 6.40 Hz, 2H),
3.21 (m, 2H), 2.85 (t, J = 6.40 Hz, 2H), 1.57 (s, 6H) and 1.11 (t,
J = 7.20 Hz, 3H). 31 534.28 (DMSO-d.sub.6) .delta. 10.62 (br s,
1H), 9.35 (s, 2H), 8.73 (d, J = 4.80 Hz, 1H), 8.38 (m, 2H), 8.13
(s, 1H), 7.35 (d, J = 4.80 Hz, 1H), 6.86 (m, 1H), 5.15 (s, 1H),
4.0-4.03 (m, 1H), 3.74 (s, 2H), 3.57 (t, J = 6.40 Hz, 2H), 3.21 (m,
2H), 3.15 (s, 3H), 2.93 (m, 2H), 1.57 (s, 6H) and 1.11 (t, J = 7.20
Hz, 3H). 32 564.3 (DMSO-d.sub.6) .delta. 10.62 (br s, 1H), 9.33 (s,
2H), 8.61 (d, J = 5.60 Hz, 1H), 8.40 (s, 1H), 8.12 (s, 1H), 8.03
(s, 1H), 7.05 (m, 1H), 6.90 (m, 1H), 5.15 (s, 1H), 4.34 (t, J =
5.60 Hz, 2H), 3.57-3.59 (m, 4H), 3.31-3.36 (m, 4H), 3.19-3.22 (m,
2H), 2.76 (t, J = 5.60 Hz, 2H), 1.57 (s, 6H) and 1.11 (t, J = 7.20
Hz, 3H). 33 548.31 (DMSO-d.sub.6) .delta. 10.61 (br s, 1H), 9.33
(s, 2H), 8.76 (d, J = 4.80 Hz, 1H), 8.39 (s, 2H), 8.13 (s, 1H),
7.42 (m, 1H), 6.85 (m, 1H), 5.15 (s, 1H), 3.53-3.58 (m, 5H),
3.18-3.25 (m, 2H), 2.50 (m, 2H), 2.32 (m, 2H), 1.57 (s, 6H), 1.38
(d, J = 6.80 Hz, 3H), and 1.11 (t, J = 7.20 Hz, 3H). 34 554.25
(DMSO-d.sub.6) .delta. 10.63 (br s, 1H), 9.33 (s, 2H), 8.76 (d, J =
4.80 Hz, 1H), 8.43 (s, 1H), 8.38 (s, 1H), 8.14 (s, 1H), 7.43 (m,
1H), 6.86 (m, 1H), 5.16 (s, 1H), 3.79 (s, 2H), 3.18-3.24 (m, 2H),
2.92-2.99 (m, 2H), 2.78 (t, J = 6.80 Hz, 2H), 2.23-2.34 (m, 2H),
1.57 (s, 6H) and 1.11 (t, J = 7.20 Hz, 3H). 35 536.28
(DMSO-d.sub.6) .delta. 10.63 (br s, 1H), 9.32 (s, 2H), 8.75 (d, J =
4.80 Hz, 1H), 8.50 (s, 1H), 8.38 (s, 1H), 8.13 (s, 1H), 7.42 (d, J
= 4.80 Hz, 1H), 6.86 (t, J = 5.20 Hz, 1H), 5.15 (m, 2H), 3.78 (s,
2H), 3.18-3.33 (m, 2H), 2.80-2.89 (m, 2H), 2.66-2.68 (m, 1H),
2.39-2.50 (m, 1H), 2.12-2.19 (m, 1H), 1.89-1.98 (m, 1H), 1.56 (s,
6H) and 1.11 (t, J = 7.20 Hz, 3H). 36 536.26 (DMSO-d.sub.6) .delta.
10.62 (br s, 1H), 9.32 (s, 2H), 8.75 (d, J = 4.80 Hz, 1H), 8.43 (s,
1H), 8.38 (s, 1H), 8.13 (s, 1H), 7.43 (d, J = 4.80 Hz, 1H), 6.86
(t, J = 5.20 Hz, 1H), 5.15 (m, 2H), 3.78 (s, 2H), 3.19-3.23 (m,
2H), 2.80-2.89 (m, 2H), 2.64-2.76 (m, 1H), 2.41-2.45 (m, 1H),
2.11-2.21 (m, 1H), 1.85-1.96 (m, 1H), 1.56 (s, 6H) and 1.11 (t, J =
7.20 Hz, 3H). 37 568.3 (DMSO-d.sub.6) .delta. 10.64 (br s, 1H),
9.32 (s, 2H), 8.77 (d, J = 5.20 Hz, 1H), 8.41 (s, 1H), 8.36 (s,
1H), 8.14 (s, 1H), 7.36-7.42 (m, 1H), 6.88 (m, 1H), 5.16 (s, 1H),
3.76 (s, 2H), 3.12-3.25 (m, 4H), 2.72 (t, J = 11.20 Hz, 2H),
1.86-1.93 (m, 2H), 1.69 (m, 2H), 1.57 (s, 6H) and 1.11 (t, J = 7.20
Hz, 3H). 38 578.31 (DMSO-d.sub.6) .delta. 10.60 (br s, 1H), 9.33
(s, 2H), 8.61 (d, J = 5.60 Hz, 1H), 8.38 (s, 1H), 8.12 (s, 1H),
8.01 (s, 1H), 7.04 (m, 1H), 6.86 (m, 1H), 5.15 (s, 1H), 4.26 (t, J
= 6.0 Hz, 2H), 3.57 (m, 4H), 3.17-3.24 (m, 2H), 2.44-2.46 (m, 2H),
2.37 (br s, 4H), 1.91-1.98 (m, 2H), 1.56 (s, 6H) and 1.11 (t, J =
7.20 Hz, 3H). 39 436.19 (DMSO-d.sub.6) .delta. 10.78 (br s, 1H),
9.81 (s, 1H), 9.36 (s, 2H), 8.89 (s, 1H), 8.71 (s, 1H), 8.56 (s,
1H), 8.22 (s, 1H), 6.92 (m, 1H), 5.16 (s, 1H), 3.21 (m, 2H), 1.57
(s, 6H) and 1.11 (t, J = 7.20 Hz, 3H) 40 437 (CDCl.sub.3) .delta.
9.04 (s, 2H), 8.79-8.71 (m, 1H), 8.04-7.76 (m, 4H), 7.31-7.26 (m,
3H), 4.94 (t, J = 4.5 Hz, 1H), 4.02 (ddd, J = 25.6, 11.5, 4.5 Hz,
2H), 3.34 (dd, J = 3.3, 1.6 Hz, 2H), 1.22 (t, J = 7.3 Hz, 3H). 41
429.98 (CDCl.sub.3) .delta. 8.87 (1 H, d, J = 1.8 Hz), 8.13 (1 H,
dd, J = 8.2 and 1.8 Hz), 7.74 (1 H, s), 7.46 (1 H, d, J = 8.2 Hz),
3.87 (2 H, s), 3.46 (2 H, m), 2.44 (6 H, s), 1.64 (6 H, s), 1.30 (3
H, t, J = 7.2 Hz). 42 548.34 (DMSO-d.sub.6) .delta. 9.32 (s, 2H),
8.75 (d, J = 5.20 Hz, 1H), 8.42 (s, 1H), 8.37 (s, 1H), 8.12 (s,
1H), 7.41 (d, J = 4.80 Hz, 1H), 6.90 (m, 1H), 5.15 (s, 1H), 3.90
(m, 1H), 3.77 (s, 2H), 3.21 (m, 3H), 3.15 (s, 3H), 2.72-2.76 (m,
1H), 2.59-2.65 (m, 1H), 2.54 (m, 1H), 1.97-2.04 (m, 1H), 1.57-1.72
(m, 1H), 1.57 (s, 6H) and 1.11 (t, J = 7.20 Hz, 3H). 43 450.24
(DMSO-d.sub.6) .delta. 10.70 (br s, 1H), 9.34 (s, 2H), 9.27 (s,
1H), 8.55 (m, 2H), 8.25 (s, 1H), 6.83 (m, 1H), 5.16 (s, 1H), 3.21
(m, 2H), 2.60 (s, 3H), 1.57 (s, 6H) and 1.11 (t, J = 7.20 Hz, 3H)
44 471.96 (CDCl.sub.3) .delta. 10.8 (1 H, br s), 8.91 (1 H, d, J =
1.9 Hz), 8.11 (1 H, dd, J = 8.2 and 1.9 Hz), 7.78 (1 H, s), 7.48 (1
H, dd, J = 8.2 and 0.6 Hz), 4.98 (1 H, br s), 3.92 (2 H, s), 3.80
(4 H, br s), 3.47 (2 H, m), 2.70 (4 H, br s), 1.65 (6 H, s), 1.30
(3 H, t, J = 7.3 Hz). 45 574.20 [M - H].sup.- (DMSO-d.sub.6)
.delta. 12.43 (br s, 1H), 10.82 (br s, 1H), 9.24 (s, 2H), 8.54 (s,
1H), 7.94-8.0 (m, 2H), 7.66 (s, 1H), 7.03 (m, 1H), 6.77 (m, 1H),
5.14 (br s, 1H), 4.01-4.04 (m, 2H), 3.15-3.25 (m, 4H), 2.0-2.04 (m,
2H), 1.55 (s, 6H), 1.40-1.45 (m, 2H), 1.19 (s, 3H) and 1.09 (t, J =
7.20 Hz, 3H). 46 493.21 (DMSO-d.sub.6) .delta. 10.74 (br s, 1H),
9.32 (s, 2H), 8.69 (s, 1H), 8.45 (d, J = 8.40 Hz, 1H), 8.36 (s,
1H), 8.12 (s, 1H), 7.89 (d, J = 8.40 Hz, 1H), 7.02 (m, 1H), 5.15
(s, 1H), 3.74 (s, 2H), 3.20-3.23 (m, 2H), 1.56 (s, 6H) and 1.11 (t,
J = 7.20 Hz, 3H). 47 475.1 (CDCl.sub.3) .delta. 10.25 (s, 1H), 9.26
(s, 2H), 8.64 (dd, J = 4.6, 0.7 Hz, 1H), 7.77-7.60 (m, 3H), 7.54
(d, J = 17.3 Hz, 2H), 7.21-7.08 (m, 1H), 3.11 (dd, J = 18.7, 11.4
Hz, 2H), 1.64-1.50 (m, 2H), 1.48-1.29 (m, 4H), 1.26 (t, J = 7.3 Hz,
4H), 0.97 (t, J = 7.1 Hz, 3H). 48 440.03 (CDCl.sub.3) .delta. 8.79
(d, J = 4.3 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 8.00 (s, 1H), 7.96
(d, J = 1.0 Hz, 1H), 7.89 (s, 1H), 7.86 (dd, J = 7.9, 1.7 Hz, 1H),
7.33 (dd, J = 6.8, 5.0 Hz, 1H), 3.44-3.37 (m, 3H), 1.78 (s, 6H),
1.32 (t, J = 7.3 Hz, 3H). 49 435.12 (DMSO-d.sub.6) .delta. 10.68
(s, 1H), 9.44-9.33 (m, 1H), 9.08-8.97 (m, 1H), 8.85 (ddd, J = 4.8,
1.7, 0.9 Hz, 1H), 8.70 (d, J = 1.5 Hz, 1H), 8.52-8.38 (m, 2H),
8.09-7.97 (m, 1H), 7.49 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 6.87 (t, J
= 5.4 Hz, 1H), 3.29-3.13 (m, 2H), 1.56 (s, 6H), 1.14 (dd, J = 9.3,
5.0 Hz, 3H). 50 576.32 (DMSO-d.sub.6) .delta. 10.88 (br s, 1H),
9.32 (s, 2H), 8.34 (d, J = 5.60 Hz, 1H), 8.31 (s, 1H), 8.06 (s,
1H), 7.71 (br s, 1H), 7.28 (br s, 1H), 6.89 (m, 1H), 5.15 (br s,
1H), 3.84-3.87 (m, 2H), 3.14-3.34 (m, 4H), 2.07-2.10 (m, 2H), 1.56
(s, 6H), 1.34-1.44 (m, 2H), 1.15 (s, 3H) and 1.11 (t, J = 7.20 Hz,
3H) 51 576.34 (DMSO-d.sub.6) .delta. 12.40 (br s, 1H), 10.67 (br s,
1H), 9.29 (s, 2H), 8.21 (s, 1H), 8.07 (s, 1H), 7.67-7.71 (m, 1H),
7.62-7.64 (m, 1H), 6.93 (m, 1H), 6.89 (m, 1H), 5.13 (s, 1H),
4.14-4.17 (m, 2H), 3.38 (m, 2H), 3.21-3.24 (m, 2H), 2.07-2.11 (m,
2H), 1.56 (s, 6H), 1.45-1.50 (m, 2H), 1.19 (s, 3H) and 1.12 (t, J =
7.20 Hz, 3H). 52 577.38 (DMSO-d.sub.6) .delta. 12.50 (br s, 1H),
10.66 (br s, 1H), 9.22 (s, 2H), 8.61 (s, 1H), 8.42 (d, J = 6.0 Hz,
1H), 8.15 (s, 1H), 6.86-6.88 (m, 2H), 5.14 (s, 1H), 4.26-4.32 (m,
2H), 3.38 (m, 2H), 3.21-3.24 (m, 2H), 2.08-2.11 (m, 2H), 1.56 (s,
6H), 1.44-1.49 (m, 2H), 1.20 (s, 3H) and 1.14 (t, J = 7.20 Hz, 3H)
53 504.11 (CDCl.sub.3) .delta. 9.16 (s, 2H), 8.64 (s, 1H), 8.00 (s,
2H), 7.84 (s, 1H), 7.24 (d, J = 3.2 Hz, 1H), 4.02 (s, 2H),
3.64-3.19 (m, 2H), 2.29 (s, 1H), 1.62 (s, 6H), 1.28 (dd, J = 14.6,
7.4 Hz, 4H), 0.56 (d, J = 5.5 Hz, 3H). 54 590.34 (DMSO-d.sub.6)
.delta. 12.20 (br s, 1H), 10.55 (br s, 1H), 9.28 (s, 2H), 8.20 (d,
J = 6.0 Hz, 1H), 8.06-8.11 (m, 2H), 7.36 (s, 1H), 6.89 (m, 1H),
6.55 (m, 2H), 5.15 (s, 1H), 3.50-3.52 (m, 2H), 3.15-3.24 (m, 2H),
2.50 (m, 1H), 2.03-2.10 (m, 2H), 1.86-1.94 (m, 2H), 1.56 (s, 6H),
1.29-1.38 (m, 2H) and 1.09-1.13 (m, 6H). 55 520.25 (DMSO-d.sub.6)
.delta. 10.70 (br s, 1H), 9.32 (s, 2H), 8.75 (d, J = 4.40 Hz, 1H),
8.37-8.42 (m, 2H), 8.12 (s, 1H), 7.43 (d, J = 4.40 Hz, 1H), 6.87
(m, 1H), 5.30 (d, J = 5.20 Hz, 1H), 4.86 (m, 1H), 3.61-3.70 (m,
6H), 3.19 (m, 2H), 2.43-2.45 (m, 4H), 1.47 (d, J = 6.40 Hz, 3H) and
1.11 (t, J = 7.20 Hz, 3H). 56 564.31 (DMSO-d.sub.6) .delta. 10.60
(br s, 1H), 9.31 (s, 2H), 8.52 (s, 1H), 8.45 (d, J = 8.80 Hz, 1H),
8.29 (s, 1H), 8.07 (s, 1H), 7.62 (m, 1H), 6.86 (m, 1H), 5.15 (s,
1H), 4.30 (t, J = 5.60 Hz, 2H), 3.59 (br s, 4H), 3.21 (m, 2H), 2.75
(t, J = 5.60 Hz, 2H), 2.45-2.50 (m, 4H), 1.56 (s, 6H) and 1.09 (t,
J = 7.20 Hz, 3H). 57 449.11 (DMSO-d.sub.6) .delta. = 10.58 (bs,
1H), 9.35 (s, 2H), 8.84 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.54 (d, J
= 8.3 Hz, 1H), 8.41 (d, J = 1.6 Hz, 1H), 8.16 (d, J = 1.3 Hz, 1H),
8.10-7.98 (m, 1H), 7.48 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 6.92 (bt,
J = 5.5 Hz, 1H), 5.15 (s, 1H), 3.18 (dd, J = 13.0, 6.7 Hz, 2H),
1.59 (s, 6H), 1.53 (dd, J = 14.2, 7.3 Hz, 2H), 0.93 (t, J = 7.4 Hz,
3H). 58 447.1 (DMSO-d.sub.6) .delta. 10.61 (s, 1H), 9.32 (s, 2H),
8.83 (d, J = 4.0 Hz, 1H), 8.53 (d, J = 8.2 Hz, 1H), 8.40 (d, J =
1.1 Hz, 1H), 8.14 (s, 1H), 8.02 (td, J = 8.1, 1.7 Hz,
1H), 7.46 (dd, J = 7.0, 5.2 Hz, 1H), 6.86 (d, J = 5.3 Hz, 1H), 5.28
(d, J = 6.0 Hz, 1H), 3.38 (dd, J = 14.0, 7.0 Hz, 2H), 1.42-1.28 (m,
1H), 1.12 (t, J = 7.0 Hz, 3H), 0.54-0.46 (m, 2H), 0.46-0.33 (m,
2H). 59 435.1 (DMSO-d.sub.6) .delta. 10.62 (s, 1H), 9.32 (s, 2H),
8.90-8.76 (m, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.39 (d, J = 1.5 Hz,
1H), 8.14 (d, J = 1.2 Hz, 1H), 8.02 (td, J = 7.8, 1.8 Hz, 1H), 7.46
(ddd, J = 7.5, 4.9, 0.8 Hz, 1H), 6.87 (t, J = 5.3 Hz, 1H), 5.21 (d,
J = 5.9 Hz, 1H), 4.63 (dt, J = 11.7, 5.8 Hz, 1H), 3.27-3.16 (m,
2H), 1.98-1.73 (m, 2H), 1.18-1.06 (m, 3H), 0.90 (t, J = 7.4 Hz,
3H). 60 463.1 (DMSO-d.sub.6) .delta. 10.62 (s, 1H), 9.33 (s, 2H),
8.83 (ddd, J = 4.8, 1.7, 0.8 Hz, 1H), 8.54 (d, J = 8.3 Hz, 1H),
8.40 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.2 Hz, 1H), 8.08-7.95 (m,
1H), 7.46 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 6.86 (t, J = 5.5 Hz,
1H), 5.02 (d, J = 6.7 Hz, 1H), 4.44 (d, J = 6.8 Hz, 1H), 3.26-3.18
(m, 2H), 1.12 (t, J = 7.2 Hz, 3H), 0.95 (s, 9H). 61 449.1
(DMSO-d.sub.6) .delta. 10.59 (s, 1H), 9.32 (s, 2H), 8.83 (ddd, J =
4.8, 1.7, 0.9 Hz, 1H), 8.53 (d, J = 8.4 Hz, 1H), 8.39 (d, J = 1.6
Hz, 1H), 8.14 (d, J = 1.4 Hz, 1H), 8.07-7.97 (m, 1H), 7.46 (ddd, J
= 7.5, 4.9, 0.9 Hz, 1H), 6.87 (t, J = 5.4 Hz, 1H), 5.20 (d, J = 6.0
Hz, 1H), 4.70 (dt, J = 7.4, 5.8 Hz, 1H), 3.26- 3.18 (m, 2H),
1.93-1.69 (m, 2H), 1.50-1.27 (m, 2H), 1.12 (t, J = 7.2 Hz, 3H),
0.91 (t, J = 7.4 Hz, 3H). 62 520.06 (MeOD) .delta. 9.21 (s, 2H),
8.77 (d, J = 3.1 Hz, 1H), 8.47 (s, 1H), 8.28 (d, J = 8.1 Hz, 1H),
8.21 (d, J = 1.5 Hz, 1H), 8.00 (d, J = 1.5 Hz, 1H), 7.95 (td, J =
7.8, 1.8 Hz, 1H), 7.40 (dd, J = 7.0, 5.3 Hz, 1H), 6.04 (q, J = 6.8
Hz, 1H), 3.87 (s, 1H), 3.35 (t, J = 3.6 Hz, 2H), 1.75 (d, J = 6.8
Hz, 3H), 1.24 (t, J = 7.2 Hz, 3H), 1.12 (d, J = 7.0 Hz, 6H). 63
520.04 (MeOD) .delta. 9.21 (s, 2H), 8.82-8.74 (m, 1H), 8.47 (s,
1H), 8.29 (d, J = 8.2 Hz, 1H), 8.21 (d, J = 1.6 Hz, 1H), 7.96 (ddd,
J = 11.0, 9.8, 1.7 Hz, 2H), 7.44-7.35 (m, 1H), 6.02 (q, J = 6.8 Hz,
1H), 3.90 (d, J = 4.4 Hz, 1H), 3.36 (t, J = 7.2 Hz, 2H), 1.75 (d, J
= 6.8 Hz, 3H), 1.23 (d, J = 7.2 Hz, 3H), 1.13 (dd, J = 7.0, 2.1 Hz,
6H). 64 522.3 (DMSO-d.sub.6) .delta. 10.62 (br s, 1H), 9.32 (s,
2H), 8.75 (d, J = 4.40 Hz, 1H), 8.37- 8.43 (m, 2H), 8.13 (s, 1H),
7.42 (br s, 1H), 6.86 (m, 1H), 5.29 (s, 2H), 4.87 (br s, 1H), 3.78
(s, 2H), 3.21 (m, 2H), 2.80-2.83 (m, 2H), 2.66 (m, 1H), 1.93-2.18
(m, 3H), 1.47 (d, J = 6.0 Hz, 3H) and 1.10 (t, J = 6.40 Hz, 3H). 65
506.23 (DMSO-d.sub.6) .delta. 10.73 (br s, 1H), 9.32 (s, 2H), 8.72
(d, J = 4.80 Hz, 1H), 8.36 (m, 2H), 8.11 (s, 1H), 7.34 (m, 1H),
6.98 (m, 1H), 5.29-5.36 (m, 2H), 4.86- 4.89 (m, 1H), 4.23 (m, 1H),
3.72 (s, 2H), 3.56 (m, 2H), 3.21 (m, 2H), 2.85 (m, 2H), 1.47 (d, J
= 6.80 Hz, 3H) and 1.11 (t, J = 7.20 Hz, 3H). 66 520.27
(DMSO-d.sub.6) .delta. 10.62 (br s, 1H), 9.32 (s, 2H), 8.72 (d, J =
4.80 Hz, 1H), 8.36 (m, 2H), 8.12 (s, 1H), 7.37 (m, 1H), 6.68 (m,
1H), 5.29 (d, J = 5.6 Hz, 1H), 5.22 (br s, 1H), 4.87 (m, 1H), 3.74
(s, 2H), 3.19-3.26 (m, 4H), 2.97 (m, 2H), 1.47 (t, J = 6.80 Hz,
3H), 1.38 (s, 3H) and 1.09 (t, J = 7.20 Hz, 3H). 67 548.3
(DMSO-d.sub.6) .delta. 12.18 (br s, 1H), 9.40 (s, 2H), 9.07 (s,
1H), 8.88 (br s, 1H), 8.58 (s, 1H), 8.20 (s, 1H), 7.65-7.70 (m,
1H), 7.28 (br s, 1H), 7.28 (s, 1H), 4.60 (m, 2H), 3.56 (m, 1H),
3.09-3.37 (m, 7H), 1.90-2.01 (m, 2H) 1.57 (s, 6H) and 1.06-1.21 (m,
5H). 68 534.14 (DMSO-d.sub.6) .delta. = 10.62 (s, 1H), 9.33 (s,
2H), 8.77 (d, J = 4.9 Hz, 1H), 8.42 (s, 1H), 8.37 (d, J = 1.6 Hz,
1H), 8.14 (d, J = 1.2 Hz, 1H), 7.47 (d, J = 5.1 Hz, 1H), 6.88 (t, J
= 5.5 Hz, 1H), 5.30 (d, J = 5.6 Hz, 1H), 4.96-4.83 (m, 1H), 4.11
(d, J = 14.4 Hz, 1H), 3.67 (ddd, J = 10.7, 7.3, 3.2 Hz, 2H), 3.58-
3.47 (m, 1H), 3.39 (d, J = 14.0 Hz, 1H), 3.27-3.19 (m, 3H), 2.61
(dt, J = 11.7, 2.6 Hz, 1H), 2.50-2.44 (m, 1H), 2.24 (ddd, J = 12.6,
9.8, 3.2 Hz, 1H), 1.51 (d, J = 6.6 Hz, 3H), 1.14 (t, J = 7.2 Hz,
3H), 1.06 (d, J = 6.3 Hz, 3H). 69 548.18 (DMSO-d.sub.6) .delta. =
10.64 (s, 1H), 9.34 (s, 2H), 8.77 (d, J = 5.3 Hz, 1H), 8.43 (s,
1H), 8.38 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.4 Hz, 1H), 7.44 (dd,
J = 5.0, 1.0 Hz, 1H), 6.90 (t, J = 5.4 Hz, 1H), 5.30 (d, J = 5.6
Hz, 1H), 4.97-4.83 (m, 1H), 3.70-3.57 (m, 4H), 3.28-3.17 (m, 2H),
2.75 (d, J = 10.2 Hz, 2H), 1.75 (t, J = 10.7 Hz, 2H), 1.51 (d, J =
6.6 Hz, 3H), 1.14 (t, J = 7.2 Hz, 3H), 1.05 (d, J = 6.3 Hz, 6H). 70
528.18 (DMSO-d.sub.6) .delta. = 10.64 (bs, 1H), 9.34 (s, 2H),
8.84-8.71 (m, 1H), 8.43 (s, 1H), 8.38 (d, J = 1.6 Hz, 1H), 8.14 (d,
J = 1.4 Hz, 1H), 7.45 (dd, J = 5.1, 1.2 Hz, 1H), 6.90 (bt, J = 5.4
Hz, 1H), 5.30 (d, J = 5.6 Hz, 1H), 4.99-4.82 (m, 1H), 3.66 (s, 2H),
3.24 (tt, J = 12.9, 6.5 Hz, 2H), 1.51 (d, J = 6.6 Hz, 3H), 1.14 (t,
J = 7.2 Hz, 3H). 71 548.19 (DMSO-d.sub.6) .delta. = 10.64 (bs, 1H),
9.33 (s, 2H), 8.77 (d, J = 5.0 Hz, 1H), 8.43 (d, J = 13.5 Hz, 1H),
8.37 (s, 1H), 8.14 (d, J = 1.1 Hz, 1H), 7.55-7.40 (m, 1H), 6.90
(bt, J = 5.3 Hz, 1H), 5.30 (d, J = 5.6 Hz, 1H), 4.97-4.81 (m, 1H),
4.18 (d, J = 14.5 Hz, 0.5H), 3.77 (d, J = 14.5 Hz, 0.5H), 3.73-3.50
(m, 3H), 3.28-3.17 (m, 3H), 2.86-2.76 (m, 0.5H), 2.72-2.59 (m,
0.5H), 2.45-2.29 (m, 1.5H), 1.86 (dd, J = 11.4, 10.3 Hz, 0.5H),
1.51 (d, J = 6.6 Hz, 3H), 1.14 (t, J = 7.2 Hz, 3H), 1.10-0.95 (m,
6H). 72 548.06 (DMSO-d.sub.6) .delta. 9.32 (s, 2H), 8.80-8.75 (m,
1H), 8.44 (brs, 1H), 8.34 (d, J = 1.6 Hz, 1H), 8.13 (d, J = 1.5 Hz,
1H), 7.48 (d, J = 5.1 Hz, 1H), 7.08 (t, J = 5.1 Hz, 1H), 4.89 (q, J
= 6.6 Hz, 1H), 4.13 (d, J = 14.1 Hz, 1H), 3.83 (d, J = 14.2 Hz,
1H), 3.28-3.20 (m, 5H), 3.11-2.98 (m, 2H), 2.14 (ddd, J = 16.5,
12.3, 8.2 Hz, 2H), 1.97-1.85 (m, 2H), 1.85-1.74 (m, 3H), 1.13 (dd,
J = 9.4, 5.0 Hz, 3H). 73 532.15 (DMSO-d.sub.6) .delta. 10.63 (s,
1H), 9.34 (s, 2H), 8.75 (d, J = 5.5 Hz, 1H), 8.49-8.27 (m, 2H),
8.14 (d, J = 1.5 Hz, 1H), 7.36 (d, J = 5.5 Hz, 1H), 6.88 (t, J =
5.5 Hz, 1H), 5.30 (d, J = 5.6 Hz, 1H), 4.99-4.83 (m, 1H), 4.64 (s,
4H), 3.68 (s, 2H), 3.41 (s, 4H), 3.23 (dd, J = 7.2, 5.8 Hz, 2H),
1.51 (d, J = 6.6 Hz, 3H), 1.14 (t, J = 7.2 Hz, 3H). 74 576.19
(Acetone-d.sub.6) .delta. 8.79 (s, 2H), 8.75 (dd, J = 5.2, 0.7 Hz,
1H), 8.49 (s, 1H), 8.22 (d, J = 1.6 Hz, 1H), 7.89 (d, J = 1.6 Hz,
1H), 7.58 (dd, J = 5.2, 1.6 Hz, 1H), 7.17 (s, 1H), 4.50-4.42 (m,
2H), 3.44-3.32 (m, 4H), 2.20-2.12 (m, 2H), 1.62 (s, 6H), 1.53-1.44
(m, 2H), 1.29 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H). 75 548.12 [M -
H].sup.- (DMSO-d.sub.6) .delta. 10.96 (br s, 1H), 10.73 (br s, 1H),
9.32 (s, 2H), 8.68 (d, J = 5.60 Hz, 1H), 8.35 (s, 1H), 8.15 (s,
1H), 7.93 (s, 1H), 7.13 (d, J = 5.60 Hz, 1H), 7.00 (br s, 1H), 4.87
(m, 1H), 4.69 (m, 2H), 3.81 (m, 3H), 3.64 (m, 2H), 3.54-3.57 (m,
2H), 3.19-3.24 (m, 5H), 1.47 (t, J = 6.40 Hz, 3H) and 1.11 (t, J =
7.20 Hz, 3H). 76 518.09 [M - H].sup.- (DMSO-d.sub.6) .delta. 10.62
(br s, 1H), 9.32 (s, 2H), 8.73 (d, J = 4.40 Hz, 1H), 8.37-8.39 (m,
2H), 8.13 (s, 1H), 7.36 (d, J = 4.40 Hz, 1H), 6.85 (m, 1H), 5.30
(d, J = 5.60 Hz, 1H), 4.86-4.91 (m, 1H), 4.02 (m, 1H), 3.76 (br s,
2H), 3.59 (m, 2H), 3.21 (m, 2H), 3.15 (s, 3H), 2.95 (m, 2H), 1.48
(d, J = 6.40 Hz, 3H) and 1.09 (t, J = 7.20 Hz, 3H). 77 518.11 [M -
H].sup.- (DMSO-d.sub.6) .delta. 10.63 (br s, 1H), 9.32 (s, 2H),
8.74 (d, J = 4.80 Hz, 1H), 8.42 (s, 1H), 8.37 (s, 1H), 8.12 (s,
1H), 7.41 (d, J = 4.80 Hz, 1H), 6.88 (m, 1H), 5.30 (d, J = 5.20 Hz,
1H), 4.85-4.89 (m, 1H), 4.74 (d, J = 4.40 Hz, 1H), 4.22 (m, 1H),
3.68-3.72 (m, 2H), 3.38 (m, 1H), 3.20-3.23 (m, 2H), 2.67-2.72 (m,
2H), 2.38-2.41 (m, 1H), 1.98-2.05 (m, 1H), 1.55-1.61 (m, 1H), 1.47
(d, J = 6.80 Hz, 3H) and 1.09 (t, J = 7.20 Hz, 3H). 78 509.1
(DMSO-d.sub.6) .delta. 10.63 (br s, 1H), 9.21 (s, 2H), 8.61 (s,
1H), 8.26 (d, J = 5.20 Hz, 1H), 8.20 (s, 1H), 7.82 (m, 1H), 6.84
(m, 1H), 6.55 (d, J = 5.60 Hz, 1H), 5.17 (s, 1H), 3.78 (m, 2H),
3.63 (m, 2H), 3.38 (s, 3H), 3.20 (m, 2H), 1.55 (s, 6H) and 1.11 (t,
J = 7.20 Hz, 3H) 79 548.19 (DMSO-d.sub.6 + D.sub.2O): .delta. 9.32
(s, 2H), 8.68 (s, 1H), 8.56 (d, J = 6.80 Hz, 1H), 8.30 (s, 1H),
7.18 (d, J = 6.80 Hz, 1H), 3.67 (m, 4H), 3.18-3.22 (m, 6H), 2.34
(m, 2H), 1.55 (s, 6H), 1.29 (t, J = 7.20 Hz, 3H) and 1.09 (t, J =
7.20 Hz, 3H) 80 509.16 (DMSO-d.sub.6 + D.sub.2O): .delta. 9.31 (s,
2H), 8.65 (d, J = 5.20 Hz, 1H), 8.21-8.24 (m, 1H), 8.15 (s, 1H),
7.96 (s, 1H), 7.23 (m, 1H), 4.36-4.45 (m, 2H), 3.74 (m, 2H), 3.36
(s, 3H), 3.14-3.18 (m, 2H), 1.55 (s, 6H) and 1.10 (t, J = 7.20 Hz,
3H). 81 506.12 (DMSO-d.sub.6) .delta. 10.63 (bs, 1H), 9.35 (s, 2H),
8.85 (dd, J = 4.8, 0.8 Hz, 1H), 8.55 (d, J = 8.3 Hz, 1H), 8.42 (d,
J = 1.5 Hz, 1H), 8.16 (d, J = 1.4 Hz, 1H), 8.04 (td, J = 7.9, 1.8
Hz, 1H), 7.56-7.41 (m, 1H), 6.88 (bs, 1H), 5.33 (d, J = 5.8 Hz,
1H), 4.93 (dd, J = 12.8, 5.7 Hz, 1H), 3.55 (t, J = 4.6 Hz, 4H),
3.29-3.18 (m, 2H), 2.88 (dd, J = 12.6, 5.5 Hz, 1H), 2.79-2.69 (m,
1H), 2.59-2.53 (m, 2H), 2.50-2.42 (m, 2H), 1.14 (t, J = 7.2 Hz,
3H). 82 421.06 (DMSO-d.sub.6) .delta. 10.97 (bs, 1H), 9.34 (s, 2H),
8.85 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.54 (d, J = 8.3 Hz, 1H),
8.40 (d, J = 1.6 Hz, 1H), 8.15 (d, J = 1.6 Hz, 1H), 8.08-7.97 (m,
1H), 7.48 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 7.06 (bd, J = 4.3 Hz,
1H), 5.15 (s, 1H), 2.77 (d, J = 4.6 Hz, 3H), 1.59 (s, 6H). 83
407.07 (DMSO-d.sub.6) .delta. 10.75 (bs, 1H), 9.34 (s, 2H),
8.91-8.79 (m, 1H), 8.54 (d, J = 8.3 Hz, 1H), 8.40 (d, J = 1.5 Hz,
1H), 8.15 (s, 1H), 8.09-7.95 (m, 1H), 7.48 (ddd, J = 7.5, 4.9, 0.8
Hz, 1H), 6.80 (d, J = 3.7 Hz, 1H), 5.30 (d, J = 5.6 Hz, 1H),
4.99-4.78 (m, 1H), 2.78 (d, J = 4.5 Hz, 3H), 1.50 (d, J = 6.6 Hz,
3H). 84 534.13 (DMSO-d.sub.6) .delta. 10.66 (br s, 1H), 9.32 (s,
2H), 8.74 (d, J = 4.80 Hz, 1H), 8.43 (br s, 1H), 8.37 (s, 1H), 8.13
(s, 1H), 7.44 (m, 1H), 6.92 (m, 1H), 5.30 (d, J = 5.20 Hz, 1H),
4.86 (m, 1H), 4.62 (br s, 1H), 3.76 (br s, 2H), 3.33 (m, 2H), 3.20
(m, 2H), 2.59-2.75 (m, 2H), 1.76 (m, 2H), 1.47 (t, J = 6.40 Hz,
3H), 1.25 (s, 3H) and 1.09 (t, J = 6.80 Hz, 3H). 85 495.19
(DMSO-d.sub.6) .delta. 10.64 (br s, 1H), 9.21 (s, 2H), 8.61 (s,
1H), 8.24 (m, 1H), 8.15 (s, 1H), 7.76 (m, 1H), 6.86 (m, 1H), 6.54
(d, J = 6.0 Hz, 1H), 5.15 (s, 1H), 4.74 (m, 1H), 3.29 (m, 4H), 3.21
(m, 2H), 1.56 (s, 6H) and 1.11 (t, J = 7.20 Hz, 3H) 86 521.26
(DMSO-d.sub.6) .delta. 10.62 (br s, 1H), 9.21 (s, 2H), 8.61 (s,
1H), 8.40 (d, J = 6.0 Hz, 1H), 8.19 (s, 1H), 6.91 (br s, 1H), 6.43
(d, J = 6.0 Hz, 1H), 5.84 (s, 1H), 5.15 (s, 1H), 4.10 (br s, 4H),
3.21 (m, 2H), 1.56 (s, 6H), 1.49 (s, 3H) and 1.12 (t, J = 7.20 Hz,
3H) 87 575.23 [M - H].sup.- (DMSO-d.sub.6) .delta. 12.54 (br s,
1H), 10.72 (br s, 1H), 9.33 (s, 2H), 8.71 (s, 1H), 8.43 (s, 1H),
8.15 (s, 1H), 7.69 (s, 1H), 6.99 (m, 1H), 5.15 (br s, 1H),
4.26-4.28 (m, 2H), 3.38 (m, 2H), 3.20 (m, 2H), 2.04-2.11 (m, 2H),
1.57 (s, 6H), 1.40-1.45 (m, 2H), 1.22 (s, 3H) and 1.11 (t, J = 7.20
Hz, 3H) 88 562.18 (Acetone-d.sub.6) .delta. 8.80 (s, 2H), 8.76 (dd,
J = 5.0, 0.6 Hz, 1H), 8.40 (s, 1H), 8.22 (d, J = 1.6 Hz, 1H), 7.90
(d, J = 1.6 Hz, 1H), 7.47 (dd, J = 5.1,
0.9 Hz, 1H), 5.02 (q, J = 6.5 Hz, 1H), 4.50-4.42 (m, 2H), 3.43-3.33
(m, 4H), 2.19-2.13 (m, 2H), 1.54-1.44 (m, 5H), 1.29 (s, 3H), 1.21
(t, J = 7.2 Hz, 3H). 89 560.9 (CDCl.sub.3) .delta. 9.84 (br s, 1H),
9.06 (s, 2H), 8.56 (d, J = 4.2 Hz, 1H), 7.91 (dd, J = 11.7, 4.5 Hz,
2H), 7.83-7.67 (m, 2H), 7.55 (d, J = 12.7 Hz, 1H), 7.15 (dd, J =
7.1, 5.0 Hz, 1H), 3.72 (s, 2H), 3.59-3.40 (m, 4H), 2.47 (s, 4H),
2.36 (s, 3H), 1.90 (s, 6H), 1.31 (t, J = 7.2 Hz, 3H). 90 435.16 [M
- H].sup.- (DMSO-d.sub.6) .delta. 10.85 (br s, 1H), 10.61 (br s,
1H), 9.30 (s, 2H), 8.50 (m, 1H), 8.34 (s, 1H), 8.09 (s, 1H), 7.80
(s, 1H), 6.87 (m, 2H), 5.31 (d, J = 5.60 Hz, 1H), 4.88 (m, 1H),
3.21 (m, 2H), 1.47 (d, J = 6.40 Hz, 3H) and 1.11 (t, J = 7.20 Hz,
3H) 91 564.24 (DMSO-d.sub.6 + D.sub.2O): .delta. 9.25 (s, 2H), 8.55
(s, 1H), 8.24 (s, 2H), 6.80 (s, 1H), 4.09 (s, 2H), 3.91 (br s, 2H),
3.76 (br s, 2H), 3.58 (br s, 4H), 3.16-3.24 (m, 4H), 1.54 (s, 6H)
and 1.08 (t, J = 7.20 Hz, 3H) 92 495.27 (DMSO-d.sub.6) .delta.
10.59 (br s, 1H), 9.33 (s, 2H), 8.61 (m, 1H), 8.40 (s, 1H), 8.12
(s, 1H), 8.05 (s, 1H), 7.05 (d, J = 5.20 Hz, 1H), 6.86 (m, 1H),
5.30 (d, J = 5.20 Hz, 1H), 4.87 (m, 1H), 4.36 (m, 2H), 3.73 (m,
2H), 3.33 (s, 3H), 3.21 (m, 2H), 1.49 (d, J = 6.40 Hz, 3H) and 1.11
(t, J = 7.20 Hz, 3H). 93 507.17 (DMSO-d.sub.6) .delta. 10.62 (br s,
1H), 9.20 (s, 2H), 8.60 (s, 1H), 8.42 (d, J = 6.0 Hz, 1H), 8.16 (s,
1H), 6.85 (m, 1H), 6.44 (d, J = 5.60 Hz, 1H), 5.33 (d, J = 5.60 Hz,
1H), 4.86 (t, J = 6.40 Hz, 1H), 4.45 (m, 3H), 4.04 (br s, 2H), 3.30
(s, 3H), 3.22 (m, 2H), 1.48 (d, J = 6.40 Hz, 3H) and 1.11 (t, J =
7.20 Hz, 3H) 94 507.27 (DMSO-d.sub.6) .delta. 10.65 (br s, 1H),
9.22 (s, 2H), 8.61 (s, 1H), 8.48 (d, J = 6.0 Hz, 1H), 8.16 (s, 1H),
6.85-6.88 (m, 2H), 5.31 (d, J = 5.60 Hz, 1H), 4.88 (m, 1H),
3.75-3.81 (m, 8H), 3.22 (m, 2H), 1.48 (d, J = 6.80 Hz, 3H) and 1.11
(t, J = 7.20 Hz, 3H) 95 420.28 (DMSO-d.sub.6) .delta. 10.61 (br s,
1H), 8.99 (s, 1H), 8.81 (m, 1H), 8.51 (d, J = 8.0 Hz, 1H), 8.30 (m,
2H), 7.98-8.02 (m, 2H), 7.62 (m, 1H), 7.45 (m, 1H), 6.86 (m, 1H),
5.45 (d, J = 4.40 Hz, 1H), 4.81 (q, J = 5.60 Hz, 1H), 3.21 (m, 2H),
1.43 (d, J = 6.40 Hz, 3H) and 1.11 (t, J = 7.20 Hz, 3H) 96 474.2
(DMSO-d.sub.6) .delta. 10.63 (br s, 1H), 9.11 (s, 1H), 8.83 (m,
1H), 8.53 (d, J = 8.0 Hz, 1H), 8.42 (m, 1H), 8.35 (s, 1H), 8.07 (s,
1H), 8.0 (m, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.44 (m, 1H), 7.10 (m,
1H), 6.85 (br s, 1H), 5.22 (m, 1H), 3.21 (m, 2H) and 1.11 (t, J =
6.8 Hz, 3H) 97 577.37 (DMSO-d.sub.6) .delta. 12.53 (br s, 1H),
10.67 (br s, 1H), 9.23 (s, 2H), 8.62 (s, 1H), 8.42 (br s, 1H), 8.16
(s, 1H), 6.88 (m, 2H), 5.16 (br s, 1H), 4.32 (m, 2H), 3.37 (m, 2H),
3.22 (m, 2H), 2.07-2.11 (m, 2H), 1.56 (s, 6H), 1.44-1.49 (m, 2H),
1.20 (s, 3H) and 1.12 (t, J = 7.20 Hz, 3H) 98 463.11 (DMSO-d.sub.6)
.delta. 10.64 (br s, 1H), 9.37 (s, 2H), 8.83 (br d, J = 3.9 Hz,
1H), 8.54 (d, J = 8.3 Hz, 1H), 8.42 (d, J = 1.5 Hz, 1H), 8.16 (s,
1H), 8.02 (td, J = 7.9, 1.8 Hz, 1H), 7.46 (dd, J = 7.1, 5.2 Hz,
1H), 6.85 (t, J = 5.4 Hz, 1H), 4.89 (s, 1H), 99 576.22
(Acetone-d.sub.6) .delta. 8.79 (s, 2H), 8.75 (dd, J = 5.2, 0.7 Hz,
1H), 8.49 (s, 1H), 8.22 (d, J = 1.6 Hz, 1H), 7.89 (d, J = 1.6 Hz,
1H), 7.58 (dd, J = 5.2, 1.6 Hz, 1H), 4.46 (dt, J = 13.8, 4.2 Hz,
2H), 3.43-3.33 (m, 4H), 2.20-2.13 (m, 2H), 1.62 (s, 6H), 1.53-1.44
(m, 2H), 1.29 (s, 3H), 1.21 (t, J = 7.2 Hz, 3H). 100 571.08
(DMSO-d.sub.6) .delta. 10.62 (s, 1H), 9.39 (s, 2H), 8.92-8.76 (m,
1H), 8.55 (d, J = 8.3 Hz, 1H), 8.42 (d, J = 1.5 Hz, 1H), 8.17 (d, J
= 1.1 Hz, 1H), 8.04 (td, J = 7.8, 1.8 Hz, 1H), 7.48 (ddd, J = 7.4,
4.9, 0.8 Hz, 1H), 6.87 (t, J = 5.4 Hz, 1H), 5.30 (s, 1H), 3.84 (td,
J = 11.0, 2.2 Hz, 2H), 3.79-3.69 (m, 2H), 3.29-3.18 (m, 2H),
2.33-2.21 (m, 2H), 1.78 (d, J = 12.1 Hz, 2H), 1.14 (t, J = 7.2 Hz,
3H). 101 535.21 (DMSO-d.sub.6) .delta. 11.51 (br s, 1H), 10.96 (br
s, 1H), 9.37 (s, 2H), 9.17 (d, J = 4.80 Hz, 1H), 8.97 (s, 1H), 8.30
(s, 1H), 7.74 (d, J = 4.80 Hz, 1H), 7.14 (m, 1H), 4.75 (s, 2H),
4.00 (br s, 4H), 3.62-3.64 (m, 2H), 3.35 (br s, 2H), 3.21 (m, 2H),
1.57 (s, 6H) and 1.11 (t, J = 7.20 Hz, 3H). 102 535.22
(DMSO-d.sub.6 + D.sub.2O): .delta. 9.77 (s, 1H), 9.34 (s, 2H), 8.88
(s, 1H), 8.53 (s, 1H), 8.21 (s, 1H), 4.68 (s, 2H), 4.03 (br s, 2H),
3.85 (br s, 2H), 3.60 (br s, 2H), 3.49 (br s, 2H), 3.20 (m, 2H),
1.55 (s, 6H) and 1.09 (t, J = 7.20 Hz, 3H) 103 523.24
(DMSO-d.sub.6) .delta. 10.64 (br s, 1H), 9.21 (s, 2H), 8.62 (s,
1H), 8.24 (d, J = 5.60 Hz, 1H), 8.14 (s, 1H), 7.57 (m, 1H), 6.81
(m, 1H), 6.65 (d, J = 6.0 Hz, 1H), 5.17 (s, 1H), 4.53 (s, 1H), 3.67
(d, J = 5.20 Hz, 1H), 3.36 (m, 1H), 3.20 (m, 2H), 1.55 (s, 6H),
1.23 (s, 6H) and 1.11 (t, J = 7.20 Hz, 3H) 104 521.2 (DMSO-d.sub.6)
.delta. 10.64 (br s, 1H), 9.33 (s, 2H), 8.60 (d, J = 5.60 Hz, 1H),
8.38 (s, 1H), 8.12 (s, 1H), 8.03 (s, 1H), 7.05 (m, 1H), 6.95 (m,
1H), 4.84-4.89 (m, 1H), 4.18-4.24 (m, 3H), 3.79-3.84 (m, 2H),
3.67-3.73 (m, 1H), 3.19-3.27 (m, 2H), 2.01-2.13 (m, 1H), 1.85-1.93
(m, 2H), 1.70-1.73 (m, 1H), 1.49 (d, J = 6.40 Hz, 3H) and 1.11 (t,
J = 7.20 Hz, 3H). 105 493.15 (DMSO-d.sub.6) .delta. 10.61 (br s,
1H), 9.20 (s, 2H), 8.61 (s, 1H), 8.40 (d, J = 6.0 Hz, 1H), 8.16 (s,
1H), 6.83 (m, 1H), 6.42 (d, J = 6.0 Hz, 1H), 5.90 (d, J = 6.80 Hz,
1H), 5.32 (d, J = 5.60 Hz, 1H), 4.88 (m, 1H), 4.70 (m, 1H), 4.52
(br s, 2H), 4.09 (br s, 2H), 3.21 (m, 2H), 1.48 (d, J = 6.40 Hz,
3H) and 1.11 (t, J = 7.20 Hz, 3H) 106 525.22 (DMSO-d.sub.6) .delta.
10.67 (br s, 1H), 9.21 (s, 2H), 8.52-8.54 (m, 2H), 8.16 (s, 1H),
6.82 (m, 1H), 5.30 (d, J = 5.60 Hz, 1H), 4.86 (m, 1H), 3.86 (m,
4H), 3.80 (m, 4H), 3.20 (m, 2H), 1.48 (d, J = 6.40 Hz, 3H) and 1.11
(t, J = 7.20 Hz, 3H) 107 578.28 (DMSO-d.sub.6 + D.sub.2O): .delta.
9.29 (s, 2H), 8.59 (s, 1H), 8.52 (d, J = 6.40 Hz, 1H), 8.22 (s,
1H), 7.06 (d, J = 6.80 Hz, 1H), 3.56-3.79 (m, 8H), 3.37 (m, 2H),
3.33 (s, 3H), 3.21 (m, 2H), 2.50 (m, 2H), 1.54 (s, 6H) and 1.09 (t,
J = 7.20 Hz, 3H) 108 573.21 (DMSO-d.sub.6) .delta. 10.62 (br s,
1H), 9.11 (s, 1H), 8.76 (d, J = 4.80 Hz, 1H), 8.41 (m, 2H), 8.33
(s, 1H), 8.06 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.44 (m, 1H), 7.10
(m, 1H), 6.85 (m, 1H), 5.22 (m, 1H), 3.64 (s, 2H), 3.61 (m, 4H),
3.21 (m, 2H), 2.43 (m, 4H) and 1.11 (t, J = 6.8 Hz, 3H) 109 563.25
(DMSO-d.sub.6) .delta. 10.97 (br s, 1H), 9.38 (s, 2H), 8.69 (br s,
1H), 8.41 (s, 1H), 8.14 (s, 1H), 7.66 (br s, 1H), 7.22 (m, 1H),
5.29 (m, 1H), 4.88 (m, 1H), 4.28 (m, 2H), 3.20 (m, 2H), 2.06 (m,
2H), 1.48 (d, J = 6.40 Hz, 3H), 1.33 (m, 2H), 1.22 (m, 2H) and
1.09-1.12 (m, 6H) 110 562.22 (DMSO-d.sub.6) .delta. 12.29 (br s,
1H), 10.55 (br s, 1H), 9.32 (s, 2H), 8.37 (d, J = 6.0 Hz, 1H), 8.32
(s, 1H), 8.06 (s, 1H), 7.74 (br s, 1H), 6.91 (m, 2H), 5.14 (br s,
1H), 4.08-4.11 (m, 2H), 3.16-3.22 (m, 2H), 3.02-3.07 (m, 2H), 2.55
(m, 1H), 1.91-1.94 (m, 2H), 1.60-1.62 (m, 2H), 1.57 (s, 6H) and
1.11 (t, J = 7.20 Hz, 3H) 111 477.09 (DMSO-d.sub.6) .delta. 10.62
(s, 1H), 9.39 (s, 2H), 8.92-8.76 (m, 1H), 8.55 (d, J = 8.3 Hz, 1H),
8.42 (d, J = 1.5 Hz, 1H), 8.17 (d, J = 1.1 Hz, 1H), 8.04 (td, J =
7.8, 1.8 Hz, 1H), 7.48 (ddd, J = 7.4, 4.9, 0.8 Hz, 1H), 6.87 (t, J
= 5.4 Hz, 1H), 5.30 (s, 1H), 3.84 (td, J = 11.0, 2.2 Hz, 2H),
3.79-3.69 (m, 2H), 3.29-3.18 (m, 2H), 2.33-2.21 (m, 2H), 1.78 (d, J
= 12.1 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H). 112 560.17 (DMSO-d.sub.6)
.delta. 10.62 (s, 1H), 9.33 (s, 2H), 8.76 (d, J = 5.0 Hz, 1H),
8.44-8.32 (m, 2H), 8.14 (s, 1H), 7.42 (d, J = 4.9 Hz, 1H), 6.88 (t,
J = 5.3 Hz, 1H), 5.30 (d, J = 5.6 Hz, 1H), 4.89 (p, J = 6.5 Hz,
1H), 4.28 (d, J = 5.6 Hz, 4H), 3.60 (s, 2H), 3.24 (dt, J = 14.0,
7.0 Hz, 2H), 2.34 (s, 4H), 1.83 (d, J = 4.9 Hz, 4H), 1.50 (d, J =
6.6 Hz, 3H), 1.14 (t, J = 7.2 Hz, 3H). 113 449.05 (DMSO-d.sub.6)
.delta. 10.63 (s, 1H), 9.45 (s, 2H), 8.89-8.80 (ddd, J = 4.8, 1.7,
0.6 Hz 1H), 8.55 (d, J = 8.0 Hz, 1H), 8.44 (d, J = 1.4 Hz, 1H),
8.20 (d, J = 1.4 Hz, 1H), 8.04 (td, J = 8.0, 1.7 Hz, 1H), 7.56-7.44
(ddd, J = 12.2, 4.8, 0.6 Hz, 1H), 6.87 (t, J = 5.2 Hz, 1H), 6.42
(s, 1H), 5.08 (d, J = 6.7 Hz, 2H), 4.77 (d, J = 6.7 Hz, 2H),
3.28-3.20 (m, 2H), 1.14 (t, J = 7.2 Hz, 3H). 114 546.21 [M -
H].sup.- (DMSO-d.sub.6) .delta. 10.61 (br s, 1H), 9.33 (s, 2H),
8.73 (m, 1H), 8.38 (d, J = 6.40 Hz, 2H), 8.13 (s, 1H), 7.37 (m,
1H), 6.85 (m, 1H), 5.15 (s, 1H), 3.75 (s, 2H), 3.18-3.23 (m, 4H),
3.10 (s, 3H), 3.06 (m, 2H), 1.57 (s, 6H), 1.40 (s, 3H) and 1.09 (t,
J = 7.20 Hz, 3H). 115 422.2 (DMSO-d.sub.6) .delta. 10.74 (br s,
1H), 9.23 (s, 2H), 9.09 (d, J = 4.80 Hz, 2H), 8.71 (s, 1H), 8.23
(s, 1H), 7.57 (t, J = 4.80 Hz, 1H), 6.86 (m, 1H), 5.33 (d, J = 5.60
Hz, 1H), 4.87 (m, 1H), 3.22 (m, 2H), 1.48 (d, J = 6.40 Hz, 3H) and
1.12 (t, J = 7.20 Hz, 3H) 116 603.3 (DMSO-d.sub.6) .delta. 10.64
(br s, 1H), 9.11 (s, 1H), 8.74 (d, J = 4.0 Hz, 1H), 8.42 (m, 2H),
8.38 (s, 1H), 8.06 (m, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.36 (m, 1H),
7.12 (m, 1H), 6.86 (m, 1H), 5.22 (m, 1H), 4.02 (m, 1H), 3.76 (s,
2H), 3.58 (br s, 2H), 3.21 (m, 2H), 3.15 (s, 3H), 2.95 (br s, 2H)
and 1.11 (t, J = 7.20 Hz, 3H) 117 563.31 (DMSO-d.sub.6) .delta.
12.70 (br s, 1H), 10.92 (br s, 1H), 9.35 (s, 2H), 8.72 (br s, 1H),
8.45 (m, 1H), 8.35 (s, 1H), 7.12 (m, 1H), 7.02 (m, 1H), 4.88 (m,
1H), 3.54 (m, 2H), 3.22 (m, 2H), 2.53 (m, 3H), 2.20 (m, 2H), 1.57
(m, 2H), 1.49 (d, J = 6.40 Hz, 3H), 1.24 (s, 3H) and 1.12 (t, J =
7.20 Hz, 3H) 118 451.1 (DMSO-d.sub.6) .delta. 10.62 (s, 1H), 9.33
(s, 2H), 8.83 (d, J = 4.2 Hz, 1H), 8.53 (d, J = 8.0 Hz, 1H), 8.39
(s, 1H), 8.14 (s, 1H), 8.02 (t, J = 7.6 Hz, 1H), 7.54-7.40 (m, 1H),
6.80 (d, J = 54.2 Hz, 1H), 5.06 (d, J = 6.5 Hz, 1H), 4.54 (d, J =
5.6 Hz, 1H), 4.49 (t, J = 5.7 Hz, 1H), 4.09 (dd, J = 11.5, 5.6 Hz,
1H), 3.28-3.16 (m, 2H), 1.12 (t, J = 7.1 Hz, 3H), 1.07 (d, J = 6.3
Hz, 3H). 119 461.12 (DMSO-d.sub.6) .delta. 10.61 (s, 1H), 9.32 (s,
2H), 8.83 (d, J = 4.1 Hz, 1H), 8.52 (d, J = 8.2 Hz, 1H), 8.39 (d, J
= 1.4 Hz, 1H), 8.14 (s, 1H), 8.02 (td, J = 7.9, 1.7 Hz, 1H), 7.46
(dd, J = 7.2, 5.1 Hz, 1H), 6.87 (t, J = 5.4 Hz, 1H), 5.08 (s, 1H),
3.26 120 535.22 (DMSO-d.sub.6) .delta. 10.72 (br s, 1H), 9.24 (s,
2H), 8.99 (s, 2H), 8.69 (s, 1H), 8.22 (s, 1H), 6.83 (m, 1H), 5.16
(s, 1H), 3.60-3.63 (m, 6H), 3.22 (m, 2H), 2.44 (br s, 4H), 1.56 (s,
6H) and 1.10 (t, J = 7.20 Hz, 3H). 121 520.13 (DMSO-d.sub.6)
.delta. 10.62 (s, 1H), 9.32 (s, 2H), 8.76 (d, J = 5.2 Hz, 1H), 8.42
(s, 1H), 8.36 (d, J = 1.6 Hz, 1H), 8.12 (d, J = 1.4 Hz, 1H), 7.44
(dd, J = 5.1, 1.0 Hz, 1H), 6.89 (t, J = 5.3 Hz, 1H), 5.28 (d, J =
5.6 Hz, 1H), 4.94-4.82 (m, 1H), 3.65 (s, 2H), 3.64-3.58 (m, 4H),
3.29-3.14 (m, 2H), 2.47-2.41 (m, 4H), 1.49 (d, J = 6.6 Hz, 3H),
1.12 (t, J = 7.2 Hz, 3H). 122 520.13 (DMSO-d.sub.6) .delta. 10.64
(s, 1H), 9.32 (s, 2H), 8.76 (d, J = 4.9 Hz, 1H), 8.42 (s, 1H), 8.36
(d, J = 1.6 Hz, 1H), 8.12 (d, J = 1.5 Hz, 1H), 7.44 (dd, J = 5.1,
1.0 Hz, 1H), 6.92 (s, 1H), 5.28 (d, J = 5.6 Hz, 1H), 4.88 (p, J =
6.5 Hz, 1H), 3.65 (s, 2H), 3.64-3.59 (m, 4H), 3.21 (dt, J = 12.8,
6.5 Hz, 2H), 2.47-2.40 (m, 4H), 1.49 (d, J = 6.6 Hz, 3H), 1.12 (t,
J = 7.2 Hz, 3H). 123 549.09 (DMSO-d.sub.6) .delta. 10.67 (s, 1H),
9.43 (s, 2H), 8.85 (dd, J = 5.0, 0.9 Hz, 1H), 8.56 (d, J = 8.1 Hz,
1H), 8.44 (d, J = 1.4 Hz, 1H), 8.19 (d, J = 1.4 Hz, 1H), 8.04 (td,
J = 8.1, 1.8 Hz, 1H), 7.48 (dd, J = 7.0, 5.0 Hz, 1H), 6.88 (s, 1H),
5.14 (d, J = 7.4 Hz, 2H), 4.93 (d, J = 7.4 Hz, 2H), 3.24 (m, 2H),
2.75 (t, J = 6.7 Hz, 2H), 2.57 (t, J = 6.7 Hz, 2H), 1.14 (t, J =
7.2 Hz, 3H). 124 551.12 (DMSO-d.sub.6) .delta. 12.18 (s, 1H), 10.64
(s, 1H), 9.38 (s, 2H), 8.85 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 8.55
(d, J = 8.4 Hz, 1H), 8.43 (d, J = 1.6 Hz, 1H), 8.18 (d, J = 1.6 Hz,
1H), 8.10-7.97 (m, 1H), 7.48 (ddd, J = 7.5, 4.9, 0.9 Hz,
1H), 6.88 (t, J = 5.2 Hz, 1H), 5.47 (s, 1H), 4.50 (d, J = 10.6 Hz,
1H), 4.37 (d, J = 10.6 Hz, 1H), 3.23 (m, 2H), 2.50-2.38 (m, 4H),
1.58 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H). 125 576.18 (DMSO-d.sub.6)
.delta. 10.60 (s, 1H), 9.39 (s, 2H), 8.78 (d, J = 4.9 Hz, 1H), 8.45
(s, 1H), 8.41 (d, J = 1.6 Hz, 1H), 8.16 (d, J = 1.2 Hz, 1H), 7.46
(dd, J = 5.1, 1.0 Hz, 1H), 6.87 (t, J = 5.4 Hz, 1H), 5.30 (s, 1H),
3.84 (td, J = 11.0, 2.2 Hz, 2H), 3.77-3.70 (m, 2H), 3.66 (s, 2H),
3.65-3.60 (m, 4H), 3.24 (dd, J = 7.1, 5.8 Hz, 2H), 2.49-2.41 (m,
4H), 2.29 (td, J = 13.6, 4.8 Hz, 2H), 1.79 (d, J = 12.2 Hz, 2H),
1.14 (t, J = 7.2 Hz, 3H). 126 478.02 (DMSO-d.sub.6) .delta. 9.38
(s, 2H), 8.84 (d, J = 3.7 Hz, 1H), 8.59-8.43 (m, 4H), 8.39 (s, 1H),
8.16 (s, 1H), 8.04 (t, J = 7.4 Hz, 1H), 7.54-7.42 (m, 1H), 7.34
(brs, 1H), 6.08-5.92 (m, 1H), 4.01-3.86 (m, 2H), 3.27-3.18 (m, 2H),
1.70 (d, J = 6.6 Hz, 3H), 1.13 (t, J = 7.1 Hz, 3H). 127 493.11
(DMSO-d.sub.6) .delta. 10.62 (s, 1H), 9.37 (s, 2H), 8.83 (d, J =
4.0 Hz, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.40 (d, J = 1.5 Hz, 1H),
8.15 (br s, 1H), 8.02 (td, J = 7.9, 1.8 Hz, 1H), 7.47 (dd, J = 7.1,
5.2 Hz, 1H), 6.87 (t, J = 5.4 Hz, 1H), 5.23 (s, 1H), 3.28-3.18 (m,
2H), 3.14-2.97 (m, 2H), 2.55-2.51 (m, 2H), 2.36-2.25 (m, 2H),
2.09-1.99 (m, 2H), 1.12 (t, J = 7.2 Hz, 3H). 128 490.1
(DMSO-d.sub.6) .delta. 10.71 (br s, 1H), 9.38 (s, 2H), 8.87-8.83
(m, 1H), 8.55 (m, J = 8.4 Hz, 1H), 8.42 (d, J = 1.6 Hz, 1H), 8.23
(br s, 1H), 8.17 (d, J = 1.6 Hz, 1H), 8.06-8.01 (m, 1H), 7.48 (ddd,
J = 7.5, 4.9, 0.9 Hz, 1H), 6.96 (t, J = 5.5 Hz, 1H), 5.21 (s, 1H),
3.28-3.16 (m, 4H), 2.71-2.61 (m, 2H), 2.36-2.23 (m, 5H), 1.83 (br
d, J = 12.3 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H). 129 535.11
(DMSO-d.sub.6) .delta. 10.80 (br s, 1H), 9.60 (br s, 2H), 9.36 (s,
2H), 8.85 (d, J = 4.7 Hz, 1H), 8.54 (d, J = 7.8 Hz, 1H), 8.40 (s,
1H), 8.26 (br s, 3H), 8.16 (s, 1H), 8.04 (t, J = 7.8 Hz, 1H), 7.49
(dd, J = 7.0, 4.7 Hz, 1H), 7.11 (br s, 1H), 4.19 (s, 2H), 3.29-3.16
(m, 6H), 1.87 (s, 6H), 1.13 (t, J = 7.1 Hz, 3H). 130 487.1
(CDCl.sub.3) .delta. 8.98 (s, 2H), 8.63 (d, J = 23.2 Hz, 1H),
8.01-7.64 (m, 4H), 7.24-7.19 (m, 1H), 6.14-5.66 (m, 1H), 4.92 (d, J
= 55.8 Hz, 1H), 4.29-4.10 (m, 1H), 3.29-3.23 (m, 2H), 1.11 (t, J =
6.7 Hz, 3H). 131 505.1 (CDCl.sub.3) .delta. 9.08 (s, 2H), 8.78 (d,
J = 4.4 Hz, 1H), 8.07-7.76 (m, 4H), 7.34-7.27 (m, 1H), 5.20 (s,
1H), 4.67 (d, J = 7.1 Hz, 1H), 3.48-3.36 (m, 2H), 1.26 (t, J = 7.2
Hz, 3H). 132 505.88 (DMSO-d.sub.6) .delta. 10.81 (bs, 1H), 9.37 (s,
2H), 8.84 (d, J = 4.1 Hz, 1H), 8.54 (d, J = 8.2 Hz, 1H), 8.47-8.29
(m, 4H), 8.16 (d, J = 1.3 Hz, 1H), 8.04 (t, J = 7.7 Hz, 1H), 7.49
(dd, J = 7.1, 4.9 Hz, 1H), 7.11 (bs, 1H), 4.25-4.06 (m, 1H),
3.29-3.13 (m, 2H), 1.91 (s, 3H), 1.81 (s, 3H), 1.54 (d, J = 7.1 Hz,
3H), 1.13 (t, J = 7.1 Hz, 3H). 133 521.09 (DMSO-d.sub.6) .delta.
10.75 (s, 1H), 9.33 (s, 2H), 8.86-8.79 (m, 1H), 8.53 (d, J = 8.4
Hz, 1H), 8.39 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H),
8.06-7.97 (m, 1H), 7.50-7.42 (m, 1H), 6.99 (s, 1H), 5.85 (q, J =
6.7 Hz, 1H), 3.22 (dd, J = 7.1, 5.7 Hz, 2H), 2.69-2.59 (m, 2H),
2.55 (dd, J = 13.1, 6.8 Hz, 2H), 1.61 (d, J = 6.8 Hz, 3H), 1.12 (t,
J = 7.2 Hz, 3H). 134 521.1 (DMSO-d.sub.6) .delta. 10.80 (s, 1H),
9.33 (s, 2H), 8.82 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.53 (d, J =
8.4 Hz, 1H), 8.39 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H),
8.06-7.97 (m, 1H), 7.50-7.42 (m, 1H), 7.03 (s, 1H), 5.85 (q, J =
6.7 Hz, 1H), 3.22 (dd, J = 7.1, 5.7 Hz, 2H), 2.67-2.59 (m, 2H),
2.47-2.40 (m, 2H), 1.61 (d, J = 6.8 Hz, 3H), 1.12 (t, J = 7.2 Hz,
3H). 135 550.18 (DMSO-d.sub.6) .delta. 10.62 (s, 1H), 9.35 (s, 2H),
8.78 (d, J = 4.8 Hz, 1H), 8.44 (s, 1H), 8.39 (s, 1H), 8.15 (s, 1H),
7.45 (d, J = 4.8 Hz, 1H), 6.88 (m, 1H), 5.04 (s, 1H), 4.68 (t, J =
6.0 Hz, 1H), 3.82-3.70 (m, 2H), 3.66 (s, 2H), 3.63 (s, 4H), 3.24
(dd, J = 12.9, 6.8 Hz, 2H), 2.45 (s, 4H), 1.52 (s, 3H), 1.14 (t, J
= 6.8 Hz, 3H). 136 506.06 (DMSO-d.sub.6) .delta. 9.39 (s, 2H), 8.84
(d, J = 4.1 Hz, 1H), 8.69 (s, 3H), 8.54 (d, J = 8.1 Hz, 1H), 8.40
(d, J = 1.2 Hz, 1H), 8.17 (d, J = 1.3 Hz, 1H), 8.04 (t, J = 7.2 Hz,
1H), 7.49 (dd, J = 7.1, 4.9 Hz, 1H), 7.21 (s, 1H), 5.95 (q, J = 6.7
Hz, 1H), 3.28-3.17 (m, 2H), 1.70 (d, J = 6.7 Hz, 3H), 1.62 (s, 6H),
1.13 (t, J = 7.2 Hz, 3H). 137 492.05 (DMSO-d.sub.6) .delta. 9.39
(s, 2H), 8.84 (d, J = 4.1 Hz, 1H), 8.69 (s, 3H), 8.54 (d, J = 8.1
Hz, 1H), 8.40 (d, J = 1.2 Hz, 1H), 8.17 (d, J = 1.3 Hz, 1H), 8.04
(t, J = 7.2 Hz, 1H), 7.49 (dd, J = 7.1, 4.9 Hz, 1H), 7.21 (s, 1H),
5.95 (q, J = 6.7 Hz, 1H), 3.28-3.17 (m, 2H), 1.70 (d, J = 6.7 Hz,
3H), 1.62 (s, 6H), 1.13 (t, J = 7.2 Hz, 3H). 138 576.2
(DMSO-d.sub.6) .delta. 10.61 (s, 1H), 9.36 (s, 2H), 8.84-8.81 (m,
1H), 8.52 (d, J = 8.3 Hz, 1H), 8.40 (d, J = 1.6 Hz, 1H), 8.15 (d, J
= 1.4 Hz, 1H), 8.04-7.99 (m, 1H), 7.48-7.44 (m, 1H), 6.87 (t, J =
5.4 Hz, 1H), 5.32 (s, 1H), 3.79 (d, J = 12.6 Hz, 2H), 3.30-3.18 (m,
4H), 2.10 (td, J = 13.0, 4.4 Hz, 2H), 1.79 (d, J = 12.7 Hz, 2H),
1.43 (s, 9H), 1.12 (t, J = 7.2 Hz, 3H). 139 509.1 (DMSO-d.sub.6)
.delta. 10.62 (br s, 1H), 9.38 (s, 2H), 8.85-8.81 (m, 1H), 8.52 (d,
J = 8.3 Hz, 1H), 8.40 (d, J = 1.5 Hz, 1H), 8.15 (d, J = 1.5 Hz,
1H), 8.04-7.99 (m, 1H), 7.46 (ddd, J = 7.5, 4.9, 0.8 Hz, 1H),
6.92-6.86 (m, 1H), 5.60 (s, 1H), 3.27-3.18 (m, 2H), 3.03-2.94 (m,
4H), 2.48-2.41 (m, 2H), 2.35-2.23 (m, 2H), 1.12 (t, J = 7.2 Hz,
3H). 140 520.07 (DMSO-d.sub.6) .delta. 10.63 (s, 1H), 9.33 (s, 2H),
8.84 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 8.56 (d, J = 8.4 Hz, 1H),
8.42 (d, J = 1.5 Hz, 1H), 8.16 (d, J = 1.5 Hz, 1H), 8.03 (dt, J =
7.6, 1.8 Hz 1H), 7.48 (ddd, J = 7.6, 4.9, 0.9 Hz, 1H), 6.87 (t, J =
5.4 Hz, 1H), 3.27-3.20 (m, 2H), 3.18 (s, 2H), 2.27 (s, 6H), 1.80
(s, 6H), 1.14 (t, J = 7.2 Hz, 3H). 141 562.13 (DMSO-d.sub.6)
.delta. 10.63 (s, 1H), 9.33 (s, 2H), 8.84 (ddd, J = 4.9, 1.7, 0.8
Hz, 1H), 8.56 (d, J = 8.3 Hz, 1H), 8.42 (d, J = 1.5 Hz, 1H), 8.16
(d, J = 1.5 Hz, 1H), 8.03 (td, J = 7.7, 1.7 Hz, 1H), 7.48 (ddd, J =
7.7, 4.9, 0.8 Hz, 1H), 6.86 (t, J = 5.4 Hz, 1H), 3.61-3.54 (m, 4H),
3.25 (s, 2H), 3.23 (m, 2H), 2.54 (m, 4H), 1.80 (s, 6H), 1.14 (t, J
= 7.2 Hz, 3H). 142 548.29 (DMSO-d.sub.6) .delta. 10.60 (s, 1H) 9.32
(s, 2H), 8.75 (d, J = 5.2 Hz, 1H), 8.41 (s, 1H), 8.38 (d, J = 1.2
Hz, 1H), 8.12 (s, 1H), 7.42 (d, J = 5.2 Hz, 1H), 6.90 (t, J = 5.2
Hz, 1H), 5.30 (d, J = 5.6 Hz, 1H), 4.88 (p, J = 6.4 Hz, 1H), 3.61
(m, 4H), 3.22 (m, 2H), 2.72 (d, J = 10.8 Hz, 2H), 1.73 (t, J = 10.8
Hz, 2H), 1.48 (d, J = 6.4 Hz, 3H), 1.12 (t, J = 7.2 Hz, 3H), 1.03
(d, J = 6.4 Hz, 6H). 143 548.27 (DMSO-d.sub.6) .delta. 10.60 (s,
1H) 9.32 (s, 2H), 8.75 (d, J = 5.2 Hz, 1H), 8.41 (s, 1H), 8.38 (d,
J = 1.2 Hz, 1H), 8.12 (s, 1H), 7.42 (d, J = 5.2 Hz, 1H), 6.90 (t, J
= 5.2 Hz, 1H), 5.30 (d, J = 5.6 Hz, 1H), 4.88 (p, J = 6.4 Hz, 1H),
3.61 (m, 4H), 3.22 (m, 2H), 2.72 (d, J = 10.8 Hz, 2H), 1.73 (t, J =
10.8 Hz, 2H), 1.48 (d, J = 6.4 Hz, 3H), 1.12 (t, J = 7.2 Hz, 3H),
1.03 (d, J = 6.4 Hz, 6H). 144 534 (DMSO-d.sub.6) .delta. 10.86 (bs,
1H), 9.33 (s, 2H), 8.91-8.78 (m, 1H), 8.57 (d, J = 8.3 Hz, 1H),
8.41 (d, J = 1.6 Hz, 1H), 8.16 (d, J = 1.6 Hz, 1H), 8.10-7.99 (m,
1H), 7.91 (s, 2H), 7.56-7.42 (m, 1H), 7.17 (bs, 1H), 3.32-3.14 (m,
2H), 2.80 (dd, J = 12.8, 6.5 Hz, 2H), 2.39 (t, J = 6.7 Hz, 2H),
1.79 (s, 6H), 1.69-1.50 (m, 4H), 1.14 (t, J = 7.2 Hz, 3H). 145
562.18 (DMSO-d.sub.6) .delta. 10.83 (bs, 1H), 10.22 (bs, 1H), 9.34
(s, 2H), 8.85 (d, J = 4.0 Hz, 1H), 8.57 (d, J = 8.2 Hz, 1H), 8.41
(d, J = 1.5 Hz, 1H), 8.16 (d, J = 1.5 Hz, 1H), 8.09-7.97 (m, 1H),
7.49 (dd, J = 7.2, 5.0 Hz, 1H), 7.15 (bs, 1H), 3.22 (dd, J = 12.3,
6.9 Hz, 2H), 3.11-2.97 (m, 2H), 2.74 (d, J = 4.9 Hz, 6H), 2.41 (t,
J = 7.1 Hz, 2H), 1.79 (s, 6H), 1.77-1.67 (m, 2H), 1.64-1.48 (m,
2H), 1.14 (t, J = 7.2 Hz, 3H). 146 492.07 (DMSO-d.sub.6) .delta.
10.87 (bs, 1H), 9.36 (s, 2H), 8.85 (d, J = 4.2 Hz, 1H), 8.54 (d, J
= 8.1 Hz, 1H), 8.39 (d, J = 1.3 Hz, 1H), 8.33 (s, 2H), 8.16 (d, J =
1.3 Hz, 1H), 8.04 (t, J = 7.2 Hz, 1H), 7.49 (dd, J = 7.1, 5.0 Hz,
1H), 7.21 (bs, 1H), 3.89 (d, J = 5.5 Hz, 2H), 3.32-3.11 (m, 2H),
1.86 (s, 6H), 1.13 (t, J = 7.1 Hz, 3H). 147 540.22 (DMSO-d.sub.6)
.delta. 10.63 (br s, 1H), 9.33 (s, 2H), 8.76 (d, J = 4.40 Hz, 1H),
8.38-8.41 (m, 2H), 8.13 (s, 1H), 7.40 (m, 1H), 6.86 (m, 1H), 5.16
(s, 1H), 3.89 (s, 2H), 3.69-3.76 (m, 4H), 3.21 (m, 2H), 1.57 (s,
6H) and 1.09 (t, J = 7.20 Hz, 3H) 148 576.18 (DMSO-d.sub.6) .delta.
10.63 (s, 1H), 9.44 (s, 2H), 8.78 (d, J = 5.0 Hz, 1H), 8.48-8.37
(m, 2H), 8.19 (d, J = 1.0 Hz, 1H), 7.45 (dd, J = 5.0, 1.0 Hz, 1H),
6.88 (t, J = 5.4 Hz, 1H), 6.42 (s, 1H), 5.08 (d, J = 6.7 Hz, 2H),
4.78 (d, J = 6.7 Hz, 2H), 3.69-3.59 (m, 4H), 3.29-3.18 (m, 2H),
2.75 (d, J = 10.5 Hz, 2H), 1.76 (t, J = 10.5 Hz, 2H), 1.14 (t, J =
7.2 Hz, 3H), 1.05 (d, J = 6.3 Hz, 6H). .sup. 149.sup.a 498.97 [M -
H].sup.- (DMSO-d.sub.6) .delta. 9.08 (s, 2H), 8.61 (d, J = 4.2 Hz,
1H), 8.07 (d, J = 8.2 Hz, 1H), 7.86 (s, 1H), 7.82 (s, 1H), 7.71 (t,
J = 7.2 Hz, 1H), 7.49 (s, 1H), 7.21 (dd, J = 7.0, 5.1 Hz, 1H),
5.35-5.19 (m, 1H), 3.14 (dd, J = 13.2, 6.9 Hz, 2H), 1.44 (d, J =
6.6 Hz, 3H), 1.06 (t, J = 7.2 Hz, 3H). 154 548.18 (DMSO-d.sub.6):
.delta. 10.62 (s, 1H), 9.44 (s, 2H), 8.78 (d, J = 5.0 Hz, 1H),
8.55-8.33 (m, 2H), 8.19 (d, J = 1.1 Hz, 1H), 7.46 (d, J = 5.0 Hz,
1H), 6.88 (t, J = 5.5 Hz, 1H), 6.42 (s, 1H), 5.08 (d, J = 6.7 Hz,
2H), 4.78 (d, J = 6.7 Hz, 2H), 3.67 (s, 2H), 3.64 (t, J = 4.5 Hz,
4H), 3.28-3.19 (m, 2H), 2.48-2.42 (m, 4H), 1.14 (t, J = 7.2 Hz,
3H). 155 573.26 (DMSO-d.sub.6): .delta. 10.64 (br s, 1H), 9.11 (s,
1H), 8.74 (d, J = 4.0 Hz, 1H), 8.42 (m, 2H), 8.38 (s, 1H), 8.06 (m,
1H), 7.76 (d, J = 7.6 Hz, 1H), 7.36 (m, 1H), 7.12 (m, 1H), 6.86 (m,
1H), 5.22 (m, 1H), 4.02 (m, 1H), 3.76 (s, 2H), 3.58 (br s, 2H),
3.21 (m, 2H), 3.15 (s, 3H), 2.95 (br s, 2H) and 1.11 (t, J = 7.20
Hz, 3H) 156 568.28 (DMSO-d.sub.6): .delta. 10.62 (br s, 1H), 9.33
(s, 2H), 8.77 (d, J = 4.80 Hz, 1H), 8.43 (s, 1H), 8.38 (s, 1H),
8.13 (s, 1H), 7.45 (d, J = 4.80 Hz, 1H), 6.85 (m, 1H), 5.15 (s,
1H), 3.72 (s, 2H), 3.21 (m, 2H), 2.56 (m, 4H), 2.04 (m, 4H), 1.57
(s, 6H) and 1.11 (t, J = 7.2 Hz, 3H) 157 451.09 (DMSO-d.sub.6):
.delta. 10.62 (s, 1H), 9.36 (s, 2H), 8.91-8.78 (m, 1H), 8.55 (d, J
= 8.3 Hz, 1H), 8.41 (d, J = 1.4 Hz, 1H), 8.16 (d, J = 1.4 Hz, 1H),
8.09-7.97 (m, 1H), 7.48 (ddd, J = 7.5, 4.9, 0.8 Hz, 1H), 6.88 (t, J
= 5.3 Hz, 1H), 5.04 (s, 1H), 4.66 (t, J = 6.1 Hz, 1H), 3.81-3.66
(m, 2H), 3.29-3.17 (m, 2H), 1.52 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H).
158 435.17 (DMSO-d.sub.6): .delta. 10.64 (br s, 1H), 9.31 (s, 2H),
8.65 (s, 1H), 8.43 (d, J = 8.40 Hz, 1H), 8.34 (s, 1H), 8.10 (s,
1H), 7.84 (d, J = 8.0 Hz, 1H), 6.90 (m, 1H), 5.31 (d, J = 5.60 Hz,
1H), 4.86 (m, 1H), 3.21 (m, 2H), 2.40 (s, 3H), 1.48 (d, J = 6.40
Hz, 3H) and 1.11 (t, J = 7.20 Hz, 3H) 159 547.31 (DMSO-d.sub.6):
.delta. 10.62 (br s, 1H), 9.33 (s, 2H), 8.75 (d, J = 4.80 Hz, 1H),
8.40 (m, 2H), 8.13 (s, 1H), 7.41 (d, J = 4.8 Hz, 1H), 6.88 (br s,
1H), 5.15 (s, 1H), 3.62 (s, 2H), 3.21 (m, 2H), 2.35-2.50 (m, 8H),
2.15 (s, 3H), 1.57 (s, 6H) and 1.11 (t, J = 7.20 Hz, 3H) 160 518.22
(DMSO-d.sub.6): .delta. 10.16 (d, J = 4.8 Hz, 1H), 9.39 (s, 2H),
9.03 (d, J = 4.7 Hz, 1H), 8.85 (d, J = 4.0 Hz, 1H), 8.54 (d, J =
8.2 Hz, 1H), 8.41 (d, J = 1.5 Hz,
1H), 8.18 (d, J = 1.5 Hz, 1H), 8.04 (td, J = 8.0, 1.6 Hz, 1H), 7.49
(dd, J = 7.1, 4.9 Hz, 1H), 7.18 (s, 1H), 6.01 (q, J = 6.7 Hz, 1H),
4.61-4.44 (m, 1H), 3.37-3.17 (m, 4H), 2.45-2.28 (m, 1H), 2.18 (dq,
J = 14.2, 7.3 Hz, 1H), 2.07-1.91 (m, 2H), 1.72 (d, J = 6.7 Hz, 3H),
1.13 (t, J = 7.2 Hz, 3H). 161 518.15 (DMSO-d.sub.6): .delta. 10.16
(d, J = 4.8 Hz, 1H), 9.39 (s, 2H), 9.03 (d, J = 4.7 Hz, 1H), 8.85
(d, J = 4.0 Hz, 1H), 8.54 (d, J = 8.2 Hz, 1H), 8.41 (d, J = 1.5 Hz,
1H), 8.18 (d, J = 1.5 Hz, 1H), 8.04 (td, J = 8.0, 1.6 Hz, 1H), 7.49
(dd, J = 7.1, 4.9 Hz, 1H), 7.18 (s, 1H), 6.01 (q, J = 6.7 Hz, 1H),
4.61-4.44 (m, 1H), 3.37-3.17 (m, 4H), 2.45-2.28 (m, 1H), 2.18 (dq,
J = 14.2, 7.3 Hz, 1H), 2.07-1.91 (m, 2H), 1.72 (d, J = 6.7 Hz, 3H),
1.13 (t, J = 7.2 Hz, 3H). 162 548.14 (DMSO-d.sub.6): .delta. 10.41
(br s, 1H), 9.41 (s, 2H), 8.83 (dd, J = 4.8, 0.9 Hz, 1H), 8.53 (d,
J = 8.3 Hz, 1H), 8.42 (d, J = 1.6 Hz, 1H), 8.17 (d, J = 1.4 Hz,
1H), 8.03 (td, J = 7.9, 1.8 Hz, 1H), 7.51-7.44 (m, 1H), 6.86 (t, J
= 5.3 Hz, 1H), 6.44 (s, 1H), 4.40 (br s, 2H), 4.01 (d, J = 8.3 Hz,
2H), 3.28-3.17 (m, 2H), 1.42 (s, 9H), 1.12 (t, J = 7.2 Hz, 3H). 163
448.1 (DMSO-d.sub.6): .delta. 10.64 (s, 1H), 9.49 (s, 2H), 9.19 (s,
1H), 8.84 (ddd, J = 4.8, 1.7, 0.9 Hz, 2H), 8.53 (d, J = 8.3 Hz,
1H), 8.43 (d, J = 1.6 Hz, 1H), 8.21 (d, J = 1.5 Hz, 1H), 8.08-7.99
(m, 1H), 7.48 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H), 6.92 (t, J = 5.5 Hz,
1H), 4.64-4.52 (m, 2H), 4.23-4.11 (m, 2H), 3.29-3.14 (m, 2H), 1.12
(t, J = 7.2 Hz, 3H). 164 562.2 (DMSO-d.sub.6): .delta. 10.63 (bs,
1H), 9.35 (s, 2H), 8.78 (d, J = 4.9 Hz, 1H), 8.43 (s, 1H), 8.39 (d,
J = 1.6 Hz, 1H), 8.15 (d, J = 1.4 Hz, 1H), 7.44 (dd, J = 5.1, 1.0
Hz, 1H), 6.89 (t, J = 5.4 Hz, 1H), 5.15 (s, 1H), 3.76-3.52 (m, 4H),
3.29-3.17 (m, 2H), 2.75 (d, J = 10.2 Hz, 2H), 1.75 (t, J = 10.7 Hz,
2H), 1.59 (s, 6H), 1.14 (t, J = 7.2 Hz, 3H), 1.05 (d, J = 6.3 Hz,
6H). 165 589.05 HCl salt (DMSO-d.sub.6): .delta. 10.84 (bs, 1H),
9.82 (bs, 1H), 9.33 (s, 2H), 9.00 (t, J = 5.8 Hz, 1H), 8.85 (d, J =
4.1 Hz, 1H), 8.55 (d, J = 8.1 Hz, 2H), 8.40 (d, J = 1.3 Hz, 1H),
8.16 (d, J = 1.3 Hz, 1H), 8.04 (t, J = 7.1 Hz, 1H), 7.49 (dd, J =
7.1, 4.9 Hz, 1H), 7.17 (bs, 1H), 4.24-4.16 (m, 2H), 4.03 (qd, J =
17.8, 5.9 Hz, 2H), 3.22 (dd, J = 17.0, 10.5 Hz, 4H), 2.30 (dd, J =
17.4, 9.5 Hz, 1H), 1.87 (t, J = 7.9 Hz, 2H), 1.81 (d, J = 3.1 Hz,
6H), 1.13 (t, J = 7.2 Hz, 3H). 166 531.92 HCl salt (DMSO-d.sub.6):
.delta. 10.87 (bs, 1H), 10.07 (bs, 1H), 9.37 (s, 2H), 8.85 (d, J =
4.1 Hz, 2H), 8.59-8.50 (m, 1H), 8.41 (d, J = 1.0 Hz, 1H), 8.17 (d,
J = 1.1 Hz, 1H), 8.04 (t, J = 7.3 Hz, 1H), 7.49 (dd, J = 7.0, 4.8
Hz, 1H), 7.20 (s, 1H), 4.56-4.40 (m, 1H), 3.32-3.13 (m, 4H),
2.45-2.21 (m, 2H), 1.98 (dd, J = 13.1, 6.7 Hz, 2H), 1.92 (s, 3H),
1.81 (s, 3H), 1.13 (t, J = 7.1 Hz, 3H). 167 676.25 (DMSO-d.sub.6):
.delta. 12.35 (s, 1H), 10.70 (s, 1H), 9.44 (s, 2H), 8.78 (d, J =
5.5 Hz, 1H), 8.46 (s, 1H), 8.42 (d, J = 1.4 Hz, 1H), 8.18 (d, J =
1.4 Hz, 1H), 7.45 (d, J = 5.5 Hz, 1H), 6.93 (s, 1H), 5.14 (d, J =
7.5 Hz, 2H), 4.94 (d, J = 7.5 Hz, 2H), 3.68-3.59 (m, 4H), 3.27-3.19
(m, 2H), 2.74 (m, 4H), 2.57 (m, 2H), 1.76 (t, J = 10.7 Hz, 2H),
1.14 (t, J = 7.2 Hz, 3H), 1.05 (d, J = 6.3 Hz, 6H). 168 465.21
(Acetone) .delta. 9.26 (s, 2H), 8.85 (d, J = 2.2 Hz, 1H), 8.85 (d,
J = 2.2 Hz, 1H), 8.42 (d, J = 8.2 Hz, 1H), 8.35 (d, J = 1.6 Hz,
1H), 8.05 (d, J = 1.6 Hz, 1H), 8.01 (dd, J = 8.6, 2.0 Hz, 1H), 7.21
(d, J = 24.2 Hz, 1H), 5.05 (q, J = 6.7 Hz, 1H), 4.96-4.89 (m, 1H),
4.53 (s, 1H), 4.38 (d, J = 5.2 Hz, 1H), 1.54 (dd, J = 6.6, 4.4 Hz,
6H), 1.21 (t, J = 7.2 Hz, 3H). 169 605.12 (DMSO-d.sub.6): .delta.
10.63 (s, 1H), 9.33 (s, 2H), 8.84 (ddd, J = 4.8, 1.7, 0.8 Hz, 1H),
8.55 (d, J = 7.9 Hz, 1H), 8.40 (d, J = 1.5 Hz, 1H), 8.14 (d, J =
1.5 Hz, 1H), 8.08-7.98 (m, 1H), 7.48 (ddd, J = 7.9, 4.8, 0.8 Hz,
1H), 6.90 (t, J = 5.4 Hz, 1H), 3.56-3.52 (m, 4H), 3.39 (s, 2H),
3.28-3.20 (m, 2H), 2.63 (t, J = 6.2 Hz, 2H), 2.40-2.30 (m, 6H),
1.80 (s, 6H), 1.14 (t, J = 7.2 Hz, 3H). 170 549.95 (DMSO-d.sub.6):
.delta. 10.86 (bs, 1H), 9.61 (bs, 2H), 9.36 (s, 2H), 8.84 (s, 1H),
8.53 (d, J = 7.8 Hz, 1H), 8.40 (s, 1H), 8.16 (s, 1H), 8.04 (t, J =
7.2 Hz, 1H), 7.49 (s, 1H), 7.22 (s, 1H), 3.91 (s, 2H), 3.22 (bs,
2H), 1.86 (s, 6H), 1.13 (t, J = 6.9 Hz, 3H). 171 549.93 HCl salt -
(DMSO-d.sub.6): .delta. 10.83 (bs, 1H), 9.33 (s, 2H), 8.84 (s, 1H),
8.53 (d, J = 7.7 Hz, 1H), 8.46 (s, 3H), 8.39 (s, 1H), 8.15 (s, 1H),
8.03 (t, J = 6.9 Hz, 1H), 7.48 (s, 1H), 7.18 (s, 1H), 4.20 (s, 1H),
3.22 (s, 2H), 3.01 (qd, J = 17.5, 5.3 Hz, 2H), 1.81 (d, J = 7.2 Hz,
6H), 1.13 (t, J = 6.1 Hz, 3H). (COOH signal obscured by H.sub.2O)
172 519.97 HCl salt - (DMSO-d.sub.6): .delta. 10.88 (bs, 1H), 9.34
(s, 2H), 8.85 (dd, J = 4.8, 0.8 Hz, 1H), 8.58 (d, J = 8.3 Hz, 1H),
8.42 (d, J = 1.6 Hz, 1H), 8.16 (d, J = 1.5 Hz, 1H), 8.07-7.90 (m,
4H), 7.53-7.46 (m, 1H), 7.20 (bs, 1H), 3.23 (dd, J = 6.8, 4.9 Hz,
2H), 2.87 (dd, J = 14.8, 6.0 Hz, 2H), 2.48 (d, J = 7.4 Hz, 2H),
1.86-1.79 (m, 8H), 1.14 (t, J = 7.2 Hz, 3H). 173 525.15
(DMSO-d.sub.6): .delta. 10.62 (br s, 1H), 9.40 (s, 2H), 8.86-8.80
(m, 1H), 8.53 (d, J = 8.3 Hz, 1H), 8.41 (d, J = 1.5 Hz, 1H), 8.17
(d, J = 1.2 Hz, 1H), 8.02 (td, J = 7.8, 1.8 Hz, 1H), 7.47 (dd, J =
7.1, 5.2 Hz, 1H), 6.91-6.81 (m, 1H), 5.81 (s, 1H), 3.43-3.33 (m,
2H), 3.26-3.17 (m, 2H), 3.17-3.05 (m, 2H), 2.64 (t, J = 11.5 Hz,
2H), 2.39-2.21 (m, 2H), 1.12 (t, J = 7.2 Hz, 3H) 174 476.07
(DMSO-d.sub.6): .delta. 10.61 (br s, 1H), 9.41 (s, 2H), 8.85-8.82
(m, 1H), 8.54-8.50 (m, 2H), 8.41 (d, J = 1.5 Hz, 1H), 8.39-8.29 (m,
1H), 8.18 (d, J = 1.5 Hz, 1H), 8.05-8.00 (m, 1H), 7.50-7.45 (m,
1H), 6.90-6.84 (m, 1H), 5.70 (s, 1H), 3.28-3.14 (m, 6H), 2.41-2.29
(m, 2H), 2.12-2.00 (m, 2H), 1.12 (t, J = 7.2 Hz, 3H). 175 548.25
(DMSO-d.sub.6) .delta. 10.62 (br s, 1H), 9.33 (s, 2H), 8.73 (d, J =
4.40 Hz, 1H), 8.39 (m, 2H), 8.13 (s, 1H), 7.36 (d, J = 4.0 Hz, 1H),
6.86 (m, 1H), 5.16 (s, 1H), 4.08 (m, 1H), 3.74 (s, 2H), 3.58 (m,
2H), 3.35 (m, 2H), 3.19-3.23 (m, 2H), 2.93 (m, 2H), 1.57 (s, 6H)
and 1.06-1.13 (m, 6H) 176 388.14 (DMSO-d.sub.6) .delta. 10.62 (br
s, 1H), 8.95 (s, 2H), 7.73 (s, 1H), 7.69 (s, 1H), 6.68 (m, 1H),
5.09 (s, 1H), 3.84 (s, 3H), 3.15-3.22 (m, 2H), 1.54 (s, 6H) and
1.09 (t, J = 7.20 Hz, 3H) 177 376.11 (DMSO-d.sub.6) .delta. 10.80
(br s, 1H), 9.04 (s, 2H), 7.89-8.01 (m, 2H), 6.71 (m, 1H), 5.14 (s,
1H), 3.16-3.22 (m, 2H), 1.54 (s, 6H) and 1.09 (t, J = 7.20 Hz, 3H)
178 469.08 (DMSO/Acetone) .delta. 9.20 (s, 2H), 8.54 (d, J = 5.5
Hz, 1H), 8.48 (s, 1H), 8.14 (d, J = 1.6 Hz, 1H), 8.11 (s, 1H),
7.56-7.31 (m, 1H), 7.29 (t, J = 4.6 Hz, 1H), 5.30 (s, 1H),
4.90-4.81 (m, 1H), 4.02 (s, 3H), 3.24-3.14 (m, 2H), 1.47 (d, J =
6.6 Hz, 3H), 1.10 (t, J = 7.2 Hz, 3H). 179 563.98 HCl salt -
(DMSO-d.sub.6): .delta. 11.03 (s, 1H), 9.36 (s, 2H), 9.34 (s, 2H),
8.85 (d, J = 4.6 Hz, 1H), 8.55 (d, J = 8.0 Hz, 1H), 8.40 (d, J =
1.3 Hz, 1H), 8.16 (d, J = 1.3 Hz, 1H), 8.05 (dt, J = 8.0, 1.2 Hz,
1H), 7.50 (dd, J = 7.2, 4.6 Hz, 1H), 7.38 (s, 1H), 4.10 (s, 2H),
3.58 (s, 1H), 3.32-3.08 (m, 4H), 2.73 (t, J = 7.3 Hz, 2H), 1.86 (s,
6H), 1.13 (t, J = 7.3 Hz, 3H). 180 531.94 HCl salt -
(DMSO-d.sub.6): .delta. = 10.85 (bs, 1H), 9.40 (bs, 1H), 9.35 (s,
2H), 9.26 (bs, 1H), 8.85 (d, J = 4.1 Hz, 1H), 8.57 (d, J = 8.2 Hz,
1H), 8.42 (d, J = 1.4 Hz, 1H), 8.17 (d, J = 1.4 Hz, 1H), 8.03 (dd,
J = 11.1, 4.4 Hz, 1H), 7.49 (dd, J = 7.1, 4.9 Hz, 1H), 7.15 (bs,
1H), 3.45-3.31 (m, 3H), 3.26-3.14 (m, 4H), 2.24 (q, J = 6.9 Hz,
2H), 1.82 (d, J = 16.6 Hz, 6H), 1.13 (t, J = 7.2 Hz, 3H). 181
547.97 HCl salt - (DMSO-d.sub.6): .delta. 10.87 (bs, 1H), 10.02
(bs, 1H), 9.63 (bs, 1H), 9.39 (s, 2H), 8.85 (d, J = 4.2 Hz, 1H),
8.56 (d, J = 8.2 Hz, 1H), 8.42 (d, J = 1.2 Hz, 1H), 8.18 (d, J =
1.3 Hz, 1H), 8.05 (t, J = 7.7 Hz, 1H), 7.49 (dd, J = 7.1, 5.0 Hz,
1H), 7.19 (bs, 1H), 4.46 (s, 2H), 4.01-3.88 (m, 2H), 3.76 (t, J =
9.8 Hz, 1H), 3.24 (dd, J = 17.6, 11.7 Hz, 3H), 3.15 (bs, 1H), 1.87
(d, J = 32.2 Hz, 6H), 1.13 (t, J = 7.2 Hz, 3H). 182 428.19
(DMSO-d.sub.6) .delta. 10.62 (br s, 1H), 9.02 (s, 2H), 7.69-7.70
(m, 2H), 6.68 (m, 1H), 5.14 (s, 1H), 3.92 (d, J = 6.80 Hz, 2H),
3.14-3.21 (m, 2H), 1.54 (s, 6H), 1.18-1.20 (m, 1H), 1.08 (t, J =
7.20 Hz, 3H), 0.50-0.55 (m, 2H) and 0.27-0.31 (m, 2H) 183 432.13
(DMSO-d.sub.6) .delta. 10.63 (br s, 1H), 9.01 (s, 2H), 7.71-7.74
(m, 2H), 6.68 (m, 1H), 5.11 (s, 1H), 4.20 (t, J = 4.80 Hz, 2H),
3.64 (t, J = 4.80 Hz, 2H), 3.24 (s, 3H), 3.16-3.20 (m, 2H), 1.53
(s, 6H), and 1.09 (t, J = 7.20 Hz, 3H) 184 616 (DMSO-d.sub.6):
.delta. 10.96 (s, 1H), 9.78-9.06 (m, 2H), 9.34 (s, 2H), 8.85 (d, J
= 4.5 Hz, 1H), 8.55 (d, J = 8.1 Hz, 1H), 8.41 (d, J = 1.4 Hz, 1H),
8.17 (d, J = 1.4 Hz, 1H), 8.05 (td, J = 8.1, 1.7 Hz, 1H), 7.50 (dd,
J = 7.1, 4.5 Hz, 1H), 7.26 (s, 1H), 4.12 (s, 4H), 3.58 (s, 2H),
3.32-3.15 (m, 4H), 1.87 (s, 6H), 1.13 (t, J = 7.2 Hz, 3H). 185
536.12 (DMSO-d.sub.6): .delta. 10.69 (s, 1H), 9.33 (s, 2H), 8.77
(d, J = 5.0 Hz, 1H), 8.45-8.33 (m, 2H), 8.14 (d, J = 1.4 Hz, 1H),
7.44 (d, J = 5.0 Hz, 1H), 7.02-6.89 (m, 1H), 5.30 (s, 1H), 4.90 (d,
J = 5.8 Hz, 1H), 3.70 (s, 2H), 3.23 (dd, J = 13.3, 6.5 Hz, 2H),
2.70 (dd, J = 18.3, 6.0 Hz, 8H), 1.51 (d, J = 6.6 Hz, 3H), 1.14 (t,
J = 7.2 Hz, 3H). 186 418.2 (DMSO-d.sub.6) .delta. 10.68 (br s, 1H),
9.06 (s, 2H), 7.71-7.73 (m, 2H), 6.78 (m, 1H), 5.12 (s, 1H), 4.88
(t, J = 5.20 Hz, 1H), 4.12 (t, J = 5.20 Hz, 2H), 3.70 (t, J = 4.80
Hz, 2H), 3.14-3.21 (m, 2H), 1.54 (s, 6H), and 1.08 (t, J = 7.20 Hz,
3H) 187 550.23 (DMSO-d.sub.6) .delta. 10.60 (br s, 1H), 9.32 (s,
2H), 8.76 (d, J = 4.80 Hz, 1H), 8.36-8.40 (m, 2H), 8.13 (s, 1H),
7.42 (d, J = 4.40 Hz, 1H), 6.85 (m, 1H), 5.13 (s, 1H), 3.67 (s,
2H), 3.20-3.23 (m, 2H), 2.66-2.69 (m, 8H), 1.57 (s, 6H) and 1.11
(t, J = 7.20 Hz, 3H) 188 566.23 (DMSO-d.sub.6) .delta. 10.62 (br s,
1H), 9.32 (s, 2H), 8.78 (d, J = 4.80 Hz, 1H), 8.44 (s, 1H), 8.37
(s, 1H), 8.13 (s, 1H), 7.45 (d, J = 4.80 Hz, 1H), 6.86 (m, 1H),
5.15 (s, 1H), 3.75 (s, 2H), 3.18-3.25 (m, 2H), 2.93 (m, 4H),
2.69-2.79 (m, 4H), 1.57 (s, 6H) and 1.11 (t, J = 7.60 Hz, 3H) 189
445.22 (DMSO-d.sub.6) .delta. 10.68 (br s, 1H), 8.98 (s, 2H), 7.83
(s, 1H), 7.58 (s, 1H), 6.70 (m, 1H), 5.11 (br s, 1H), 3.18 (m, 4H),
3.07 (s, 3H), 2.89 (m, 2H), 2.54 (s, 3H), 1.53 (s, 6H), and 1.08
(t, J = 7.20 Hz, 3H) 190 514.98 (DMSO-d.sub.6) .delta. 10.60 (br s,
1H), 9.39 (s, 2H), 8.85 (d, J = 4.6 Hz, 1H), 8.61-8.49 (m, 1H),
8.47-8.38 (m, 1H), 8.22-8.15 (m, 1H), 8.04 (t, J = 7.8 Hz, 1H),
7.49 (dd, J = 7.3, 4.9 Hz, 1H), 6.98-6.88 (m, 1H), 5.09 (d, J = 7.5
Hz, 2H), 3.25-3.21 (m, 2H), 1.88 (s 6H), 1.16-1.11 (m, 3H). 191
582.23 (DMSO-d.sub.6 + D.sub.2O) .delta. 9.25 (s, 2H), 8.74 (d, J =
4.80 Hz, 1H), 8.35 (s, 1H), 8.30 (s, 1H), 8.06 (s, 1H), 7.45 (d, J
= 5.20 Hz, 1H), 3.84 (s, 2H), 3.11-3.21 (m, 6H), 2.94 (m, 4H), 1.54
(s, 6H) and 1.07 (t, J = 7.20 Hz, 3H) 192 524.22 (DMSO-d.sub.6)
.delta. 10.64 (br s, 1H), 9.01 (s, 2H), 7.85 (s, 1H), 7.71 (s, 1H),
6.98 (s, 1H), 6.90 (m, 2H), 6.69 (m, 1H), 5.08-5.10 (m, 3H), 3.73
(s, 3H), 3.71 (s, 3H), 3.17-3.20 (m, 2H), 1.51 (s, 6H), and 1.09
(t, J = 7.20 Hz,
3H) 193 444.16 (DMSO-d.sub.6) .delta. 10.62 (br s, 1H), 8.99 (s,
2H), 7.72 (s, 1H), 7.70 (s, 1H), 6.68 (m, 1H), 5.27 (d, J = 5.20
Hz, 1H), 4.82 (m, 1H), 3.99-4.13 (m, 3H), 3.63-3.70 (m, 2H),
3.16-3.20 (m, 2H), 1.90-1.96 (m, 1H), 1.64-1.80 (m, 2H), 1.59-1.64
(m, 1H), 1.46 (d, J = 6.80 Hz, 3H) and 1.09 (t, J = 7.20 Hz, 3H)
194 429.24 (DMSO-d.sub.6) .delta. 10.68 (br s, 1H), 9.05 (s, 2H),
7.79 (s, 1H), 7.61 (s, 1H), 6.70 (m, 1H), 5.27 (d, J = 5.60 Hz,
1H), 4.82 (m, 1H), 3.48 (m, 4H), 3.16-3.19 (m, 2H), 2.73 (m, 4H),
1.45 (d, J = 6.40 Hz, 3H) and 1.08 (t, J = 7.20 Hz, 3H) 195 442.31
(DMSO-d.sub.6) .delta. 9.11 (s, 2H), 7.69 (m, 1H), 7.30 (s, 1H),
7.05 (m, 1H), 6.57 (m, 1H), 5.14 (s, 1H), 3.19 (m, 5H), 1.98-2.01
(m, 2H), 1.53 (s, 6H), 1.27-1.35 (m, 4H) and 1.08 (m, 3H) 196
508.09 (DMSO-d.sub.6): .delta. 9.32 (s, 2H), 8.75 (d, J = 5.0 Hz,
1H), 8.47 (s, 1H), 8.36 (d, J = 1.5 Hz, 1H), 8.20 (s, 1H), 8.13 (d,
J = 1.5 Hz, 1H), 7.45 (d, J = 5.0 Hz, 1H), 6.99 (t, J = 5.5 Hz,
1H), 3.94 (s, 3H), 3.53 (t, J = 5.7 Hz, 2H), 3.21 (tt, J = 13.0,
6.5 Hz, 2H), 2.68 (t, J = 5.7 Hz, 2H), 2.54 (s, 1H), 1.57 (s, 6H),
1.12 (t, J = 7.2 Hz, 3H). 197 420 (CD.sub.3OD) .delta. 8.80 (d, J =
5.2 Hz, 2H), 8.56 (s, 1H), 8.15-8.11 (m, 2H), 8.04 (s, 1H),
7.94-7.88 (m, 2H), 7.43 (s, 2H), 7.35 (t, J = 7.2 Hz, 1H), 5.03 (q,
J = 6.0 Hz, 1H), 3.42-3.38 (m, 2H), 1.60 (d, J = 6.4 Hz, 3 H), 1.26
(t, J = 7.2 Hz, 3H). 198 542.3 (DMSO-d.sub.6): .delta. 10.61 (s,
1H), 9.33 (s, 2H), 8.76 (d, J = 5.2 Hz, 1H), 8.42 (s, 1H), 8.37 (d,
J = 1.3 Hz, 1H), 8.13 (d, J = 0.7 Hz, 1H), 7.44 (dd, J = 5.0, 1.1
Hz, 1H), 6.88 (t, J = 5.1 Hz, 1H), 5.75 (s, 1H), 5.13 (s, 1H), 3.64
(s, 2H), 3.26-3.17 (m, 2H), 1.57 (s, 6H), 1.12 (t, J = 7.2 Hz, 3H).
199 487.21 (DMSO-d.sub.6) .delta. 10.63 (br s, 1H), 9.04 (s, 2H),
7.75 (s, 1H), 7.70 (s, 1H), 6.68 (m, 1H), 5.10 (s, 1H), 4.17 (t, J
= 5.20 Hz, 2H), 3.53 (m, 4H), 3.15-3.21 (m, 2H), 2.64 (t, J = 5.20
Hz, 2H), 2.37 (m, 4H), 1.53 (s, 6H) and 1.08 (t, J = 7.20 Hz, 3H)
200 448.14 (DMSO-d.sub.6) .delta. 10.84 (br s, 1H), 8.93 (s, 2H),
7.63-7.69 (m, 2H), 6.72 (m, 1H), 5.21 (br s, 1H), 3.37 (t, J = 6.40
Hz, 2H), 3.11-3.15 (m, 5H), 2.98 (t, J = 6.40 Hz, 2H), 1.58 (s,
6H), and 1.04 (t, J = 6.80 Hz, 3H) 201 464.14 (DMSO-d.sub.6)
.delta. 11.06 (br s, 1H), 9.03 (s, 2H), 7.92-7.98 (m, 2H), 6.79 (m,
1H), 5.27 (br s, 1H), 3.65 (m, 1H), 3.45 (m, 1H), 3.02-3.15 (m,
6H), 2.85-2.89 (m, 1H), 1.57 (s, 6H), and 1.05 (t, J = 7.20 Hz, 3H)
202 451.21 (DMSO-d.sub.6): .delta. 10.59 (s, 1H), 9.33 (s, 2H),
8.63 (d, J = 6 Hz, 1H), 8.38 (d, J = 0.8 Hz, 1H), 8.12 (s, 1H),
8.02 (d, J = 1.2 Hz, 1H), 7.05 (dd, J = 5.6, 2 Hz, 1H), 6.87 (br t,
J = 5.2 Hz, 1H), 5.30 (d, J = 5.2 Hz, 1H), 4.88 (p, J = 6 Hz, 1H),
3.99 (s, 3H), 3.21 (p, J = 6.4 Hz, 2H), 1.49 (d, J = 6.4 Hz, 3H),
1.12 (t, J = 7.2 Hz, 3H). .sup.aCompound 149 was prepared by
coupling Precursor 81 with Intermediate 1 under Suzuki coupling
conditions as previously described then was subsequently converted
to the target compound as follows. Zinc (177 mg) was added to a
solution of
1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimid-
in-2-yl]ethyl bis(2,2,2-trichloroethyl) phosphate (230 mg) in a
mixture of pyridine (1.5 mL) and acetic acid (0.3 mL) and the
mixture stirred at RT for 2 h. The mixture was filtered through
celite, washing with pyridine (3 .times. 10 mL) and concentrated in
vacuo. The residue was treated with MeOH (30 mL) to give a solid,
which was collected by filtration. This was purified by reverse
phase chromatography eluting with 0-100% ACN/H.sub.2O, followed by
50% MeOH/H.sub.2O 50% ammonia) to give Compound 149 as the bis
ammonium salt (50 mg).
ADME Assays
[0672] The following assay(s) may be used to assess the properties
of a prodrug and the potential suitability of the prodrug to
deliver a compound in vivo.
Chemical Stability Assay
[0673] Compounds may be tested for chemical stability across four
pH values i.e. 2.1, 4.5, 7.4 and 9.1 and in water. Stress solutions
are prepared with 10% acetonitrile and samples introduced from DMSO
stocks (2 mM) to give a final concentration of 16 .mu.M. Test
samples are analysed by HPLC using a C8 reverse phase column
(Phenomenex Kinetex.TM. 2.6 .mu.m C8 100 .ANG. LC Column 50.times.3
mm or similar) with an elution gradient of 5-100%
acetonitrile:water+0.1% formic acid. The assay is conducted over 24
hrs with 2-hourly injections. Data analysis is performed using peak
areas at 254 nm and LCMS for mass determination.
[0674] In an alternative method, compounds are dissolved in DMSO
are diluted to produce triplicate 10 .mu.M solutions in HEPES pH
7.4 containing 5% DMSO. The samples are incubated for 24 h at
37.degree. C. and analysed by LCMS following the addition of 2
volumes of methanol. The percentage of compound remaining is
determined by comparing peak areas to a T0 sample.
[0675] The chemical stability of representative Compounds 19, 123,
133 and 134 were tested and determined to be chemically stable at
pH 7.4 with .gtoreq.95% of the compound remaining at 24 hours.
Thermodynamic Solubility
[0676] In a 1.5 mL eppendorf tube, approximately 2 mg of compound
is resuspended in a volume of HEPES buffer pH 7.4 to achieve a 5
mg/mL suspension. The tubes are placed on an orbital shaker at room
temperature and following shaking for 24 hours the tubes are spun
at 1400 rpm in a bench top centrifuge to pellet the undissolved
compound. Duplicate 150 .mu.L aliquots of the supernatant are then
transferred into two ultracentrifuge tubes and spun at 357440 g for
4 hours at 20.degree. C. 50 .mu.L of the supernatant from each tube
is then diluted with 100 .mu.L of methanol and analysed by HPLC or
LCMS to determine the concentration of compound in solution by
comparing to a standard curve. The thermodynamic solubility of
representative Compounds 19, 123, 134 and 153 were tested and
determined to be highly soluble, at .gtoreq.2 mg/mL, at pH 7.4.
Microsomal Stability
[0677] In a 96 well polypropylene plate, 10 .mu.M compound is
prepared in 100 mM KPO.sub.4 buffer pH 7.4, 5 mM MgCl.sub.2, 25
.mu.g/ml Alamethicin, 1 mg/ml (protein) liver microsomes (mouse)
and a final DMSO concentration of 0.1% in 100 .mu.l in duplicate.
The plate is pre-incubated at 37.degree. C. for 10 minutes after
which reactions are initiated by the addition of NADPH and UDPGA to
a final concentration of 1 mM and 5 mM respectively. Reactions are
incubated at 37.degree. C. and terminated by the addition of 100
.mu.l DMSO at 0, 10, 30 and 60 minutes. Samples of 100 .mu.l are
withdrawn and added to 50 .mu.l ice cold methanol and mixed on an
orbital shaker for 10 minutes to precipitate the proteins. The
samples are then centrifuged at 4000 rpm and 10.degree. C. for 30
minutes and supernatants are analysed by LCMS. The T1/2 and
clearance are determined by linear regression from the peak areas.
The microsomal stability of representative Compounds 19, 123, 133
and 134 were tested and determined to be unstable, in each case the
major metabolite being the parent alcohol, with a half-life less
than 20 mins.
Plasma Stability
[0678] Compounds dissolved in DMSO are diluted to produce duplicate
50 .mu.l aliquots of 10 .mu.M solutions in neat plasma containing
1% DMSO in 96 well polypropylene plates. Following incubation at
37.degree. C. for 5 hours, 100 .mu.l ice cold acetonitrile is added
to the samples and mixed on an orbital shaker for 10 minutes to
precipitate the proteins. The samples are then centrifuged at 4000
rpm and 10.degree. C. for 30 minutes and supernatants are analysed
by LCMS. The recovery and percentage of compound remaining is
determined by comparing peak areas to a DMSO stock and T0 sample
respectively.
Biological Data
[0679] The in vitro and in vivo antiviral activity of the compounds
of the invention may be determined using the following
protocols.
On-Target Enzyme Assay: Determination of Gyrase ATPase Activity
[0680] Gyrase converts ATP into ADP and inorganic phosphate. The
released phosphate can be detected by the addition of malachite
green solution and measured by monitoring the increase in
absorbance at 600 nm. The ATPase assay is carried out in a buffer
containing 2 mU/.mu.L Gyrase enzyme (A.sub.2B.sub.2 complex from
Staphylococcus aureus), 0.08 mg/mL double-stranded DNA, 8 mM
HEPES.KOH pH 7.6, 100 mM K glutamate, 2 mM Mg acetate, 2 mM DTT,
0.01 mg/mL BSA, and 5% DMSO solution containing the inhibitor.
Alternatively, the ATPase assay is carried out in a buffer
containing 4.8 .mu.g/mL Gyrase enzyme (A.sub.2B.sub.2 complex from
Escherichia coli), 0.08 .mu.g/mL ssDNA, 35 mM Tris pH 7.5, 24 mM
KCl, 2 mM MgCl.sub.2, 6.5% Glycerol, 2 mM DTT, 1.8 mM Spermidine,
0.5 mg/mL BSA and 5% DMSO solution containing the inhibitor. The
reaction is started by adding ATP to a final concentration of 1 mM
and allowed to incubate at 30.degree. C. for 60 minutes. The
reaction is stopped by adding 200 .mu.L of malachite green solution
(0.034% malachite green, 10 mM ammonium molybdate, 1 M HCl, 3.4%
ethanol, 0.01% tween 20). Colour is allowed to develop for 5
minutes and the absorbance at 600 nm is measured
spectrophotometrically. The IC.sub.50 values are determined from
the absorbance readings using no compound and no enzyme
controls.
[0681] The compounds of the invention demonstrated on target enzyme
activity with the majority of compounds tested showing Gyrase
ATPase activity IC.sub.50 values less than 1 .mu.g/mL, with most of
these being less than 0.1 .mu.g/mL.
Bacterial Assay: Determination of Antibacterial Activity
[0682] Compounds of the invention were tested for antimicrobial
activity by susceptibility testing in liquid or on solid media.
MICs for compounds against each strain were determined by the broth
microdilution or agar dilution method according to the guidelines
of the Clinical Laboratories and Standards Institute, formerly the
National Committee for Clinical Laboratory Standards (Clinical
Laboratories and Standards Institute. Methods for Dilution
Antimicrobial Susceptibility Tests for Bacteria That Grow
Aerobically; Approved Standard--Seventh Edition. Document M7-A7.
CLSI, Wayne, Pa., 2006; Clinical Laboratories and Standards
Institute. The Gram positive bacterial strains tested include S.
aureus (Staphylococcus aureus (Isolate ID ATCC 29213)), S.
epidermidis (Staphylococcus epidermidis (Isolate ID ATCC 12228)),
E. faecalis (Enterococcus faecalis (Isolate ID ATCC 29212)), E.
faecium (Enterococcus faecium (Isolate ID ATCC 700221)), S.
pyogenes (Streptococcus pyogenes (Isolate ID ATCC 51339)) and S.
pneumoniae (Streptococcus pneumoniae (Isolate ID ATCC 49619)). The
Gram negative bacterial strains tested include H. influenzae
(Haemophilus influenzae (Isolate ID ATCC 49247)), A. baumannii
(Acinetobacter baumannii (Isolate ID ATCC 19606)), E. coli
(Escherichia coli (Isolate ID ATCC 25922)), K. pneumoniae
(Klebsiella pneumoniae (Isolate ID ATCC 13882)), L. pneumophila
(Legionella pneumophila (Isolate ID ATCC 33152)), M. catarrhalis
(Moraxella catarrhalis (Isolate ID ATCC 25240)) and N. gonorrhoeae
(Neisseria gonorrhoeae (Isolate ID ATCC 49226)).
Gram Positive Antibacterial Activity
[0683] Representative compounds of the invention were tested for
activity against one or more Gram positive bacterial strains and
the results are presented in Tables 1 and 2.
TABLE-US-00013 TABLE 1 S. aureus (ATCC 29213) minimal inhibitory
concentration (MIC) MIC (.mu.g/mL) Representative compound example
number .ltoreq.1 1, 2, 3, 4, 6, 7, 8, 10, 12, 13, 14, 15, 17, 18,
22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 42, 43, 48, 49, 50, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
63, 64, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 80, 81, 82, 83,
84, 87, 88, 92, 93, 94, 95, 96, 98, 100, 101, 104, 106, 107, 108,
111, 112, 113, 114, 115, 116, 118, 119, 120, 121, 122, 125, 127,
128, 130, 131, 154, 155, 156, 157, 158, 162, 164, 168, 173, 175,
176, 177, 178, 182, 183, 185, 187, 188, 191, 192, 193, 197, 198,
202 2 16, 20, 45, 52, 65, 66, 79, 85, 91, 99, 103, 109, 110, 150,
151, 159, 196, 199 4 11, 21, 46, 51, 97, 186 8 9, 47, 72, 86, 89,
174 16 5, 41, 44, 90, 102, 105, 117, 194
TABLE-US-00014 TABLE 2 S. pyogenes (ATCC 51339) minimal inhibitory
concentration (MIC) MIC (.mu.g/mL) Representative compound example
number .ltoreq.1 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16,
17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,
35, 36, 37, 38, 39, 40, 42, 43, 45, 48, 49, 50, 51, 52, 53, 54, 55,
56, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74,
75, 76, 77, 78, 80, 81, 82, 83, 84, 85, 86, 87, 88, 91, 92, 93, 94,
95, 96, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 108, 109,
110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122,
125, 127, 128, 130, 131, 154, 155, 156, 157, 158, 159, 162, 164,
168, 173, 175, 176, 178, 182, 183, 185, 187, 188, 191, 192, 197 2
13, 57, 79, 89, 90, 151, 174, 177, 186, 193, 199 4 46 8 47, 72,
150, 163 16 41, 44, 102
Gram Negative Antibacterial Activity
[0684] Selected compounds of the invention were also tested for
activity against the Gram negative bacterial strain H. influenzae
(ATCC 49247) and the results are presented in Table 3.
TABLE-US-00015 TABLE 3 H. influenzae (ATCC 49247) minimal
inhibitory concentration (MIC) MIC (.mu.g/mL) Representative
compound example number .ltoreq.2 1, 6, 7, 8, 10, 15, 17, 22, 23,
27, 28, 30, 31, 32, 35, 36, 38, 39, 40, 43, 53, 55, 56, 58, 59, 61,
62, 63, 64, 68, 69, 70, 71, 73, 74, 75, 76, 80, 81, 82, 83, 87, 88,
92, 95, 96, 99, 100, 104, 111, 113, 114, 115, 116, 118, 119, 121,
122, 125, 127, 130, 131, 154, 155, 157, 158, 168, 173, 175, 178,
185, 187, 198, 202
Pharmacokinetic Assays: Determination of PK Profile
[0685] The pharmacokinetic profiles of compounds are determined by
measuring the compound concentration in plasma by LC/MS/MS
following a single intravenous or peroral administration of the
compounds at a dose of 1 or 3 mg/kg individually or in a cassette
of up to 5 compounds. The concentrations are described as the mean
plasma concentrations at each time point from three animals.
Intravenous dose formulation is administered as a single bolus dose
through the tail vein. Oral dose formulation is administered to
animals by an oral gavage needle. In both cases the dose volume is
5.0 mL/kg. Blood is collected from rats using a jugular vein
catheter and from anesthetized mice through a capillary guided into
the retro-orbital plexus. The collected blood is then centrifuged
to obtain plasma and the compounds extracted into methanol prior to
determining the compound concentration by LC/MS/MS.
[0686] The pharmacokinetic profiles of selected compounds of the
invention were compared directly with their primary alcohol
analogues, Compounds A and B below, in the rat assay (IV).
1-Ethyl-3-[5-[2-(hydroxymethyl)pyrimidin-5-yl]-7-(2-pyridyl)-1,3-benzothia-
zol-2-yl]urea (Compound A)
##STR00193##
[0688] MS: 406.99 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 10.66 (s, 1H), 9.34 (s, 2H), 8.84 (d, J=4.1 Hz, 1H), 8.54
(d, J=8.2 Hz, 1H), 8.40 (d, J=1.1 Hz, 1H), 8.16 (s, 1H), 8.03 (td,
J=8.0, 1.6 Hz, 1H), 7.48 (dd, J=7.0, 5.0 Hz, 1H), 6.91 (s, 1H),
5.39 (t, J=6.1 Hz, 1H), 4.72 (d, J=5.9 Hz, 2H), 3.26-3.21 (m, 2H),
1.14 (t, J=7.2 Hz, 3H).
1-Ethyl-3-[5-[6-(hydroxymethyl)-3-pyridyl]-7-(2-pyridyl)-1,3-benzothiazol--
2-yl]urea (Compound B)
##STR00194##
[0690] MS: 406.15 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
d 10.62 (br s, 1H), 9.0 (d, J=2.0 Hz, 1H), 8.82 (d, J=4.40 Hz, 1H),
8.50 (d, J=8.0 Hz, 1H), 8.30-8.32 (m, 2H), 7.98-8.03 (m, 2H), 7.60
(d, J=8.40 Hz, 1H), 7.44-7.47 (m, 1H), 6.87 (m, 1H), 5.49 (t,
J=5.60 Hz, 1H), 4.65 (d, J=5.60 Hz, 2H).
[0691] The results are shown in Table 4 and presented graphically
in FIGS. 1A and 1B where the X axis denotes time (hours) and the Y
axis denotes plasma concentration (.mu.g/mL). The AUC.sub.iv,
clearance and Tin values are provided in the following table where
AUC.sub.iv is area under the curve for intravenous (IV) and
T.sub.1/2 represents the compound half-life. Surprisingly, the
compounds of the invention demonstrated improved clearance and an
increase in AUC.sub.iv and half-life when compared with Compounds A
and B.
TABLE-US-00016 TABLE 4 AUC.sub.iv, clearance and half-life values
for selected compounds compared against their primary alcohol
substituted analogue compounds A and B in the rat assay. Dose
AUC.sub.iv Clearance T.sub.1/2 Cpd No. (mg/kg) (.mu.g hr/mL) (mL
min/kg) (min) A 3 2 25 81 B 3 1.8 28 60 1 1 3.1 4.3 203 17 3 4 12
107 27 1 1.13 13 158
Animal Models of Infection
[0692] Suitable models of infection will be familiar to those
skilled in the art and include the following suitable for
intravenous (IV) or oral (PO) dosing.
Thigh Infection Model(s)
[0693] Mouse:
[0694] The thighs of female CD-1 mice (18-22 g), rendered
neutropenic by the intraperitoneal administration of
cyclophosphamide (150 mg/kg at day -4 and 100 mg/kg at day -1),
were inoculated with approximately 2.times.10.sup.5 cfus of S.
aureus Smith prepared from a fresh overnight culture. Compounds
were administered as indicated 2 hours later and the cfus
enumerated at various times post dosing by harvesting the thighs,
homogenising in saline on ice and plating serial dilutions onto
charcoal containing plates for growth overnight and colony
counting. For example, when dosed IV at 30 mg/kg Compounds 1 and 17
demonstrated a .gtoreq.3 log drop in colony forming units compared
to the control. Similarly, when dosed PO at 100 mg/kg Compound 1
demonstrated a .gtoreq.3 log drop in colony forming units compared
to the control.
[0695] Rat:
[0696] The thighs of Sprague-Dawley rats (250-275 g), rendered
neutropenic by the intraperitoneal administration of
cyclophosphamide (75 mg/kg on days -4 and -1), were inoculated with
approximately 1.times.10.sup.7 cfus of S. aureus ATCC29213.
[0697] Compounds were administered as indicated 2 hours later and
the cfus enumerated at various times post dosing by harvesting the
thighs, homogenising in PBS on ice and plating serial dilutions
onto CLED agar plates for growth at 37.degree. C. and colony
counting. For example, when dosed IV at .ltoreq.40 mg/kg Compound 1
demonstrated a .gtoreq.3 log drop in colony forming units compared
to the control.
Lung Infection Model(s)
[0698] Mouse (Gram Positive):
[0699] Anaesthetised female CD-1 mice (18-22 g) were inoculated
intranasally with approximately 10.sup.6 cfus of S. pneumoniae
ATCC6301 prepared from a fresh overnight culture by placing 50
.mu.l of inoculum on the nares and allowing the mice to inhale.
Compounds were administered as indicated at 24 hours post
inoculation and the cfus enumerated at 48 hours post inoculation by
harvesting the lungs, homogenising in PBS on ice and plating serial
dilutions onto TSA+5% blood plates for growth overnight at
37.degree. C. and colony counting. For example, when dosed IV at 30
mg/kg Compound 1 demonstrated a .gtoreq.3 log drop in colony
forming units compared to the control.
[0700] Rat (Gram Negative):
[0701] Anaesthetised Sprague-Dawley rats (180-200 g), rendered
neutropenic by the intraperitoneal administration of
cyclophosphamide, were inoculated intratracheally with
approximately 5.times.10.sup.7 cfus of H. influenzae prepared from
a fresh culture by delivering 0.5 ml of inoculum in molten agar.
Compounds were administered as indicated at 5 hours post
inoculation followed by additional daily treatments and the cfus
enumerated at 96 hours post inoculation by harvesting the lungs,
homogenising in PBS on ice and plating serial dilutions onto
bacterial growth medium for cfu determination.
[0702] Mouse Survival Model:
[0703] Anaesthetised female CD-1 mice (18-22 g) were inoculated
intranasally with approximately 10.sup.6 cfus of S. pneumoniae
ATCC6301 prepared from a fresh overnight culture by placing 50
.mu.l of inoculum on the nares and allowing the mice to inhale.
Compounds are administered as indicated at 24, 48 and 72 hours post
inoculation and the mice monitored for survival for seven or nine
days after infection. For example, Compound 1 was dosed IV at 10
mg/kg and the results are shown in FIG. 2. Compound 1 demonstrated
improved efficacy with 80% of mice surviving at seven or nine days.
In comparison, mice dosed with 10 mg/kg Linezolid were dead by day
six. Similarly, when Compound 17 was dosed IV at 30 mg/kg 90% of
mice survived at day seven.
Skin Infection Model(s)
[0704] Mouse:
[0705] An area of the skin was stripped from the back dorsal
surface of anaesthetised female CD-1 mice (18-22 g) by abrading
with a fine emery board following removal of the fur by shaving. An
infection was initiated by placing 5 .mu.l of inoculum, containing
approximately 10.sup.7 cfus of S. aureus Smith prepared from a
fresh overnight culture, onto the damaged skin. Compounds were
administered as indicated at 4, 20, 28, 44, 52, 68 and 76 hours
post inoculation and the cfus enumerated after 5 days post
inoculation by harvesting the wounds, homogenising in PBS on ice
and plating serial dilutions onto charcoal containing plates for
growth overnight and colony counting.
Septicaemia Infection Model(s)
[0706] Mouse:
[0707] Female CD-1 mice (18-22 g) were inoculated intraperitoneally
with approximately 5.times.10.sup.5 cfus of S. aureus Smith
prepared from a fresh overnight culture suspended in 5% hog gastric
mucin. Compounds were administered as indicated at 2 hours post
inoculation and the mice monitored for survival for five days after
infection.
[0708] Throughout this specification and the claims which follow,
unless the context requires otherwise, the word "comprise", and
variations such as "comprises" and "comprising", will be understood
to imply the inclusion of a stated integer or step or group of
integers or steps but not the exclusion of any other integer or
step or group of integers or steps.
[0709] The reference in this specification to any prior
publication, or information derived from it, or to any matter which
is known, is not, and should not be taken as an acknowledgement or
admission or any form of suggestion that that prior publication, or
information derived from it, or known matter forms part of the
common general knowledge in the field of endeavour to which this
specification relates.
* * * * *